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S U M M A R Y
The gene encoding glycoprotein gB of EHV-4 strain 1942 was 
located within a BamHI genomic library by a combination of dot 
blot and Southern blot hybridisation using probes derived from 
the HSV-1 gB DNA sequence, and its DNA sequence determined. The 
major portion of the gene mapped to a 2.9kb fragment at the
left-hand end of BamHI-C with the transcriptional control
domains and start of the coding sequences of the gene located at 
the right-hand end of BamHI-M. The unprocessed EHV-4 gB protein 
was predicted to be 975 amino acids (HOkDa) in size and
composed of an unusually long amino-terminal signal sequence, a 
hydrophilic surface domain containing 11 potential N-linked 
glycosylation sites and 10 cysteine residues, a hydrophobic 
transmembrane domain thought to span the membrane three times 
and a highly charged carboxyl-terminal cytoplasmic anchor
domain. A potential internal proteolytic cleavage site was 
identified near the centre of the protein. The EHV-4 gB protein 
demonstrated high levels of conservation of primary amino acid 
sequence with other herpesvirus gB-like proteins. Furthermore, 
the conservation of all cysteine residues and some N-linked 
glycosylation sites in the surface domain between the gB-like 
proteins suggested possible conservation of secondary and 
tertiary structures. The gB-like proteins may have a similar, 
conserved function across the herpesviruses.
With a view to evaluating EHV-4 gB as a potential candidate 
for development as a subunit vaccine, segments from the 
hydrophilic surface domain were expressed as fusion proteins 
using prokaryotic vector systems and fusion proteins
XIV
successfully purified. Three peptides from the EHV-4 gB amino 
acid sequence were also synthesised. Fusion proteins and 
peptides were examined for their ability to induce strong immune 
responses in hamsters. No peptide could stimulate the production 
of virus neutralising antibodies or confer protective immunity 
in hamsters. Similarly, fusion proteins could not stimulate the 
production of virus neutralising antibodies in hamsters although 
immunisation with one fusion protein protected one out of three 
animals from a lethal EHV-1 challenge. Furthermore, immunisation 
of hamsters with all three peptides induced lymphocytes to 
proliferate in response to whole virus antigen in vitro. These 
results suggested that EHV-4 gB may have a more important role 
in cell-mediated immunity than in humoral immunity.
The DNA sequence of the EHV-4 genome between 0.067 and
0.122 map units was determined. The EHV-4 genome was 
demonstrated to have an identical gene arrangement with the HSV- 
1 (IL) and VZV genomes in this region and DNA sequence for genes 
analogous to HSV-1 UL51 to UL47 and VZV genes 7 to 11 was
obtained. One of these EHV-4 genes is that for the unique
glycoprotein gplO, although its gene product does not possess 
features characteristic of herpesvirus envelope glycoproteins. 
gplO is a glycosylated non-envelope protein which probably 
resides in the virus tegument as does the analogous but
unglycosylated protein specified by HSV-1 UL47. Additional DNA 
sequence data for BamHI-Q demonstrated that this genomic 
fragment encodes part of the major DNA binding protein of EHV-4.
Suitable approaches for the development of recombinant 
herpesyirus vaccines and the genetic relatedness between 
herpesvirus genomes are discussed.
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CHAPTER 1
General Introduction
THE FAMILY HERPESVXRIDAE
General Description
The herpesviruses are infectious agents which are widely 
distributed throughout the animal kingdom and infect many 
species including birds, fish, reptiles and mammals such as 
monkeys, apes and man. Over 80 different herpesviruses are known 
(Roizman, 1982) and more are continuing to be identified. They 
are genetically complex and possess large, linear, double­
stranded DNA genomes with base pair compositions of 32 to 75% 
G+C containing of the order of 60 to 100 genes, and show
considerable variation with respect to host range and biological 
properties. To date, six distinct human herpesviruses have been 
identified and characterised, namely herpes simplex virus types 
1 (HSV-1) and 2 (HSV-2), varicella-zoster virus (VZV) , human
cytomegalovirus (HCMV), Epstein-Barr virus (EBV) and human 
herpesvirus-6 (HHV-6). Another human herpesvirus, HHV-7, has 
very recently been identified.
HSV-1, which is regarded as the prototype of the
Herpesviridae. is the most extensively studied herpesvirus. 
HSV-1 and its closely related counterpart, HSV-2, are the 
causative agents of similar kinds of clinical syndromes. These 
include minor skin infections of the face (cold sores, blisters) 
and genital organs, more fatal complications in the exposed 
newborn and immunocompromised host, viral encephalitis and 
possible involvement in urogenital cancers (Spear and Roizman, 
1980, and references therein). The common childhood ailment of 
chicken pox is a result of primary infection with VZV and
infected individuals can suffer from painful shingles in later
1
life as a result of virus reactivation. Infection with HCMV is 
often subclinical, but can lead to mortality in foetuses and 
neonates and can cause serious problems in immunocompromised 
individuals such as those undergoing surgery or suffering from 
acquired immune deficiency syndrome (Stagno et al.. 1983;
Meyers, 1985) . EBV immortalises human B lymphocytes and is the 
causative agent of infectious mononucleosis. It has also been 
associated with Burkitt's lymphoma and nasopharyngeal carcinoma 
(Epstein et al.. 1964? Klein, 1979). HHV-6 has been isolated 
from patients with acquired immune deficiency syndrome and 
lymphoproliferative disease (Salahuddin et al., 1986; Tedder et 
al. . 1987) and is capable of infecting B and T lymphocytic cell 
lines in addition to cells of neuronal origin (Ablashi et al.. 
1987).
Infection of animals with herpesviruses can cause serious 
diseases which often lead to large economic losses. Bovine 
herpesvirus 1 (BHV-1) gives rise to numerous clinical conditions 
in cattle such as rhinotracheitis, vulvovaginitis,
conjuctivitis, abortion and fatal systemic infection in newborn 
calves (Ludwig, 1983). Pseudorabies virus (PRV) causes 
Aujeszky's disease in swine which can be lethal in young pigs 
(Gustafson, 1986) . Equine herpesviruses 1 (EHV-1) and 4 (EHV-4)
(previously known as EHV-1 subtypes 1 and 2, respectively) cause 
a number of diseases in the horse. Whilst both viruses are 
associated with severe respiratory illness, EHV-1 can also cause 
abortion, neonatal foal death and neurological disease (Campbell 
and Studdert, 1983; O'Callaghan et al. . 1983; Allen and Bryans, 
1986). Herpesviruses infecting birds include Marek's disease 
virus (MDV) (Churchill and Biggs, 1967) and herpesvirus of
2
turkeys (HVT) (Kawamura et al., 1969). MDV causes cytolytic 
infection of B and T cells and induces T cell lymphomas in 
chickens, whereas HVT is non-oncogenic, only mildly infectious 
and is not associated with any apparent disease (Payne, 1982). 
An example of a herpesvirus of fish is channel catfish virus 
(CCV) (Wolf and Darlington, 1971), whilst green iguana virus is 
one herpesvirus which infects reptiles (Zeigel and Clark, 1972). 
Herpesvirus saimiri (HVS) of the squirrel monkey (Melendez et 
al., 1968) is a well known herpesvirus that infects non-human 
primates.
The variable biological properties of the herpesviruses are 
such that infection can lead to fatal systemic illnes, localised 
infection or even no apparent symptoms in the host. However, one 
distinct property common to all herpesviruses is the ability to 
establish a latent infection. The state of latency is 
established after primary infection, in which the virus lies 
dormant in the host. Reactivation of latent virus leads to 
renewed episodes of disease and may occur on any number of 
occasions during the lifetime of the host, or not at all. 
Attempts to control herpesvirus infection by vaccination have 
been hindered by the latent nature of these viruses.
Structure of the Herpesvirion
All members of the Herpesviridae show a remarkably high 
degree of conservation of virion structure. The virion consists 
of four distinct structural elements: the core, capsid, tegument 
and envelope (for reviews see Wildy et al.. 1960; Roizman and 
Furlong, 1974). A schematic representation of a herpesvirus 
virion is shown in Figure 1.1. The electron-opaque core contains
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Figure 1.1 Schematic representation of the herpesvirus virion 
showing the main structural components (see text for details).
DNA wrapped around a fibrillar spool (core cylinder) (Furlong et 
al.. 1972) and the ends of the fibres are attached to the 
underside of the caps id shell. The core is enclosed by the 
caps id, which has a diameter of 100 to HOnm and contains 12 
pentameric and 150 hexameric capsomeres arranged in the form of 
an icosadeltahedron on the surface - these two features of 
capsid structure are especially typical of the herpesviruses. 
The hexameric capsomeres are approximately 12.5nm long and 
contain a hole 4nm in diameter which runs through the long axis 
of the structure. The tegument surrounds the capsid and contains 
globular material which is often asymmetrically distributed and 
variable in amount from virion to virion, even in the same cell. 
The outer envelope, which immediately surrounds the tegument, is 
a membrane composed of a lipid bilayer and contains a number of 
immunologically important glycoproteins which protrude as spikes 
from the outer surface. The overall diameter and volume of the 
virion depends on the diameter of the capsid and the volume of 
the tegument, which can be variable. In addition, 
discontinuities in the envelope may be present which tend to 
increase the overall diameter of the virion.
Classification
Newly isolated herpesviruses have readily been identified 
as such on the basis of morphology since their virions share 
structural features as described in the previous section. 
However, with the increasing number of herpesviruses that have 
been identified over the last 50 years, the need for a suitable 
subclassification system has become of paramount importance. 
Recent studies have demonstrated that they have undergone much
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divergence during the course of their evolution in terms of 
antigenic and biological properties and the size, composition 
and arrangement of their double-stranded DNA genomes. Although 
the antigenic properties of virions can be a useful system for 
identifying closely related viruses, this approach cannot 
provide a firm foundation for subclassification. Due to their 
complexity, the herpesviruses are difficult to subclassify 
unequivocally. Despite such limitations, attempts have been made 
to divide them into subfamilies on the basis of biological 
properties and, to a lesser extent, genome structure.
Biological Properties as a Subclassification System
The Herpesviridae have been quite successfully divided into 
three subfamilies on the basis of biological properties, namely 
alpha-, beta- and gammaherpesviruses (Honess and Watson, 1977; 
Roizman et al.. 1981; Roizman, 1982; Honess, 1984). The proposal 
of these subfamilies was based largely upon host range, 
characteristics of latent infection, length of replication cycle 
and cytopathology. Features of the Alphaheroesvirinae are 
that they can replicate in a wide variety of cells in vivo and 
in vitro and have a relatively short replication cycle (<18hr). 
They spread rapidly in tissue culture with mass destruction of 
infected cells and carrier cultures of susceptible cells 
harbouring non-defective genomes are difficult to establish. 
Common clinical manifestations include mild primary infection of 
the epithelial cells of the skin, genitalia, eyes and 
respiratory tract, giving rise to vesicular lesions, and they 
can also cause severe generalised infection in neonates and 
immunocompromised adults. They persist in a latent form
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frequently, but not exclusively, in the neurones of ganglia 
serving the primary infected area (Wildy et al.. 1982; Wildy,
1985). The Alohaheroesvirinae comprise two subgroups, and
o<2/ the members of which more closely resemble HSV and VZV, 
respectively. Members of the o<2 subgroup differ from those of 
the subgroup in that they replicate more slowly, have a
narrow host cell range and usually remain cell-associated 
(Wildy, 1985). The vast majority of alphaherpesviruses belong to 
the o<2 subgroup and include HSV-1, HSV-2, PRV, BHV-1 and EHV-1, 
whilst the only members of the o(2 subgroup are VZV, Liverpool 
vervet monkey virus, patas monkey herpesvirus and simian 
varicella virus (Honess, 1984). The Betaheroesvirinae. or 
cytomegaloviruses, have a very narrow host range in vitro and in 
vivo (species-specific) and generally replicate best in host 
fibroblast cells in vitro. They have a relatively long 
replication cycle, infected cells may become enlarged 
(cytomegalia) and carrier cultures of infected cells are readily 
established. Infection in adults is usually subclinical but 
severe generalised disease can result in neonates or 
immunocompromised adults of their natural host. They persist in 
a latent form in the salivary gland epithelium, lymphoreticular 
cells, kidneys and other tissues. Members of this subfamily 
include HCMV, equine cytomegalovirus (EHV-2) and herpesvirus 
aotus types 1 and 3 (H. aotus-1 and -3). The Gammaheroesvirinae 
have a very narrow host cell range in vivo and are usually 
restricted to the same family or order as the host they 
naturally infect, and their replication cycle is variable in 
length. All members of this subfamily replicate in 
lymphoblastoid cells and some can cause lytic infection of
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epithelial and fibroblast cells. They immortalise either B 
lymphocytes ( subgroup) or T lymphocytes ( X 2 subgroup) and 
some can cause lymphoproliterative disease in the host eg. HVS 
and MDV. Latent virus can usually be detected in lymphoid tissue 
of the host. Members of the X -j. subgroup comprise EBV and 
related viruses of Old World monkeys and apes, whilst the $ 2 
subgroup includes HVS and viruses of New World monkeys and lower 
vertebrates (Honess, 1984).
Genome Structure as a Subclassification System
The three main features of genome structure which can be 
considered when attempting to group herpesviruses are base 
composition (G+C content), genome size and the arrangement of 
reiterated sequences within the genome (Roizman, 1982). Grouping 
on the basis of G+C content is a rather arbitrary approach. 
However, the base composition of their genomes does show some 
correlation with the biological subgroupings described in the 
previous section. For instance, the 12 herpesviruses with a G+C 
content greater than 60% all belong to the alphaherpesvirus 
subfamily, the betaherpesviruses have a G+C content of 50 to 60% 
whilst the % 2 herpesviruses typically have a G+C content of 
less than 50% (Honess, 1984) . In addition, the ^ 2 
herpesviruses are characterised by possessing genomes of low G+C 
content in their coding sequences with a high G+C content in 
their repeat sequences. Despite the large variations in genome 
size (120 to 240 kilobases [kb]), the only information that can 
be gleaned from this is that the betaherpesviruses possess 
relatively large genomes. The only useful method for grouping on 
the basis of genome structure is by analysis of reiterated
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sequences within the genome, which must consist of at least 100 
base pairs (bp) (Roizman, 1982) . Using this approach, five 
distinct groups, A to E, have been proposed. The genome 
structure of each group is shown diagrammatically in Figure 1.2.
i) Group A
Genomes in this group comprise a unique long sequence (UL) 
which is bounded by a single reiteration of one set of sequences 
in the same orientation at both termini. The sole known member 
of the group is CCV (Chousterman et al.. 1979).
ii) Group B
Group B genomes are also terminally redundant, comprising a 
UL sequence bounded by multiple reiterations of one set of 
sequences in the same orientation at both termini. Members of 
this group include the viruses of non-human primates HVS 
(Bomkamm et al.. 1976), herpesvirus ateles (H. ateles)
(Fleckenstein et al., 1978) and herpesvirus aotus type 2 (H.
aotus-2) (Fuchs et al.. 1985), and the viruses of non-primates 
bovine cytomegalovirus (BHV-4) (Ehlers et al., 1985),
herpesvirus sylvilagus (Medveczkv et al.. 1989) and alcelaphine 
herpesvirus 1 (AHV-1) (Bridgen et_al., 1989). Their genomes
consist of an A+T-rich UL sequence flanked by G+C-rich direct 
terminal repeats. The genomes of HVS and H. ateles are about 
160kb and the direct terminal repeats, which account for about 
one-third of the genome, comprise a variable number of identical 
tandemly repeated sequences of 1444bp and 1600bp, respectively 
(Bomkamm et al. . 1976; Fleckenstein et al.. 1978; Fleckenstein 
and Desrosiers, 1982). The genome of H. aotus-2 is about 151kb 
and its direct terminal repeats comprise two repeat units of 
2.3kb and 2.7kb which are homologous over at least 1.3kb of
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Figure 1.2 Schematic diagram showing the arrangement of 
DNA sequences in the herpesvirus genomes of groups A, B, C, 
D and E. Unique sequences are represented by horizontal 
lines and their possible orientations are indicated by 
arrows. Single repeat sequences are shown as unfilled boxes 
and their orientation is indicated by arrows. The letters 
a, b, c and their complements a', b', c' are also used to 
indicate the orientation of these repeat sequences. 
Multiple tandem repeat sequences (Xn, Yn) are shown as 
vertical lines. The use of Xn and Yn does not imply 
homology between the tandem repeat sequences of different 
herpesviruses. The number of isomers for each genome type 
and examples of herpesviruses that possess such genome 
structures are also indicated.
F I G U R E  1.2 
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their sequences, are tandemly arranged in a random order and 
represent 41kb of sequence (Fuchs et al., 1985). The genome of 
BHV-4 is about 144kb and contains polyrepetitive DNA segments 
composed of about 15 monomeric units of either 1.95kb, 2.35kb or 
2.7kb which are present in a tandem orientation at both genomic 
termini and account for 20 to 25% of the genome (Ehlers et al.,
1985). Herpesvirus sylvilagus has a genome comprising a UL 
sequence of 120kb and direct terminal repeats containing 
tandemly arranged repeat units of 553bp which are variable in 
number (Medveczky et_al., 1989). The genome of AHV-1 (isolate 
WC-11) possesses a 130kb UL sequence and a further 30kb of 
tandemly arranged direct repeats. The major repeat unit is 950bp 
and is interspersed with a smaller number of related sequences 
of different lengths (Bridgen et al.. 1989). Another AHV-1 
isolate, C500, differs from isolate WC-11 in that only one type 
of repeat unit of 1050bp is present (Bridgen et al.. 1989).
iii) Group C
Genomes in this group contain multiple reiterations of one 
set of sequences in the same orientation at both termini in 
addition to a variable number of internal tandem reiterations of 
different sequences. The best studied member of this group is 
the B lymphotropic virus of man, EBV, which possesses a genome 
of about 172kb in length. The direct terminal repeats are about 
0.5kb and there are 4 to 8 copies at each terminus. The genome 
is divided into long (UL) and short (Ug) unique regions by up to 
12 internal direct sequence repeats of 3kb (Given and Kieff, 
1979) . The complete DNA sequence of the B95-8 strain of EBV has 
revealed the presence of many other repeat sequences distributed 
throughout the genome (Baer et al. . 1984). The other members of
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this group are the primate B lymphotropic viruses herpesvirus 
papio (HV papio) (Heller et al.. 1981) and herpesvirus pan (HV 
pan) (Heller et al.. 1982), whose genomes are similar in size 
and organisation to that of EBV.
iv) Group D
Examples of viruses possessing a group D genome are PRV, 
EHV-1, equine herpesvirus 3 (EHV-3), EHV-4, VZV and BHV-1. Their 
genomes comprise two covalently linked segments, L (long) and S 
(short). L is a unique sequence (UL) and S consists of a unique 
sequence (Us) bounded by inverted repeats, namely an internal 
repeat (IRS) and a terminal repeat (TRS) . The L segment is in a 
fixed orientation but the S component can invert relative to L, 
thus giving rise to two isomeric forms of the genome.
Such a genome structure was deduced by electron microscopic 
studies of self-annealed single strands of the DNA of PRV 
(Stevely, 1977; Ben-Porat et al. . 1979), EHV-1 (Ruyechan et_al.,
1982), EHV-3 (Atherton et al.. 1982), EHV-4 (Cull inane et_al.,
1988) and VZV (Ecker and Hyman, 1982). Single strands of DNA 
reannealed to form a single-stranded loop (the Us region) at one 
end of a double-stranded region (the reannealed repeats), with a 
long segment of single-stranded DNA (the UL region) emerging 
from the other end of the double-stranded region. The existence 
of two isomeric forms of the genome was shown by cleavage of 
genomic DNA with a restriction endonuclease that cleaves only 
within UL and Us and not within the repeat sequences. Such 
analysis yielded four 0.5 molar (M) fragments (relative to the 
molarity of intact DNA) and revealed the presence of three 
terminal fragments of which two are present in 0.5M 
concentrations and are located at the ends of the S region,
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whilst the other is present at a concentration of 1M. This 
indicated that the S segment can invert to give two terminal 
fragments, whilst the L segment is fixed and yields only one 
terminal fragment (Dumas et al., 1981; Henry et al.. 1981;
Whalley et al.. 1981; Atherton et al.. 1982). Variant strains of 
PRV have been reported whose genomes contain a sequence at the 
left end of the L component that has been translocated to the 
right end of the L component next to the inverted repeat, IRS. 
Such strains have thus acquired a genome in which both the L and 
S components can invert relative to each other, giving rise to 
four isomeric forms (see Group E, below). This was first 
demonstrated with the Norden vaccine strain of PRV (Lomniczi et 
al., 1984a), and the nucleotide sequence of regions of the 
genome of three strains with an invertible L component that 
contain the translocated segment has been determined (Lu et al., 
1989). It was concluded that the size of the translocated 
fragments is fairly similar (1.3kb to 1.4kb) and the 
translocation of such sequences is accompanied by the deletion 
of sequences from the right end of the L component which ranged 
from 0.8kb to 2.3kb. Similarly, the genome of VZV has been shown 
to contain an inverted repeat sequence of 88.5bp from the left 
end of the L segment which is also present at the L-S junction, 
and about 5% of virion DNA contains an invertible component 
(Davison, 1984). However, since the reiterated sequence is less 
than the lOObp minimum required for classification purposes 
(Roizman, 1982), the VZV genome remains classified as a group D 
member,
v) Group E
Group E genomes are exemplified by the extensively
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characterised members of the Herpesviridae. HSV-1 and HSV-2. HSV 
DNA exists as two covalently linked components, L and S. L 
consists of a unique long sequence (UL) bounded by inverted 
repeats (IRL, TRL) and S comprises a unique short sequence (Us) 
bounded by inverted repeats (IRS, TRg). The L and S components 
can both invert relative to each other and DNA extracted from 
wild-type virions consists of a mixture of four equimolar 
isomers differing in the relative orientations of L and S, 
designated prototype (P), inversion of S (Is), inversion of L 
(IL) and inversion of both S and L (Igi,) components (Hayward et 
al.. 1975; Roizman, 1979).
The elucidation of the genome structure was accomplished by 
electron microscopic studies of self-annealed single strands of 
HSV DNA (Sheldrick and Berthelot, 1975) . Upon reannealing, 
single strands formed two single-stranded loops of unequal size 
(corresponding to UL and Us) bridged by a double-stranded 
region (the reannealed inverted repeats), resulting in a barbell 
structure. The reiterated sequences bracketing the L component 
(IRl, TRl) each account for about 6% of the total DNA. 
Similarly, reiterated sequences bracketing the S component (IRS, 
TRS) each represent 4.3% of the total DNA. Such conclusions were 
arrived at by measurement of the double-stranded regions formed 
by self-annealing of single strands and by partial denaturation 
studies of intact molecules (Wadsworth et al.. 1975). That the L 
and S components can invert relative to each other was 
demonstrated by the use of restriction endonucleases that cleave 
only within UL and Us and not within the inverted repeats. 
Cleavage of the P isomer of HSV-1 DNA in this way (Roizman, 
1979) produces three sets of fragments. The first set comprises
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four terminal fragments, each present in 0.5M concentrations 
relative to the molarity of intact DNA. The second set consists 
of four fragments spanning the L-S junction which are each 
present at a 0.25M concentration, and the third set contains 1M 
fragments which are situated between the terminal and junction 
fragments. The generation of three sets of fragments in this way 
is consistent with the assortment of the L and S components at 
random relative to each other (Hayward et al.. 1975).
Bovine mammillitis virus (BHV-2) was the first non-human 
herpesvirus shown to have a similar genome arrangement to HSV 
(Buchman and Roizman, 1978a,b) . Other members of this group 
include HCMV (Weststrate et al.. 1980), MDV and its closely 
related counterpart HVT (Cebrian et_al., 1982), and the primate 
herpesviruses H. aotus-1 and -3 (Ebeling et al.. 1983).
Limitations of Subclassification Methods
Although subclassification on the basis of biological 
properties is considered as the dominant criterion for the 
grouping of herpesviruses (Roizman, 1982) and the vast majority 
have been assigned to three such subgroups, there exist numerous 
herpesviruses which have not been assigned to any such subgroup 
eg. black stork herpesvirus (Kaleta et al., 1980) . In a similar 
vein, the majority of herpesviruses have not been assigned to 
any of the groups A to E on the basis of genome structure eg. 
guinea pig cytomegalovirus (Nayak, 1971). Of particular 
significance is the fact that subclassification of some 
herpesviruses by biological properties has been directly 
contradicted by analysis of their genome structure. For example, 
whilst BHV-4 was originally classified as a betaherpesvirus
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since it had a comparable pathobiology with the 
cytomegaloviruses of other species (Storz et al., 1984),
analysis of its genome structure revealed that it has a similar 
arrangement to those of the $2 herpesviruses HVS, H. ateles and 
H. aotus-2 (Ehlers et al., 1985) . MDV and the closely related 
HVT were originally classified as 2 herpesviruses mainly due 
to their tropism for lymphocytes (Roizman, 1982), but electron 
microscopic studies revealed that they possess a similar genome 
structure to HSV (Cebrian et al., 1982) . Furthermore, the
mapping and sequencing of numerous genes from these two viruses 
shows that they are more homologous to the alphaherpesviruses 
HSV and VZV than to the gammaherpesvirus EBV, and their genomes 
appear to be colinear with that of VZV at least within UL 
(Buckmaster et al. . 1988). Thus, as the DNA sequence and genome 
structure of more herpesviruses comes to light, more importance 
may be placed on genome structure and gene conservation as a 
suitable criterion for the subclassification of herpesviruses.
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HERPESVIRUS GLYCOPROTEINS
General Description
The membrane glycoproteins play major roles in the early 
stages of viral infection and are important in determining the 
biological and pathogenic properties of the virus (for review 
see Spear, 1984) . They are exposed on the surfaces of the virion 
envelope and membranes of infected cells and are targets for 
both humoral and cellular immune responses. They are involved in 
the recognition, adsorption and penetration of virus into 
susceptible host cells, mediate the cell-to-cell spread of 
infection by cell fusion and play a role in the envelopment and 
release of progeny virus from infected cells. Furthermore, 
glycoproteins are associated with the expression of receptors 
for the C3b component of complement and the Fc region of 
immunoglobulin G (IgG) by the virus-infected cells.
The following sections describe the basic structure of 
glycoproteins, review the advances made in the identification of 
the glycoproteins of HSV and describe their roles in the 
infectious process. Finally, glycoproteins specified by other 
herpesviruses and their relation to those of HSV is reviewed.
Glycoprotein Structure
The advent of recombinant DNA technology has brought about 
major advances in the determination of glycoprotein structure. 
Much information on the domains of virus glycoproteins has been 
obtained from the study of a number of non-herpesvirus membrane- 
bound glycoproteins, such as the G protein of vesicular 
stomatitis virus (VSV) (Schlesinger and Schlesinger, 1987).
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Subsequent studies of the glycoproteins of HSV led to the 
conclusion that they are similar in structure and adopt an 
orientation in membranes similar to the VSV G protein.
Viral glycoproteins consist of four distinct domains: the
signal sequence, surface, transmembrane and cytoplasmic anchor 
domains. The signal sequence, which is located at the amino- 
terminus of the molecule, plays a central role in the process of 
protein export as defined by the signal hypothesis (Blobel and 
Dobberstein, 1975). Most exported proteins, which include 
membrane-bound glycoproteins and secreted proteins, are 
synthesised by membrane-bound ribosomes on the rough endoplasmic 
reticulum (RER) and the signal sequence serves to attach the 
nascent peptide to the membranes of the RER. The signal sequence 
then initiates export of the growing protein chain across the 
membrane of the RER. Upon emergence of the nascent peptide from 
the ribosome, the polypeptide-ribosome complex interacts with a 
cytosolic nucleoprotein called the signal recognition protein 
(SRP), leading to a rapid decrease or even total arrest of 
translation (Walter and Blobel, 1981). After this structure is 
presented to the surface of the RER it associates with the SRP- 
receptor or 'docking protein' (Gilmore et al. . 1982; Meyer et 
al.. 1982), resulting in the displacement of the SRP from the
polypeptide chain and thus facilitating the subsequent 
translocation of the protein across the membrane of the RER. 
During translocation the signal sequence interacts with at least 
two more membrane components, the signal sequence receptor 
(Wiedmann et al., 1987) and the signal peptidase (von Heijne,
1984). The signal peptidase cleaves the signal sequence at a 
specific site consisting of three amino acids. The mature
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protein is then incorporated into the plasma membrane of the 
cell, whilst secreted proteins are released into the surrounding 
medium. Thus, the signal sequence serves to export the protein 
across the membranes of the RER and to insert the protein into 
the plasma membrane of the cell. The largest domain is the 
surface domain which is oriented such that it is exposed on the 
outer surface of the plasma membrane. This domain is hydrophilic 
and contains antigenic sites against which virus neutralising 
antibodies are directed. Additionally, sites at which both N- 
linked and 0-1inked oligosaccharides are added reside in this 
domain. Potential N-linked glycosylation sites are defined by 
the consensus sequence Asn-X-Ser/Thr (Hubbard and Ivatt, 1981) 
where X is any amino acid except proline, with oligosaccharides 
being added to the Asn residue of this motif. The hydrophobic 
transmembrane domain is located towards the carboxyl-terminus 
and spans the lipid bilayer, being oriented such that the small 
hydrophilic cytoplasmic domain at the carboxyl-terminus projects 
into the cytoplasm. The cytoplasmic domain is highly charged and 
anchors the glycoprotein into the membrane.
Glycoproteins Specified bv HSV
The existence of four major, antigenically distinct 
glycoprotein species in the envelope of HSV-1 and the plasma 
membrane of HSV-l-infected cells has been known for some time 
(Spear, 1976; Baucke and Spear, 1979; Norrild, 1980). These 
species were designated gB, gC, gD and gE. More recently, the 
use of monoclonal antibody techniques and DNA sequence analysis 
has allowed the characterisation of a further three minor 
species, namely gG, gH and gl. Thus HSV-1 encodes at least seven
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glycoproteins, and homologues of all these glycoproteins have 
been detected in HSV-2. The determination of the DNA sequence of 
HSV-1 has identified the genes which specify the glycoproteins 
mentioned above (McGeoch et al.. 1985, 1988a). This analysis has 
identified another, as yet uncharacterised, potential 
glycoprotein which is encoded by gene US5 (McGeoch et al.,
1985). The vast majority of work regarding HSV glycoprotein 
function has been carried out on HSV-1. The following 
description of individual glycoprotein function is therefore 
biased towards HSV-1, with occasional reference being made to 
their HSV-2 counterparts.
Functions of HSV Glycoproteins
Of the seven characterised glycoproteins of HSV, the 
structural genes for three of them are located within the UL 
component of the genome (gB, gC and gH) , whilst the remaining 
four species are encoded by the Us region (gD, gE, gG and gl).
i) Glycoprotein B fqB)
gB is one of the most extensively characterised 
glycoproteins of HSV and the DNA sequence of the gene encoding 
gB has been determined for both HSV-1 (Bzik et al., 1984a?
Pellett et al.. 1985b) and HSV-2 (Bzik et al.. 1986; Stuve et 
al., 1987). gB was the first glycoprotein shown to be required 
for virus infectivity (Sarmiento et al., 1979). That gB is 
indeed essential for viral entry and the production of 
infectious virus was shown by the study of the gB temperature- 
sensitive mutants tsB5 (Manservigi et al., 1977) and tsJ12
(Little et al.. 1981). Such mutants replicate normally at 34°C 
but at 39°C virus produced is non-infectious due to inhibition
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of virus penetration, and these mutants are unable to fully 
glycosylate the major gB precursor to the mature form 
(Manservigi et al.. 1977; Sarmiento et al.. 1979; Little et al., 
1981). Since these non-infectious mutant viruses can bind to 
cells and treatment of cell-adsorbed mutant virus with the 
membrane-fusing agent polyethylene glycol greatly enhances virus 
infectivity (Sarmiento et al.. 1979; Little et al.. 1981), the 
defect in these mutants is in the membrane fusing activity 
required for viral penetration. Therefore, gB has a role in such 
a membrane-fusing activity required for viral entry.
The role of gB in cell fusion was studied using the tsB5 
mutant virus which, in addition to being temperature-sensitive, 
is also syncytial (Manservigi et al., 1977) . This ability to 
promote fusion of infected cell membranes is due to a syncytial 
mutation in the gB gene as mapped by DeLuca et al. (1982) . tsB5 
enters cells more rapidly at 30°C than does the wild-type KOS 
strain. The mutation responsible for this fast-entry phenotype 
also maps within the gB gene and is separate from the syncytial 
and temperature-sensitive mutations (DeLuca et al.. 1982). DNA 
sequencing subsequently revealed that these phenotypes arise due 
to point mutations in the gB gene of tsB5, with the 
substitutions valine-to-alanine at residue 552 and arginine-to- 
histidine at residue 857 of the gB protein relative to KOS 
accounting for the fast-entry and syncytial phenotypes, 
respectively (Bzik et al.. 1984b). This places the syncytial 
mutation in the cytoplasmic domain of the protein. In addition, 
the temperature-sensitive lesions for two mutants defective in 
accumulation of gB and viral growth, tsJ12 and tsJ20, are also 
the result of point mutations in the gB sequence, resulting in
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an arginine-to-cysteine substitution at residue 376 for tsJ12 
and a valine-to-isoleucine substitution at residue 272 for tsJ20 
(Bzik et al., 1984a).
It has been shown by the use of gB-defective mutants which 
fail to synthesise gB as a transmembrane protein that gB is not 
essential for viral assembly and nucleocapsid envelopment (Cai 
et al.. 1987).
ii) Glycoprotein C (a C )
Together with gB and gD, gC is a prominent and highly 
immunogenic antigen on the surface of virions and HSV-1- 
infected cells (Glorioso et al.. 1983, 1984). The gC gene of 
HSV-1 (gC-1) has been mapped and sequenced (Frink et al., 1983)
and its HSV-2 counterpart, gC-2, has also been mapped (Zezulak 
and Spear, 1984) and sequenced (Dowbenko and Lasky, 1984). A 
number of discrete functions have been assigned to gC. It is 
not essential for virus growth in tissue culture since a number 
of viral mutants that fail to produce gC-1 have emerged (Holland 
et al.. 1983a, 1984b), and an HSV-2 mutant that fails to
synthesise gC-2 has also been reported (Zezulak and Spear, 
1984). An interesting observation regarding such mutants is that 
they are also associated with a syncytial phenotype and it has 
previously been suggested that the inability to express gC may 
be directly responsible for the syncytial phenotype (Manservigi 
et al.. 1977). However, this was shown not to be the case for 
the strain HSV-1 (MP), when insertion of the gC-1 gene into the 
locus specifying the thymidine kinase (TK) gene resulted in the 
successful expression of gC-1 without altering the syncytial 
phenotype (Lee et al., 1982b) . It thus seems likely that there 
exists some, as yet, undefined relationship between the gC-
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negative and syncytial phenotypes. The fact that such mutant 
strains exhibit a syncytial plaque morphology suggests that gC 
may inhibit cell fusion, and it seems likely that gC influences 
virus infectivity and virulence by inhibiting gB-promoted cell 
fusion between host cell and virion membrane (Epstein et al.,
1984) and between infected cells (Manservigi et al., 1977).
Endothelial cells infected with HSV-1 develop receptors for 
the C3b component of complement and it has been demonstrated 
that gC-1 does indeed form part of, or act as, such a receptor 
(Friedman et al.. 1984). This study showed that a gC-negative 
mutant could not express C3b receptors and monoclonal antibodies 
against gC-1 were found to block C3b-binding activity. The 
mutant which failed to express gC-1, and therefore could not 
express C3b receptors, was shown to be viable, thus suggesting 
that receptor activity is not essential for HSV-1 replication in 
cell culture. It has recently been reported that the C3b 
receptor is expressed on cells transfected with the gC-1 and gC- 
2 genes (Seidel-Dugan et al.. 1988) and that purified gC-1 and 
gC-2 can both bind complement component C3b (Eisenberg et al.,
1987). It has been been demonstrated by the use of monoclonal 
antibodies directed against cell-derived gC-1 that the central 
segment of gC-1 is not involved in C3b binding (Huemer et al.,
1989). All three monoclonal antibodies recognised sites in the 
central third of the molecule (which is hydrophobic and non­
glycosylated) although none of them affected C3b binding to gC- 
1, which is a glycosyl at ion-dependent process. Marlin et al. 
(1985) identified two major antigenic sites in gC-1 by using 
monoclonal antibodies specific for gC-1. Site I is thought to be 
located in the carboxyl-terminal half of the molecule, whilst
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site II probably resides in the amino-terminal half which 
contains a clustering of sites for N-lihked glycosylation. 
Monoclonal antibodies against sites I and II directly block C3b 
binding by gC-1 (Friedman et al.. 1986). These independent 
studies suggested that only the amino- and carboxyl-terminal 
segments of gC-1 are involved in the binding of the C3b 
component of complement,
iii) Glycoprotein D (aD)
The gD genes of HSV-1 and HSV-2 have been successfully 
mapped and were the first HSV glycoprotein genes to be 
sequenced (Lee et al.. 1982a? Watson et al.. 1982; Watson,
1983) . The role of HSV-1 gD in the infectious process has been 
widely studied. The first function assigned to gD was that of 
promoting the fusion of infected cells, as was shown by the 
ability of anti-gD monoclonal antibodies to inhibit HSV-1-
induced cell fusion (Noble et al. , 1983). A role in virus 
attachment to cells was demonstrated by the use of monoclonal
antibodies specific for gD which inhibited adsorption (Fuller
and Spear, 1985). Such a role was also suggested by Johnson et 
al. (1984) who demonstrated that liposomes containing gD were 
able to bind cells. However, gD is not essential for adsorption 
as mutant viruses lacking gD can still adsorb to cells (Ligas 
and Johnson, 1988). However, gD is essential for viral 
penetration of cells and therefore indispensable for virus 
infectivity, since mutant viruses lacking gD are unable to 
penetrate cells (Ligas and Johnson, 1988). gD is a very abundant 
and immunogenic component of the HSV virion, being a primary 
target for virus neutralising antibodies (Cohen et al. . 1984;
Para et al.. 1985). Such neutralising antibodies are thought to
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inhibit virus penetration of the cell surface membrane 
(Highlander et al., 1987). Further evidence that gD plays an 
important role in the viral penetration of infected cells was 
provided by experiments which showed that some anti-gD 
monoclonal antibodies block HSV-1 infection by inhibiting fusion 
of the virus and cell at the cell surface, although adsorption 
remained unaffected (Fuller and Spear, 1987). Cell lines that 
express gD have been shown to inhibit the penetration of HSV-1 
but not virus adsorption to cells (Campadelli-Fiume et al.,
1988). Similar conclusions by Johnson and Ligas (1988) led to 
the proposal of a model by which gD promotes viral penetration. 
They showed that pretreatment of cells with ultraviolet (UV)- 
inactivated virions containing gD rendered them resistant to 
infection with HSV-1 and HSV-2, whilst pretreatment with UV- 
inactivated virions lacking gD resulted in successful infection, 
and the prior addition of infectious HSV-1 to UV-inactivated 
virions containing gD also resulted in the successful entry and 
replication of infectious virus. On the basis of these results, 
it was proposed that virions containing gD bind a set of cell 
surface receptors which are limited in number, thus promoting 
viral penetration (Johnson and Ligas, 1988). Since virions 
lacking gD were unable to bind these receptors, it is apparent 
that gD is an essential receptor-binding polypeptide,
iv) Glycoproteins E (gE) and I (al)
In addition to expressing receptors for the C3b component 
of complement, virions and cells infected with HSV-1 and HSV-2 
also express receptors which have affinity for the Fc domain of 
IgG. gE is present on the surface of virions (Para et al.. 1980) 
and of infected cells (Baucke and Spear, 1979) . gE has been
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implicated as being a component of the Fc receptor as 
solubilised HSV-1 gE (gE-1) and HSV-2 gE (gE-2) have Fc-binding 
activity (Baucke and Spear, 1979; Para et al.. 1982b).
Furthermore, anti-gE-1 antiserum can neutralise virus 
infectivity in the presence of complement and the F(ab/)2 
fragments of this antiserum partly block the Fc-binding activity 
of HSV-l-infected cells (Para et al., 1982a). Support for gE as 
the Fc receptor was provided by analysis of mutant viruses 
devoid of gE, which were unable to express Fc receptors 
(Neidhardt et al.. 1987). The gene for HSV-1 gE has been mapped 
to the Us component of the genome (Lee et al.. 1982a? Para et 
al., 1982b) and sequenced (McGeoch et al., 1985). Para et al.
(1982b) identified the antigenically related gE glycoprotein of 
HSV-2 in infected cell extracts and its gene has been partially 
sequenced (McGeoch et al.. 1987).
More recently, a minor glycoprotein distinct from gE was 
detected. Longnecker et al. (1987) identified a monoclonal 
antibody specific for the product of HSV-1 gene US7 (McGeoch et 
al., 1985) which was then used to characterise the gene product, 
.a glycoprotein designated gl. In a similar vein, a novel 
glycoprotein (g70) which binds human or rabbit IgG in 
conjunction with gE was identified, and it was proposed that g70 
forms a complex with gE which binds IgG and that gE alone cannot 
bind IgG (Johnson and Feenstra, 1987) . Further studies with a 
monoclonal antibody specific for g70 revealed that this 
glycoprotein is encoded by gene US7 and is therefore identical 
to gl (Johnson et al., 1988a) . This monoclonal antibody could 
precipitate gl and a fraction of gE from infected cell extracts 
and rabbit IgG could precipitate such a complex from cells
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harbouring a plasmid containing a HSV-1 fragment encompassing 
the genes for gE and gl (Johnson et al.. 1988a). Rabbit IgG
could not bind cells infected with mutant viruses which do not 
express gE or gl whereas cells coinfected with mutant viruses, 
one of which failed to express gE and one of which failed to 
express gl, were able to bind IgG to a similar level as wild- 
type virus (Johnson et al.. 1988a). These studies demonstrated 
that gE and gl form a complex which binds to the Fc domain of 
IgG and that neither gE or gl alone can bind IgG. Both gE 
(Longnecker and Roizman, 1986) and gl (Longnecker et al., 1987)
are deletable genes that are not essential for viral growth in 
tissue culture. Neidhardt et al. (1987) also showed that mutant 
viruses lacking gE are viable, being able to replicate to a 
level only slightly lower than wild-type virus. It has recently 
been reported that gE may have a role in the induction of 
infected cell fusion, since it was shown that a monoclonal 
antibody against gE inhibits syncytium formation in human cells 
by HSV-1 and a mutant devoid of gE failed to induce syncytium 
formation in tissue culture (Chatterjee et al.. 1989).
v) Glvcoorotein G (gG)
This minor glycoprotein was originally identified in HSV-2 
by Marsden et al. (1984) who named it g92K and mapped its gene 
to the Us component in a genomic region distinct from gD and gE. 
Ruyechan et al. (1979) mapped a 124 kilodalton (kDa) 
glycoprotein to a genomic region between 0.65 and 0.70 map units 
(m.u.) and named it gC, but it was subsequently found that this 
mapping was incorrect and the 124kDa protein was remapped to the 
Us component and renamed gG-2 (Roizman et al., 1984) . The map 
locations of the 92kDa and 124kDa proteins suggested that they
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are the same species and the size anomaly was attributed to the 
use of different gel systems for resolving proteins. Although it 
was originally thought that HSV-1 did not encode a gG-2 
homologue, the sequence of the Us component of the HSV-1 genome 
revealed that gG-1 was potentially encoded by gene US4 (McGeoch 
et al.. 1985). Subsequently, the HSV-2 gG-2 sequence was
determined and it was demonstrated that HSV-2 US4 actually 
encodes gG-2 by the use of antiserum raised against a 
dodecapeptide representing amino acids near the carboxyl- 
terminus of the HSV-2 US4 gene product (McGeoch et al., 1987) .
However, very little is known about the precise functions 
of gG in the infectious process. Anti-gG-1 antibody can 
neutralise virus infectivity in the presence of complement 
(Sullivan and Smith, 1987) and gG-1 is the target of monoclonal 
antibodies (Ackermann et al. . 1986). The gene for gG (US4) is 
dispensable for growth in tissue culture (Longnecker et al., 
1987? Weber et al.. 1987) and the US4 gene may be involved in 
viral pathogenesis in the central nervous system of mice (Weber 
et al.. 1987).
vi) Glycoprotein H (gH)
This minor glycoprotein species was first identified in 
HSV-l-infected cells and purified virions as a HOkDa protein 
which was recognised by monoclonal antibody 52S (Showalter et 
al., 1981). A neutralising monoclonal antibody (LP11) was shown 
to precipitate a glycoprotein similar to that precipitated by 
52S (Buckmaster et al.. 1984). The gene for this glycoprotein 
was mapped by the use of intertypic recombinants (Buckmaster et 
al., 1984) and by marker transfer studies (Gompels and Minson, 
1986) to the left of the gene coding for TK between map
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coordinates 0.27 and 0.31. The HOkDa protein was named gH-1 
(Buckmaster et al., 1984) and the DNA sequence of its gene
determined (Gompels and Minson, 1986; McGeoch and Davison,
1986).
A number of important roles have been assigned to gH. It 
can elicit the production of complement-mediated neutralising 
antibodies (Showalter et al.. 1981; Buckmaster et al.. 1984).
Unlike most other neutralising antibodies, those specific for gH 
can inhibit plaque formation and thus the transfer of virus from 
infected to uninfected cells by syncytial or non-syncytial HSV-1 
strains (Buckmaster et al.. 1984; Gompels and Minson, 1986). It 
was thus inferred that gH has a role in virus release from 
infected cells or in the formation of intercellular junctions 
between cells and, consequently, the cell-to-cell spread of 
virus. A temperature-sensitive mutant of HSV-1, tsQ26, has been 
isolated (Chu et al.. 1979) and the mutation mapped to a
specific genomic fragment shown to reside within the coding 
sequence of gH (McGeoch and Davison, 1986). This mutant has an 
amino acid substitution in gH (Desai et al.. 1988).
Investigation of the phenotype of this mutant by Desai et al. 
(1988) revealed that at the non-permissive temperature the virus 
could enter cells and replicate to yield near normal levels of 
infectious virus, but intracellular virions contained an 
immature form of gH and no gH was expressed on the surface of 
infected cells. Virus particles excreted by these cells were 
devoid of gH and not infectious, whereas virus particles 
excreted at the permissive temperature were infectious and 
contained gH. The temperature-sensitive phenotype occurred due 
to the loss of gH from virions during transport to the cell
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surface and resulted in a loss of infectivity. Thus gH was shown 
to be essential for virus infectivity. Furthermore, it was 
recently reported that three neutralising monoclonal antibodies 
specific for gH were able to block viral penetration without 
inhibiting adsorption of virus to cells, which supports the 
essential role of gH, like both gB and gD, in viral penetration 
of infected cells (Fuller et al.. 1989).
Glycoproteins Specified bv PRV
Five envelope glycoproteins (gl, gll, gill, gIV and gV), in 
addition to the glycoprotein gX which is not incorporated into 
virions, have been defined for PRV (Hampl et al., 1984) . The
genes for six glycoproteins have been mapped and sequenced. The 
first glycoprotein gene to be sequenced was that for gX, a
secreted glycoprotein, which was mapped to the Us component of 
the genome and was shown to be antigenically distinct from, and 
not a proteolytic cleavage product of, any of the envelope 
glycoproteins (Rea et al.. 1985). The gene for gp50, a minor 
species in the envelope, has been mapped to Us (Wathen and 
Wathen, 1984). This glycoprotein is unusual in that it is not N-
glycosylated (Petrovskis et al.. 1986a) and determination of the
DNA sequence of its gene indicated that it shows some homology 
to HSV-1 gD (Petrovskis et al., 1986a) . It is not known whether 
gp50 corresponds to the gIV or the gV species defined above. The 
gill gene has been mapped to the component (Robbins et al., 
1984; Wathen and Wathen, 1986) and sequenced (Robbins et al.. 
1986a) . gill is a major glycoprotein species and is the 
homologue of HSV-1 gC. The gene for gl was mapped by
hybridisation-selection, in vitro translation and
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immunoprecipitation techniques to the region 0.86 to 0.89 m.u. 
within Us (Mettenleiter et al., 1985a). The gene encoding the 
glycoprotein complex gll was mapped to UL (Mettenleiter et al.,
1986) and subsequent sequencing analysis revealed that gll 
shows strong homology to HSV-1 gB (Robbins et al.. 1987) . gll is 
the species corresponding to that identified by Lukacs et al. 
(1985) as a disulphide-linked dimer. Petrovskis et al. (1986c) 
used the ^gtll system described by Young and Davis (1983a,b) to 
isolate two genes encoding glycoproteins. Mapping studies 
revealed that one of these genes was identical to the previously 
mapped glycoprotein gene for gl whilst the other was a 
previously unidentified species, named gp63. The gl and gp63 
species mapped adjacent to each other within Ug and the DNA 
sequence of these genes revealed that gl shares homologous 
sequences with HSV-1 gE and gp63 is the homologue of HSV-1 gl. 
All PRV glycoproteins identified to date have homologues in HSV, 
with the exception of gX which is secreted into the medium of 
infected cells and appears to be unique to PRV.
Functions of PRV Glycoproteins
The best studied PRV glycoprotein is gill, the HSV-1 gC 
homologue, which has been shown to be multifunctional. A role 
for gill in adsorption was first suggested by Hampl et al. 
(1984) who demonstrated that monoclonal antibodies against gill 
can neutralise PRV in vitro by blocking adsorption of virus to 
cells. Using such gill-specific monoclonal antibodies, mutant 
viruses containing a deletion in the gill gene were isolated, 
and these mutant viruses were able to successfully propagate in 
tissue culture, implying that gill is not essential for viral
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growth in vitro (Robbins et al., 1986b). However, gill is 
required for efficient viral growth since glll“ mutants grow 
much more slowly than wild-type virus (Whealy et al., 1988). Two 
mutant viruses isolated which were resistant to neutralisation 
by gill-specific monoclonal antibodies were also shown to be 
associated with a syncytial phenotype. Such mutants either did 
not express gill or only expressed a truncated form (Wathen and 
Wathen, 1986). It therefore appears that gill inhibits cell 
fusion. It was confirmed that gill has an important role in the 
adsorption process as gill” mutants are much less readily 
adsorbed to cells, producing a lower yield of infectious virus 
(Schreurs et al.. 1988). Since gill” mutants are still
infectious, it was suggested that the adsorption of virus to 
cells can also occur by another slower, gill-independent process 
(Schreurs et al., 1988), a proposal which was later confirmed in 
further studies which showed that this occurs by interaction 
with a cellular heparin-like receptor (Mettenleiter et al.,
1990). gill is also thought to have a role in virus release from 
infected cells (Schreurs et al.. 1988). Thus, like HSV-1 gC, 
gill is not essential for viral growth and inhibits cell fusion. 
However, no evidence exists that gill can bind to the C3b 
component of complement as does HSV-1 gC, and by the same token 
HSV-1 gC has not been shown to play a role in virus adsorption 
to cells and virus release as has been suggested for gill.
It is known that gX, which accumulates in large amounts in 
the medium of infected cells, is not essential for viral growth 
in tissue culture (Thomsen et al.. 1987). Since mutant viruses 
lacking gX are highly virulent (Thomsen et al.. 1987) and PRV 
can still kill animals in the presence of anti-gX antibodies, it
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appears that gX does not contribute to PRV virulence. No 
specific functions for gX have yet been elucidated.
Very little is understood about the precise functions of 
gll and gp50. It appears that both gll and gp50 are involved in 
viral entry as antibodies specific for these species inhibit the 
penetration of adsorbed virus (Zuckermann et al.. 1989). Such a 
role for these glycoproteins seems feasible in view of the fact 
that their HSV-1 homologues, gB and gD, also play a major role 
in viral penetration. gp50 is important in the immune response 
to viral infection in as much as monoclonal antibodies specific 
for gp50 can protect mice from virus challenge (Wathen et al.,
1985) and it can elicit the production of complement-independent 
virus neutralising antibodies (Wathen and Wathen, 1984) .
PRV gl has been demonstrated to play a major role in virus 
release and contributes to PRV virulence. Such functions were 
deduced from the the study of vaccine strains of PRV. Two such 
strains, Norden and Bartha, have deletions in Ug (Lomniczi et 
al., 1984a). Genes deleted from this region are necessary for
virulence and the Bartha strain is also defective in other genes 
necessary for the expression of virulence (Lomniczi et al.. 
1984bj . In a similar vein, Bems et al. (1985) demonstrated that 
genes responsible for virulence are located within Ug, and three 
avirulent strains of PRV contain a deletion in Ug and/or TRg 
that results in no expression of gl and a 40kDa polypeptide 
(Mettenleiter et al.. 1985b). The deletion in the Norden strain 
deletes all the gl coding region but gp63 coding sequences 
remain intact, although a modified form of gp63 is produced 
in infected cells (Petrovskis et al., 1986b) . In the Bartha 
strain, the deletion removes all the gl coding region and all
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but 89 amino acids of the gp63 coding sequence, and no gl or 
gp63 is detected in infected cells (Petrovskis et al., 1986b).
Restoration of an intact Us to the Bartha strain increases the 
extent of virus release and the size of plaques formed on rabbit 
kidney cells (Ben-Porat et al., 1986b). Mettenleiter et al. 
(1987a) investigated whether gl or gp63 plays a role in virus 
release by introducing deletions into the genomes of wild-type 
virus and a rescued Bartha strain ie. one which has an intact Us 
restored. These deletions abolished gl or both gl and gp63 
expression. Deletion mutants of the wild-type virus defective in 
gl or gl and gp63 showed similar levels of virus release and 
plaque size as wild-type virus on rabbit kidney cells, whereas 
the rescued Bartha strain with a deleted gl caused a large 
decrease in virus release and plaque size. Thus a role for gl in 
virus release was demonstrated, although this function was in 
conjunction with another viral function which was present in 
wild-type virus but absent from the Bartha strain. Only when 
this viral function is absent is gl essential for virus release, 
gl plays a vital role in virulence with the aid of other viral 
genes which are absent from the Bartha strain (Mettenleiter et 
al.. 1987b). gl and gp63 are noncovalently linked to each other, 
though this complex does not possess Fc receptor activity as 
does its homologue, the gE-gl complex of HSV-1 (Zuckermann et 
al., 1988).
Glycoproteins of VZV
VZV specifies six to eight glycoproteins that are 
expressed on the surface of virions and virus-infected cells 
(Shemer et al.. 1980; Grose et al.. 1981). On the basis of their
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serological reactivity with monoclonal antibodies, these 
glycoproteins have been divided into four distinct groups in 
accordance with a new common nomenclature (Davison et al.,
1986). Analysis of the complete DNA sequence of the VZV genome 
has identified the genes encoding gpl to gpIV and a further 
glycoprotein gene, gpV (Davison and Scott, 1986a). However, 
determination of the exact functions of these species in the 
infectious process has been hampered by difficulties with the in 
vitro growth of VZV.
gpl, gpll and gpIII are the major glycoprotein species 
specified by VZV. gpl is the most abundant and immunogenic 
species (Keller et al.. 1984) and stimulates the production of 
antibodies which neutralise virus infectivity in vitro in the 
presence of complement (Forghani et al.. 1984; Keller et al.. 
1984). The gene for gpl has been mapped to the right end of Us 
(Ellis et al.. 1985) and shows limited homology to HSV-1 gE
(Davison and McGeoch, 1986).
The gpll glycoprotein has been resolved as polypeptides in 
two size ranges, 115kDa to 140kDa and 57kDa to 66kDa, is the 
second most abundant and immunogenic species (Keller et al.. 
1984) and can elicit the production of complement-dependent and 
complement-independent virus neutralising antibodies (Keller et 
al., 1984? Edson et al.. 1985; Wroblewska et al.. 1985). Cross­
reactive monoclonal antibodies have been isolated that recognise 
both a 63kDa species of gpll and HSV-1 gB, implying that these 
molecules share common antigenic epitopes (Edson et al., 1985).
Mature gpll migrates as a doublet of about 60kDa under reducing 
conditions but as a single species of 120kDa to 140kDa . under 
non-reducing conditions, and consequently gpll has been referred
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to as a disulphide-linked dimer (Grose et al.. 1984). gpll is 
highly homologous to HSV-1 gB (Keller et al., 1986) and, as
such, can be expected to play similar roles in the infectious 
process.
The gene for gpIII has been mapped and sequenced (Keller et 
al., 1987) and its product is the least immunogenic of the three 
major glycoproteins (Keller et al.. 1984). However, it contains 
at least one epitope that can stimulate production of antibodies 
which neutralise virus infectivity in the absence of complement 
(Keller et al.. 1984? Montalvo and Grose, 1986) . gpIII is the 
homologue of HSV-1 gH (McGeoch and Davison, 1986) and is 
essential for the cell-to-cell spread of virus, as monoclonal 
antibodies to gpIII inhibit plaque formation in infected cells 
(Keller et al.. 1987). This function is shared with its HSV-1 
homologue, gH.
gpIV has been identified as a 45kDa to 55kDa species which 
reacted with antibodies directed against a peptide from the 
carboxyl-terminus of the the 39kDa gene product from Us (Davison 
et al., 1985), and is the the homologue of HSV-1 gl (Davison and 
McGeoch, 1986).
The fifth glycoprotein species, gpV, is the homologue of 
HSV-1 gC. However, this species remains to be characterised. The 
five distinct glycoprotein species encoded by VZV all possess 
homologues in HSV and PRV, although it remains to be 
determined whether such species have conserved functions.
Glycoproteins of BHV-1
BHV-1 is thought to specify up to 11 glycoproteins (Misra 
et al., 1981). The four major species are designated gl to gXV
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as defined by a new nomenclature (van Drunen Littel-van den Hurk 
and Babiuk, 1986) . The genes for gl and gill have been mapped 
and sequenced (Lawrence et al.. 1986; Misra et al., 1988;
Whitbeck et al., 1988; Fitzpatrick et al., 1989). gl, gll, gill 
and gIV are homologues of HSV-1 gB, gE, gC and gD, respectively, 
gl and gill can elicit the formation of virus neutralising 
antibodies and antibodies that participate in the complement- 
mediated lysis of infected cells (van Drunen Littel-van den Hurk 
et al.. 1984, 1985). Although gl was originally thought to play 
an important role in virus neutralisation and to contain a site 
for viral attachment (van Drunen Littel-van den Hurk et al..
1984), the work of Marshall et al. (1986) suggests that a lesser 
role is played by gl in this process, gll is of minor importance 
in immunity since antibodies against this species are unable to 
neutralise infectivity or to play a role in the immune lysis of 
the infected cell (van Drunen Littel-van den Hurk et al., 1984). 
The precise roles of these glycoproteins in the infectious 
process is still unclear, gl, like its HSV-1 gB counterpart, 
promotes cell fusion (Fitzpatrick et al.. 1988) and gill is 
thought to be the protein that mediates the attachment of 
virions to cells (Okazaki et al.. 1987). Additionally, gl may 
interfere with cellular proteins associated with the cytopathic 
effects of BHV-1 infection, as plaques formed on gl-expressing 
fibroblasts infected with BHV-1 or HSV-1 are smaller than those 
observed on normal fibroblasts infected with these viruses 
(Chase et al.. 1989). Since the actual number of plaques formed 
is the same in both normal and gl-expressing infected 
fibroblasts, gl does not appear to inhibit viral entry and cells 
expressing gill are also fully susceptible to BHV-1 infection
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(Chase et al., 1989).
Glycoproteins of HCMV
HCMV is known to specify several envelope glycoproteins 
(Farrar and Oram, 1984) that can elicit the production of 
antibodies that neutralise virus infectivity in vitro (Britt, 
1984? Rasmussen et al,. 1984, Kari et al.. 1986) and in vivo 
(Rasmussen et al. . 1985; Cranage et al. . 1986? Gonczol et al., 
1986). The most extensively studied and abundant species is a 
disulphide-linked heterodimer comprising two glycosylated 
proteins of molecular weight 55kDa and 116kDa (Britt, 1984), 
which is referred to as gp55-116. The gene for this glycoprotein 
has been sequenced (Cranage et al., 1986) and is homologous to 
the HSV-1 gB gene. The gp55-116 (gB) complex of HCMV is a very 
important target for the immune response since it is the most 
abundantly expressed glycoprotein species and can stimulate the 
production of virus neutralising antibodies (Britt, 1984? 
Cranage et al.. 1986? Britt et al.. 1988) . HCMV specifies one 
more glycoprotein known to have a homologue in HSV, and that 
species is the counterpart of gH. The gene for the HCMV gH 
homologue has been sequenced and expressed in vaccinia virus 
(Cranage et al., 1988) . gH was precipitated as an 86kDa species 
from cells infected with HCMV and from recombinant vaccinia 
virus-infected cells by a monoclonal antibody that neutralised 
virus infectivity, which indicates that gH is a neutralising 
target (Cranage et al.. 1988). However, in contrast to results 
obtained with vaccinia virus expression of HCMV gB (Cranage et 
al., 1986), recombinant vaccinia virus-infected cells did not
express gH on their surfaces, which indicates that the normal
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transport of gH to the cell surface may require other HCMV- 
specific gene products.
Glycoproteins of EBV
The complete DNA sequence of the genome of EBV strain B95-8 
predicted the existence of at least five glycoprotein genes, 
namely open reading frames (ORFs) BLLFla, BLLFlb, BDLF3, BILF2 
and BALF4 (Baer et al., 1984). Three major glycoprotein species 
have long been recognised: gp350, gp220 and gp85 (Stmad et al.. 
1982? Edson and Thorley-Lawson, 1983). The most prominent
species, gp350 and gp220, were mapped to the BamHI-L region of 
the genome by hybrid-select translation (Hummel et al.. 1984)
and have both been shown to be encoded by ORF BLLF1 (Baer et 
al., 1984; Beisel et al., 1985). gp350 and gp220 are involved in 
attachment of virus to its receptor on B cells (Nemerow et al., 
1987; Tanner et al.. 1987). Antibodies against gp350 and gp220 
can neutralise virus infectivity (Thorley-Lawson and Geilinger, 
1980; Thorley-Lawson and Poodry, 1982) and epitope mapping of 
gp350/gp220 identified seven epitopes of which two could elicit 
the production of virus neutralising antibodies (Qualtiere et 
al.. 1987). Antibodies to gp85 neutralise virus infectivity
(Stmad et al.. 1982) and gp85 appears to have a role in the 
fusion of EBV with B cell membranes since a monclonal antibody 
to gp85 inhibited cell fusion but not virus attachment (Miller 
and Hutt-Fletcher, 1988) . gp85 is encoded by BXLF2 and is the 
homologue of glycoprotein gH of other herpesviruses (McGeoch and 
Davison, 1986). Since Baer et al. (1984) did not identify the 
product of BXLF2 as a glycoprotein, it appears that EBV may 
actually encode at least six glycoproteins. BALF4 encodes the
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homologue of HSV-1 glycoprotein gB (Pellett et al., 1985a),
which is known as gpl 10 (Gong et al.. 1987). The glycoprotein 
encoded by BILF2 has been characterised and is known as gp78/55 
(Mackett et al., 1990). However, the glycoprotein predicted to 
be encoded by BDLF3 remains to be characterised.
The glycoproteins specified by HSV (gB, gC, gD, gE, gG, gH 
and gl) and the nomenclature used for naming their known 
counterparts in PRV, VZV, BHV-1, HCMV and EBV is summarised in 
Table 1.1.
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T A B L E  1,1 
Herpesvirus Glycoprotein Nomenclature
HSV PRV VZV BHV-1 HCMV EBV
gB gll gpll gi gp55-116 gpllO
gc gill gpV gill - -
gD gp50 - gIV - -
gE gl gpl gll - -
gG - - 7 -
gn gH gpin 7 gpss gp85
gl gp63 gpiv 7 - -
Table 1.1 Nomenclature used to identify HSV glycoprotein 
homologues in PRV, VZV, BHV-1, HCMV and EBV. Glycoproteins which 
do not have known homologues in HSV are not included. (-), no 
homologue; (?), unknown.
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THE EQUINE HERPESVIRUSES
Introduction
The equine herpesviruses are a group of antigenically 
distinct infectious agents which cause a wide range of natural 
infections. EHV-1, also known as equine abortion virus and
equine rhinopneumonitis virus, is the best studied member of
this group. It is now known that EHV-1 is not a single virus but
two antigenically distinct subtype viruses, referred to as 
EHV-1 subtypes 1 and 2. EHV-1 subtype 1 is the major agent 
responsible for abortion and neonatal foal death and has also
been implicated in respiratory disease and neurological 
disorders, whereas subtype 2 appears to be predominantly 
associated with respiratory disease (O'Callaghan et al.. 1983?
Allen and Bryans, 1986). EHV-1 subtypes 1 and 2 are now more 
commonly referred to as EHV-1 and EHV-4, respectively.
EHV-2 does not appear to cause any specific disease 
(Studdert, 1974) although the majority of horses appear to be 
infected (Roeder and Scott, 1975). Members of this group are 
slow growing with a limited host range in vitro. being 
restricted mainly to equine cells, although fast growing 
isolates have been reported (Karpas, 1966? Mumford and Thompson,
1978). Since the majority of strains are slow growing and remain 
cell-associated, EHV-2 has been classified as a cytomegalovirus 
(Wharton et al., 1981). Infection occurs during early life by 
inhalation of infectious virus and infected horses become 
persistent carriers and constantly shed virus (Studdert, 1974). 
EHV-2 has been isolated from a wide range of tissues including 
the vagina, mammary gland, bone marrow and kidney (Plummer and
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Waterson, 1963; Kono and Kobayashi, 1964; Karpas, 1966;
Studdert, 1974). EHV-2 has not been isolated from foetal tissue 
and does not therefore appear to cross the placental barrier 
(Studdert, 1974).
EHV-3 is the cause of a mild progenital disease in horses, 
known as equine coital exanthema. Lesions, which initially 
appear as small vesicles or papules which rapidly progress to 
pustules and ulcers, are localised mainly, but not exclusively, 
to the external genitalia and infected animals show no signs of 
systemic illness (Bryans and Allen, 1973; Studdert, 1974). 
Lesions may also appear on the conjuctivae, lips and nasal 
mucosa. The virus is usually spread venereally although other 
routes of transmission appear likely. Virus replication is 
restricted to equine cells and rabbit kidney cells.
Abortion Induced by EHV-1
Viral abortion as a clinical entity was first reported by 
Dimock and Edwards (1932) and further studies proceeded to 
define clinical aspects of disease and pathological lesions 
observed in aborted foals (Dimock, 1940; Dimock et al.. 1942).
Most mares abort during the last four months of gestation (Doll, 
1952; Doll and Bryans, 1963) and, on rarer occasions, may abort 
again after an interval of more than two years (Dimock et al.. 
1942). Although viral abortion is usually a disease of late 
pregnancy, it can be induced experimentally as early as the 
third month of gestation (Doll et al. . 1955). Horses are
infected in early life and continue to be reinfected at 
intervals of 3 to 6 months throughout their life. The virus is 
transmitted via airborne secretions, contaminated food and water
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and by close contact with mares and their aborted foetuses. Most 
pregnant mares previously exposed to the virus are relatively 
immune to abortion as a result of reinfection since they develop 
sufficiently high levels of virus neutralising antibodies, and 
reinfection is generally not observable (Bryans, 1969). 
Susceptible pregnant mares may abort 14 to 120 days after 
infection without displaying signs of disease (Doll and Bryans,
1962). The aborted foetus dies by suffocation due to placental 
separation from the endometrium or by the inability to respire 
after delivery due to pulmonary oedema and viral pneumonitis 
(Bryans and Prickett, 1970). Foetuses aborted prior to the 6th 
month of gestation are severely autolysed and their lesions are 
not associated with a local inflammatory response as is observed 
in older foetuses (Prickett, 1970). Those aborted after seven 
months gestation display a variety of macroscopic lesions as 
described by Dimock et al. (1942, 1947) which include jaundice, 
pulmonary oedema, splenic enlargement with prominent lymphoid 
follicles, necrotic foci in the liver and petechiation of mucous 
membranes. Microscopic lesions include pneumonitis, 
bronchiolitis and focal necrosis of liver and spleen. Foetuses 
aborted between the 6th and 7th month of gestation show a 
mixture of lesions characteristic of both early and late 
abortion. The lesions found in the foetus are therefore 
dependent upon the age of the foetus and the degree of maturity 
of the foetal immune system.
Respiratory Disease Caused by EHV-1
A number of investigators originally noted viral abortion 
was closely associated with respiratory disease (Manninger and
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Csontos, 1941; Manninger, 1949). This disease was first studied 
experimentally by Doll et al. (1954b) who showed that equine 
abortion virus was a cause of respiratory disease in young 
horses and proceeded to demonstrate that a number of putative 
influenza virus isolates were identical to equine abortion virus 
(Doll and Kintner, 1954; Doll et a h . 1954a). Further studies 
led to equine abortion virus being designated equine 
rhinopneumonitis virus (Doll et al.. 1957) which was
subsequently renamed EHV-1 on the basis of electron microscopy 
(Plummer and Waterson, 1963). Infection with either subtype of 
EHV-1 results in acute respiratory disease, mainly in young 
foals. Clinical signs include fever, coughing, anorexia, 
congested nasal mucosa and excessive nasal discharge which may 
become mucopurulent (Doll et al.. 1954b; Coggins, 1979). A 
leucocyte-associated viraemia and neutropenia are associated 
with subtype 1 respiratory tract infections (Doll et al.. 1954a; 
Bryans, 1969). Infected animals shed large amounts of virus 
(Burrows and Goodridge, 1975) which is recoverable for up to 12 
days after infection from the nasopharynx (Bryans, 1969). 
Respiratory disease is rarely fatal. However, secondary 
bacterial infections may result in bronchopneumonia, * due to 
virus reaching the lungs, and chronic respiratory infection 
(Bryans, 1964; Prickett, 1970). Infection of perinatal foals can 
lead to fatal bronchopneumonia (Bryans, 1969) . Immunity to the 
disease is more short-lived than that to abortigenic disease and 
reinfection occurs every 3 to 6 months throughout the lifetime 
of the horse (Doll, 1961; Bryans, 1969, 1981), although clinical 
signs of the disease are rarely seen in the older horse. 
However, such animals continue to produce and shed virus and act
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as a reservoir of infection for other horses. This disease 
appears to be associated with the 'poor performance' syndrome 
amongst racehorses (Mumford and Rossdale, 1980).
Neurological Disease Caused by EHV-1
Clinical manifestations of this disease were first reported 
by Manninger (1949) who noted that mares inoculated with EHV-1 
recovered from aborted foetuses readily developed myelitis. The 
first true link of EHV-1 to neurological disease was 
demonstrated by Saxegaard (1966) who isolated EHV-1 from the 
nervous tissue of horses suffering from paralysis. Since then 
the disease has been widely reported in many countries 
containing large horse herds (Charlton et al.. 1976; Dinter and 
Klingebom, 1976; Greenwood and Simson, 1980; Batra et al..
1982). Although usually associated with abortion or respiratory 
disease, natural outbreaks of neurological disease have been 
reported to occur without concurrent abortion or respiratory 
disease (Dinter and Klingebom, 1976; Thein, 1981) . The disease 
has been reproduced experimentally by inoculation of virus both 
subcutaneously and intranasally (Jackson and Kendrick, 1971; 
Jackson et al., 1977). Clinical signs of infection include
severe to mild ataxia, incoordination and, in more severe cases, 
complete paralysis of both fore and hind limbs. The disease has 
a variable histopathology. In most cases, vasculitis of small 
arteries and veins and degeneration of nervous tissue are the 
principal lesions (Jackson and Kendrick, 1971; Jackson et al.. 
1977). More severe lesions such as disseminated 
meningoencephalitis have been reported by Charlton et al. 
(1976) , who were able to culture EHV-1 from brain and lung
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tissue. Naturally occuring deaths are usually due to pneumonia, 
pulmonary congestion, bowel atony, ruptured urinary bladder or 
intussusception. Recovery from the disease may vary from a few 
days to up to three months, whilst some horses may continue to 
demonstrate slight but permanent signs of infection, such as 
incoordination. In common with other herpesviruses, EHV-1 is 
able to spread from the infected cell to contiguous cells 
without an extracellular phase. It is in this way that, in the 
presence of high levels of serum virus neutralising antibodies, 
the virus is able to infect endothelial cells via infected 
leucocytes circulating in the blood to the vascular structures 
of the central nervous system. This accounts for the severe and 
generalised vasculitis associated with EHV-1 infection (Jackson 
et al., 1977). Malacic foci develop subsequent to thrombosis of 
local vessels, and paralysis appears to be a direct result of 
ischaemia and metabolic changes in the nervous tissue (Jackson 
et al., 1977) . The vascular damage and ischaemic injury to the 
nervous system is probably due to immunological reaction of the 
host to the presence of EHV-1 in the infected vascular 
epithelium (Platt et al., 1980).
Neonatal Foal Disease Caused by EHV-1
In recent years neonatal foal disease due to infection with 
EHV-1 in utero during the late stages of gestation has been 
reported (Dixon et al.. 1978; Hartley and Dixon, 1979). Foals 
may be bom alive but weak and depressed and die within 24 hours 
of birth. Other foals may appear normal at birth but develop 
severe respiratory distress soon after birth and die within 72 
hours. The neonatal syndrome described by Bryans et al. (1977)
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involves foals suffering from respiratory distress, weakness and 
severe diarrhoea during the first two weeks of life prior to 
succumbing to a variety of secondary bacterial infections. 
Generally, foals afflicted by this disease exhibit extensive 
lymphoreticular, pulmonary, hepatic and, in some cases, adrenal 
damage.
Differentiation Between EHV-1 Subtype Viruses
That EHV-1 comprises two subtypes was first suggested by 
Shimizu et al. (1959) who demonstrated that EHV-1 isolates could 
be grouped into two distinct yet cross-neutralising serotypes. 
It remained for Burrows and Goodridge (1973) to show that the 
majority of abortigenic and respiratory isolates belong to 
antigenic subtypes 1 and 2, respectively. Subsequent comparative 
studies showed that subtype 1 abortigenic isolates replicate 
much more rapidly than subtype 2 respiratory isolates in a wider 
range of host cells in vitro. Additionally, subtype 1 isolates 
are able to multiply rapidly in the nasopharynx of non-immune 
horses with extensive shedding of virus, readily produce a 
leucocyte-associated viraemia and are adaptable to hamsters 
(Burrows and Goodridge, 1973, 1975; Studdert and Blackney,
1979) . None of these characteristics are shared with subtype 2 
isolates. Plaques produced by subtype 1 isolates in tissue 
culture are smaller than those produced by subtype 2 isolates. 
Patel et al. (1982) showed by immunofluorescence studies in 
experimentally infected foals that a subtype 2 isolate could 
only replicate in the epithelial cells of the nasopharynx and 
was disseminated via macrophages into the lymph nodes draining 
the respiratory tract, and no further. In contrast, the
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penetration of subtype 1 virus was more widespread, infecting 
both epithelial and endothelial cells of the nasopharynx and 
lungs in addition to circulating leucocytes. Furthermore, it has 
been shown that, unlike subtype 2 strains, subtype 1 strains 
are able to infect the brain of mice after intracerebral 
inoculation of virus (Patel and Edington, 1983).
Further support for the existence of two distinct subtypes 
came from the use of restriction endonuclease analysis of viral 
DNA to discriminate between abortigenic and respiratory isolates 
(Sabine et al.. 1981; Studdert et al.. 1981; Turtinen et al., 
1981). This powerful method highlighted clear genetic variation 
between the two subtypes which possessed few, if any, common 
restriction endonuclease cleavage sites, whereas isolates of the 
same subtype shared a very similar pattern. The intersubtypic 
differences were so extensive it was proposed that EHV-1 
subtypes 1 and 2 should no longer be regarded simply as 
antigenic variants of the same virus but as distinct equine 
herpesvirus species: EHV-1 abortigenic strains and EHV-4
respiratory strains, respectively (Studdert et al.. 1981). This 
new nomenclature shall be used throughout the rest of this 
thesis. Application of this DNA fingerprinting methodology has 
confirmed that EHV-1 can cause respiratory and neurological 
disease in addition to abortion, whilst EHV-4 rarely causes 
abortion and neurological disease and is the predominant agent 
responsible for respiratory disease (Allen et al.. 1983b;
Studdert, 1983; Studdert et al.. 1984). In addition, three EHV-1 
strains which caused myeloencephalitis possessed different DNA 
fingerprint patterns to non-myeloencephalitis strains, which 
suggested the presence of a marker for neurovirulence at the DNA
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level (Studdert et al., 1984).
Another approach to the differentiation of EHV-1 and EHV-4 
has been employed by Yeargan et al. (1985), who constructed 
type-specific pools of monoclonal antibodies which were then 
used in enzyme immunofiltration and direct immunofluorescence 
assays to rapidly type isolates. This method can rapidly type 
many isolates at one time, is accomplished within 3 hours of 
virus isolation in tissue culture and remains a powerful tool 
for discriminating between EHV-1 and EHV-4.
Multiple passage of EHV-1 strains in non-equine cells in 
vitro and in hamsters in vivo gives rise to alterations in the 
genomic fingerprint pattern with the loss or gain of restriction 
endonuclease cleavage sites (Allen et al.. 1983a). The passage 
of EHV-1 in equine cells has little effect on genome structure 
and stability (Allen et al.. 1983a).
The use of a kinetic analysis of DNA-DNA reassociation has 
demonstrated that the EHV-1 and EHV-4 genomes share only 17% of 
their sequences (Allen and Turtinen, 1982) , a value far removed 
from the 47% DNA homology predicted between HSV-1 and HSV-2 
(Kieff et al.. 1972). Furthermore, EHV-1 and EHV-4 show no
detectable homology to EHV-2, which indicates that EHV-1 and 
EHV-4 have a common ancestral origin (Allen and Turtinen, 1982).
Intratvoic Genetic Variation
The DNA fingerprinting technique has demonstrated 
significant intratypic variation amongst EHV-1 and EHV-4 
isolates. The most notable study was that of Allen et al. 
(1983b) who analysed over 300 isolates recovered from 148 
outbreaks of abortion and 24 outbreaks of respiratory disease
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during a 22 year period in Kentucky. Using five different 
restriction endonucleases, it was shown that EHV-1 isolates 
could be grouped into at least 16 electropherotypes on the basis 
of their DNA fingerprint patterns, of which the two dominant 
electropherotypes caused over 90% of abortions during this 
period. EHV-1 isolates demonstrated relatively little genetic 
variation as 67% of abortions were due to EHV-1 isolates that 
had identical DNA fingerprint patterns. The genetic variability 
of EHV-1 isolates was actually less than has been observed for a 
number of human herpesviruses (Roizman and Buchman, 1979). In 
contrast, EHV-4 isolates exhibited extensive genetic variability 
with 13 distinct fingerprints identified amongst only 21 
unrelated isolates (Allen et al., 1983b).
Genome Structure of EHV-1 and EHV-4
The genome structure of EHV-1 has been known for some time. 
It consists of a 145kb linear, double-stranded DNA molecule 
with a buoyant density of 1.716g/cm and a G+C content of 57%. 
The genome is arranged as two covalently linked regions, L 
(lllkb) and S (34kb). The S component comprises a short unique 
region (Us) bounded by inverted repeats (IR^ , TRg). The L 
segment is fixed and the S component can invert relative to the 
L component to give two isomeric forms, corresponding to a 
group D genome as described in Chapter 1. Restriction 
endonuclease cleavage maps of the genome for a number of enzymes 
have been derived for two EHV-1 strains: the low-passage tissue 
culture field isolate HVS-25 (Whalley et al., 1981) and the
high-passage tissue culture KyA (L-M cell) strain (Henry et al., 
1981; Baumann et al.. 1986). Although the data of Henry et al.
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F I G U R E  1,3 
Physical Maps of the Genomes of EHV-1 and EHV-4
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Ficrure 1.3 Physical maps of the EHV-1 and EHV-4 genomes showing 
the location of restriction sites for BamHI and EcoRI. (a) BamHI 
and EcoRI restriction maps of EHV-1 strain HVS-25. Derived by 
Whalley et al. (1981) . (b) BamHI and EcoRI restriction maps of 
EHV-4 strain 1942. Derived by Cullinane et al. (1988).
The shaded boxes represent the repeat regions. Only one
orientation of the S region is shown.
(1981) suggested that the KyA strain possesses a genome with an 
inverted region relative the HVS-25 strain, a subsequent 
reassessment has shown that the genomes of the two strains have 
a similar distribution of restriction endonuclease cleavage 
sites (Baumann et al., 1986). Recently it was shown that the 
EHV-4 (strain 1942) genome adopts a similar structure to that of 
EHV-1 strains (L, 109kb? S, 35kb) and restriction endonuclease 
cleavage maps have been derived for BamHI and EcoRI 
(Cullinane et al., 1988). The BamHI and EcoRI restriction maps 
of the EHV-1 (HVS-25) and EHV-4 (1942) genomes are shown in 
Figure 1.3. The arrangement of BamHI and EcoRI restriction sites 
is clearly different between the EHV-1 and EHV-4 genomes.
The EHV-1 genome is col inear with that of EHV-3 and the 
limited DNA homology (10%) is dispersed throughout UL (Baumann 
et al.. 1986). Although substantial homology exists between the 
inverted repeats of these two viruses, none is detectable in the 
Us region.
Proteins of the EHV-1 and EHV-4 Virions
The EHV-1 and EHV-4 virions are morphologically 
indistinguishable from those of other herpesviruses ie. an 
internal DNA-containing core enclosed by an icosahedral capsid 
to form a nucleocapsid, which is immediately surrounded by the 
tegument and the loose outer envelope (Abodeely et al. . 1970;
O'Callaghan and Randall, 1976). Detailed studies on the
morphology of the EHV-1 and EHV-4 virions and the proteins they 
contain have been carried out by a number of workers (Perdue et 
al., 1974, 1975, 1976; Kemp et al.. 1974; Turtinen et al.. 1981; 
Turtinen and Allen, 1982; Turtinen, 1983). The protein content
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T A B L E  1,2
Virion Proteins of EHV-1 and EHV-4
EHV-1 Virion Proteins EHV-4 Virion Proteins
Protein Size Nature Location Protein Size Nature Location 
(kDa) (kDa)
1 250 G E 1 250 G E
**2 190-240 G(M) E **2 190-240 G(M) E
9 140 - NC 9 140 - NC
9a 140 G E
10a 128 G E
10 124 G(M) E 10 124 G(M) E
11 117 - T 11 117 - T
12 110 - T
*13 96 G(M) E *13 110 G(M) E
13a 98 - T
14a 94 7 7
*14 90 G(M) E *14b 87 G(M) E
14c 84 7 7
15 82 - T 15 82 - T
16 74 G E 16 74 G E
17a 70 - T
17 68 G E 17 68 G E
18a 64 - T
*18 63 G(M) E *18 61 G(M) E
19 60 - T 19 60 - T
20 54 - NC 20 54 - NC
21 45 G E 21 45 G E
22a 41 G(M) E 22a 41 G(M) E
22b 39 - NC 22b 39 - NC
23 36 - T 23 36 - T
23a 33 - T 23a 33 G E
*24a 31 - NC *24a 32 - NC
24b 27 - NC 24b 27 - NC
*25 24 G E *25 25 G E
*26a 18 - T *2 6a 19 - T
*26b 17 - NC *2 6b 18 - NC
27 16 - T 27 16 — T
Table 1.2 Virion proteins of EHV-1 and EHV-4. G, glycoprotein; 
G(M), major glycoprotein; E, envelope; T, tegument; NC, 
nucleocapsid; (-) , not determined; (*), exhibits intertypic 
electrophoretic mobility differences; (**), exhibits intratypic 
electrophoretic mobility differences. From Allen and Bryans 
(1986).
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of the EHV-1 and EHV-4 virions is summarised in Table 1.2. 
Although the envelope glycoproteins of HSV have been well 
characterised, the currently available information on those of 
EHV-1 and EHV-4 is limited. The important role of EHV-1 
glycoproteins in the immune response to viral infection was 
first demonstrated by Papp-Vid and Derbyshire (1978, 1979) . They 
showed that immunisation of hamsters with envelope-containing 
material offered protection against virus challenge. 
Furthermore, antibodies to the envelope could neutralise EHV-1 
infectivity whereas those to the nucleocapsid showed no such 
neutralising activity. Thus the envelope glycoproteins were 
demonstrated to be important target antigens of the host immune 
response.
A number of comprehensive studies of the envelope 
glycoproteins have been carried out for both EHV-1 and EHV-4 
(Turtinen and Allen, 1982; Turtinen, 1983). Six major and six 
minor glycoprotein species were identified for each virus type. 
The six major species were designated VGP2, 10, 13, 14, 18 and 
22a. Intertypic mobility differences were demonstrated for VGP2, 
13, 14, 18 and 25 and phosphoproteins VP24a, 26a and 26b (Table 
1.2). Since the only species to exhibit intratypic mobility 
differences was VGP2, the electrophoretic protein profiles could 
be reliably used to distinguish between EHV-1 and EHV-4 
isolates. Turtinen et al. (1981) investigated the serological 
relatedness between two EHV-4 (respiratory tract) isolates and 
the Army 183, KyA-ha and KyA-LM EHV-1 strains. Intertypic 
mobility differences were demonstrated for VGP13, 16, 17, 18,
23, 25 and 26a, whilst VGP8a was only detected in the KyA-ha
strain and only small amounts of VP19 were present in the
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respiratory tract isolates. The EHV-4 respiratory tract isolates 
showed little cross-neutralisation with the EHV-1 Army 183 and 
KyA-ha strains in plaque-reduction neutralisation tests.
The studies of Turtinen (1983) on the glycoproteins of 
EHV-1 and EHV-4 has yielded further valuable information. The 
bulk of virus-specific antibody is directed against VGP2, 10,
13, 14 and 22a and the serological cross-reactivity of EHV-1 and 
EHV-4 is due to type-common epitopes residing on VGP2, 10, 13
and 14. VGP2 and 14 appear to be the most cross-reactive species 
whilst VGP2, 10, 13 and 14 are the most immunogenic species. 
Only VGP18 and 22a were found to contain type-specific epitopes.
The nature of the epitopes on these glycoproteins was 
investigated using a panel of monoclonal antibodies specific for 
EHV-1 and EHV-4 glycoproteins (Yeargan et al.. 1985). It was 
concluded from this study that four distinct types of epitopes 
can be found on EHV-1 and EHV-4 glycoproteins: type-specific
epitopes common to all isolates of the same virus type, type- 
specific epitopes common to some isolates of the same virus 
type, type-common epitopes present on all isolates of both 
virus types and type-common epitopes present on some isolates of 
both virus types.
Intratvoic Antigenic Variation
It is well documented that virtually all isolates of the 
homologous virus type are very closely related at the antigenic 
level (Turtinen et al.. 1981; Turtinen, 1983). The only report 
to date which demonstrates antigenic variation within the same 
virus type is that of Yeargan et al. (1985) who used the 
powerful resolving ability of monoclonal antibodies specific to
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EHV-1 and EHV-4 glycoproteins to group isolates into distinct 
monoclonal serotypes. Nine antigenically distinct serotypes were 
identified amongst 12 epizootically unrelated and genetically 
diverse EHV-1 isolates analysed, and this antigenic reactivity 
pattern did not correlate with the DNA fingerprint pattern 
(Allen and Bryans, 1986).
Cross-Protection Between EHV-1 and EHV-4 and the Nature of the 
Immune Response to Viral Infection
The fact that EHV-1 and EHV-4 are closely related at the 
antigenic level has prompted an assessment of the potential of a 
respiratory tract EHV-4 infection to cross-protect against 
subsequent infection with EHV-1 abortigenic strains (Allen and 
Bryans, 1986). Using the Syrian hamster model, it was 
demonstrated that a dose of EHV-4 ten-fold greater than EHV-1 
was necessary to achieve the same level of protection against 
EHV-1 virus challenge. A single experimental infection of the 
respiratory tract of young foals with EHV-1 or EHV-4 offered 
. little cross-protection between EHV-1 and EHV-4 since foals 
infected with either EHV-1 or EHV-4 were resistant to challenge 
by the homologous virus type, but susceptible to challenge with 
the heterologous virus type, after an interval of four weeks. 
However, repeated infections with EHV-4 at regular intervals ie. 
every six months, resulted in significant levels of immunity to 
infection with abortigenic EHV-1 isolates.
The nature of the immune response to EHV-1 and EHV-4 
infection has been extensively studied. Such a response is 
short-lived as reinfecton is generally observable within three 
months of initial infection (Allen and Bryans, 1986). Although
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horses infected with EHV-1 or EHV-4 usually develop antibodies 
to that virus, this antibody response does not always protect 
against reinfection (Bryans, 1969). However, the lack of such 
antibody is not usually associated with increased susceptibility 
to disease (Dutta and Shipley, 1975), indicating that cell-
mediated immunity may play an important role in protecting
horses against EHV-1 and EHV-4 infection. The nature of the 
immune response to EHV-1 and EHV-4 infection was further 
investigated using colostrum-deprived specific pathogen-free 
foals vaccinated with either EHV-1 or EHV-4 and then 
successively challenged with EHV-1 followed by EHV-4, or EHV-4 
followed by EHV-1 (Fitzpatrick and Studdert, 1984). This study 
indicated that both humoral (antibody-mediated) immunity and 
cell-mediated immunity to EHV-1 and EHV-4 exists. The virus
neutralising antibody response to EHV-1 was type-specific
whereas that to EHV-4 was cross-reactive with equal amounts of 
antibody to both virus types being produced. The cellular immune 
responses involved were cross-reactive.
Additional evidence for the existence of immune mechanisms 
independent of virus neutralising antibody production came from 
the study of the ability of a commercially available vaccine 
(Pneumabort-K, inactivated EHV-1 Army 183 strain) to protect 
horses against challenge with EHV-1 strains (Burrows et al.. 
1984) and EHV-4 strains (Mumford and Bates, 1984). This vaccine 
did not protect against challenge with EHV-1 despite the 
presence of neutralising antibodies to EHV-1 in the sera of 
vaccinated animals, although limited protection was afforded 
against EHV-4 challenge.
Cell-mediated immunity has long been recognised as being
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Important in recovery from, and resistance to, viral infection 
and was first demonstrated as an immune mechanism to EHV-1 by 
Wilks and Coggins (1976, 1977). Cell-mediated immunity was 
principally examined using an in vitro lymphocyte transformation 
assay, a technique which is an indirect index of the cell- 
mediated immune response (Wilks and Coggins, 1976; Gerber et 
al., 1977; Dutta et al.. 1980). Wilks and Coggins (1977) 
assessed the immune response of horses experimentally infected 
with EHV-1 by measuring cytotoxicity for EHV-1 infected target 
cells. Peripheral blood leucocytes from a horse recovered from 
EHV-1 infection were capable of lysing target cells. 
Cytotoxicity of both serum and peripheral blood leucocytes 
following experimental infection of specific pathogen-free foals 
was detected as early as one day post-infection (p.i.) and could 
persist for up to 20 days p.i. Cytotoxic antibodies or cells 
were therefore concluded to play an important role in the 
control of the spread of infection.
A most rigorous and elegant study on cell-mediated and 
antibody-mediated immune responses to EHV-1 was carried out by 
Gerber et al. (1977) who investigated the nature of these 
responses in young horses, older horses and pregnant mares. 
Following vaccination and revaccination five weeks later of 
young horses (6 to 8 months old) with a modified live vaccine of 
EHV-1, very little increase in virus neutralising antibody 
levels occured although a strong cell-mediated (lymphocytic) 
immune response developed. In contrast, older horses (18 to 21 
months old) showed large increases in virus neutralising 
antibody levels at 7 days post-vaccination which remained 
elevated for 9 weeks post-vaccination (4 weeks post­
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revaccination), but the cell-mediated immune response was 
suppressed during this time. The cell-mediated immune response 
only increased at 13 weeks post-vaccination (8 weeks post­
revaccination) and correlated with a decrease in the level of 
virus neutralising antibodies. Thus, the level of the cell- 
mediated immune response increased in the absence of virus 
neutralising antibodies and decreased in the presence of virus 
neutralising antibodies. Pregnant mares during the late stages 
of gestation showed a heavily suppressed cell-mediated immune 
response but demonstrated a 16-fold increase in virus 
neutralising antibody levels after exposure to virulent EHV-1. 
Suppression of the cell-mediated immune response reaches a 
maximum during the late stages of pregnancy and accounts for the 
high incidence of abortion during this period (Doll and Bryans,
1963). In accordance with these studies, Dutta et al. (1980) 
also demonstrated a lymphocytic response to EHV-1 infection 
which appeared within 2 days and peaked at 7 to 10 days prior to 
decreasing.
More recently, Bridges and Edington (1987) developed a 
cytotoxic T lymphocyte (CTL) assay to investigate the immune 
response to EHV-1 and EHV-4 infection, a system which uses skin 
explants as targets for assaying CTL activity. They proceeded to 
demonstrate a genetically restricted CTL activity in ponies 
following an EHV-4 infection and this CTL activity was type- 
specific (Edington et al., 1988).
Two cellular immune mechanisms which have been the subject 
of investigation are antibody-dependent cellular cytotoxicity 
(ADCC) and complement-dependent antibody lysis (CDL). ADCC is 
mediated by peripheral mononuclear cells which, when armed with
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antibody, are able to specifically kill virus-infected cells. 
CDL is a result of activation of complement by the classical 
pathway following the attachment of virus-specific antibody to 
target antigens on the infected cell surface. Stokes and Wardley 
(1988) investigated the ability of ADCC and CDL to afford 
protection in the horse following vaccination or challenge with 
EHV-1. The sera from horses vaccinated with Pneumabort-K and 
that from non-vaccinated horses challenged with EHV-1 were 
capable of mediating ADCC and CDL to both EHV-1 and EHV-4. This 
was the first demonstration of these immune mechanisms operating 
in vitro after EHV-1 infection. However, the authors concluded 
that ADCC and CDL only appear to be of importance in recovery 
from EHV-1 infection and are not thought to play a role in 
protection following vaccination, and that other immune 
mechanisms may have a protective role.
A hamster model has recently been developed that will prove 
to be a useful system for studying the immune response to viral 
infection and evaluating the immunogenicity of individual EHV-1 
and EHV-4 antigens (Stokes et al.. 1989). CDL appears to play a 
major role in protection in this model. In addition, the authors 
investigated the role of the six major glycoproteins of EHV-1 in 
the immune response to viral infection by the use of monoclonal 
antibodies specific for each of these six antigens (Allen and 
Yeargan, 1987). Hamsters inoculated with all six monoclonal 
antibodies were fully protected against virus challenge with 
EHV-1 (KyD strain) by the intranasal route and 80% were 
protected after challenge by the intraperitoneal route. More 
specifically, monoclonal antibodies to gpl3, 14 and 17/18 were 
capable of eliciting passive protection individually. The
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mechanism of protection is unknown since these monoclonal 
antibodies were unable to neutralise EHV-1 KyD in vitro and 
could only mediate ADCC when all six monoclonal antibodies were 
used, although it was suggested that either an ADCC or 
complement-mediated immune response may operate in vivo (Stokes 
et al.. 1989).
A number of infected-cell polypeptides have been
identified which are recognised by equine lymphocytes after an 
EHV-4 infection (Bridges et al., 1988). This cellular response 
was directed against the EHV-4 major glycoproteins gplO, 13, 14, 
18 and 21/22a, and possibly gp9. Identical proteins of EHV-1
which share epitopes were also recognised by this response with 
the exception of gpl8 which is antigenically type-specific. 
Hyperimmune equine serum from animals exposed to both EHV-1 and 
EHV-4 recognised ten polypeptides from both virus types of which 
four were also recognised by the cellular immune responses 
(Bridges et al., 1988).
Seven monoclonal antibodies have been characterised which 
recognise EHV-1 and EHV-4 (Sinclair et al., 1989). Of these, 
three were able to neutralise the EHV-1 Army 183 strain in the 
presence of complement but were unable to neutralise the EHV-4 
MD strain. The target antigen for all three neutralising 
antibodies was an 83kDa EHV-1 glycoprotein which probably 
corresponds to gpl3 (see Table 1.2). The remaining four non­
neutralising antibodies recognised target antigens of molecular 
weights >205kDa, >205kDa, 97kDa and 13kDa. The two high
molecular weight polypeptides probably correspond to the highly 
abundant envelope glycoprotein gpl/2 whose function is unknown 
and which were recognised in both EHV-1 and EHV-4. The 13kDa
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species was recognised in both EHV-1 and EHV-4 and the 97kDa 
species was only recognised in EHV-4.
Latency Associated With EHV-1 and EHV-4 Infection
The ability of virus to persist in the host in a latent 
state is a serious problem associated with most herpesvirus 
infections, including those by HSV (Baringer and Swoveland, 
1973; Stevens, 1975; Wildy et al., 1982), PRV (Sabo and Rajcani, 
1976; Beran et al.. 1980) and BHV-1 (Pastoret et al.. 1984).
Latent virus may be reactivated, usually under stress, at any
time during the life of the host whereupon the virus is shed, 
leading to renewed outbreaks of disease in both the host and 
other susceptible individuals. It is well proven that the
sensory ganglia are a site of latent infection for HSV (Baringer 
and Swoveland, 1973; Baringer, 1974), PRV (Beran et al. . 1980)
and BHV-1 (Homan and Easterday, 1980).
The evidence for the existence of latency for EHV-1 and
EHV-4 based on field observations is purely circumstantial since 
the methods of tissue culture explantation and corticosteroid 
administration used to successfully demonstrate latency in other 
herpesviruses have failed to reactivate EHV-1 and EHV-4 from 
horses, with the exception of a single case where EHV-4 was
detected in trigeminal ganglia (Gleeson and Coggins, 1980; 
Burrows and Goodridge, 1984; Allen and Bryans, 1986). Early 
indications for the reactivation of latent EHV-l/EHV-4 came from 
the vaccination of horses with African horse sickness virus, 
which subsequently developed respiratory illness (Erasmus, 
1966). Stress-related activities such as weaning, castration and 
rehousing resulted in the shedding of virus from a number of
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ponies which had had no contact with other horses for the last 
ten years (Burrows and Goodridge, 1984). Many of these ponies 
had previously developed significant increases in levels of 
EHV-l/EHV-4 neutralising antibodies although they showed no 
signs of illness (Burrows and Goodridge, 1978, 1979). However, 
infectious virus was undetectable following culture of tissue 
explants and corticosteroid administration.
The first experimental demonstration of EHV-1 latency was 
provided by Edington et al. (1985) who infected eight ponies 
with EHV-1 intranasally which were then maintained in isolation 
for three months, during which time levels of complement fixing 
antibodies decreased at least four-fold. All ponies demonstrated 
clinical and serological signs of infection and virus could be 
isolated from nasal swabs and leucocytes. The corticosteroids 
dexamethasone and prednisolone were administered and following 
this immunosuppression virus was recovered from six ponies 
within 14 days; five of these ponies were viraemic, three shed 
virus, only four showed significant increases in levels of 
complement fixing antibodies and two had raised levels of 
neutralising antibodies. The detection of viraemia without nasal 
shedding in three animals suggested a reactivation of latent 
virus by the corticosteroids as opposed to a secondary 
infection. The conclusion that latent EHV-1 could be 
reactivated following immunosuppression with corticosteroids in 
the presence of circulating antibodies correlated well with 
previous reports of increased levels of virus neutralising 
antibodies and shedding of EHV-1 in stressful situations 
(Burrows and Goodridge, 1978, 1984) . Using a similar approach, 
reactivation of latent EHV-4 has also been demonstrated
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(Browning et al., 1988).
EHV-1 has been successfully recovered from leucocytes 
following respiratory infection with the virus (Bryans, 1969; 
Gleeson and Coggins, 1980). Since virus can only be isolated 
from viable, undisrupted leucocytes it seems likely that the 
virus may be present in a noninfectious form, and that this 
cell-associated viraemia represents a latent infection of equine 
leucocytes by EHV-1 (Gleeson and Coggins, 1980; Scott et al.,
1983).
Lvtic Infection With EHV-1
EHV-1 replicates rapidly in both the mouse L-M cell line 
(O'Callaghan et al.. 1968b, 1983) and the Syrian hamster
(Bracken and Randall, 1957; O'Callaghan et al.. 1972) with 'one- 
step' growth kinetics. Following infection, maximum virus titres 
are obtained after 10 to 12hr in the hamster and 18 to 24hr in 
the L-M cell line. Following inoculation of Syrian hamsters with 
108 LD50 of virus, all animals die after approximately 12hr and 
display a marked viraemia with 95% of the hepatic parenchymal 
cells showing a typical intranuclear inclusion. In the L-M cell 
line only 5% of virus remains cell-associated.
Initiation of Infection
The virus envelope has a major role in the early stages of 
infection ie. the attachment and penetration of virus into the 
host cell. It is now widely accepted that following adsorption 
of virus to the host cell, the virion envelope fuses with the 
cell surface membrane to liberate the nucleocapsid into the 
cytoplasm (Morgan et al.. 1968). This hypothesis for viral entry
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is supported by electron microscopic studies on the 
intracellular distribution of nucleocapsids after exposure of 
cells to infectious virions or non-infectious nucleocapsids 
(Abodeely et al., 1970). For HSV, adsorption and penetration of 
infectious virus is mediated by three glycoproteins, gB, gD and 
gH, as has been reviewed in Chapter 1.
The attachment of EHV-1 to L-M cells occurs within 5min of 
exposure to virus and penetration is complete after 15min as is 
demonstrated by the presence of virions in cytoplasmic vacuoles. 
The fact that the virus contained inside cytoplasmic vacuoles is 
enveloped suggests that EHV-1 gains entry by viropexis (Abodeely 
et al.. 1970). Uncoating of virus is complete within 4hr p.i. as 
is demonstrated by transcriptional studies.
Transcription and Viral Protein Synthesis
Huang et al. (1971) used competitive hybridisation 
techniques to first demonstrate that EHV-1 mRNA synthesis (gene 
expression) is temporally regulated. EHV-l-specific mRNA was 
present by 4hr p.i. of L-M cells and by 12hr p.i. additional 
mRNA species appeared, thus demonstrating that the synthesis of 
viral transcripts varied during infection. Cohen et al. (1975b) 
identified two classes of EHV-1 transcripts whose ratio varied 
at different times p.i. within infected cells. In L-M cells 
infected with EHV-1 in the presence of the viral DNA synthesis 
inhibitor 5'-fluoro-2-deoxyuridine, the synthesis of a major 
portion of the transcripts comprising the major RNA class was 
inhibited, indicating that the transcriptional regulation of 
EHV-1 was linked to the onset of viral DNA replication (Cohen et 
al., 1977b). These initial observations strongly suggested that
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EHV-1 gene expression is highly regulated and sequentially 
ordered in a manner similar to that described for HSV-1.
The synthesis of HSV polypeptides has been shown to be 
coordinately regulated and sequentially ordered in a cascade 
fashion (Honess and Roizman, 1974, 1975). On the basis of 
temporal order and metabolic requirements for their synthesis, 
these polypeptides fall into three major groups: o< (immediate- 
early, IE), P (early) and X (late). The IE polypeptides are 
the first species synthesised and transcription of their genes 
occurs in the absence of protein synthesis and is mediated by 
host cell RNA polymerase II which recognises unique IE promoters 
(Costanzo et al.. 1977; Mackem and Roizman, 1980, 1981). These 
IE polypeptides are defined as those which are expressed 
immediately after the withdrawal of a protein synthesis block 
eg. by puromycin or cycloheximide, which was present prior to 
infection. The synthesis of IE polypeptides reaches a peak at 2 
to 4hr p.i. The synthesis of early polypeptides is dependent 
upon the presence of functional IE polypeptides and occurs prior 
to, and independent of, viral DNA synthesis and their synthesis 
reaches a peak at 5 to 7hr p.i. The late polypeptides are only 
synthesised during the late stages of infection and their 
synthesis requires the presence of functional IE and early 
polypeptides and is dependent on viral DNA synthesis. The late 
polypeptides comprise mainly structural proteins whose peak 
synthetic rate is at 15 to 18hr p.i. The onset of synthesis of 
early polypeptides inhibits further synthesis of the IE 
polypeptides and, in a similar manner, early polypeptide 
synthesis is inhibited by the commencement of late polypeptide 
synthesis.
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The first demonstration that EHV-1 infected-cell 
polypeptide (ICP) synthesis is temporally regulated in a manner 
similar to HSV was carried out by examining ICP synthesis during 
a productive EHV-1 infection in rabbit kidney (RK) cells and the 
effect of metabolic inhibitors on gene expression (Caughman et 
al., 1985). At least 34 ICP species in the range 16.5kDa to 
213kDa were identified of which 22 comigrated with virion 
structural proteins. Four ICPs (203kDa, 176kDa, 151kDa, 129kDa)
were abundantly synthesised in infected RK cells labelled in the 
presence or absence of actinomycin D immediately after release 
from a 4hr protein synthesis block with cycloheximide. These 
ICPs were not detected in unblocked infected cells and were 
classed as IE polypeptides. 17 ICPs were classed as early 
proteins of which at least three (137kDa, 74kDa, 31.5kDa) 
accumulated in larger amounts in cultures treated with the viral 
DNA synthesis inhibitor phosphonoacetic acid (PAA) than in 
untreated cultures, suggesting that the decline in the synthesis 
of these species may be partly regulated by the onset of viral 
DNA replication. 12 ICPs were classified as late proteins on the 
basis of their greatly reduced synthesis in cultures in which 
viral DNA replication was inhibited by PAA. All but one of these 
species corresponded to virion structural proteins.
Gray et al. (1987a) characterised the temporal regulation 
of EHV-1 transcription in infected RK cells using metabolic 
inhibitors and demonstrated that transcription is coordinately 
regulated and sequentially ordered into IE, early and late 
phases, which supports the findings of Caughman et al. (1985) 
that EHV-1 ICP synthesis is also temporally regulated in such a 
manner. Sequences in the S component of the genome were the
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first to be transcribed and it is interesting that only a single 
IE transcript (6.0kb) was identified that could be synthesised 
in the absence of protein synthesis, although 4 IE polypeptides 
have been detected. This IE transcript mapped within the 
inverted repeats at 0.78-0.83 and 0.95-1.00 m.u. Following IE 
gene expression, early genes in the S region were expressed and 
sequences at 0.84-0.87 and 0.91-0.94 m.u. were highly 
transcribed during the early stages of infection and a l.Okb 
transcript was synthesised from these sequences. Early genes in 
the L region were the next to be expressed and during late viral 
transcription all regions of the genome were transcriptionally 
active.
It was subsequently shown that EHV-1 gene expression is 
regulated at the level of transcription although regulation at 
the translational level is also possible (Gray et al., 1987b).
The authors also constructed a transcriptional map of EHV-1 IE, 
early and late mRNAs; the presence of a single 6.0kb transcript 
which mapped to the inverted repeats was confirmed and a 4.4kb 
early transcript was found that could be transcribed from 
sequences involved in the synthesis of the 6.0kb IE transcript, 
which suggested that these sequences are differentially 
regulated during IE and early gene expression. 41 to 45 early 
transcripts (0.8kb to 6.4kb) and 18 to 20 late transcripts 
(0.8kb to lO.Okb) were also identified and mapped to individual 
restriction endonuclease fragments of the EHV-1 genome. The use 
of in vitro translation of hybrid-selected messages has mapped 
10 distinct viral proteins to the S region of the EHV-1 genome 
(Robertson et al., 1988a).
Further studies have been concerned with the
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characterisation of the EHV-1 IE proteins. Caughman et al. 
(1988) investigated the relationship between the four IE 
proteins (IE1, IE2, IE3, IE4) by analysis of their limited
proteolytic digestion profiles, antigenic cross-reactivity and 
pulse-chase patterns. It was concluded that the four IE species 
are closely related as they shared very similar peptide 
profiles, were antigenically cross-reactive and were either
produced simultaneously from the 6.0kb IE transcript or rapidly 
processed to give rise to the individual forms. IE1 was the most 
abundant and most highly phosphorylated species. The in vitro 
translation products of the EHV-1 IE mRNA were analysed by 
Robertson et al. (1988b) who demonstrated that the family of IE 
polypeptides generated by in vitro translation of the 6.0kb IE 
mRNA were of the same size and antigenicity as those detected in 
infected cells. A series of time-course and pulse-chase
experiments showed that synthesis of IE1 (193kDa), IE3 (166kDa) 
and IE4 (130kDa) occurred concomitantly, none of these species 
could be chased into another and at least two minor species were 
processed following synthesis. Since the major IE proteins were 
all successfully produced in vitro and none of the larger 
species could be chased into the smaller species, it was 
concluded that random proteolytic processing did not account for 
the production of the smaller IE proteins in vitro and in vivo. 
Furthermore, it was demonstrated that the 6.0kb IE mRNA species 
isolated during the early and late stages of infection could be 
translated to produce all of the major IE proteins, indicating
that their synthesis was not dependent on the accumulation of IE 
mRNA which occurs during a cycloheximide protein block 
(Robertson et al., 1988b).
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EHV-1 DNA Synthesis
The kinetics of EHV-1 DNA synthesis has been investigated 
in L-M cells (O'Callaghan et al.. 1968a,b) and in the Syrian 
hamster (O'Callaghan et al.. 1972) by pulse-labelling of
infected cells or animals with [3H]-deoxythymidine at different 
times during the infectious cycle and quantitation of the amount 
of radioactivity incorporated into viral DNA. This method showed 
that in infected L-M cells, EHV-1 DNA synthesis begins at 4 to 
6hr p.i., increases rapidly and reaches a peak at 12hr p.i., 
following which DNA synthesis decreases rapidly. In EHV-1- 
infected Syrian hamsters, EHV-1 DNA synthesis begins at 3 to 4hr 
p.i. and continues to increase until 8hr p.i., after which DNA 
synthesis decreases and animals die at 12 to 14hr p.i.
Enzymatic Activities Associated With EHV-1 Infection
EHV-1 has been demonstrated to encode a number of enzymes. 
These include a TK (Allen et al.. 1978b, 1979; McGowan et al.. 
1979), DNA polymerase (Kemp et al.. 1975? Allen et al., 1977)
and a ribonucleotide reductase (Cohen et al.. 1975a; Cohen et 
al.. 1977a; Allen et al.. 1978a). EHV-1 virions have also been
reported to contain a protein kinase, identifiable on the basis 
of its ability to phosphorylate viral proteins (Randall et al.. 
1972). It has been speculated that EHV-1 may also encode a 
deoxyribonuclease (Stock and Gentry, 1969).
Effect of EHV-1 Infection on Host Macromolecular Synthesis
In common with other herpesviruses, EHV-1 has a profound 
effect on macromolecular synthesis in the host. Inhibition of 
cellular DNA synthesis in EHV-l-infected L-M cells commences at
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approximately 6hr p.i. and progresses to a maximum inhibition of 
95% at 12hr p.i., the time of maximum EHV-1 DNA replication 
(O'Callaghan et al.. 1968a,b). In contrast, infection of Syrian 
hamsters with EHV-1 has little effect on cellular DNA synthesis 
in resting liver cells and a low level of DNA synthesis is 
maintained during the infectious cycle (O'Callaghan et al., 
1972). Inhibition of DNA synthesis is associated with a dramatic 
decrease in the activity of host cell DNA polymerase (Cohen et 
al., 1975a; Kemp et al.. 1975). A marked inhibition of cellular 
RNA synthesis is evident in EHV-l-infected cells which 
commences at 2hr p.i. with the onset of IE transcription and 
reaches a maximum inhibition level of 95% at 12hr p.i., the time 
of maximum EHV-1 DNA replication. (O'Callaghan et al.. 1968b;
Lawrence, 1971). The analysis of EHV-1 ICP synthesis during 
productive infection suggests that the shut-off of host protein 
synthesis is a gradual but progressive process (Caughman et al.. 
1985).
Assembly and Envelopment of EHV-1 Capsids
In common with other herpesviruses, the assembly of EHV-1
nucleocapsids takes place in the nucleus of the infected cell
and the site of envelopment appears to be the inner nuclear
membrane (O'Callaghan and Randall, 1976; O'Callaghan et al., 
1978; Spear and Roizman, 1980).
Three morphological forms of caps ids have been purified and 
characterised from EHV-l-infected cells (Perdue et al.. 1974,
1975, 1976; O'Callaghan and Randall, 1976; O'Callaghan et al..
1977, 1978). The light (L) capsids are essentially hollow shells 
since they contain no internal core structure and are devoid of
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viral DNA, intermediate (I) capsids do not possess a mature core 
structure but exhibit an internal cross-like structure and heavy 
(H) capsids are mature capsid species rich in DNA which exhibit 
the morphology of core-containing nucleocapsids. Pulse-labelling 
and pulse-chase experiments in EHV-l-infected L-M cells 
suggested that the I capsids are the chief precursor to the H 
capsids and the L capsids are defective by-products that 
accumulate during infection (O'Callaghan and Randall, 1976? 
Perdue et al.. 1976). Upon acquisition of viral DNA by the I 
capsids, the DNA becomes associated with the two major core 
proteins (45kDa, 30kDa) and is subsequently collapsed and 
packaged into a toroidal structure to form the mature H capsid. 
The detection of polyglutamic acid in mature H capsids has led 
to the suggestion that it may play a role in the collapse and 
packaging of viral DNA (O'Callaghan and Randall , 1976; Perdue 
et al.. 1976).
The envelopment of EHV-1 nucleocapsids at the nuclear 
membrane occurs by the mechanisms of budding or invagination of 
the nuclear membrane (Darlington and Moss, 1968; O'Callaghan and 
Randall, 1976? O'Callaghan et al.. 1978).
Oncogenic Transformation and Persistent Infection bv EHV-1
Preparations of EHV-1 enriched for defective interfering 
particles (DIPs) (Robinson et al.. 1980b? Dauenhauer et al.. 
1982), and UV-irradiated EHV-1 virus (Robinson et al.. 1980a),
have been shown to oncogenically transform primary hamster 
embryo fibroblasts in culture. The inoculation of EHV-1- 
transformed cells into adult syngeneic hamsters leads to the 
formation of highly metastatic tumours (Robinson et al., 1980a;
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Dauenhauer et al.. 1982). Transformed and tumour cell lines have 
been established which express viral proteins and contain stably 
integrated viral DNA sequences (Robinson et al.. 1981;
O'Callaghan et al.. 1983; Robinson and O'Callaghan, 1983). The 
region of the EHV-1 genome that is stably integrated corresponds 
to 0.32 to 0.38 m.u., implying that integration of EHV-1
sequences is associated with oncogenic transformation (Robinson 
et al.. 1981; Robinson and O'Callaghan, 1983). In addition to 
establishing oncogenic transformation, EHV-1 DIPs are also 
associated with the establishment of persistent infection 
(Robinson et al., 1980b; Dauenhauer et al., 1982). Persistently 
infected cell lines (DI cells) have been established which, 
unlike the tumour cell lines, contain a small proportion of 
cells that continue to release standard EHV-1 virus and DIPs 
even after extensive passage in culture (Robinson et al., 1980b; 
Dauenhauer et al.. 1982). The vast majority of DI cells are 
oncogenically transformed and, in common with EHV-l-transformed 
cells, can produce tumours in adult syngeneic hamsters. Viral 
transcription in EHV-1 DIP-enriched infections is temporally 
regulated in an IE, early and late manner as in a standard EHV- 
1 infection (Gray et al., 1989).
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CHAPTER 2
General Materials and Methods
The materials and methods described in this chapter are those 
routinely used throughout the experiments presented in this 
thesis. Methods specifically related to work in individual 
chapters are described in detail in the Materials and Methods 
section of that chapter.
M A T E R I A L S
Materials used during the course of the studies presented in 
this thesis were obtained from the sources listed below.
DNA
Plasmids pUC8 and pBR322, A“HindiII size markers:- Bethesda 
Research Laboratories (BRL), Paisley, U.K.
Bluescript plasmid and Bluescript-specific primers:- Northumbria 
Biologicals Limited (NBL), Cramlington, U.K.
Plasmid pGEX-2T:- Pharmacia LKB Biotechnology, Milton Keynes, 
U.K.
Plasmid pACYC-EcoRI(F) :- kindly provided by Dr. J. B. Clements, 
MRC Institute of Virology, Glasgow, U.K.
Plasmid pUR288:- kindly provided by Mr. Robert MacFarlane, 
Beatson Institute for Cancer Research, Glasgow, U.K.
EHV-4 genomic library cloned in pUC9:- kindly provided by Dr. 
Ann Cullinane, Irish Equine Centre, Naas, Eire.
Restriction Endonucleases/Modifvinq Enzymes 
Restriction endonucleases, T4 DNA ligase:- BRL.
Calf intestinal alkaline phosphatase (molecular biology grade), 
Klenow fragment of T4 DNA polymerase I, proteinase K, DNase I,
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RNase A:- Boehringer Corporation Limited (BCL), Lewes, U.K.
Nick translation kit:- Amersham International pic, Amersham, 
U.K.
Bacterial Strains
Escherichia coli (E.coli) strains JM101 and Y1090:- NBL. 
Chemicals
Tris-equilibrated phenol:- Rathbum Chemicals Limited, 
Walkerbum, U.K.
FOrmamide:- Fluka Chemicals Limited, Glossop, U.K.
Ampicillin, tetracycline, caesium chloride, deoxynucleotide 
triphosphates, dideoxynucleotide triphosphates:- BCL.
Agarose, low melting point agarose, acrylamide, methylene- 
bisacrylamide, tetramethylethylenediamine (TEMED) , ammonium 
persulphate:- BRL.
Sephadex G-50, bromophenol blue, xylene cyanol, Bind-Silane, 
Repel-Silane:- Pharmacia-LKB Biotechnology.
Tryptone, yeast extract, bacteriological agar, bactopeptone:- 
Oxoid Limited, Basingstoke, U.K.
PBS tablets:- Flow Laboratories, Rickmansworth, U.K. 
Radioisotopes
[©<-35S]dATP, [o<-32P]dCTP:- Amersham International pic. 
Miscellaneous Items
Polaroid type 57 film:- Polaroid (U.K.) Limited, St. Albans, 
U.K.
X-ray film (Hyperfilm):- Amersham International pic.
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Spin-X filter centrifuge tubes:- NBL.
Whatman 3MM paper:- Whatman International Limited, Maidstone, 
U.K.
Gene Screen hybridisation membranes:- DuPont (U.K.) Limited, 
Stevenage, U.K.
All other materials were obtained from BDH Limited, Poole, U.K. 
or Sigma Chemical Company Limited, Poole, U.K.
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M E T H O D S
Growth and Storage of Parental Plasmids
The E.coli strain JM101 carrying the appropriate plasmid 
was inoculated into 5ml of L broth containing the appropriate 
antibiotic at the standard working concentration (Table 2.1).
. . .  . T?All plasmids used carried the ampicillin resistance (Amp ) gene 
with the exception of plasmid pACYC184-EcoRI(F) which carried 
the gene for tetracycline resistance (Tet). Bacterial cultures 
were grown by shaking in an orbital incubator for 16 to 20hr at 
37°C. 1ml of this culture was used to prepare a glycerol stock 
by adding an equal volume of 80% v/v glycerol/2% w/v 
bactopeptone, and this stock was then stored at -20°C until 
required. Of the remaining culture, Iml was inoculated into 
500ml of L broth containing antibiotic and incubated in an 
orbital shaker for 16 to 20hr at 37°C. Bacterial cells were 
pelleted by centrifugation (7000rpm/10min/4°C) in a Beckman 
JS7.5 rotor.
Large Scale Isolation of Plasmid DNA
Plasmid DNA was isolated by a modification of the alkaline 
lysis procedure previously described by Birnboim and Doly 
(1979). The pellet of a 500ml bacterial culture carrying 
recombinant plasmid was resuspended in 50ml of solution I (Table
2.1) and the lysate was left on ice for 30min. 80ml of 
solution II (Table 2.1) was added with gentle mixing to the 
lysate and kept on ice for lOmin. 40ml of solution III (Table
2.1) was then added with gentle mixing and the lysate incubated 
on ice for a further 15min. The lysate was centrifuged
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(7000rpm/20min/4°C) in a Beckman JS7.5 rotor to pellet bacterial 
cell debris. The supernatant was retained and filtered through 
sterile cotton gauze, if necessary, to remove any floating 
debris. Plasmid DNA was precipitated by the addition of 100ml 
(0.6 volume) of isopropanol followed by centrifugation 
(7000rpm/20min/0°C) in a Beckman JS7.5 rotor. The pellet was 
resuspended in 19ml of TE buffer (lOmM TrisHCl pH 8.0, ImM 
EDTA), to which was added 20g of caesium chloride and 1.8ml of 
3mg/ml ethidium bromide. The refractive index of the solution 
was checked (should be 1.388 to 1.390), the sample loaded into 
two 12ml Beckman 'Quick-Seal' centrifuge tubes and the tubes 
sealed using a Beckman heat sealing apparatus. Samples were 
centrifuged in a Beckman fixed angle 50Ti rotor at 40000rpm and 
18°C for 40 to 48hr. Using such an isopycnic gradient RNA 
pellets at the bottom of the tube and any protein present forms 
a pellet at the top of the tube. Two bands formed on the 
gradient- the lower, largest band was the desired closed 
circular plasmid DNA and the upper, very faint band consisted of 
linear and nicked circular plasmid DNA. The closed circular 
plasmid DNA was harvested by insertion of a 19-gauge syringe 
needle into the side of the tube and withdrawal of the band into 
a 2ml syringe. Ethidium bromide was removed from the DNA by 
addition of an equal volume (1 to 2ml) of isopropanol, vigorous 
mixing and retention of the lower aqueous phase. This was 
repeated at least four times, with 0.2ml of distilled water 
(dH20) being added to the aqueous phase between extractions to 
maintain the volume, until all traces of ethidium bromide were 
removed from the aqueous phase. Finally, the DNA was dialysed 
against O.lxTE buffer for 3 x 2hr to remove caesium chloride,
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aliquoted into 1.5ml centrifuge tubes and precipitated with two 
volumes of ethanol in the presence of 0.3M sodium acetate (pH 
6.0) at -70°C for 30min. The DNA was pelleted by centrifugation 
in a benchtop microcentrifuge at 13000rpm for lOmin, briefly 
washed with 70% ethanol and dried in a vacuum dessicator. DNA 
was resuspended in dH20 to a final concentration of 0.5mg/ml and 
stored at -20°C until required.
Restriction Endonuclease Digestion of Plasmid DNA
The structure of plasmid DNA was routinely confirmed by 
digestion with several restriction endonucleases which were used 
according to the suppliers instructions. Typically, 1 to 3ug of 
plasmid DNA was added to 0.1 volume of the appropriate 
lOx restriction endonuclease buffer (BRL, React buffer system). 
dH20 was added to bring the buffer to the working concentration 
and spermidine (Table 2.1) was added to a final concentration of 
ImM. The appropriate restriction endonuclease was added (3 
units/ug of DNA), the contents gently mixed and incubated at 
37°C for 3hr. Digestion was terminated by the addition of 0.1 
volume of sample loading dye (50% w/v glycerol, 0.1% w/v 
bromophenol blue).
Agarose Gel Electrophoresis
Agarose gel electrophoresis was carried out on horizontal 
agarose gel slabs submerged in lxTBE electrophoresis buffer 
(Table 2.1). Agarose (0.8g) was dissolved to a final 
concentration of 0.8% in lxTBE buffer (100ml) by heating in a 
microwave oven. After cooling to 50°C, the molten agarose was 
poured into the gel box and the well-forming comb inserted.
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After the gel had solidified, the comb was removed and the gel 
submerged in electrophoresis buffer. All agarose gels shown in 
this thesis were 0.8% and run in lxTBE buffer. Samples were 
loaded into the wells and gels run at a constant voltage of 2 to 
5V/cm for lhr to overnight. Gels were stained with ethidium 
bromide in dH20 at lug/ml for 30min and destained in dH20 for 
30min. DNA was visualised on a 302nm UV transilluminator and 
photographed using Polaroid type 57 film.
Purification of DNA Fragments from Agarose Gels
Plasmid DNA digested with restriction endonucleases was run 
on an agarose gel in lxTBE buffer. The gel was stained and 
destained as described previously and the appropriate DNA 
fragments were excised using a sterile scalpel. Excised gel 
slices were transferred to Spin-X filter centrifuge tubes, 
stored at -20°C for 20min and then centrifuged at 13000rpm in a 
benchtop microcentrifuge for 30min. The eluate was successively 
extracted with an equal volume of phenol (phenol is equilibrated 
with 1M TrisHCl, pH 8.0), phenol/chloroform (1:1), chloroform 
and then ether and the DNA was precipitated with two volumes of 
ethanol in the presence of 0.3M sodium acetate (pH 6.0) at -70°C 
for 30min. The DNA was pelleted by centrifugation, washed 
briefly with 70% ethanol and dried in a vacuum dessicator. This 
precipitation procedure was repeated once more, the DNA was 
finally resuspended in 20 to 50ul of dH20 and stored at -20°C 
until required.
Alternatively, where larger amounts of DNA fragment were 
required DNA was purified through low melting point agarose 
gels. In this case the desired DNA fragment was excised from the
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gel, the gel melted by incubation at 65°C for lOmin and diluted 
with two volumes of dH20 (5 to 10ml) . Residual agarose was 
removed by three successive phenol extractions and one 
chloroform extraction and the volume was reduced to about 0.5ml 
by several extractions with butanol. Finally, the DNA was 
precipitated and recovered as described above. In each case, the 
purity of the recovered DNA fragment was checked by running a 
small aliquot on an agarose gel.
Construction of Recombinant Plasmids
When a restriction fragment with homologous ends was to be 
cloned, alkaline phosphatase treatment of linearised vector DNA 
was carried out to prevent recircularisation of vector DNA 
during the ligation reaction. 5ug of plasmid DNA was digested 
with the appropriate restriction endonuclease for 3hr using 
standard conditions. At the end of the digestion 8 units of calf 
intestinal alkaline phosphatase (molecular biology grade) was 
added to the digested DNA and the incubation continued at 37°C 
for a further 30min. The DNA was extracted with equal volumes of 
phenol, phenol/chloroform (1:1), chloroform and ether, and then 
precipitated with two volumes of ethanol in the presence of 0.3M 
sodium acetate (pH 6.0) at -70°C for 30min. DNA was pelleted by 
centrifugation, washed with 70% ethanol, dried in a vacuum 
dessicator, resuspended in 20 to 50ul of dH20 and its purity 
checked by agarose gel electrophoresis.
Alkaline phosphatase treatment was not necessary when 
vector DNA was digested with two restriction endonucleases 
giving non-homologous termini, since the possibility of 
recircularisation of vector DNA in this case is minimal.
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However, it was necessary to purify vector DNA digested in this 
manner by agarose gel electrophoresis to remove the smaller DNA 
fragment which would otherwise interfere with the ligation 
reaction.
Recombinant plasmids were constructed by ligation of vector 
and insert DNA fragments as follows. Generally, lOOng of vector 
DNA was ligated to a three molar excess of insert DNA with 
compatible termini using 2 units of T4 DNA ligase in the 
presence of 50mM TrisHCl pH 7.6, lOmM MgCl2, lmM ATP, ImM DTT, 
5% w/v PEG-8000 (T4 DNA ligase buffer, BRL) , in a total volume 
of 20ul, at 14°C for 16 to 20hr. For each ligation reaction 
lOOng of vector DNA was tested for the ability to self-ligate 
in a separate reaction. This acted as a negative control and 
served to indicate the efficiency of preparation of the vector 
DNA.
Transformation of Competent E.Coli Cells With Plasmid DNA
E.coli cells competent for DNA uptake were prepared by the 
calcium chloride method (Maniatis et al.. 1982). Essentially,
lml of an overnight culture of E.coli strain JM101 was
inoculated into 100ml of L broth and grown at 37°C with 
constant shaking in an orbital incubator until the optical 
density (OD) reading at 600nm was approximately 0.4 (took 2.5 
to 3hr). Bacterial cells were pelleted by centrifugation in 50ml 
polypropylene conical tubes in a benchtop centrifuge at 2500rpm
for 5min at 4°C, resuspended in 30ml of 0.1M MgS04 and placed
on ice for 30min. Cells were pelleted by centrifugation as 
above, resuspended in 30ml of 0.05M CaCl2 and incubated on ice 
for 15min. Cells were again recovered by centrifugation,
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resuspended in 2ml of 0.05M CaCl2 and stored on ice if required 
within 24hr or stored in 15% glycerol at -70°C for use at a 
later date.
The contents of each ligation reaction were added to 0.2ml 
of competent E.coli cells prepared as described above and 
incubated on ice for 30min. This cell-DNA mixture was heat 
shocked by incubating at 37°C for 5min to facilitate entry of 
DNA into the bacterial cells. To the heat shocked mixture was 
added 1ml of L broth and the bacteria were incubated at 37°C 
for 1.5hr to allow expression of antibiotic resistance genes. 
Cells were spread onto five L agar plates (Table 2.1) containing 
the appropriate antibiotic and plates were incubated for 15min 
at room temperature to allow the liquid to be absorbed. Plates 
were inverted and incubated at 37°C for 16 to 20hr. 
Transformants appeared as separate, well-defined colonies on the 
surface of the agar plates.
Small Scale Preparation of Plasmid DNA by the Boiling Method
Transformants were screened for the presence of the desired 
recombinant plasmid by small scale isolation of plasmid DNA 
according to the boiling method (Holmes and Quigley, 1981). 8
to 24. bacterial colonies were picked from agar plates into 3ml 
of L broth containing ampicillin using sterile cocktail sticks. 
Cultures were grown in an orbital shaker at 37°C for 16 to 20hr. 
The cells from 1ml of each culture were pelleted by 
centrifugation at 13000rpm for lmin in a benchtop 
microcentrifuge, the remaining 2ml being retained as a stock 
preparation. Cells were resuspended in 75ul of STET buffer 
(Table 2.1) and 25ul of a freshly prepared solution of lysozyme
81
(lOmg/ml in dH20) was added. Samples were mixed by gentle 
vortexing, boiled in a water bath for 40 seconds and the lysates 
were centrifuged at 13000rpm for lOmin in a benchtop 
microcentrifuge. Plasmid DNA was precipitated from the 
supernatants by addition of an equal volume (lOOul) of 
isopropanol and storage at -70°C for 30min. DNA was pelleted by 
centrifugation at 13000rpm for lOmin in a benchtop centrifuge, 
washed with 70% ethanol, dried in a vacuum dessicator and 
resuspended in 30ul of dH20. lOul of DNA was digested in each 
restriction endonuclease reaction as previously described. Using 
this method, yields of lug DNA/ml of culture were routinely 
obtained.
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T A B L E  2,1 
General Stock Solutions and Buffers
L Broth Medium
tryptone lOg
yeast extract 5g
sodium chloride lOg
d20 to 1 litre
Sterilise by autoclaving.
L Aaar (1.5%)
L broth 200ml
agar 3g
Sterilise by autoclaving.
NZCYM Medium
Ampicillin
NZ amine (Type-A hydrolysate 
of casein) lOg
NaCl 5g
yeast extract 5g
casamino acids lg
MgS04.7H20 2g
dH20 to 1 litre
Sterilise by autoclaving.
Ampicillin (sodium salt) at lOOmg/ml in dH20. 
Sterilise by filtration. Store at -20°C. Use at 
final concentration of lOOug/ml.
Tetracycline
Tetracycline hydrochloride at 12.5ug/ml in 50% 
ethanol. Sterilise by filtration. Store at -20°C. 
Use at final concentration of 12.5ug/ml.
Solution I
Solution II
Solution III
0.2M EDTA (pH 8.0) 
1M TrisHCl (pH 8.0) 
1M glucose 
dH20
5M NaOH 
10% SDS 
dH20
5M potassium acetate 
glacial acetic acid 
dH20
2.5ml 
1.25ml 
2.5ml 
43.75ml
3.2ml 
8.0ml 
68. 8ml
60ml
11.5ml
28.5ml
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STET Buffer
lOxTBE
0.2M EDTA (pH 8.0) 
1M TrisHCl (pH 8.0) 
Triton X-100 
sucrose 
dH20
Tris base
boric acid
0.2M EDTA (pH 8.0)
dH20
25ml
5ml
5ml
8g
to 100ml
108g 
55g 
50ml 
to 1 litre 
Use at final concentration of lx.
3M Sodium Acetate
sodium acetate trihydrate 40.81g.
Dissolve in 80ml dH20. Adjust to pH 6.0 with 
glacial acetic acid. Make up volume to 100ml with 
dH20. Sterilise by autoclaving.
0.1M Spermidine
145mg spermidine in 10ml dH20. 
Sterilise by filtration.
1M Tris
Tris base
dH^O
121.lg 
800ml
Adjust to required pH with concentrated HC1. Make 
up volume to 1 litre with dH20. Sterilise by 
autoclaving.
0.2M EDTA (pH 8.0^  
EDTA 74.4g 
800ml
Adjust to pH 8.0 with NaOH. Make up volume to 1 
litre with dH20. Sterilise by autoclaving.
dH20
5M NaCl
NaCl 292.2g 
to 1 litre 
Sterilise by autoclaving.
dH20
5M NaOH
NaOH 
dH20
200g 
to 1 litre
10% SDS
Sterilise by filtration.
sodium dodecyl sulphate 
dH20
lOOg 
to 1 litre
Ethidium Bromide (lOma/ml)
ethidium bromide 
dH20
Store away from light.
ig
to 1 litre
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SM
NaCl 5.8g
MgS04.7H20 2.Og
1M TrisHCl (pH 7.5) 50ml
2% gelatin 5ml
dH2° to 1 litre
Sterilise by autoclaving.
Proteinase K
Proteinase K at 20mg/ml in dH20. Store at -20°C. 
Use at final concentration of 50ug/ml.
RNase
RNase A at lOmg/ml in dH20. Boil for lOmin. Store 
at -20°C. Use at final concentration of lug/ml.
DNase
DNase I at 3mg/ml in dH20. Store at -20°C. Use at 
final concentration of lug/ml.
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CHAPTER 3
Identification and Restriction Endonuclease Mapping 
of the EHV-4 Glycoprotein gB Gene
I N T R O D U C T I O N
Currently available vaccines licensed to protect against 
EHV-induced abortion and respiratory disease are generally 
considered to be disappointing from the standpoint of efficacy 
and safety. Consequently, in recent years emphasis has been 
placed on the development of safer, more effective vaccines by 
the use of recombinant DNA technology. The first step in the 
development of such vaccines involves the characterisation of 
the individual glycoprotein species of the virus envelope. 
Antigens that elicit a protective immune response could be 
developed for use as subunit vaccines by their expression in 
prokaryotic vector systems.
At the onset of the studies presented in this thesis no 
glycoprotein genes of EHV-4 had been sequenced. In this chapter 
data is presented on the genomic location of the glycoprotein gB 
gene of EHV-4. This particular envelope component was chosen for 
further study for a number of reasons. As discussed in Chapter 1 
of this thesis, extensive studies on the gB; component of HSV-1 
have demonstrated essential roles for gB in viral infectivity 
(Sarmiento et al. . 1979; Little et al.. 1981) and cell fusion
(Manservigi et al. . 1977; DeLuca et al.. 1982). Moreover, gB can
invoke both humoral (Norrild, 1980; Glorioso et al. . 1984;
Eberle et al.. 1985; Blacklaws et al.. 1987; Cantin et al..
1987) and cell-mediated (Lawman et al. . 1980; Carter et al..
1981; Chan et al.. 1985; Zarling et_al., 1986a; Blacklaws et 
al., 1987) immune responses, and can confer protective immunity 
(Chan et al. . 1985; Blacklaws et al.. 1987; Cantin et al..
1987) . As such, gB is an attractive virion envelope component
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for vaccine development.
At the onset of the studies presented in this thesis it was 
known that gB homologues were encoded by the betaherpesvirus 
HCMV (Cranage et al.. 1986) and the gammaherpesvirus EBV (Baer 
et al., 1984? Pellett et al.. 1985a) in addition to the
alphaherpesviruses HSV-1 (Bzik et al.. 1984a; Pellett et al.. 
1985b), HSV-2 (Bzik et_al., 1986; Stuve et al.. 1987) and VZV 
(Davison and Scott, 1986a? Keller et al.. 1986). The fact that 
gB is encoded by representatives of all three herpesvirus 
subgroups (o<, 3 and X ) suggested that this glycoprotein may 
have important conserved functions. It thus seemed likely that 
EHV-1 (and therefore EHV-4) would also specify gB on the surface 
of their envelopes. Unequivocal evidence for this was presented 
by Snowden et al. (1985) who used an antiserum to the oligomeric 
form of HSV-1 gB strain 17 to immunoprecipitate gB-related 
protein species from cells infected with EHV-1. The tryptic 
peptide profiles of the EHV-1 and HSV-1 gB proteins were 
similar, confirming that the two proteins share a high degree of 
structural homology. In a separate study, gB-related 
polypeptides were detected by Western blotting in HSV-1-, 
HSV-2-, BHV-2- and EHV-l-infected cells using polyvalent rabbit 
antiserum against EHV-1 (Snowden and Halliburton, 1985).
Thus, given the essential role of gB in viral infectivity 
and immunity and evidence for its presence in EHV-1 virions, it 
was undertaken to determine the genomic location of gB in EHV-4 
strain 1942. The gene for EHV-4 gB was identified within a 
genomic library by a combination of dot blot and Southern blot 
hybridisation analysis using probes derived from the HSV-1 gB 
gene. The derivation of probes from the HSV-1 gB DNA sequence
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was facilitated by the available mapping and DNA sequence data 
for the genomic region of HSV-1 which encodes the gB gene. 
Analysis of HSV-1 mutants temperature-sensitive for growth and 
accumulation of gB localised the gB gene to between 0.345 and 
0.368 m.u. (Little et al.. 1981; DeLuca et al. . 1982; Holland et 
al., 1983b). Independent studies mapped a mRNA of approximately 
3.1 to 3.3kb in this region (Bzik et al.. 1984a; Holland et al.. 
1984a) and this mRNA was confirmed to be that for gB by Rafield 
and Knipe (1984), who showed that the polypeptide produced by in 
vitro translation of this species could be immunoprecipitated 
with monoclonal antibodies to gB. Nucleotide sequence analysis 
of the gB gene has been carried out for HSV-1 strain KOS (Bzik 
et al., 1984a) and strain F (Pellett et al., 1985b) .
Localisation of the EHV-4 gB gene was facilitated by the known 
colinearity of the EHV-4 genome with the Il”Isl arrangement of 
the HSV-1 genome (Cull inane et_al., 1988). The available map 
position for the HSV-1 gB gene allowed a prediction of the EHV-4 
genomic region that may contain the gB gene and the 57 and 3' 
boundaries were determined using 5' and 3' HSV-1 gB DNA probes. 
Hybridisation data was confirmed by restriction endonuclease 
mapping of the genomic region to which the HSV-1 gB sequences 
hybridised. The restriction endonuclease map of this region 
identified a suitable fragment for subcloning into a plasmid 
vector for subsequent detailed sequence analysis of this gene.
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M A T E R I A L S  A N D  M E T H O D S
Cloning of HSV-1 aB DNA Sequences
The plasmid pACYC-EcoRI(F) was double-digested with 
KpnI/XhoI, the products of digestion separated on a 0.8% agarose 
gel and the 3.3kb fragment excised and purified through Spin-X 
tubes as previously described. This fragment was ligated between 
the Kpnl and Xhol sites of plasmid vector pIC20R using 
techniques described previously to generate the plasmid pICgB.
Restriction Endonuclease Mapping of EHV-4 DNA
Restriction endonucleases were used according to the 
suppliers instructions (BRL). The products of restriction 
endonuclease digests were separated by electrophoresis through 
0.8% agarose gels run in lxTBE buffer. Bacteriophage lambda (,X ) 
DNA fragments generated by digestion with Hindlll were used as 
size markers.
Dot Blot Analysis
The C, F and M viral restriction fragments from an EHV-4 
library cloned in the BamHI site of pUC9 were excised with BamHI 
and purified through low melting point agarose gels as 
previously described. Purified fragments were spotted onto Gene 
Screen hybridisation membranes, previously wetted in Gene Screen 
transfer buffer (Table 3.1), in lOOng, 200ng and 400ng amounts. 
In a subsequent experiment, the four subfragments of BamHI-C 
obtained by digestion with Smal were spotted onto membranes as 
described above. In all experiments, lOOng of plasmid vectors 
pBR322 and pUC8 were used as negative controls and lOOng of
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unlabelled probe DNA was used as a positive control. The DNA was 
left to dry onto membranes for 5min at room temperature. 
Membranes were placed, DNA facing upwards, on a sheet of Whatman 
3MM paper saturated with denaturation solution (0.5M NaOH/1.5M 
NaCl) for 2 x 5min at room temperature, ensuring that the 
uppermost surface of the membranes did not become covered in 
solution. DNA was neutralised by 2 x 5min exposures of membranes 
to 1M TrisHCl pH 8.0/1.5M NaCl as described above. Membranes 
were briefly air dried and DNA was immobilised by baking 
membranes between two sheets of Whatman 3MM paper at 80°C for 
2hr.
Southern Blot Analysis
The 13.6kb BamHI-C fragment of EHV-4 (which was cloned in 
pUC9) was subjected to Southern blot analysis (Southern, 1975). 
2ug of plasmid DNA was digested with restriction endonuclease 
BamHI and also double-digested with BamHI and each of the 
restriction endonucleases Bgll, EcoRI, PstI, PvuII, and Smal to 
release viral DNA sequences from vector sequences, using 
standard conditions. Double digests were carried out in a single 
step in React 2 buffer (BRL) (50mM TrisHCl pH 8.0, lOmM MgCl2, 
50mM NaCl) except for BamHI/Smal digestion which required 
sequential digestions (Smal will not operate in React 2 buffer 
and requires its own buffer, React 4: 20mM TrisHCl pH 7.4, 5mM 
MgCl2, 50mM KC1) . Digested DNA was electrophoresed on 0.8% gels 
in lxTBE buffer, stained with ethidium bromide and photographed 
under UV light as previously described. The gel was placed in a 
glass baking dish and any unused areas of the gel were removed 
with a sharp scalpel. The DNA was denatured by soaking the gel
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in 250ml of 0.5M NaOH/1.5M NaCl for 2 x 15min at room 
temperature with gentle shaking. The gel was rinsed with dH2° 
and then neutralised by soaking in 250ml of 1M TrisHCl pH 8.0/ 
1.5M NaCl for 2 x 15min. at room temperature with gentle 
shaking. The gel was rinsed with dH20 and then soaked for 3 x 
20min in Gene Screen transfer buffer at room temperature with 
gentle shaking. The gel was now ready for Southern transfer to a 
hybridisation membrane. A suitably sized glass plate (to act as 
a support) was placed on top of four rubber bungs in a glass 
dish (6 to 8cm in depth) - this glass dish acted as a buffer 
reservoir during transfer. A sheet of Whatman 3MM paper (58cm x 
68cm) was cut into quarters and these four sheets were wrapped 
around the glass plate support, so that the overhanging
edges could act as wicks for buffer transfer. Gene Screen 
transfer buffer was added to the dish until the level was just 
below the glass support and any air bubbles present in the 3MM 
paper were removed. The gel was placed onto the saturated 3 MM 
paper and air bubbles between the gel and the 3MM paper were 
removed. A piece of Gene Screen membrane, cut to the required 
size, was briefly soaked in transfer buffer and placed in 
position on the gel, and all air bubbles between the gel and the 
membrane were removed. Four sheets of 3MM paper, cut to the same 
size as the gel, were wet in transfer buffer and placed on top 
of the membrane and all air bubbles were removed. A stack of 
paper towels (6 to 8cm high) was placed on the 3MM paper and a 
glass plate was put on the top of the stack. A light weight was 
applied to the stack to ensure even contact during transfer. 
Finally, the area around the gel was surrounded with Saran wrap 
to prevent the short-circuiting of fluid between the 3MM
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paper under the gel and the paper towels. Transfer was allowed 
to proceed for 16 to 20hr, the membrane was carefully removed 
and soaked in transfer buffer for 5min. Excess fluid was drained 
from the membrane which was then briefly air dried at room 
temperature. The membrane was placed between two sheets of 3MM 
paper and baked at 80°C for 2hr to immobilise DNA.
Preparation of DNA Probes (Nick Translation)
All probes were prepared by the method of nick translation 
in which DNA is labelled to high specific activity by E.coli DNA 
polymerase I (Rigby et al.. 1977). Generally, 0.5 to lug of DNA 
fragment previously purified through low melting point agarose 
gels or Spin-X tubes was used in a nick translation reaction. 
The reaction was set up as follows: lOul 5x nick translation 
nucleotide/buffer solution (Amersham), 5ul enzyme solution 
(Amersham) , lOul (lOOuCi) [©<-32P]dCTP (S.A.>800 Ci/mmole) , 0.5
to lug DNA in TE, dH20 to 50ul. The contents were mixed by
pipetting and the reaction was incubated at 14°C for 2.5hr. The 
reaction was terminated by the addition of 5ul of 0.2M EDTA. 
Unincorporated label was removed from incorporated label by 
separation through a Sephadex G-50 column. Sephadex G-50 was 
prepared by adding 30g of powder to 250ml of TE and heating at 
65°C for 2hr. After cooling to room temperature, the supernatant 
was replaced with an equal volume of TE. A Sephadex G-50 
column was prepared by packing a 5ml glass pipette plugged 
with glass wool with Sephadex G-50 prepared as described above, 
and the column was washed with two column volumes of TE. The
DNA sample was applied to the column and once the sample had
entered the matrix a reservoir of TE was connected to the
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column. . The separation of labelled DNA from free labelled 
nucleotide was monitored with a Geiger counter- two peaks were 
observed, the leading peak corresponding to the labelled DNA. 
The labelled DNA was collected into a 1.5ml centrifuge tube 
(an eluate of 1 to 1.5ml), the radioactivity measured by 
counting in a liquid scintillation counter (a specific activity 
of 1 to 2 x 108 cpm/ug of DNA was routinely obtained) and the 
labelled DNA stored at -20°C until required. Labelled DNA was 
denatured prior to use in hybridisations by boiling for lOmin.
Hybridisation of Immobilised DNA to Labelled DNA Probes
Membranes containing immobilised DNA were hybridised to 
radioactively labelled DNA probes as follows. Membranes were wet 
in transfer buffer and then prehybridised in 10ml of 
hybridisation buffer (Table 3.1) at 42°C for 16 to 20hr, with 
constant agitation, in heat-sealable plastic bags. All air 
bubbles were expelled from the bags prior to sealing. Denatured 
probe DNA was added to the prehybridised membranes at a 
concentration of lOng/ml of hybridisation buffer (106 cpm/ml 
of hybridisation buffer for a probe of specific activity
O t .
10 cpm/ug of DNA) . This was accomplished by mixing the 
appropriate volume of probe DNA with 2ml of hybridisation 
buffer, adding this to the bags containing the membranes in 
hybridisation buffer, mixing evenly by hand and expelling all 
air bubbles prior to resealing the bags. Hybridisation was 
carried out at 42°C for 16 to 20hr with constant shaking. 
Following hybridisation, membranes were carefully removed from 
the bags and prewashed in 2xSSC for 2 x 15min at room 
temperature. Unbound probe was removed from membranes by washing
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in either 2xSSC-0.1% SDS, lxSSC-0.1% SDS, or 0.1xSSC-0.1% SDS 
for 3 x 20min at 65°C with constant shaking. Finally, membranes 
were rinsed in O.lxSSC, air dried, sealed in plastic bags, and 
exposed to X-ray film at -70°C for 18 to 24hr.
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T A B L E  3.1
Hybridisation Stock Solutions and Buffers
20xSSC
Gene Screen Transfer Buffer f40x)
NaH2P04 156g
Na2HP04 178g
dH20 800ml
Adjust to pH 6.5 with HC1. Make up volume to 1 litre
with dH20. Use at final concentration of lx.
NaCl 175.3g
sodium citrate 88.2g
dH2° 800ml
Adjust to pH 7.0 with NaOH. Make up volume to 1 litre
with dH20.
Denatured Salmon Sperm DNA
Salmon sperm DNA at lOmg/ml in dH20. Shear by- 
repeated passage through a 21-gauge needle. Boil for 
lOmin. Store at -20°C. Boil for 5min just before use.
Dextran Sulphate (50%)
50g dextran sulphate in 80ml dH20. Dissolve by 
vigorous stirring. Make up volume to 100ml with dH20. 
Store at -20°C.
Denhardt's Solution (50x)
Ficoll 5g
polyvinlypyrrolidone 5g
bovine serum albumin (Fraction V) 5g
dH20 to 500ml
Store at -20°C.
Hybridisation Buffer
40% formamide 
5xDenhardt's solution 
5xSSC
10% dextran sulphate 
2xGene Screen transfer buffer 
0.1% SDS
lOOug/ml denatured salmon sperm DNA
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R E S U L T S
Derivation of HSV-1 gB DNA Hybridisation Probes
The derivation of probes was aided by an available 
restriction endonuclease map of the HSV-1 EcoRI-F fragment which 
contains the gB gene (Figure 3.1). The 3.3kb KpnI/XhoI fragment 
(the smallest subfragment of EcoRI-F which contains the entire 
gB gene) was excised from plasmid pACYC-EcoRI(F) (Figures 3.2 
and 3.3) and inserted between the Kpnl and Xhol sites of plasmid 
vector pIC20R to generate the recombinant plasmid pICgB (Figure
3.4). Analysis of the HSV-1 gB DNA sequence demonstrated the 
fortuitous location of Narl and PstI restriction endonuclease 
sites that would allow the generation of 5' and 3' probes. Thus, 
digestion of pICgB with Narl would release a 650bp fragment 
encoding amino acids 121 to 337 of the gB protein. This was 
called the 5' Narl probe (Figure 3.4) . Digestion of pICgB with 
PstI would release an 810bp fragment encoding amino acids 531 to 
800 of the gB protein. This was called the 3' PstI probe (Figure
3.4). The restriction endonuclease analysis of pICgB is shown in 
Figure 3.5. The salient features of the HSV-1 gB gene and the 
regions used as probes are shown in Figure 3.6.
Dot Blot Analysis
Initial experiments were carried out to unequivocally 
identify the EHV-4 BamHI genomic fragment which contains the gB 
gene by dot blot analysis. On the basis of previous colinearity 
studies between EHV-4 and HSV-1 (Cullinane et al., 1988), the
EHV-4 gB gene was predicted to map within BamHI-C. The 
contiguous BamHI-C, F and M fragments of the EHV-4 genome were
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used in dot blot analysis. The 5' Narl probe hybridised only to 
BamHI-C (Figure 3.7) . The 3' PstI probe also hybridised only to 
BamHI-C (Figure 3.8). Since BamHI-C is a large fragment 
(13.6kb), it was necessary to identify the exact region of this 
fragment to which the HSV-1 gB probes hybridised.
The structure of the plasmid pUC9 containing the EHV-4 
BamHI-C fragment is shown in Figure 3.9. Restriction 
endonuclease analysis of this plasmid with Smal and BamHI/Smal 
revealed that three Smal sites are present in BamHI-C which 
dissect it into four subfragments of approximately 6.5kb, 3.4kb, 
2.3kb and 1.4kb, and that the rightmost Smal site occurs 3.4kb 
from the right terminus of BamHI-C (Figure 3.10a, lanes 1 and 
2). As such, each of these four subfragments of BamHI-C could 
then be analysed by dot blotting to determine which subfragment 
contains the gB gene. Prior to this it was necessary to obtain a 
restriction map of BamHI-C complete for Smal. This was 
constructed by a series of digests shown in Figure 3.10a (lanes 
3 to 8). There is a single Kpnl site in BamHI-C giving two 
fragments of 9.4kb and 4.2kb (lane 3). To determine the order of 
the two remaining Smal sites and the single Kpnl site, purified 
9.4kb and 4.2kb BamHI/Kpnl sub fragments of BamHI-C were digested 
with EcoRI, since the position of the EcoRI sites within BamHI-C 
was known. Since the 9.4kb BamHI/Kpnl and 6.5kb Smal-generated 
fragments contained the two EcoRI sites (lanes 4 and 6) and the 
4.2kb BamHI/Kpnl fragment did not (lane 5), it was concluded 
that the first Smal site occurs 6.5kb, and the first Kpnl site 
9.4kb, from the left terminus of BamHI-C. The position of the 
remaining Smal site was determined by digestion of the 9.4kb and 
4.2kb BamHI/Kpnl fragments with Smal (lanes 7 and 8). The
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restriction map of BamHI-C complete for EcoRI, Kpnl and Smal, 
consistent with the mapping data in Figure 3.10a, is shown in 
Figure 3.10b.
Dot blot analysis of the four subfragments of EHV-4 BamHI-C 
generated by BamHI/Smal digestion demonstrated that both the 5' 
Narl and 3' PstI HSV-1 gB probes hybridised only to the 6.5kb 
BamHI/Smal left-terminal subfragment (Figures 3.11 and 3.12).
Southern Blot Analysis
The plasmid pUC9 containing EHV-4 BamHI-C was digested with 
BamHI and double-digested with BamHI and each of the restriction 
endonucleases Bgll, EcoRI, PstI, PvuII and Smal to release EHV-4 
sequences from vector sequences. A gel showing the fractionated 
fragments is presented in Figure 3.13 and the estimated sizes of 
these fragments are presented in Table 3.2. The results of 
hybridisation of the HSV-1 gB probes to the transferred 
fragments are shown in Figures 3.14 and 3.15 and the EHV-4 
fragments to which each probe hybridised are denoted in Table 
3.3. . In conclusion, these results demonstrate that the major 
portion of the EHV-4 gB gene resides within the 2.9kb BamHI/ 
EcoRI subfragment at the left terminus of BamHI-C (Figure 
3.10b), the smallest EHV-4 fragment demonstrated to contain the 
regions to which both HSV-1 gB probes hybridised.
Derivation of a Restriction Map of the 2.9kb Fragment Containing 
the EHV-4 gB Gene
A restriction map of the 2.9kb BamHI/EcoRI fragment for 
Bgll and PvuII is shown in Figure 3.16b. This was deduced by 
restriction endonuclease analysis of subfragments of, and
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intact, EHV-4 BamHI-C (Figure 3.16a) and is consistent with the 
Southern blot hybridisation data presented. As can be seen from 
Table 3.3 and Figures 3.14 and 3.15, the only differences 
between the hybridisation pattern of the two . probes is that the 
5' Narl probe hybridised to 0.4kb and 4.2kb fragments in the 
BamHI/Bgll lane and to a 0.6kb fragment in the BamHI/PvuII lane, 
whereas the 3' PstI probe only hybridised to a 4.2kb fragment in 
the BamHI/Bgll lane and to a 2.7kb fragment in the BamHI/PvuII 
lane. The genomic mapping of the EHV-4 gB gene and the region to 
which the HSV-1 gB probes hybridised are summarised in Figure 
3.17.
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Figure 3.1 Map of restriction endonuclease fragments for BamHI, 
Kpnl and Xhol within the HSV-1 EcoRI-F fragment. Fragment sizes 
are shown in base pairs. The smallest fragment containing the 
entire HSV-1 gB gene is indicated by an arrow. Adapted from 
Holland et al. (1984a).
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Figure 3.2 Physical map of plasmid pACYC-EcoRI (F). The broken 
line represents pACYC184 DNA and the solid line represents the 
16.5kb HSV-1 EcoRI-F fragment. Sizes are shown in kilobases. 
The EcoRI (E), Kpnl (K) and Xhol (X) sites are indicated. The 
3.3kb Kpnl/Xhol fragment which contains the entire HSV-1 gB gene 
is denoted by a thick bar.
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Figure 3.3 Restriction endonuclease analysis of plasmid 
pACYC-EcoRI(F). The plasmid was digested with EcoRI (lane 1), 
Kpnl (lane 2) , Xhol (lane 3) and KpnI/XhoI (lane 4) . Hindlll 
digested X DNA fragments were used as size markers.
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Figure 3.4 Physical map of plasmid pICgB. The broken line
represents pIC20R DNA and the solid line represents HSV-1 gB
DNA. Sizes are shown in kilobases. The EcoRI (E), Kpnl (K) , Narl 
(N), PstI (P) and Xhol (X) sites are indicated. The direction of 
transcription of the HSV-1 gB gene is denoted by an arrow. The
regions of the plasmid from which the 5' and 3' HSV-1 gB DNA
probes were derived are also indicated.
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Figure 3.5 Restriction endonuclease analysis of plasmid pICgB. 
The plasmid was digested with EcoRI (lane 1), Narl (lane 2), 
PstI (lane 3) and Xhol (lane 4) . Hindlll digested X  DNA 
fragments were used as size markers.
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Figure 3.6 Salient features of the HSV-1 gB gene. The putative 
TATA box, CAT box, mRNA initiation site, initiation codon, 
termination codon, polyadenylation signal and poly (A) addition 
site are shown according to Bzik et al. (1984a) and Pellett et 
al. (1985b). The relative positions of the 5' and 3' HSV-1 gB 
DNA fragments used as hybridisation probes are also indicated.
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Figure 3.7 Dot blot analysis of EHV-4 DNA. The EHV-4 BamHI-C, F 
and M fragments were probed with 32P-labelled 650bp Narl HSV-1 
gB (5') DNA. Hybridisation was only observed when membranes were 
washed at low stringency (2xSSC/0.1% SDS at 65°C). Some 
hybridisation of probe to vector DNA (pUC8, pBR322) was observed 
and was probably due to cross-hybridisation of G+C-rich 
sequences.
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Figure 3.8 Dot blot analysis of EHV-4 DNA. As in Figure 3.7 but 
with the 810bp PstI HSV-1 gB (3') DNA as a hybridisation probe.
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Figure 3.9 Physical map of plasmid pUC9/EHV-4 BamHI-C. The 
broken line represents pUC9 DNA and the solid line represents 
EHV-4 BamHI-C DNA. Sizes are shown in kilobases. The BamHI (B), 
EcoRI (E) and Smal (Sm) sites are indicated. The orientation of 
the EHV-4 DNA insert is denoted by an arrow.
Figure 3.10 Mapping of the Kpnl and Smal sites in EHV-4 
BamHI-C by restriction endonuclease analysis, (a) Agarose 
gels showing the products of digestion of intact BamHI-C 
and various subfragments of BamHI-C with EcoRI, Kpnl or 
Smal. The samples shown are as follows:-
BamHI-C digested with Smal (lane 1), BamHI/Smal (lane 2) 
and BamHI/Kpnl (lane 3); 9.4kb BamHI/Kpnl subfragment of 
BamHI-C digested with EcoRI (lane 4) and Smal (lane 8) ; 
4. 2kb BamHI/Kpnl subfragment of BamHI-C digested with EcoRI 
(lane 5) and Smal (lane 7); 6.5kb BamHI/Smal subfragment of 
BamHI-C digested with EcoRI (lane 6). Hindlll digested \  
DNA fragments were used as size markers.
(b) Deduced restriction map of BamHI-C showing the location 
of sites for EcoRI (E), Kpnl (K) and Smal (Sm) . B, BamHI.
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Figure 3.11 Dot blot analysis of EHV-4 BamHI-C DNA. The 6.5kb, 
3.4kb, 2.3kb and 1.4kb subfragments of EHV-4 BamHI-C generated
by digestion with Smal were probed with 32P-labelled 650bp Narl 
HSV-1 gB (5') DNA. Hybridisation was only observed when 
membranes were washed at low stringency (2xSSC/0.1% SDS at 
65°C).
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DNA Using the 3' HSV-1 gB Probe
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Figure 3.12 As in Figure 3.11 but with the 810bp PstI HSV-1 gB 
(3') DNA as a hybridisation probe.
Figure 3.13 Restriction endonuclease analysis of plasmid 
pUC9/EHV-4 BamHI-C. Plasmid DNA was digested with BamHI 
(lane 1), BamHI/Bglll (lane 2), BamHI/EcoRI (lane 3), 
BamHI/PstI (lane 4), BamHI/PvuII (lane 5) and BamHI/Smal 
(lane 6). Samples were run in duplicate prior to being 
separately transferred to membranes for hybridisation to 5' 
and 3' HSV-1 gB DNA probes. Gels were run in 0.8% agarose 
and lxTBE buffer. P-labelled Hindlll digested A DNA 
fragments were used as size markers.
F I G U R E  3.13
Restriction Endonuclease Analysis of 
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T A B L E  3.2
Sizes of Fragments Generated bv Digestion of EHV-4 
BamHI-C DNA With the Restriction Endonucleases 
Bgll. EcoRI, PstI, PvuII and Smal
Restriction
Endonuclease
Size of EHV-4 
Fragments (kb)
Size of pUC9 
Fragments (kb)
Bgll 4.2 1.4
3.4 1.2
2.2
1.2
0.8
0.7
0.6
0.4
0.1
0.1
EcoRI 10.0
2.9
0.7
2.7
PstI 3.4
3.0 
2.8 
2.8
1.0 
0.6
2.7
PvuII 4.3 2.4
4.0 0.2
2.7
1.5
0.6
0.4
0.1
0.1
Smal 6.5
3.4
2.3
2.7
1.4
Table 3.2 Approximate sizes of fragments generated by digestion 
of the pUC9 plasmid containing EHV-4 BamHI-C DNA with the 
restriction endonucleases Bgll, EcoRI, PstI, PvuII and Smal. 
Fragment sizes were predominantly estimated from electrophoretic 
mobilities in the 0.8% agarose gel shown in Figure 3.13. The 
sizes of the pUC9 vector fragments generated are also indicated.
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Figure 3.14 Southern blot analysis of EHV-4 BamHI-C DNA. 
Fragments generated by restriction endonuclease digestion, 
separated by electrophoresis and transferred to 
hybridisation membranes were probed with 32P-labelled 650bp 
Narl HSV-1 gB (5') DNA. Hybridisation was only observed 
when membranes were washed at low stringency (2xSSC/0.1%SDS 
at 65°C).
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Figure 3.15 As in Figure 3.14 but with the 810bp PstI HSV-1 gB 
(3') DNA as a hybridisation probe.
T A B L E  3,3
Summary of Hybridisation of HSV-1 gB 
DNA Probes to EHV-4 BamHI-C DNA
HSV-1 gB Probe Size of EHV-4 Restriction 
Endonuclease Fragment (kb)
BamHI Bgll EcoRI PstI PvuII Smal
650bp Narl (5') 13.6 4.2
0.4
2.9 3.0 0.6 6.5
810bp PstI (3') 13.6 4.2 2.9 3.0 2.7 6.5
Table 3.3 Pattern of hybridisation of the HSV-1 gB DNA probes 
to EHV-4 BamHI-C restriction endonuclease fragments. Weak 
hybridisation of the probes to pUC9 vector fragments was also 
observed and was possibly due to cross-hybridisation of G+C-rich 
sequences.
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Figure 3.16 Derivation of a restriction map of the 2. 9 kb 
BamHI/EcoRI left-terminal subfragment of EHV-4 BamHI-C that 
contains the gB gene, (a) Restriction endonuclease analysis 
of the 2.9kb and lO.Okb BamHI/EcoRI subfragments of 
BamHI-C. The samples shown on the gel are as follows:- 
lO.Okb BamHI/EcoRI subfragment of BamHI-C digested with 
PvuII (lane 1) and Bgll (lane 2)? 2.9kb BamHI/EcoRI
subfragment of BamHI-C digested with Bgll (lane 3), 
Bgll/PvuII (lane 4) and PstI (lane 5). Lanes 6 to 10 are 
the same as lanes 1 to 5 except that the samples were run 
for a shorter time to allow visualisation of particularly 
small fragments. Hindlll digested A DNA fragments were 
used as size markers.
(b) Deduced restriction map of the 2.9kb BamHI/EcoRI left- 
terminal subfragment of BamHI-C showing the sites for Bgll 
(Bg) and PvuII (Pv) . The first Bgll, EcoRI (E) and PvuII 
sites to the right of the 2. 9kb BamHI/EcoRI subfragment are 
shown. The arrow indicates the direction of transcription 
of the gB gene. B, BamHI.
F I G U R E  3.16
Restriction Mapping of the 2.9kb BamHI/EcoRI Subfraament 
of EHV-4 BamHI-C That Contains the gB Gene
(a) 1 2 3 4 5 A 6 7 8 9 10 A
Figure 3.17 Map of the EHV-4 genome showing restriction 
endonuclease sites and DNA fragments used in studying the 
glycoprotein gB gene, (a) Structure of the EHV-4 genome.
(b) Arrangement of BamHI and EcoRI sites along the genome.
(c) Location of EcoRI and Smal sites in the 13. 6kb BamHI-C 
fragment of the genome. (d) Detailed restriction 
endonuclease mapping of the the 2.9kb BamHI/EcoRI 
subfragment of BamHI-C, which contains the major portion of 
the gB gene. The first Bgll, PvuII and Smal sites to the 
right of the 2.9kb BamHI/EcoRI subfragment are indicated by 
arrows, (e) Arrows showing the regions of the 2.9kb 
BamHI/EcoRI subfragment of BamHI-C to which the 5' and 3' 
HSV-1 gB DNA probes hybridised, bp, Base pairs.
F I G U R E  3.17
Summary of Genomic Mapping of the EHV-4 aB Gene
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D I S C U S S I O N
The major portion of the EHV-4 gB gene has been 
successfully mapped using molecular hybridisation techniques to 
a 2.9kb BamHI/EcoRI fragment at the left terminus of the 
BamHI-C genomic fragment, corresponding to 0.408 to 0.438 m.u., 
and is transcribed in a rightward direction. Since the 5' Narl 
HSV-1 gB probe did not contain the first 357 nucleotides of the 
HSV-1 gB gene, it was predicted that a corresponding portion of 
the EHV-4 gB gene and its transcriptional control domains will 
reside in the BamHI-M fragment immediately to the left of BamHI- 
C. The genomic location and orientation of the EHV-4 gB gene are 
consistent with the general colinearity observed between the 
EHV-4 and HSV-1 genomes (Cullinane et al.. 1988). This approach 
to the detection of homologous genes in herpesvirus genomes was 
particularly well exploited by Davison and Wilkie (1983) who 
used molecular hybridisation to investigate homologous regions 
in the genomes of HSV-1, HSV-2, VZV, PRV and EHV-1. The use of 
cloned HSV-1 probes demonstrated high levels of conservation of 
the major DNA binding protein, major capsid protein, DNA 
polymerase, immediate-early protein VmwIE175 and one or both of 
the early proteins V.^136 and Vmw38, which are the two subunits 
of HSV-1 ribonucleotide reductase, between these 
alphaherpesviruses. Using HSV-1 gene probes, the genes for the 
major DNA binding protein, major capsid protein, immediate-early 
protein VmwIE175 and the two subunits of ribonucleotide 
reductase were mapped to the BamHI-M, BamHI-F, BamHI-K/P and 
BamHI-A fragments of the EHV-4 genome, respectively (Cullinane 
et al.. 1988). However, this method cannot be used for the
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identification of genes with poor homology. For example, 
attempts to identify PRV glycoproteins by using cloned HSV-1 gB, 
gC, gD and gE glycoprotein genes as probes only permitted the 
detection of the homologue of the well conserved glycoprotein gB 
in the PRV genome (Robbins et al.. 1987).
A novel approach to the identification of poorly conserved 
genes has recently been reported. Using short, degenerate 
oligonucleotide primers in a polymerase chain reaction, the TK 
homologue in feline herpesvirus 1 (FHV-1) has been identified 
(Nunberg et al.. 1989). The oligonucleotide primers were derived 
from the best conserved regions, identified by alignment, of 
several alphaherpesvirus TK proteins. An amplified 210bp 
fragment was then successfully used as a hybridisation probe to 
identify the genomic region of FHV-1 which encodes the TK gene. 
This method will prove useful in identifying new members of 
other viral and cellular gene families and will facilitate the 
isolation of other poorly conserved gene homologues in the 
herpesviruses.
Allen and Yeargan (1987) were the first workers to map
EHV-1 glycoproteins, and did so by utilising the strategy of 
Young and Davis (1983a,b) to determine the genomic location of 
the coding sequences of proteins for which monoclonal antibodies 
are available. By immunoscreening an EHV-1 genomic library
constructed in the Agtll expression vector with monoclonal
antibodies specific for each of the six major EHV-1 
glycoproteins (gp2, 10, 13, 14, 17/18, 21/22a), recombinant
bacteriophage which expressed EHV-1 glycoprotein epitopes as 
fusion products with (3-galactosidase were readily identified. 
The DNA contained in the recombinant phage was used as a
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hybridisation probe to map the insert sequences on the viral 
genome. All glycoproteins mapped to the UL region with the 
exception of gp 17/18 which was mapped to the Ug region (Figure 
3.18). The genes for gpl3 and gpl4 mapped to positions colinear 
with the gC and gB homologues, respectively, of other 
alphaherpesviruses, and the map location of gpl4 corresponds to 
that presented here for EHV-4 gB. It was subsequently proposed 
that gpl7/18 represents the homologue of HSV-1 gE (Allen and 
Coogle, 1988) . The study of Allen and Yeargan (1987) also 
identified three highly abundant glycoproteins (gp2, 10, 21/22a) 
for which no counterparts are present in HSV-1. On the 
otherhand, none of the EHV-1 glycoproteins mapped corresponded 
to the minor HSV-1 glycoprotein, gH. It was suggested that some 
of the low-abundance glycoproteins, and also possible additional 
unidentified glycoproteins, of EHV-1 may map to the Ug region of 
the genome. This remains the most comprehensive study on the 
mapping of EHV-1 glycoproteins to date, and provides valuable 
information which could be applied to the further 
characterisation of these important virion components.
104
F I G U R E  3,18 
Mapping of the Major EHV-1 Glycoprotein Genes
Kilobases
I---------------------1-------------------- 1-------------------- 1 i i I I I
0 20 4 0  60 80  100 120 140
EHV-1
t g j h m l k  a i b f c o e q p d n r s  ul
I I I  I I, I I I I I m  Bam Hl
. I I  II I ' ll . I \ eco rij o g n m h p i  a e l  b k f  t co m
gpio gp2 gp14 gp21/22a gp17/18
gp13
Figure 3.18 Physical map of the EHV-1 genome showing the 
genomic location of the genes encoding the six major EHV-1 
glycoproteins gp2, gplO, gpl3, gpl4, gpl7/18 and gp21/22a. The 
shaded boxes indicate the smallest genomic fragments that encode 
the EHV-1 glycoprotein epitopes immunoreactive with EHV-1 
monoclonal antibodies to those glycoproteins. Adapted from Allen 
and Yeargan (1987).
CHAPTER 4
DNA Sequence of the EHV-4 Glycoprotein gB Gene 
and Analysis of the Predicted Gene Product
I N T R O D U C T I O N
The identification of EHV-4 genomic fragments containing 
the EHV-4 gB gene was reported in the previous chapter. This
chapter is therefore concerned with DNA sequence analysis of the 
2. 9 kb BamHI/EcoRI fragment at the left-hand end of the BamHI-C, 
and the rightmost end of the adjacent BamHI-M, EHV-4 genomic
fragments. Sequence analysis would identify the precise limits 
of the gB gene and yield valuable information on the structure 
of the predicted gene product. The EHV-4 gB gene product could 
then be compared with the gB-like glycoproteins of other 
herpesviruses and domains which may have important conserved 
functions identified.
It has only been over the last couple of years that
information on the DNA sequence of EHV-1 glycoprotein genes has 
begun to emerge. A 6kb BamHI/EcoRI fragment between 0.114 and 
0.148 m.u. on the EHV-1 (Kentucky T431) genome was preliminary 
identified as encoding the major glycoprotein gpl3, analogous to 
the gC-like glycoproteins of other herpesviruses (Allen and
Yeargan, 1987). Further characterisation of this region more 
accurately localised the gpl3 gene to a 1765bp AccI/EcoRI 
fragment (0.136 to 0.148 m.u.), which was subsequently
sequenced (Allen and Coogle, 1988) . The gpl3 gene was identified 
as a 1404bp ORF encoding a 468 amino acid (51kDa) protein with 
features characteristic of a membrane-spanning glycoprotein, 
showing limited but significant homology at the amino acid level 
to the gC-like glycoproteins of HSV-1, HSV-2, VZV and PRV.
In parallel with the studies presented in this chapter, 
Whalley et al. (1989) identified the EHV-1 (strain HVS-25) gB
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homologue within a 4.3kb Clal/PstI fragment spanning the BamHI-A 
and BamHI-I genomic fragments at 0.40 to 0.43 m.u. The 
DNA sequence of this fragment identified a 2940bp ORF encoding 
gB. The position of the EHV-1 gB gene was identical to that of 
the gene encoding EHV-1 gpl4 (Allen and Yeargan, 1987) and to 
that encoding EHV-4 gB as demonstrated in Chapter 3 of this 
thesis.
Virtually no sequence data had been published for the 
glycoprotein genes of EHV-4 at the start of the studies 
presented in this thesis. The only information available was 
reported by Cullinane et al. (1988) who determined the DNA 
sequence of EHV-4 BamHI-L, located at the right-hand end of Ug 
and extending into TRg. The authors identified a partial ORF at 
the left-hand end of BamHI-L which encodes the carboxyl-terminal 
255 amino acids of a protein homologous to HSV-1 glycoprotein gE
(McGeoch et al.. 1985) and VZV glycoprotein gpl (Ellis et al..
-1;
1985; Davison and Scott, 1986a).
Therefore, the DNA sequence of the EHV-4 gB gene presented 
in this chapter represents the first piece of work which 
describes the complete structural analysis of any EHV-4 
glycoprotein gene. A paper reporting this work has been 
published (Riggio et al.. 1989), a bound copy of which can be 
found at the end of this thesis.
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M A T E R I A L S  A N D  M E T H O D S
DNA Sequencing
DNA was sequenced by the dideoxy chain termination method 
(Sanger et al.. 1977), using the double-stranded DNA sequencing 
technique in which single-stranded DNA template was produced by 
alkaline denaturation of plasmid DNA. DNA fragments to be 
sequenced were cloned into Bluescript M13+ (2.9kb subfragment of 
EHV-4 BamHI-C) or were already contained within pUC9 (right-hand 
end of EHV-4 BamHI-M). Stock solutions and buffers were prepared 
as described in Table 4.1.
Sequencing Primers
Commercially available primers (M13, Reverse, KS and T7) 
were diluted to 5ng/ul. Custom made EHV-4-specific primers were 
synthesised on an Applied Biosystems 381A DNA synthesiser. The 
oligonucleotide was cleaved from the synthesis column by 4 x 
30min treatments with 10M ammonium hydroxide in a total volume 
of 2ml and deprotected at 55°C for 12 to 18hr. DNA was 
precipitated as previously described and diluted in dH20 to a 
final concentration of 5ng/ul. All primers were stored at -20°C 
until required.
Radioactive Label
The radioactive label used for all sequencing reactions was 
deoxyadenosine 5-[c<-35S] thiotriphosphate triethylammonium salt 
(dATP, Sp isomer) which was purchased from Amersham. The 
specific activity of the [o<-35S]dATP label was >1200Ci/mmol and 
the concentration was lOmCi/ml.
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Denaturation Reaction
To 1 picomole of plasmid DNA (1 picomole of DNA is 2ug of a 
3 kb plasmid) was added 4ul of 1M NaOH/lmM EDTA and dH20 to a 
final volume of 20ul, and the reaction incubated for 5min at 
room temperature. Samples were immediately placed on ice and 
neutralised by the addition of 2ul of 2M ammonium acetate (pH 
5.3). DNA was precipitated by the addition of 55ul of ethanol, 
followed by incubation at -70°C for 30min. DNA was recovered by 
centrifugation at 13000rpm for lOmin in a benchtop 
microcentrifuge, briefly washed with 70% ethanol, dried in a 
vacuum dessicator and resuspended in 8.5ul of TE buffer. This 
DNA template was used immediately in the annealing reaction.
Annealing Reaction
The annealing reaction was composed of 8.5ul DNA template, 
1.5ul 10 x annealing buffer, 2ul sequencing primer and 3ul 
(30uCi) [©<-35S]dATP. The contents of the annealing reaction
were mixed well by pipetting and incubated at 37°C for 15min. 
This constituted the template/primer/label mix (TPL mix) .
Sequencing Reaction
lul (1 unit) of Klenow enzyme was added to the TPL mix and 
mixed by gentle pipetting. This constituted the 
template/primer/label/enzyme mix (TPLE mix). 3ul of the TPLE mix 
was added to the side wall of each of four 1.5ml microcentrifuge 
tubes labelled A, C, G and T, which contained 2ul of A, C, G and 
T sequencing mix, respectively. The reactions were started by 
spinning briefly in a benchtop microcentrifuge and the samples 
were incubated at 37°C for 20min. 2ul of chase mix was added to
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the side wall of each tube, mixed by spinning and the reactions 
continued at 37°C for a further 15min. Reactions were terminated 
by the addition of 5ul of stop mix and samples were stored at 
-70°C until required. Samples were boiled for 5min prior to 
loading onto a sequencing gel. 5ul of each sample was loaded 
onto the gel for a long run and another 5ul of each reaction 
loaded, following reboiling, after about 3hr for a short run.
Polyacrylamide Sequencing Gel
Solutions used in preparation of the gel are shown in Table
4.2. The concentration of acrylamide used was 6%. The Macrophor
gel sequencing system was used according to the manufacturers
instructions (Pharmacia LKB). Wedge-shaped gels were routinely 
used. To allow for easier handling, gels were bound to the 
notched glass plate by treatment with Bind-Silane. Treatment of 
the thermostatic plate with Repel-Silane prevented sticking of
this plate to the notched glass plate containing the bound gel. 
After casting of the gels and insertion of the well-forming 
combs, they were allowed to polymerise for at least lhr at room 
temperature. Gels were pre-electrophoresed for 30min at 2000V 
and 60°C in lxTBE running buffer. Sample wells were flushed with 
running buffer prior to loading of samples which were applied to 
the gels using drawn-out capillary tubes. Gels were run at 2000V 
and 60°C until the bromophenol blue band had reached the bottom 
of the gels. When a long run was also required, the remaining 
samples were loaded at this point and electrophoresis continued 
until the bromophenol blue band from this second loading had 
reached the bottom of the gels. Gels were soaked in gel fixing 
solution for 30min prior to drying onto the notched glass plate
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with a hair drier and then subjected to autoradiography in a 
light-proof exposure box for 8 to 24hr at -70°C.
Analysis of DNA Sequence Data
DNA sequence data were compiled using the Microgenie 
programme package (Queen and Korn, 1984) . Pairwise alignments of 
amino acid sequences were carried out using this programme 
package and multiple alignments were compiled manually and 
guided by previous pairwise alignments. Protein structure was 
analysed using PEPTIDESTRUCTURE and PLOTSTRUCTURE from the 
University of Wisconsin Genetics Computer Group programmes 
(Devereux et al.. 1984) and dot matrix similarity analyses were 
carried out using COMPARE and DOTPLOT from this group of 
programmes.
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T A B L E  4.1
DNA Sequencing Stock Solutions and Buffers
DeoxvNTP Stock Solutions
Stock solutions (lOmM) of dATP, dCTP, dGTP and dTTP were 
prepared in dH20 and stored at -20°C.
dNTP Working Solutions
DeoxyNTP stock solutions were diluted (1:20) in dH20 to a 
final concentration of 0.5mM and stored at -20oC.
dNTP Mixes
(for sequencing with [o<-35S]dATP)
A° C° G° ijiO
0.5mM dCTP 20ul lul 20ul 20ul
0.5mM dGTP 20ul 20ul lul 20ul
0.5mM dTTP 20ul 20ul 20ul lul
TE buffer (pH 8.0) 20ul 20ul 20ul 20ul
DideoxvNTP Stock Solutions
Stock solutions (lOmM) of ddATP, ddCTP, ddGTP and ddTTP 
were prepared in dH20 and stored at -20°C.
ddNTP Working Solutions
ddATP 0.15mM (3ul stock solution in 200ul H20) 
ddATP 0.20mM (lOul stock solution in 500ul H20) 
ddGTP O.lOmM (4ul stock solution in 400ul H20) 
ddTTP 0.50mM (5ul stock solution in lOOul H20)
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dNTP/ddNTP Mixes
A mix 25ul A° + 25ul 0.15mM ddATP
C mix 25ul C° + 25ul 0.20mM ddCTP
G mix 25ul G° + 25ul O.lOmM ddGTP
T mix 25ul T° + 25ul 0.50mM ddTTP
Chase Mix
5ul 
5ul 
5ul 
5ul 
80ul
10 x Annealing Buffer
lOOinM TrisHCl (pH 8.0)
50inM MgCl2
Stop Mix
Gently stir 100ml formamide with 5g Amberlite Mixed Bed 
resin for 30min. Filter to remove resin. Add O.lg xylene cyanol, 
O.lg bromophenol blue and 10ml 0.2M EDTA. Store at -20°C.
Gel Fixing Solution
lOmM dATP 
lOmM dCTP 
lOmM dGTP 
lOmM dTTP 
dH20
acetic acid 200ml
methano1 200ml
dH20 1600ml
T A B L E  4.2
Sequencing Gel Stock Solutions and Mixes
Stock Acrvlamide (40%) 
acrylamide
methylene-bisacrylamide
dH20
38g
2g
to 100ml
Urea Mix
stock acrylamide
lOxTBE
urea
dH20
15ml 
10ml 
42g 
to 100ml
10% Ammonium Persulphate TAPS) 
APS
dH20
Prepare fresh when required.
0.2g 
to 2 ml
Sequencing Gel Mix 
urea mix 
10% APS 
TEMED
60ml
0.4ml
40ul
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R E S U L T S
Molecular Cloning of the EHV-4 gB Gene
The 2.9kb BamHI/EcoRI subfragment of EHV-4 BamHI-C was 
excised as a 2.9kb EcoRI fragment from the plasmid pUC9/BamHI-C 
and inserted into the EcoRI site in the poly linker of Bluescript 
M13+ (Figure 4.1). The structure of the resulting recombinant 
plasmid pBSgB is shown in Figure 4.2. The orientation of the 
EHV-4 DNA insert in pBSgB was determined by restriction 
endonuclease analysis of plasmid DNA (Figure 4.3).
Determination of the DNA Sequence of the EHV-4 gB Gene
To initiate sequencing of the DNA insert of pBSgB, T7 and 
KS primers were initially used. Thereafter, extensive use was 
made of EHV-4-specific oligonucleotide primers in order to 
rapidly generate sequence data. Since BamHI-M was predicted to 
contain the start of the gB gene, the right-hand end of this 
fragment was also sequenced. The relative orientation of BamHI-M 
in pUC9 was initially unknown and it was thus necessary to 
sequence both ends of BamHI-M (Figure 4.4) using the M13 and 
Reverse primers. The strategy used for determination of the DNA 
sequence of the EHV-4 gB gene’ is shown in Figure 4.5. An 
autoradiograph of a typical sequencing gel obtained is shown in 
Figure 4.6.
Analysis of the DNA Sequence
The DNA sequence obtained represents 3636 nucleotides. 
Translation of the DNA sequence in all three reading frames 
identified only one ORF of sufficient length to code for a
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protein of the size expected for gB. The DNA sequence of this 
region and the predicted amino acid sequence of the EHV-4 gB 
protein are shown in Figure 4.7. The gB ORF is 2925 nucleotides 
in length, with an ATG initiation codon at position 270 and a 
chain termination codon at position 3195 of the sequence, and 
its predicted translation product would be a 975 amino acid 
(HOkDa) protein. This compares with a 2709 nucleotide ORF 
encoding a 903 amino acid (100.3kDa) protein for HSV-1 gB.
Comparison of the EHV-4 gB and HSV-1 gB Genes
Alignment of the DNA sequences of the EHV-4 gB and HSV-1 gB 
genes revealed that the two genes are well conserved, 
demonstrating DNA homology of 52% (Figure 4.8). The putative 
transcriptional and translational control domains pertaining to 
these genes are particularly well conserved. The putative TATA 
box (Corden et al. . 1980) of the EHV-4 gB gene, AATATAT, occurs 
at nucleotides 119 to 125 and is almost in perfect alignment 
with the HSV-1 gB TATA box, ATATATT, at nucleotides 234 to 240 
in the HSV-1 gB sequence. The first transcribed base of 
eukaryotic mRNA (mRNA initiation site) is usually an A residue 
surrounded by pyrimidine residues (Busslinger et al.. 1980;
Breathnach and Chambon, 1981). From analysis of the EHV-4 
sequence, the A residue at position 150 (within the sequence 
CAGT) is the most likely candidate for the mRNA initiation site 
of the gB gene since it is located 25 nucleotides downstream of 
the TATA box. This is consistent with the typical 24- to 32- 
nucleotide spacing between the TATA box and the mRNA initiation 
site (Busslinger et al.. 1980; Breathnach and Chambon, 1981). 
Furthermore, this putative mRNA initiation site aligns well with
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that predicted for the HSV-1 gB gene and is consistent with the 
transcript mapping reported for the EHV-1 gB gene (Bell et al.. 
1990). The sequence ATTG at nucleotides 38 to 41 of the EHV-4 gB 
sequence reads CAAT on the opposite strand and, since it is 
about 100 nucleotides upstream of the putative mRNA initiation
site, may function as a CAT box (Breathnach and Chambon, 1981).
This CAT box is identical to, and in perfect alignment with,
that predicted for the HSV-1 gB gene.
Although the HSV-1 gB gene possesses a decanucleotide just 
upstream of the CAT box which matches the consensus binding 
sequence for the cellular transcription factor Spl (Kadonaga et 
al.. 1986) at 8 out of 10 positions (nucleotides 130 to 139), no 
such sequence is observed in the EHV-4 gB sequence.
The TATA and CAT elements are conserved in all 
alphaherpesvirus gB-like genes sequenced to date, with the 
exception of the BHV-1 gl gene which does not possess a sequence 
resembling a CAT box. However, this gene is unusual in
possessing three putative Spl binding sites, two of which are
located around the position where the CAT box would have been 
expected to occur (Whitbeck et al.. 1988). As such, the BHV-1 gl 
gene appears to be the only alphaherpesvirus gB-like gene other 
than HSV-1 gB to possess an Spl binding site.
The modified scanning hypothesis of translation states that 
the first ATG following the mRNA initiation site will act as the 
initiation codon, assuming that the local environment will
allow this to occur (Kozak, 1981, 1983) . The first such ATG in
the EHV-4 gB gene occurs at nucleotide 270 and is in-frame with 
two closely located ATGs: the second ATG at nucleotide 412 is 
immediately followed by an in-frame termination codon and the
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next, available ATG is at nucleotide 438. The sequences flanking 
the first ATG codon (ACGTCATGT) are favourable for efficient 
translation initiation at this site as proposed by Kozak (1984,
1986), namely a purine (G) at -3, C at -1 and -4, although the 
favoured G at +4 is replaced by a T. The sequences surrounding 
the second possible initiation site at nucleotide 438 
(CCCCCATGT) suggest that this site is less likely to be used 
since there is no purine at position -3 or a G at +4, although C 
residues are present at -1 and -4. The first ATG at nucleotide 
270 is the most likely initiation codon for the EHV-4 gB gene.
The termination codon of the EHV-4 gB gene is at nucleotide 
3195, 9 nucleotides prior to a consensus polyadenylation signal, 
AATAAA (Berget, 1984). The poly(A) addition site of eukaryotic 
mRNAs is usually found 10 to 30 nucleotides downstream of the 
polyadenylation signal (Fitzgerald and Shenk, 1981? Bimstiel et 
al.. 1985). Since the poly(A) addition site is usually at the
dinucleotide CA or TA, the putative poly (A) addition site of the 
EHV-4 gB gene may be at nucleotide 3221 or 3225. An additional 
element, the GT-rich cluster, is usually found about 30
nucleotides downstream of the polyadenylation signal (Bimstiel
et al.. 1985) which often conforms to the consensus sequence
YGTGTTYY (Y=pyrimidine) (McLauchlan et al. . 1985) and is
associated with 3' processing of polyadenylated mRNAs. The only 
GT-rich cluster sufficiently close to the EHV-4 gB
polyadenylation signal is the sequence CTTGTGGGTTG at
nucleotides 3226 to 3236.
Identification of the putative mRNA initiation and
termination sites from the EHV-4 gB DNA sequence predicts that 
the mRNA for this gene would be about 3070 nucleotides prior to
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polyadenylation, which is similar in size to the 3050
nucleotides predicted for the HSV-1 gB mRNA (Bzik et al., 
1984a).
Comparison of the EHV-4 gB and EHV-1 gB Genes
An alignment of the EHV-4 gB and EHV-1 gB genes is shown in 
Figure 4.9. The two genes show a remarkably high degree of 
homology (80%) with only the 5' region of the genes displaying 
albeit a limited degree of divergence. A similarly high level of 
gene conservation (86%) has also been reported for the gB genes 
of the closely related herpesviruses HSV-1 and HSV-2 (Stuve et 
al., 1987).
Identification of an Upstream ORF That Overlaps the 5' End of 
the EHV-4 gB Coding Sequences
Analysis of the EHV-4 DNA sequence identified the 
termination codon of a partial upstream ORF at nucleotide 406 
which overlaps the gB coding sequences by 136 nucleotides at its 
5' end (Figure 4.7) . This upstream ORF is the homologue of the 
HSV-1 ICP18.5 gene, whose product is involved in the transport 
of viral glycoproteins (Pellett et al.. 1986). Such an overlap 
has also been reported for PRV (Robbins et al. . 1987) and BHV-1 
(Whitbeck et al.. 1988), with overlaps of 132 and 141
nucleotides, respectively. However, in HSV-1 the ICP18.5 gene 
terminates 10 nucleotides prior to the gB initiation codon 
(nucleotide 538, Figure 4.8) and inspection of the MDV (Ross et 
al. . 1989) and VZV (Davison and Scott, 1986a) DNA sequences
revealed that the upstream ORF terminates 77 and 47 nucleotides 
prior to the gB initiation codon, respectively. No
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polyadenylation signal is evident at the 3' end of the ORFs 
encoding the ICP18.5 gene homologue in any of the 
alphaherpesviruses examined, which suggests that the 3' end of 
the transcript may be coterminal with that of the gB gene as 
reported for HSV-1 (Holland et al., 1984a).
Analysis of the EHV-4 aB Gene Product and Comparison With the 
HSV-1 aB Protein
An alignment of the predicted amino acid sequences of the 
EHV-4 gB and HSV-1 gB proteins is presented in Figure 4.10. The 
unprocessed EHV-4 gB protein is predicted to be 975 amino acids 
(HOkDa) as compared to 903 amino acids (100.3kDa) for HSV-1 gB. 
In this alignment, 47% of the amino acids are perfectly matched 
between the two proteins. The codon usage and amino acid 
composition of the EHV-4 gB protein are shown in Table 4.3. The 
G+C content of the first, second and third bases of the codons 
is 51, 41 and 50%, respectively. The strong preference for a G 
or C in the third base of the codons noted for HSV-1 gB (Bzik et 
al.. 1984a) is not evident for EHV-4 gB, and is a reflection of 
the lower G+C content of the EHV-4 gB coding region (47%) when 
compared to that of HSV-1 gB (66%).
Hydropathic analysis of the EHV-4 gB protein revealed that 
it possesses features characteristic of envelope glycoproteins: 
a hydrophobic signal sequence near the amino-terminus, a large 
hydrophilic external domain, a strongly hydrophobic membrane- 
spanning domain near the carboxyl-terminus and a predominantly 
hydrophilic cytoplasmic anchor domain at the carboxyl-terminus. 
The hydropathic profiles and secondary structure analyses for 
the EHV-4 gB and HSV-1 gB proteins are presented in Figure 4.11.
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They strongly suggest that the two proteins have a very similar 
overall structure.
In the following analysis of the EHV-4 gB protein each 
domain shall be described separately. The residue numbers 
referred to correspond to those in Figure 4.10.
i) Signal sequence domain
Unlike the HSV-1 gB signal sequence, that of EHV-4 gB is 
unusually long (84 amino acids). The 'true' EHV-4 gB signal 
sequence is preceded by an additional 56 amino acids which are 
generally hydrophilic and are evident as a distinct hydrophilic 
peak in the hydropathic profile (Figure 4.11). A similar 
hydrophilic region has also been reported for the gB homologues 
of PRV (Robbins et al. . 1987) and BHV-1 (Whitbeck et al. . 1988)
which have unusually long signal sequences of 53 and 67 amino 
acids, respectively. It has been suggested that such unusually 
long signal sequences are a reflection of constraints imposed 
upon the DNA sequence to encode both a functional signal 
sequence and the carboxyl-terminal amino acids of the ICP18.5 
protein homologue encoded by the upstream ORF (Robbins et al.. 
1987).
Signal sequences are characterised by a hydrophobic core 
sequence preceded by positively charged residues (Perlman and 
Halvorson, 1983) and immediately followed by a signal peptidase 
cleavage site near a predicted beta turn (von Heijne, 1984) . A 
strongly hydrophobic sequence from Ile13 to Val26 represents the 
hydrophobic core which would be of sufficient length to span the 
membrane but not to serve as an anchor sequence. Cleavage of the 
EHV-4 gB signal sequence probably occurs after Ala28, which is 
immediately preceded by a beta turn. The proposal of this as the
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cleavage site is supported by the observation that a helix- 
breaking residue (Gly) occurs at position 22 and a polar residue 
(Glu) at position 27, which is consistent with the general 
presence of these types of residues within the eight residues 
prior to the cleavage site (Watson, 1984) . The EHV-4 gB signal 
sequence carries an Ala at its carboxyl-terminus, one of the 
most popular residues found in this position (von Heijne, 1983? 
Watson, 1984). The predicted signal sequence also conforms to 
the -3, -1 rule (von Heijne, 1983, 1984) ie. an Ala at -1 and a 
small, neutral residue (Val) at -3. The predicted EHV-4 gB 
cleavage site is in perfect alignment with that of HSV-1 gB.
ii) Hydrophilic surface domain
By analogy with HSV-1 gB, the hydrophilic surface domain of 
EHV-4 gB is predicted to extend from Val2g to Asp740, is exposed 
on the outer surface of the viral envelope and contains epitopes 
for virus neutralising antibodies (Pellett et al., 1985b). EHV-4 
gB is predicted to possess 11 potential N-l inked glycosylation 
sites (Asn-X-Ser/Thr, where X is not Pro) in the external 
domain. Four of the six potential N-linked glycosylation sites 
in HSV-1 gB are perfectly conserved with EHV-4 gB which, taken 
together with the fact that all ten cysteine residues in the 
external domain are also conserved, suggests that the two 
proteins possess similar secondary and tertiary structures. The 
secondary structure analysis of Chou and Fasman (1978) indicates 
that, as previously predicted for HSV-1 gB (Pellett et al.. 
1985b), most of the glycosylation sites in EHV-4 gB are located 
at the junction of alpha-helical and beta-sheet domains (Figure 
4.11), thereby orientating these sites to the outer surface of 
the molecule. A potential proteolytic cleavage site, not found
121
in HSV-1 gB, was identified in the EHV-4 gB sequence (Arg- 
Arg/Ser, residues 459 to 461).
iii) Hydrophobic transmembrane domain
The three hydrophobic peaks towards the carboxyl-terminus 
in the hydropathic profile of EHV-4 gB (Figure 4.11) represent, 
by analogy with HSV-1 gB, the transmembrane domain. This domain 
consists of 69 amino acids (residues 741 to 809) and is 
identical in size to that found in HSV-1 gB. This hydrophobic 
domain is predicted to contain three antiparallel segments 
connected to each other by a very short turn region which 
traverse the membrane (Pellett et al., 1985b).
iv) Cytoplasmic anchor domain
The remaining 110 amino acids of EHV-4 gB (residues 810 to 
919) are hydrophilic and predicted to adopt an alpha-helical 
conformation. This region shares primary amino acid homology of 
49% with HSV-1 gB; two particular regions of EHV-4 gB (residues 
810 to 828 and residues 849 to 878) show local similarities with 
HSV-1 gB of 84% and 74%, respectively. Of the 110 amino acids in 
the cytoplasmic domain of EHV-4 gB, 24 are positively charged 
and 17 are negatively charged, giving an overall positive charge 
as in HSV-1 gB.
Comparison of the EHV-4 gB and EHV-1 gB Proteins
An alignment of the EHV-4 gB and EHV-1 gB proteins is shown 
in Figure 4.12. The two proteins are highly homologous, sharing 
88% of their sequences. This compares with a value of 86% 
reported for the gB proteins of HSV-1 and HSV-2 (Stuve et al..
1987). The signal sequences show greatest diversity (55% 
identity) and all ten cysteine residues in the surface domains
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are conserved between the two proteins, although EHV-1 gB 
contains an extra cysteine residue at position 259 which is 
probably not involved in secondary structure formation. The nine 
N-linked glycosylation sites in EHV-1 gB are conserved with 
EHV-4 gB, but EHV-4 gB is somewhat unusual in possessing three 
such sites in succession (EHV-4 gB residues 549 to 557) with 
only one of these sites being conserved with EHV-1 gB. This 
conserved site may be the only one of these three sites 
utilised in EHV-4 gB.
Some of the amino acid changes elsewhere between the EHV-4 
gB and EHV-1 gB proteins may represent epitope sites which can 
lead to altered antigenic specificity, in particular EHV-4 gB 
residues 91 to 103 and 256 to 262. The high amino acid
conservation between the EHV-4 gB and EHV-1 gB proteins is
consistent with the type-common nature of their antigenic
epitopes (Allen and Bryans, 1986).
An identical internal proteolytic cleavage site that aligns 
with that of EHV-4 gB is present in EHV-1 gB (RR/S, EHV-1 gB 
residues 520 to 522).
Comparison of EHV-4 gB to the gB-Like Proteins of Other
Herpesviruses
The salient features of the gB-like proteins of the eight 
herpesviruses compared in this section are summarised in Table 
4.4. Alignment of EHV-4 gB with the gB-like proteins of the 
alphaherpesviruses PRV, BHV-1, MDV, VZV and HSV-1, the 
betaherpesvirus HCMV and the gammaherpesvirus EBV (Figure 4.13) 
clearly demonstrates the highly conserved nature of gB across 
the herpesviruses, with only the amino- and carboxyl-termini
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displaying marked levels of dissimilarity. The conservation of 
all ten cysteine residues on the external domain of the 
molecules across the eight viruses indicates that the proteins 
adopt similar secondary, and possibly tertiary, structures. The 
predicted similarity of tertiary structure is reinforced by the 
conservation of several N-linked glycosylation sites on the 
proteins. For example, EHV-4 gB shares three sites with FRV, 
BHV-1 and EBV, and four with MDV, HSV-1 and VZV, with five of 
the sites in EHV-4 gB being shared with at least three other gB 
proteins. Some of these sites are particularly well conserved: 
that at EHV-4 gB position 162 is only absent in MDV and HCMV, 
another corresponding to HSV-1 gB position 429 is only absent in 
EHV-4 and EBV, whilst the best conserved site is at EHV-4 gB 
position 744 and is only absent in HCMV. Several short motifs 
are well conserved between the molecules, the most noteable 
examples being CYSRP (EHV-4 gB residues 663 to 667) and GQLG 
(EHV-4 gB residues 685 to 688) which are perfectly aligned in 
all the gB proteins and may thus be of functional significance. 
Amino acids other than cysteine are also conserved: nine
phenylalanine residues are aligned in all eight proteins and 15 
proline residues are conserved in the six alphaherpesvirus 
proteins.
VZV gpll exists as a disulphide-linked dimer composed of 
two species, each of approximately 60kDa (Grose et al.. 1984).
The mature species is a heterodimer generated by in vivo 
proteolytic cleavage after the two consecutive arginine residues 
in the sequence R-R/S near the centre of the molecule (Keller et 
al., 1986). It can be seen from Figure 4.13 that a similar site 
is also present in a similar position in the gB-like proteins of
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EHV-4 (R-R/S) , PRV (R-R/S) , HCMV (R-R/S) , BHV-1 (R-R/A) , MDV (R- 
R/D) and EBV (R-R/D) , but not in HSV-1 gB which is not cleaved. 
Post-translational proteolytic cleavage during processing has 
also been reported to occur for HCMV gB (Spaete et al.. 1988;
Britt and Vugler, 1989), PRV gll (Lukacs et al.. 1985;
Mettenleiter et al.. 1986), BHV-1 gl (van Drunen Littel-van den 
Hurk and Babiuk, 1986), and EHV-1 gB and EHV-4 gB (Meredith et 
al.. 1989; Sullivan et al.. 1989). MDV gB also appears to
undergo internal proteolytic cleavage (Ross et al.. 1989).
Although EBV gB contains a putative proteolytic cleavage site, 
it does not appear to be cleaved (Gong et al., 1987) . The
predicted proteolytic cleavage sites are located within a region 
of great diversity and such local divergence of amino acid 
sequence may be a direct result of processing at these sites. 
The cleavage sites are generally contained within a stretch of 
amino acids which have no counterparts in HSV-1 gB. For example, 
EHV-4 gB contains a 47 amino acid insertion relative to HSV-1 gB 
whilst the insertion in BHV-1 gl is 24 amino acids.
The extent of similarity between EHV-4 gB and the analogous 
proteins of other herpesviruses is readily apparent from the dot 
matrix similarity analysis presented in Figure 4.14. This 
illustrates the very close relationship between EHV-4 gB and 
EHV-1 gB, the extensive similarity between EHV-4 gB and the gB- 
1 ike proteins of other alphaherpesviruses, and the more limited 
yet significant similarity with the gB proteins of the 
betaherpesvirus HCMV and the gammaherpesvirus EBV. The overall 
percentage identity for pairwise comparisons of the herpesvirus 
gB-like proteins is summarised in Table 4.5. It is concluded 
that the alphaherpesvirus gB-like proteins show a similar degree
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of homology to each other (about 50%) but significantly less 
homology to HCMV gB (about 30%) and EBV gB (about 30%) . 
Furthermore, HCMV gB and EBV gB are as dissimilar from each 
other as they are from the alphaherpesvirus gB-like proteins 
(31% identity), which suggests that each family of herpesviruses 
may have undergone considerable evolution from a common 
ancestral virus.
Comparison of the Carboxyl-Terminal Amino Acids of the Gene 
Products of Eight Herpesviruses Analogous to HSV-1 ICP18.5
An alignment of the carboxyl-terminal amino acids of the 
ICP18.5-like gene products of eight herpesviruses is shown in 
Figure 4.15. The amino acid homology in this region is close to 
that observed for the gB proteins of these viruses. HSV-1 
ICP18.5 has been shown to demonstrate an identity of 22% with 
the gene product of EBV BALF3 (Pellett et al.. 1986) and 46% 
with the gene product of VZV gene 30 (McGeoch et al. . 1988a).
ICP18.5 is also a well conserved protein of the herpesviruses 
which can be expected to have a similar function in the 
transport of viral glycoproteins in each virus.
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F I G U R E  4.1
Physical Map and Polvlinker of the Plasmid Bluescript
X an l 2640
I’ m
T7 PRDHOTKJf
BLUESCRIPT 
M13 +
M lll.r iP I.K  Cl.OH INC SITC
C .u l 2130
C l r 1 0 1  2 1 2 3
fl'MltlKCKdatKV »• I* JtMICKKCrUITlV
••KtiaucmH
Figure 4.1 Physical map and polylinker of the plasmid 
Bluescript M13+. Primer recognition sites are indicated.
F I G U R E  4.2
Physical Map of Plasmid pBSaB
Bg
Pv Sv f B H b
Pv
0-4
0-6
0*7
pBSgB
1-7
3-2 
Pv ^
Figure 4.2 Physical map of plasmid pBSgB. The broken line 
represents Bluescript DNA and the solid line represents EHV-4 gB 
DNA. Sizes are shown in kilobases. The BamHI (B) , Bgll (Bg), 
EcoRI (E) , Hindlll (H), PvuII (Pv) and Smal (Sm) sites are 
shown. The plasmid contains a small contaminating BamHI fragment 
excised from BamHI-C during the cloning process, and this 
fragment contains an additional Hindlll site. The 
transcriptional orientation of the gB gene is denoted by an 
arrow.
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Restriction Endonuclease Analysis 
of Plasmid pBSgB
X 1 2 3 4 5 X
Figure 4.3 Restriction endonuclease analysis of plasmid pBSgB. 
The plasmid was digested with BamHI (lane 1) , Bgll (lane 2) , 
EcoRI (lane 3), Hindlll (lane 4) and PvuII (lane 5). Hindlll 
digested \  DNA fragments were used as size markers.
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Physical Map of Plasmid pUC9/EHV-4 BamHI-M
H
Sa 2-1
1-4
0-9
3-8+Ss
4-0-fSs
pUC9/EHV-4(m)Ss--0*4
4*5,0/7-2
SmSa
Figure 4.4 Physical map of plasmid pUC9/EHV-4 BamHI-M. The 
broken line represents pUC9 DNA and the solid line represents 
EHV-4 BamHI-M DNA. Sizes are shown in kilobases. The BamHI (B) , 
EcoRI (E), Hindlll (H) , PstI (P) , Sail (Sa) , Smal (Sm) and SstI 
(Ss) sites are shown. The start of the EHV-4 gB gene at the 
right-hand end of BamHI-M is indicated by an arrow.
F I G U R E  4.5
Determination of the DNA Sequence 
of the EHV-4 gB Gene
M
Bam HI EcoRI
Figure 4.5 Strategy for DNA sequence determination of the EHV-4 
gB gene. Sequence data were generated with custom made 
oligonucleotide primers. Dots represent the 5' end and 
arrowheads the 3' end of each portion of the sequence. The EHV-4 
gB ORF is denoted by a thick bar.
Figure 4.6 Autoradiograph of a typical sequencing gel 
obtained in determining the DNA sequence of the EHV-4 gB 
gene. The custom made primers used were MR10 on the upper 
strand (5'-TCCATTTCGTCCACGTT-3', corresponding to 
nucleotides 1503 to 1519 of the EHV-4 gB DNA sequence shown 
in Figure 4.7) and MR11 on the lower strand (5'- 
TGTCTTCAAGCTCAGCT-3', corresponding to the complementary 
sequence of nucleotides 2568 to 2552 of the EHV-4 gB DNA 
sequence shown in Figure 4.7). These primers were annealed 
to single-stranded DNA template generated from plasmid 
pBSgB and sequencing reactions then carried out. The 
samples shown on the gel are as follows:- 
primer MR10 (long run)- A track (lane 1), C track (lane 2), 
G track (lane 3) and T track (lane 4) ? primer MR11 (long 
run)- A track (lane 5), C track (lane 6), G track (lane 7) 
and T track (lane 8); primer MR10 (short run)- A track 
(lane 9), 0 track (lane 10), G track (lane 11) and T track 
(lane 12); primer MR11 (short run)- A track (lane 13), C 
track (lane 14), G track (lane 15) and T track (lane 16).
F I G U R E  4.6
Autoradiocrraph of a Typical Sequencing Gel Obtained in 
Dptprminina the DNA Sequence of the EHV-4 gB Gene
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Figure 4.7 DNA sequence of the right-hand end of EHV-4 
BamHI-M and the 2.9kb BamHI/EcoRI left-terminal subfragment 
of EHV-4 BamHI-C. The predicted amino acid sequences of the 
EHV-4 gB protein and the carboxyl-terminal region of the 
upstream overlapping EHV-4 gene product analogous to HSV-1 
ICP18.5 are shown above the DNA sequence. The putative TATA 
box (TATA) , CAT box (CAT), mRNA initiation site (mRNA init) 
and polyadenylation signal (poly A) of the gB gene are 
underlined. The signal sequence, surface, transmembrane and 
cytoplasmic domains of the gB protein are indicated.
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DNA Sequence of the EHV-4 gB Gene
EHV-4 98
E L A R F M V T A A K G D U S I S E F Q R F Y C F E G V T G V T A T Q R L A U K  
GAACTAGCTCGGTTTATGGTTACTGCGGCTAAAGGTGATTGGTCAATTAGCGAGTTTCAAAGGTTTTATTGCTTTGAGGGTGTGACAGGTGTGACGGCCACGCAACGGCTGGCGTGGAAA 120
CAT
Y I G E L I L A A A V F S S V F H C G E V R L L R A D R T Y P N T N G A Q R C A  
TATATCGGGGAGCTCATTCTAGCTGCCGCAGTATTCTCTTCGGTTTTCCACTGCGGAGAGGTGCGCCTTCTGCGCGCAGATCGTACATATCCAAACACCAACGGCGCACAGCGCTGCGCT 240
TATA mRNA init
S G I Y I T Y E T S C P L V A V L F V A P N G V I G E E T V V I Y D S D V F S  L
(gB) H S T C C R A I C G P Q R C Y W  R R D C G N L R Q R R V L A  30
AGCGGCATTTACATAACATACGAGACGTCATGTCCACTTGTTGCCGTGCTATTTGTGGCCCCCAACGGTGTTATTGGCGAAGAGACTGTGGTAATTTACGACAGCGACGTGTTCTCGCTT 360
L Y T V L Q Q L A P G S G A N  - (ICP 18.5)
S I H R T P A A G S U L W S Q L G N V N L P A T S P M S K D S T S L G V R T I V  70
CTATACACCGTACTCCAGCAGCTGGCTCCTGGCTCTGGAGCCAATTAGGAAATGTAAACTTGCCAGCTACCTCCCCCATGTCTAAAGACTCGACATCTCTGGGGGTGAGAACAATAGTCA 480
Signal sequence/
I A C L V L L G C C I V E A V P T T P S S Q P S T P A S T Q S A K T V D Q T L L  110
TTGCGTGTTTGGTTCTCTTGGGATGTTGTATTGTGGAAGCTGTACCAACCACGCCAAGTTCTCAGCCCAGTACTCCCGCGTCAACCCAGTCCGCTAAAACCGTTGACCAAACGCTTCTAC 600
P T E T P D P L R L A V R E S G I L A E D G D F Y T C P P P T G S T V V R I E P  150
CAACTGAAACACCAGACCCGCTCAGACTGGCTGTACGCGAGTCCGGTATACTCGCAGAGGATGGAGACTTTTACACCTGCCCGCCGCCTACTGGATCCACAGTTGTACGCATTGAACCCC 720
BamHI
P R S C P K F D L G R N F T E G I A V I F K E N I A  P Y K F  R A N V Y Y K D I V  190
CACGGTCATGTCCCAAGTTTGATCTGGGGAGGAACTTCACGGAGGGCATTGCTGTTATTTTCAAGGAAAACATAGCCCCGTACAAATTTAGAGCAAACGTCTACTACAAAGACATTGTAG 840
V T K  V W K G Y S H T S L S D R Y N D R V P V S V E E I F T L I D S K G K C S S  230
TGACAAAGGTTTGGAAAGGATACAGCCACACCTCTTTATCCGATAGATACAATGACAGAGTGCCAGTTTCAGTGGAGGAGATATTCACTCTCATCGATAGCAAAGGAAAATGTTCTTCTA 960
J C A E Y L R D N  I H H H A Y H D D E D E V E L D L V P S K F A T P G A R A U Q T  270
AGGCAGAGTACCTCCGAGATAACATTATGCATCACGCTTACCACGACGACGAAGACGAGGTGGAGCTCGACCTGGTTCCGTCTAAGTTTGCTACTCCTGGGGCCAGAGCATGGCAAACCA 1080
T N D T T S Y V G U M P W R H Y T S T S V N C I V E E V E A R S V Y P Y D S F A  310
CTAACGACACCACGTCTTATGTCGGATGGATGCCATGGAGGCACTACACATCAACCTCTGTCAACTGCATTGTCGAAGAGGTAGAAGCGCGGTCTGTTTACCCATACGACTCCTTTGCCC 1200
L S T G D I V Y T S P F  Y G L R S A A O L E H N S Y A O E R F R Q V E G Y O P R  350
TATCGACCGGTGATATTGTGTACACCTCACCGTTTTACGGCCTTCGGTCAGCTGCTCAGTTAGAACACAATAGCTACGCACAGGAGCGCTTTAGACAAGTTGAAGGATACCAACCAAGAG 1320
D L D S K L Q A G E P V T K N F I T T P H V T V S U N U T E K K I E A C T L T K  390
ACTTGGACAGTAAATTACAGGCCGGAGAGCCAGTTACCAAAAACTTTATTACTACACCTCATGTTACAGTCAGCTGGAACTGGACTGAAAAAAAGATAGAGGCGTGTACACTAACTAAAT 1440
W K E V D E L V R D E F R G S Y R F T I R S I S S T F I S N T T Q F K L E D A P  430
GGAAGGAGGTTGACGAACTTGTCAGAGATGAGTTTCGGGGGTCCTACAGGTTTACTATTCGATCCATTTCGTCCACGTTTATTAGCAACACTACTCAATTTAAGCTAGAAGATGCCCCAC 1560
L T D C V S K E A K D A I D S I Y R K Q Y E S T H V F S G D V E F Y L A R G G F  470
TCACCGACTGTGTGTCAAAAGAAGCCAAAGATGCCATAGACTCTATATACCGAAAACAGTATGAGTCTACACACGTTTTTAGTGGGGATGTGGAATTTTACTTGGCACGTGGAGGGTTCT 1680
L I A F R P H I S N E L A R L Y L N E L V R S N R T Y D L K N L L N P N A N H N  510
TAATCGCATTTAGACCGATGATTTCTAACGAACTTGCCAGGCTGTACCTAAACGAGCTTGTGAGATCTAACCGCACCTATGACCTAAAAAATCTGTTAAACCCCAACGCAAACCATAATA 1800
T N R T R R S L L S I P E P T P T Q E S L H R E O I L H R L H K R A V E A A N S  550
CCAATCGAACACGCAGGTCGCTACTATCAATACCAGAACCTACTCCAACCCAAGAGAGCCTCCACAGAGAACAAATACTACATCGCCTACACAAACGAGCAGTGGAGGCTGCGAATAGTA 1920
T N S S N V T A K Q L E L I K T T S S I E F A M L Q F A Y D H I Q S H V N E M L  590
CAAACTCTTCCAACGTCACCGCCAAACAACTAGAGCTAATCAAAACAACGTCCTCTATTGAGTTTGCTATGCTACAGTTTGCATACGATCACATCCAATCCCACGTTAATGAGATGCTAA 2040
S R I A T A U C T L Q N K E R T L U N E M V K V N P S A I V S A T L D E R V A A  630
GTAGGATAGCAACTGCGTGGTGTACACTACAAAACAAAGAGCGGACCCTCTGGAATGAGATGGTAAAGGTTAACCCAAGCGCTATTGTTTCCGCCACTCTTGACGAGCGAGTTGCGGCAA 2160
R V L G D V I A I T H C V K I E G N V Y L Q N S H R S S D S N T C Y S R P P V T  670
GGGTTTTGGGAGACGTTATAGCCATAACACATTGTGTAAAAATAGAGGGCAATGTGTACTTACAAAACTCTATGCGCTCCTCGGACAGCAACACGTGCTACTCCCGCCCACCTGTAACGT 2280
F T  I T K  N A N S R G T  I E G O L G E E N E V Y T E R K L  I E P C A  I N Q K R Y  710
TTACCATTACTAAAAATGCAAACAGCAGAGGGACGATAGAGGGCCAGTTGGGAGAAGAAAACGAGGTTTATACGGAGCGCAAGCTTATCGAGCCGTGCGCTATCAATCAAAAACGATACT 2400
F K F G K E Y V Y Y E N Y T Y V R K V P P T E I E V I S T Y V E L N L T L L E D  750
TTAAGTTTGGCAAAGAGTATGTTTACTATGAGAACTACACGTACGTTCGCAAAGTGCCCCCGACTGAAATCGAAGTGATCAGCACCTACGTTGAACTAAACTTAACTCTTTTGGAAGACC 2520
R E F L P L E V Y T R A E L E D T G L L D Y S E I Q R R N O L H A L R F Y D I D  790
GCGAGTTTCTACCCCTGGAGGTTTACACGCGAGCTGAGCTTGAAGACACGGGGCTATTGGATTACAGCGAGATACAGCGCCGTAACCAGCTTCACGCCCTCCGATTCTACGATATAGACA 2640
/Transmembrane d a m  in
S V V N V D N T A V I M Q G I A T F F K G L G K V G E A V G T L V L G A A G A V  830
GCGTTGTCAACGTGGACAACACTGCTGTCATTATGCAGGGAATTGCCACCTTTTTTAAAGGCCTTGGTAAGGTGGGAGAGGCAGTTGGGACGCTTGTACTTGGAGCGGCTGGCGCGGTTG 2760
/Cytoplasmic
V S T V S G I A S F I N N P F G G L A I G L L V I A G L V A A F F A Y R Y V M Q  870
TTTCTACAGTATCGGGTATAGCCTCATTTATAAACAACCCATTTGGGGGGCTCGCAATAGGCCTGTTGGTAATTGCGGGCTTAGTGGCTGCGTTTTTTGCCTACCGGTATGTAATGCAAC 2880
domain
I R S N P M K A L Y P I T T R S L K N K A K A S Y G Q N D D D D T S D F D E A K  910
T GCGCAGCAACCCCAT GAAAGCTCTATACCCAAT AACAACCAGGAGCCTT AAAAACAAAGCCAAAGCCTCAT ACGGCCAAAACGACGATGAT GACACTAGCGACTT CGAT GAAGCCAAGC 3000
L E E A R E M I K Y H S M V S A L E K Q E K K A M K K N K G V G L I A S N V S K  950
TGGAGGAGGCACGCGAAATGATCAAATATATGTCTATGGTTTCTGCCCTGGAAAAACAGGAAAAAAAGGCAATGAAGAAAAACAAGGGGGTTGGACTTATTGCCAGCAACGTTTCAAAAC 3120
L A L R R R G P K Y T R L R E D D P M E S E K H V -  975
TCGCACTGCGCAGGCGCGGTCCGAAATATACCCGTCTTCGAGAAGACGATCCCATGGAAAGCGAAAAAATGGTTTAAAAATGTTAAATAAATATTTTGACACGTACTTGTGGGTTGACTC 3240
poly A
ATATTTGCATAACATCTTTCTAGTTCCGGCTATAAGCCTATTTAAGCCTAGTATTTTTGCCAAAAGTTTATCATCCTCTACAAGCGCACATCCTCTCAAAAGAGTTGAATTTTGCTGTTT 3360
ATTACGCTATCCTAAAGCTAAACGCCTGTAATGGAATCTCAATGCAAAACTTCTACATCAGCCGCTGATGAAACTCTGTTGGCTGCATCGCTACCGCGGCGGAAATCCAAATAAAAACAG 3480
AAGCACCCGATTCAGACACGCCCGCTGCCACGGGGTGTCAAGACCACACCTACGCTCGCCGGCTCACCGAGAATGGTGCAATCGAAGAGATAAACACGGCTGATCTACTGGAAATGGTGC 3600
TGGCTTCT GAAAACGCTCAAAGCGAACCCGGAAT T C 
EcoRI
3636
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Alignment of the EHV-4 gB and HSV-1 aB DNA Sequences
EHV-4
HSV-1
1
1
3 4
121
1 2 7
241
2 4 7
3 6 1
3 6 7
481
4 5 9
601
5 5 0
721
641
841
7 4 9
961
8 6 9
1081
989
1201
1 1 0 7
1 3 2 0
1 2 2 7
1 4 3 6
1 3 4 7
1 5 5 6
1 4 6 6
1 6 7 5
1 5 8 5
1 7 8 5
1 7 0 5
1866
GA— ACT...... AGCT................ CGGTTTAT............... GGTTACTGCGG— -CTAAA.............
II III l l l l  II I III II I l l l l  I II II
GTCAACGGGCCCCTCTTTGATCACTCCACCCACAGCTTCGCCCAGCCCCCCAACACCGCGCTGTATTACAGCGTCGAGAACGTGGGGCTCCTGCCGCACCTGAAGGAGGAGCTCGCCCGG
CAT TATA
...................GGTG— ATTGGTCAATTAGCGAGTTTCAAAGGTTTTATTGCTTTGAGGGTGTGACAGGTGTGACGGCCACGCAACGGCTGGCGTGGAAATATATC
mi inn i i inn inn nnn i i  ii inn n i m i  i in ni l  n n n in nun
TTCATCATGGGCGCGGGGGGCTCGGGTGCTCATTGGGCCGTCAGCGAATTTCAGAGGTTTTACTGTTTTGACGGCATTTCCGGAATAACGCCCACTCAGCGCGCCGCCTGGCGATATATT 
mRNA init
GGGGAGCTCATTCTAGCTGCCGCAGTATTCTCTTCGGTTTTCCACTGCGGAGAGGTGCGCCTTCTGCGCGCAGATCGTACATATCCAAACACCAACGGCGCACAGCGCTGCGCTAGCGGC
i inn in i n n n i n i inn i n inn in i i i in i n  i i n i i n i n m i n i  i i i i
CGCGAGCTGATTATCGCCACCACACTCTTTGCCTCGGTCTACCGGTGCGGGGAGCTCGAGTTGCGCCGCCCGGACTGCAGCCGCCCGACCTCCGAAGGTCGTTACCGTTACCCGCCCGGC
start
ATTTACATAACATACGAGACGTCATGTCCACTTGTTGCCGTGCTATTTGTGGCCCCCAACGGTGTTATTGGCGAAGAGACTGTGGTAATTTACGACAGCGACGTGTTCTCGCTTCTATAC
i n i n inn i inn n n in i i m m  i i i i  in in i i n n i m m  m m  m m  i n m
GTATATCTCACGTACGACTCCGACTGTCCGCTGGTGGCCATCGTCGAGAGCGCCCCCGACGGCTGTATCGGCCCCCGGTCGGTCGTGGTCTACGACGCCGACGTTTTCTCGATCCTCTAC 
ACCGTACTCCAGCAGCT- GGCTCCTGGCT- -CT-- GGAGCCA--ATTAGGAAATGTAAACTTGCCA-GCTAC CTCCCCCATGT..... CTAAAGACTCGAC— AT.... CT
i n nnn i i  n 11 n i i i i  n n i n i i in i i i i i  n i i inn n i i in i n n
TCGGTCCTCCAGCACCTCGCCCCCAGGCTACCTGACGGGGGGCACGACGGGCCCCCGTAGTCCCGCCATGCACCAGGGCGCCCCCTCGTGGCGGCGCCGGTGGTTCGTCGTATGGGCGCT
start
C-TGGGGGTGA.... GAACAAT AGT- -CAT -TGCGT GTTT G- GTTCTCTTGGGA--- TGTTGTATTGTG.......... GAA-GCTGTACCAACCACGCCAAGTTCTCAGCCCA
i inn in i i n i i m i i i i i i i n i n n i i in i i n i i i i  n i i i i i i
CTTGGGGTTGACGCTGGGGGTCCTGGTGGCGTCGGCGGCTCCGAGTTCCCCCGGCACGCCTGGGGTCGCGCGCGACCCAGGCGGCGAACGGGGGCCCTGCCACTCCGGCGCCGCCGCCCT 
GTACTCC..... CGCGTCAACCCAGTCCG...... C-TAAAACCG-TTGACCAAACGCTTCTA--- CCAACTGAAAC-ACCAGACC--CG-CTC-AGACTGG— CTGTACGCGA
i n n i i n i in i m in i  in inn n  n i i n  n mi n i i i i i i i mu
TGGCGCCGCCCCAACGGGGGACCCGAAACCGAAGAAGAACAAAAAACCGAAAAACCCAACGCCACCACGCCCCGCCGGCGACAACGCGACCGTCGCCGCGGGCCACGCCACCCTGCGCGA 
G-- TCCGG--TAT— ACTCGCAGA--- GGATGGAGACTTTTACACCTGCCCGCCGCCTACTGGATCCACAGTTGTACGCATTGAACCCCCACGGTCATGTCCCAAGTTTGATCTGGG
i i in n i n in i i i i  i m um  inn n n n n i i i i  n m i  i n i n n ii ii i m
GCACCTGCGGGACATCAAGGCGGAGAACACCGATGCAAACTTTTACGTGTGCCCACCCCCCACGGGCGCCACGGTGGTGCAGTTCGAGCAGCCGCGCCGCTGCCCGACCCGGCCCGAGGG
GAGGAACTTCACGGAGGGCATTGCTGTTATTTTCAAGGAAAACATAGCCCCGTACAAATTTAGAGCAAACGTCTACTACAAAGACATTGTAGTGACAAAGGTTTGGAAAGGATACAGCCA
i nn in n n i m u m  inn m in i m i  n i h i m  n n n n n n  i ii i i i i i  in n ii ii i
TCAGAACTACACGGAGGGCATCGCGGTGGTCTTCAAGGAGAACATCGCCCCGTACAAGTTCAAGGCCACCATGTACTACAAAGACGTCACCGTTTCGCAGGTGTGGTTCGGCCACCGCTA
CACCTCTTTATCCGATAGATACAATGACAGAGTGCCAGTTTCAGTGGAGGAGATATTCACTCTCATCGATAGCAAAGGAAAATGTTCTTCTAAGGCAGAGTACCTCCGAGATAACATTAT
i n n i i i  i i i i i  i ii n i i m m  i n in i in n in n i in inn  i n i in i
CTCCCAGTTTATGGGGATCTTTGAGGACCGCGCCCCCGTCCCCTTCGAGGAGGTGATCGACAAGATCAACGCCAAGGGGGTCTGTCGGTCCACGGCCAAGTACGTGCGCAACAACCTGGA
GCATCACGCTTACCACGACGACGAAGACGAGGTGGAGCTCGACCTGGTTCCGTCTAAGTTTGCTACTC-CTGGGGCCAGAGCATGGCAAACCACTAACGAC-ACCACGTCTTATGTCGGA
i in i in inn inn ii i ii in in i n n n i i i in i n inn inn n i i n i i in
GACCACCGCGTTTCACCGGGACGACCACGAGACCGACATGGAGCTGAAACCGGCCAACGCCGCGACCCGCACGAGCCGGGGC-TGGCACACCACCGACCTCAAGTACAACCCCTCGCGGG
tggatgccatggaggcactacacatcaacctctgtcaactgcattgtcgaagaggtagaagcgcggtctgtttacccatacgactcctttgccctaTcgaccggtgatattgtgtacacc
i i i i  n i i i m n i n m u m  inn inn n inn n n inn m m  i i i i n mi  n ii m n i i i i
tggaggcgttcca-ccggtac---gggacgacggtaaactgcatcgtcgaggaggtggacgcgcgctcggtgtacccgtacgacgagtttgtgctggcgactggcgactttgtgtacatg
tcaccgttttacggccttcggtcagctgctcagttagaacacaatagctacgcacaggagcgctttagacaagttgaaggataccaaccaagagacttggacagtaaattacaggccgga
ii n n n n n n  in i i ii m in i  i inn n inn i i i i i  h i m  i i i i in i n n i i i i i
tccccgttttacggctaccgggaggggtcgcacaccgaacacaccacgtacgccgccgaccgcttcaagcaggtcgacggcttctacgcgcgcgacctcaccaccaaggcccgggccacg
gagccagttaccaaaaactttattactacacctcatgttacagtcagctggaactggactgaaaaaaagatag-aggcgtgtacactaactaaatggaaggaggttgacgaacttgtcag
i m in in i i n n n i i n n i i i i  inn n in i i n n n i n n in i i i i  n inn  i i i
gcgccgaccacccggaacctgctcacgacccccaagttcaccgtggcctgggactgg-gtgccaaagcgcccgtcggtctgcaccatgaccaagtggcaggaagtggacgagatgctgcg
agatgagtttcgggggtcctacaggtttactattcga-tccatttcgtccacgtttattagcaacactactcaatttaagctagaagatgccccactcaccgactgtgtgtcaaaagaag
i i i i  i n i i i i i i i i  i i m i i i i  ii i i i i n i i i i i i  n i i m i i i n in i i i i i
ctccgagtacggcggctccttccgattctc-ctccgacgccatatccaccaccttcaccaccaacctgaccgagtacccgct... CTCGCGCGTGGAC— CTGGGGGACTGCA-TCG
CCAAAGATGCCATAGACTCTATATACCGAAAACAGTATGAGTCTACACACGTTTTTAGTGGGGATGTGGAATTTTACTTGGCACGTGGAGGGTTCTTAATCGCATTTAGACCGATGATTT
m n in m i n i i i i n in i i i i i n n n i i i i  i in i i i i i  i
GCAAGGACGCCCGCGACGCCATGGACCG CA..... TCTTCGCCC......... GCAGGTACAACGCGAC— GCACATCAAGGTGGGCCAGCCGCAGT..........
CTAACGAACTTGCCAGGCTGTACCTAAACGAGCTTGTGAGATCTAACCGCACCTATGACCTAAAAAATCTGTTAAACCCCAACGCAAACCATAATACCAATCGAACACGCAGGTCGCTAC
n i n i i i i  n i i i i i  i i i i i n in i in in n n m in i  i ii i
— ACTACCTGGCCA--ATG..... GGGGCTT-TCTGATC— GCGTACC-AGCCCCT..... TCT....... CA--GC AACACGCTCG- CGGAGC
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Figure 4.8- continued
1 8 2 5  TATCAATACCAGAACCTACTCCAACCCAAGAGAGCCTCCACAGAGAACAAATACTACATCGCCTACACAAACGAGCAGTGGAGGCTGCGAATAGTACAAACTCTTCCAACGTCACCGCCA
i i  i i in i nri i i i i i i  ii ii ii i i ii ii mi  i i  h i  ii 11 i i i  m m  m
1 9 3 2  TGTACGTGCGGGAA-CACCTCCGA— GAGCAGAG—  -C C G C A-AG C CC C C AAACC C C A-C G C CC C C G C ---CG CC C ---G G G G C CAG C G ..................................... C C A A C G C G TC C G ---
1 9 4 5  AACAACTAGAGCTAATCAAAACAACGTCCTCTATTGAGTTTGCTATGCTACAGTTTGCATACGATCACATCCAATCCCACGTTAATGAGATGCTAAGTAGGATAGCAACTGCGTGGTGTA
i iiii m u  ii ii m u  ii m u  ii in m m  i in i inn n in n n n in i i i i n i iimin
2 0 1 9  ............. TGGAGCGCATCAAGACCACCTCCTCCATCGAGTTCGCCCGGCTGCAGTTTACGTACAACCACATACAGCGCCATGTCAACGATATGTTGGGCCGCGTTGCCATCGCGTGGTGCG
2 0 6 5  CACTACAAAACAAAGAGCGGACCCTCTGGAATGAGATGGTAAAGGTTAACCCAAGCGCTATTGTTTCCGCCACTCTTGACGAGCGAGTTGCGGCAAGGGTTTTGGGAGACGTTATAGCCA
inn n i iiii m m  inn in in i inn i in n i n i in 111 in n iiii i i ii inn n in
2 1 3 3  AGCTACAGAATCACGAGCTGACCCTGTGGAACGAGGCCCGCAAGCTGAACCCCAACGCCATCGCCTCGGTCACCGTGGGCCGGCGGGTGAGCGCGCGGATGCTCGGCGACGTGATGGCCG
2 1 8 5  TAACACATTGTG TAAAAAT---AG AG G G C AATG TG TAC TTAC AAAAC TCTATG CG C-TC -C TC G G ACAG C AAC ACG TG CTACTC C C G C CC ACC TG TAAC G TTTAC CATTAC TAAAAATG
i i n n i i i i  in in i i n 111111 m m  n i i i i  i i m m  m m  i n i in i in n i
2253 TCTCCACGTGCGTGCCGGTGGCCGCGGACAACGTGATCGTCCAAAACTCGATGCGCATCAGCTCGCGGCCCGGGGCCTGCTACAGCCGCCCCCTGGTCAGCTTT--CGGTACGAA G
2 2 9 9  CAAACAGCAGAGGGACGATAGAGGGCCAGTTGGGAGAAGAAAACGAGGTTTATACGGAGCGCAAGCTTATCGAGCCGTGCGCTATCAATCAAAAACGATACTTTAAGTTTGGCAAAGAGT
i in i m i  inn in i i i i  n i m m  i i i i i i  i iiiiimmi i i n ii inn i n n  i i
2 3 6 7  --ACCAG-GGCCCGTTGGTCGAGGGGCAGCTGGGGGAGAACAACGAGCTGCGGCTGACGCGCGATGCGATCGAGCCGTGCACCGTGGGACACCGGCGCTACTTCACCTTCGGTGGGGGCT
2 4 1 9  ATGTTTACTATGAGAACTACACGTACGTTCGCAAAGTGCCCCCGACTGAAATCGAAGTGATCAGCACCTACGTTGAACTAAACTTAACTCTTTTGGAAGACCGCGAGTTTCTACCCCTGG
i ii i i i i  m  i in inn i ii ii ii i n in inimn i in n in i n i i i i i  ii i mini i mini
2 4 8 4  ACGTGTACTTCGAGGAGTACGCGTACTCCCACCAGCTGAGCCGCGCCGACATCACCACCGTCAGCACCTTCATCGACCTCAACATCACCATGCTGGAGGATCACGAGTTTGTCCCCCTGG
2 5 3 9  AGGTTTACACGCGAGCTGAGCTTGAAGACACGGGGCTATTGGATTACAGCGAGATACAGCGCCGTAACCAGCTTCACGCCCTCCGATTCTACGATATAGACAGCGTTGTCAACGTGGACA
i i i i  inn n m  i i i i i i  n n nil i i i i  in i m u m  iinnn i i i i  in n in in n i i i i  n n in in
2604 AGGTGTACACCCGCCACGAGATCAAGGACAGCGGCCTGCTGGACTACACGGAGGTCCAGCGCCGCAACCAGCTGCACGACCTGCGCTTCGCCGACATCGACACGGTCATCCACGCCGACG
2659 ACACTGCTGTCATTATGCAGGGAATTGCCACCTTTTTTAAAGGCCTTGGTAAGGTGGGAGAGGCAGTTGGGACGCTTGTACTTGGAGCGGCTGGCGCGGTTGTTTCTACAGTATCGGGTA
II II I III I III I I I  I II II I I I  I II I l l l l  II II II I I I II I III I l l l l  II II II I II l l l l l
2 7 2 4  CCAACGCCGCCATGTTCGCGGGCCTGGGCGCGTTCTTCGAGGGGATGGGCGACCTGGGGCGCGCGGTCGGCAAGGTGGTGATGGGACTCGTGGGCGGCGTGGTATCGGCCGTGTCGGGCG
2 7 7 9  TAGCCTCATTTATAAACAACCCATTTGGGGGGCTCGCAATAGGCCTGTTGGTAATTGCGGGCTTAGTGGCTGCGTTTTTTGCCTACCGGTATGTAATGCAACTGCGCAGCAACCCCATGA
i i i i i  n n m m  mini in n i n nnnn m m i i  i i m  n ii ii i i i i  n n ii nil i i i i  nnnnnni
2 8 4 4  TGTCCTCCTTCATGTCCAACCCCTTTCGGGCGCTGGCCGTGGGTCTGTTGGTCCTGGCCGGCCTGGCGGCGGCCTTCTTCGCCTTTCGTTACGTCATGCGGCTGCAGAGCAACCCCATGA
2 8 9 9  AAGCTCTATACCCAATAACAACCAGGAGCCTTAAAAACAAAGCCAAAGCCTCATACGGCCAAAACGACGATGATGACACTAGCGACTTCGATGAAGCCAAGCTGGAGGAGGCACGCGAAA
i n n inn i i i i  i i i i  i n n i i i n n n i n n n i n n mini n ii nnnn i inn i n i
2 9 6 4  AGGCCCTGTACCCTCTAACCACCAAGGAGCTCAAGAACCCCACC-AACCCGGACGCGTCC--GGGGAGGGCGAGGAGGGCGGCGACTTTGACGAGGCCAAGCTAGCCGAGGCCAGGGAGA
3 0 1 9  TGATCAAATATATGTCTATGGTTTCTGCCCTGGAAAAACAGGAAAAAAAGGCAATGAAGAAAAACAAGGGGGTTGGACTTATTGCCAGCAACGTTTCAAAACTCGCACTGCGCAGGCGCG
i i i i  n in i nil n in nil i i i i  i inn i m m  ii i i n n i i m  iii i n  m m  i i i i
3 0 8 1  TGATACGGTACATGGCCCTGGTGTCGGCCATGGAGCGCACGGAACACAAGGCCAAGAAGAAGGGCA-'CGAGCCGG-CTGCTCAGCGCCAAGGTCACCGACATGGTCATGCGCAAGCGCC
t e r  p o l y  A
3 1 3 9  G--TC -C G AA ATATAC C C --G TC TTCG A-G AAG AC G ATC C C ATG G A AAG CG AAA AAA TG -G TTTA AAA ATG TTAAA TA A A T-ATTTTG AC AC G TAC TTG TG G G TTG AC TCATATTTG CAT
I I I II II l l l l  II I I l l l l l l  I I II I I I  II I I I  l l l l l  I II II I I I  III III I
3 1 9 8  GCAACACCAACTACACCCAAGTTCCCAACAAAGACGGTGACGCCGACGAGGACGACCTGTGACGGGGGGTTTGTTGTA A ATAA AAACCACGCGTGTTAAACCGCATGCGCATCTTTTGGT
t e r  p o l y  A
3 2 5 1  AACATCTTTC TAGTTCCGGCTATAAGCCTATTTAAGCCTAGTATTTTTGCCAAAAGTTTATCATCCTCTACAAGCGCACATCCTCTCAAAAGAGTTGAATTTTGCTG TTTATTACG CTAT
I II I I II I II I I  I I  I I  II I II I! Ill I I I I  III I II III I I III I
3 3 1 8  --TTTTTTG TTTG G TCAGCCT-TTTGTGTGTGTGTGG GAAGAAAGAAAAAGGAACACATAAACTCCCCCGGGTG TCCGCGGCCTGT--TTCCTCTTTCCTTTCCCGTGACAAAACG-GAC
3 3 7 1  CCTAAAGCTAAACGCCTGTAATGGAATCTCAATGCAAAACTTCTACATCAGCCGCTGATG-AAACT-CTGTTGGCTGCATCGCTACCGCGGCGGAAATCCAAATAAAAACAGAAGCACCC
II I I I III I l l l l l  I II II III III II I I I I I  II I I II I I I I III II III! I I
3432 CCCCTTGGTCAGTGCCGATTTCCTCCCCCCCACGC-CTTCCTCCACGTCAAAGGCTTTTGCATTGTAAAGCTACCCGCCTACCCGCCCCTCCCAATAAAAAAAAAAGAACATACACCAAT
3489 GATTCAGACACGCCCGCTGCCACGGGGTGT--CAAGA-CCACACCTACGC-TCGCCGGCTCACCGAGAATGGTGC-AATCGAAGAGATAAACACGGCTGATCTACTGGAAATGGTGCTGG
i i i i  i i i i  i i i i  in i i n i i i i in ii n i i i i  i i i i i i i  n i i i i ii
3 5 5 1  GGGTCTTATTTGGTATTACCTGGTTTATTTAAAAAGATATACAGTAAGACATCCCATGGTACCAAAGACCGGGGCGAATCAGCGGGCCCCCATCATCTGAGAGAC-GAACAAATCGGCGG
3 6 0 4  CTTCTGAAAACGCTCAAAGCGAACCCGGAATTC
I I I  I l l l l  I II I I I
3670 C-GCGGGCCGTG-TCAACGTCCACGTGTGCTGCGCTGCTGGCGTTGACAAGGCCCCGGCCTCCGCGTTGGATGCTCCGGTTGGGATCC
Figure 4.8 Alignment of the EHV-4 gB and HSV-1 (KOS) gB DNA 
sequences. The upper sequence is that of EHV-4 gB, and the lower 
sequence that of HSV-1 gB. Identical residues are indicated with 
a vertical bar, and dashes denote spaces introduced to maximise 
homology between the two sequences. Salient features (TATA box, 
CAT box, mRNA initiation site, termination codon [ter] and 
polyadenylation signal) are indicated for each sequence. The 
HSV-1 (KOS) gB DNA sequence is from Bzik et al. (1984a).
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Alignment of the EHV-4 gB and EHV-1 aB DNA Sequences
EHV-4
EHV-1
1
1
121
121
241
241
361
361
478
481
592
601
712
721
832
841
952
961
1071
1080
1191
1200
1311
1320
1431
1440
1551
1560
1671
1680
1791
1800
1905
1920
2025
2040
CAT
gaactagctcggtttatggttactgcgcctaaaggtgattggtcaattagcgagtttcaaaggttttattcctttgagggtgtgacaggtgtgacggccacgcaacggctgccgtggaaa
ii ii i i i i i i i i  ii i i i i i i i i i i i  i i i i  ii ii ii ii i i i i i i i i i i  i i i i i i i i i i i i i i i i  ii ii i i i i i i  ii i i i i  i ii ii i i i i i i  ii ii i i i i i i i i  i i i i i i i i i i i i i i i
GAACTAGCTCGGTTTATGATTACTGCGGCTAAAGGTGATTGGTCAATTAGCGAGTTTCAAAGGTTTTATTGCTTTGAGGGAGTGACAGGTGTGACGGCCACCCAGCGGCTGGCGTGGAAA 
TATA mRNA init
TATATCGGGGAGCTCATTCTAGCTGCCGCAGTATTCTCTTCGGTTTTCCACTGCGGAGAGGTGCGCCTTCTGCGCGCAGATCGTACATATCCAAACACCAACGGCGCACAGCGCTGCGCT
TTTTTl II lllllllll lllll lllllTllllllll llllllllllllll III11111111111 lllllllllllllllll II II II III IIIMIIIIIIIIIIII
TATATCGGGGAGCTCATCCTAGCCGCCGCAGTATTCTCCTCGGTTTTCCACTGTGGAGAGGTGCGCCTCCTGCGCGCAGATCGTACCTACCCGGACTCCAGCGGCGCACAGCGCTGCGTG
start
AGCGGCATTTACATAACATACGAGACGTCATGTCCACTTGTTGCCGTGCTATTTGTGGCCCCCAACGGTGTTATTGGCGAAGAGACTGTGGTAATTTACGACAGCGACGTGTTCTCGCTT
l l l l l l l l l l l l l l l l l  IIIIII l l l l l l l l l l  II IIIIIIII II I I III II I II I IIIIIII l l l l l  l l l l l  l l l l l l l l l l l l l l l l l l l l l l l  II
AGCGGCATTTACATAACCTACGAGGCGTCATGTCCTCTGGTTGCCGTTCTGTCGGCGGCTCCACATGGGGCAATTGGCGCGGAGACGGTGGTGATTTACGACAGCGACGTGTTCTCTCTC 
CTATACACCGTACTCCAGCAGCTGGCTCCTGGCTCTGGAGCCAATTAGGAAATGT— AAACTTGCCAGCTACCTCCCCCATGTCTAAAGACTCGACATCTCTGGGGGTGAGAACAATAG
II II I II l l l l l l l l l l l l l l l l l l l l  II IIIIIIII l l l l  l l l l l  IIIIII I II III l l l l l  l l l l  l l l l  I l l l l l  I IIIIIII
CTGTATGCAGTGCTCCAGCAGCTGGCTCCTGGATCGGGAGCCAACTAGGCAATGTTGGAAACTTACTCGCCACCCCCCACCCGCTGGGAAAGCCGGCATCATCGAGGGTGGGCACAATAG 
TCATTGCGTGTTTGGTTCTCTTGGGATGTTGTATTGTGGAAGCTGTACCAACCACGCCAAGTTCTCAGCCCAGTACTCCCGC.... GTCAACCCAGTCCGCTAAAACCGTTGACCAAA
I I II IIIIII I II II III I III llll III lllll lllllllllll I I I lllllllll I IIIIII II III I II II llll I
TTCTAGCCTGTTTGTTGCTTTTTGGAAGCTGTGTTGTTAGAGCCGTACCCACCACGCCAAGCCCCCCAACTAGTACTCCCACTTCCATGTCAACGCACTCCCATGGGACAGTAGACCCTA
CGCTTCTACCAACTGAAACACCAGACCCGCTCAGACTGGCTGTACGCGAGTCCGGTATACTCGCAGAGGATGGAGACTTTTACACCTGCCCGCCGCCTACTGGATCCACAGTTGTACGCA
l l l l  II II II l l l l l  II l l l l l  l l l l l l l l l l l l l l  l l l l l l l l l l l l l l l l l l l l  IIIIIIMIIIMIIIIIIIIIIIII IIIIIIII IIIIIIII II IIIIIII
CGCTGCTCCCCACAGAAACGCCCGACCCACTCAGACTGGCTGTGCGCGAGTCCGGTATACTCGCTGAGGATGGAGACTTTTACACCTGCCCACCGCCTACCGGATCCACCGTCGTACGCA
TTGAACCCCCACGGTCATGTCCCAAGTTTGATCTGGGGAGGAACTTCACGGAGGGCATTGCTGTTATTTTCAAGGAAAACATAGCCCCGTACAAATTTAGAGCAAACGTCTACTACAAAG
I l l l l l  II I I II l l l l l l l l l l l  II l l l l l  l l l l l l l l l l l l l l  l l l l l l l l l l l  II II IIIIIIII II IIIIIIII IIIIIIII I
TCGAACCACCTAGAACTTGCCCCAAGTTTGACCTTGGGAGAAACTTCACGGAGGGGATTGCTGTTATTTTTAAGGAAAACATCGCTCCCTACAAATTCAGGGCAAACGTATACTACAAGG
ACATTGTAGTGACAAAGGTTTGGAAAGGATACAGCCACACCTCTTTATCCGATAGATACAATGACAGAGTGCCAGTTTCAGTGGAGGAGATATTCACTCTCATCGATAGCAAAGGAAAAT
l l l l  II II III II M l l l l l l l l l l l l l l l  II II I l l l l l  II II l l l l l  l l l l l l l l l l l  III l l l l l l l l l  II II IIIIIII
ACATCGTTGTAACACGTGTGTGGAAAGGATACAGCCATACGTCCCTGTCCGACAGATACAATGACAGGGTTCCGGTTTCGGTGGAGGAGATCTTCGGTCTCATCGACAGTAAGGGAAAAT
GTTCTTCTAAGGCAGAGTACCTCCGAGATAACATTATGCATCACGCTTACCACGACGACGAAGACGAGGTGGAGCTCGACCTGGTTCCGTCTAAGTTTGCTACTCC-TGGGGCCAGAGCA
l l l l  II l l l l l  l l l l l l l l l  l l l l l l l l l l  l l l l l  l l l l l  l l l l l l l l l l l l l l  II I II l l l l l  IIIIIIII l l l l l  l l l l l l l l l l l
GTTCGTCAAAGGCCGAGTACCTCAGAGATAACATCATGCACCACGCGTACCACGACGACGAGGACGAGGTGGAGCTTGA-TTTGTGCCGTCCAAGTTTGCAACTCCGGGGGGCCAGAGCC
TGGCAAACCACTAACGACACCACGTCTTATGTCGGATGGATGCCATGGAGGCACTACACATCAACCTCTGTCAACTGCATTGTCGAAGAGGTAGAAGCGCGGTCTGTTTACCCATACGAC
l l l l l  l l l l l  l l l l l  II IIIIIIII II II l l l l l l l l l l l l l l l l l l l l l l l  l l l l l  l l l l l  l l l l l  II IIIIIIII II l l l l l  IIIIII
TGGCAGACCACCAACGATACTACGTCTTACGTGGGGTGGATGCCATGGAGGCACTACACGTCAACGTCTGTCAACTGCATCGTCGAGGAGGTGGAGGCGCGGTCCGTCTACCCCTACGAC
TCCTTTGCCCTATCGACCGGTGATATTGTGTACACCTCACCGTTTTACGGCCTTCGGTCAGCTGCTCAGTTAGAACACAATAGCTACGCACAGGAGCGCTTTAGACAAGTTGAAGGATAC
l l l l l  l l l l l  II l l l l l l l l l l l l l l l l l l  I If l l l l l l l i l l l l l l  II I II l l l l  l l l l  IIIIIIII II II l l l l l l l l l l l  Ilf
TCCTTCGCCCTGTCCACCGGTGATATTGTGTACGCGTCTCCGTTTTACGGCCTGAGGGCTGCCGCTCGCATAGAGCACAATAGCTACGCGCAGGAGCGTTTCAGGCAAGTTGAAGGGTAC
CAACCAAGAGACTTGGACAGTAAATTACAGGCCGGAGAGCCAGTTACCAAAAACTTTATTACTACACCTCATGTTACAGTCAGCTGGAACTGGACTGAAAAAAAGATAGAGGCGTGTACA
ii i mu i i i i i im  i i i i  i i i i  i i i i i i  i i f i im i i i  mu mu ii mu ii r t i i i i i i i  inn if i ii ii if i i m m m i
AGGCCCCGCGACTTAGACAGTAAACTACAAGCCGAAGAGCCGGTTACCAAAAATTTTATCACTACCCCGCATGTCACCGTCAGCTGGAACTGGACCGAGAAGAAAGTCGAGGCGTGTACG
CTAACTAAATGGAAGGAGGTTGACGAACTTGTCAGAGATGAGTTTCGGGGGTCCTACAGGTTTACTATTCGATCCATTTCGTCCACGTTTATTAGCAACACTACTCAATTTAAGCTAGAA
II II IIIIIIII l l l l l  IIIIIIII l l l l l  II l l l l l  II l l l l l l l l l l l  l l l l l l l l l l l l l l l l l  l l l l l  IIIIIIII II l l l l l l l l l l l l l l l l l l  I III
CTGACCAAATGGAAAGAGGTCGACGAACTCGTCAGGGACGAGTTCCGCGGGTCCTACAGATTTACTATTCGATCCATCTCGTCTACGTTTATCAGTAACACTACTCAATTTAAGTTGGAA
GATGCCCCACTCACCGACTGTGTGTCAAAAGAAGCCAAAGATGCCATAGACTCTATATACCGAAAACAGTATGAGTCTACACACGTTTTTAGTGGGGATGTGGAATTTTACTTGGCACGT
IIIIII II II II l l l l l  II IIIIIIII II II l l l l l l l l l l l  IIIIII III l l l l l  IIIIIIII l l l l l  l l l l l  II l l l l l l l l l l  l l l l  IIIIIII
AGTGCCCCCCTTACTGAATGTGTATCCAAAGAAGCAAAGGAAGCCATAGACTCGATATACAAAAAGCAGTACGAGTCTACGCACGTCTTTAGCGGTGATGTGGAATATTACCTGGCACGC
GGAGGGTTCTTAATCGCATTTAGACCGATGATTTCTAACGAACTTGCCAGGCTGTACCTAAACGAGCTTGTGAGATCTAACCGCACCTATGACCTAAAAAATCTGTTAAACCCCAACGCA
II l l l l l l l l l l l  l l l l l  l l l l l  III I II IIIIIIII l l l l l l l l l l l l l l  II IIIIIIII III
GGGGGGTTCTTAATTGCATTCAGACCTATGCTCTCCAACGAACTCGCCAGGCTGTACCTGAACGAGCTTGTGAGATCTAACCGCACCTACGACCTAAAAAATCTATTGAACCCCAATGCA 
 AACCATAATACCAATCGAACACGCAGGTCGCTACTATCAATACCAGAACCTACTCCAACCCAAGAGAGCCTCCACAGAGAACAAATACTACATCGCCTACACAAACGAGCAGTG
i ii i i i i i i i i i i i i  n n in m in i m i  m in i m i  i i n m in i m i  m in m  i m i n i m u m
AACAATAACAATAACACCACGCGAAGACGCAGGTCTCTCCTGTCAGTACCAGAACCTCAGCCAACCCAAGATGGTGTGCATAGAGAACAAATTCTACATCGCTTGCACAAACGAGCAGTG
GAGGCTGCGAATAGTACAAACTCTTCCAACGTCACCGCCAAACAACTAGAGCTAATCAAAACAACGTCCTCTATTGAGTTTGCTATGCTACAGTTTGCATACGATCACATCCAATCCCAC
i nn n i i i i  i n n inn i i i i i i i i  inn mu i i i i i i i i  i m n n n n n n m n m n n i n i i m
GAGGCAACGGCAGGTACCGATTCTTCCAACGTCACCGCCAAACAGCTGGAGCTCATCAAAACCACGTCGTCTATCGAGTTTGCCATGCTACAGTTTGCATACGATCACATCCAATCCCAC
GTTAATGAGATGCTAAGTAGGATAGCAACTGCGTGGTGTACACTACAAAACAAAGAGCGGACCCTCTGGAATGAGATGGTAAAGGTTAACCCAAGCGCTATTGTTTCCGCCACTCTTGAC
n mu n n im i i i  I 11 11 11 11 11 11 11 1111 I II I 11 11 11 11 11 11 11 11 II I l l l l l  II l l l l l  III IIIIIII l l l l l  II II l l l l l  II IIIIII
GTCAATGAAATGCTAAGTAGAATAGCAACTGCGTGGTGTACCCTCCAAAACAAAGAGCGGACCCTATGGAACGAAATGGTGAAGATTAACCCGAGCGCCATAGTCTCCGCAACCCTTGAC
2975
7169
6169
6901
0169
99241479055965
61
99999
Figure 4.9- continued
2 1 4 5  GAGCGAGTTGCGGCAAGGGTTTTGGGAGACGTTATAGCCATAACACATTGTGTAAAAATAGAGGGCAATGTGTACTTACAAAACTCTATGCGCTCCTCGGACAGCAACACGTGCTACTCC
l l l l l l l l l l l  II l l l l l  l l l l  l l l l l  l l l l l  l l l l l  II II I l l l l l l l l l l l l l l  IIIIIIII IIIIIIII IIIIIIII IIIIII
2 1 6 0  GAGCGAGTTGCAGCGAGGGTCCTGGGGGACGTGATAGCTATAACGCACTGCGCCAAAATAGAGGGCAACGTGTACTTGCAAAACTCCATGCGCTCGATGGACAGTAACACGTGCTACTCC
2 2 6 5  CGCCCACCTGTAACGTTTACCATTACTAAAAATGCAAACAGCAGAGGGACGATAGAGGGCCAGTTGGGAGAAGAAAACGAGGTTTATACGGAGCGCAAGCTTATCGAGCCGTGCGCTATC
Mill II l l l l l  Kil l  IIIIIIII l l l l l l l l l l  IIIIIII IIIIIII IIIIII IIIIIII II IIIIII III l l l l l l l l l l l l l l  II
2280  CGCCCCCCCGTAACATTTACAATTACTAAGAATGCAAACAACAGAGGGTCGATAGAAGGCCAGCTGGGAGAGGAGAACGAGATTTTCACGGAGCGCAAGCTGATCGAGCCGTGCGCCCTC
2385 AATCAAAAACGATACTTTAAGTTTGGCAAAGAGTATGTTTACTATGAGAACTACACGTACGTTCGCAAAGTGCCCCCGACTGAAATCGAAGTGATCAGCACCTACGTTGAACTAAACTTA
l l l l l  || II l l l l l l l l l l l l l l l l l l l l l l l  IIIIIIII l l l l l l l l l l l l l  III l l l l l l l l l l l l l l  II IIIIIIII II IIIIIIII l l l l l l l l l l l l l l l l l
2400 AATCAGAAGCGCTACTTTAAGTTTGGCAAAGAGTACGTTTACTACGAGAACTACACGTTCGTCCGCAAAGTGCCCCCCACGGAAATCGAGGTTATCAGCACGTACGTTGAACTAAACTTG
2505 ACTCTTTTGGAAGACCGCGAGTTTCTACCCCTGGAGGTTTACACGCGAGCTGAGCTTGAAGACACGGGGCTATTGGATTACAGCGAGATACAGCGCCGTAACCAGCTTCACGCCCTCCGA
II l l l l l l l l l l l l l l l l l l l l l l l  l l l l l l l l l l l  IIIIIIII IIIIIIII II l l l l l  II II I II l l l f l l l l  l l l l l l l l l l l  l l f f l l l f  l l l l l  III I
2 5 2 0  a c c c t t t t g g a a g a c c g c g a g t t t c t g c c c c t g g a g g t g t a c a c g c g g g c t g a g c t g g a g g a c a c c g g c c t g c t a g a c t a c a g c g a a a t a c a g c g c c g c a a c c a g c t c c a c g c t c t c a g g
2 6 2 5  TTCTACGATATAGACAGCGTTGTCAACGTGGACAACACTGCTGTCATTATGCAGGGAATTGCCACCTTTTTTAAAGGCCTTGGTAAGGTGGGAGAGGCAGTTGGGACGCTTGTACTTGGA
II l l l l l  II IIIIIIII l l l l l l l l l l l l l l  II II II l l l l l l l l l l l  II l l l l  IIIIII II l l l l l  Mill l l l l l  l l l l l  II II l l l l l  II II II
2 6 4 0  TTTTACGACATCGACAGCGTGGTCAACGTGGACAATACCGCAGTGATTATGCAGGGGATCGCCAGCTTTTTCAAGGGCCTGGGTAAAGTGGGGGAGGCCGTGGGAACGCTCGTTCTCGGC
2 7 4 5  GCGGCTGGCGCGGTTGTTTCTACAGTATCGGGTATAGCCTCATTTATAAACAACCCATTTGGGGGGCTCGCAATAGGCCTGTTGGTAATTGCGGGCTTAGTGGCTGCGTTTTTTGCCTAC
ii ii mu i i i i i i i i  ii mu ii mu  ii iii m m m m m m m i  ii ii m m  i i i i i i i  ii i i i i ii i i i i i i i i i i i i i i  iii
2 7 6 0  GCCGCCGGCGCTGTTGTTTCAACCGTATCTGGAATAGCTTCGTTTTTAAACAACCCATTTGGGGGGCTAGCCATCGGCCTGCTGGTAATCGCCGGCCTGGTAGCTGCGTTTTTTGCTTAC
2 8 6 5  CGGTATGTAATGCAACTGCGCAGCAACCCCATGAAAGCTCTATACCCAATAACAACCAGGAGCCTTAAAAACAAAGCCAAAGCCTCATACGGCCAAAACGACGATGATGACACTAGCGAC
i i m i i i i i i i  i mu i i i i i i i i i i i i i i i i i i i m i  i i i i i i i i  i i i i  m i n i m u m  i ii nnn n  inn n n n i i i i i i
2 8 8 0  AGATATGTAATGCAGATCCGCAGTAACCCCATGAAAGCTCTATACCCCATAACAACAAAGGCCTTGAAAAACAAAGCCAAAACTTCCTACGGCCAGAACGAGGAGGACGATGGGAGCGAC
2 9 8 5  TTCGATGAAGCCAAGCTGGAGGAGGCACGCGAAATGATCAAATATATGTCTATGGTTTCTGCCCTGGAAAAACAGGAAAAAAAGGCAATGAAGAAAAACAAGGGGGTTGGACTTATTGCC
ii mu i i i i i i i i  ii mu  i i i f i n i n n n n i  n n n n n n n  m n n m i  nnn n  n ii n m in i m  n nn n  n n in
3 0 0 0  TTTGATGAGGCCAAGCTTGAAGAGGCTCGCGAAATGATCAAATACATGTCTATGGTTTCGGCCCTGGAAAAGCAGGAAAAGAAAGCTATAAAGAAAAACAGTGGGGTTGGCCTGATCGCC
t e r  p o l y  A
3 1 0 5  a g c a a c g t t t c a a a a c t c g c a c t c c g c a c g c g c g g t c c g a a a t a t a c c c c t c t t c g a g a a g a c g a t c c c a t g g a a a g c g a a a a a a t g g t t t a a a a a t g t t a a a t a a a t a t t t t g a c a c g t
ii inn  inn  n n inn m i n i m i  m in im i  n i i i inn nnn n i  n n n n n n n n  inn n n n n n  nnn n
3 1 2 0  AGTAACGTCTCAAAGCTGGCCCTGCGAAGGCGCGGTCCCAAATATACCCGACTCCAACAGAACGATACCATGGAAAATGAAAAAATGGTTTAAACATGTTTAATAAATATTATGACACGT
3 2 2 5  AC TTGTGGG TTG A-CTCATATTTGCATAACATCTTTCTAGTTCCGGCTATAAGCCTATTTAAG CCTAG TATTTTTGCCAAAAG TTTATCATCCTCTACAAG CG CACA-TCCTCTCAAAAG
in i in n n n n n n n n  n n n n n n n i  in n n n n n n n n  i in i n in n i n i i i i i i  i i i
3240 ACTCAAAGTGTGACCTCATATTTGCATAACCACTTTCTAGTTCCGGCCCCAAGGATATTTAAGCCTAGTATCTCCGCCGAGGTTTCATCCTCATTCACCAACTCACACTTAGAGTTGACG
3343 A G TTG A A TTTTG C TG TTTA TTAC G -C TA TC C T— AAAGC-TAAAC-GC C --TG TAATG G AATCTC AATG C AAAAC TTCTACATCAG C C G C TG ATG -AAAC TC TG TTG G CTG C ATC G C TA
I II II II I II I l l l l  III II II III I IIIIII l l l l  I II I II III I III l l l l l  II I I I I I I
3360 CTTCCTCTTGCGCCTTTGCTCTCGCCGCTCCTGTGTTAGCGTATACTGCCCAAGAAATGGATTCTCCACGCGGTATCTCCACAGCTACCGGTGATGCCCACGCCGAGGCCGCGGTTTCCC
3454 CCGCGGCGGAAATCCAAATAAAAACAGAAGCACCCGATTCAGACACGCCCGCTGCC— ACGGGGTGTCAAGACCACACCTACGCTCGCCGGCTCACCGAGAATGGTGCAATCGAAGAGA
i n n i i i i i i i i  nnnn  inn i i i i i i  i i i i ii i hi ii i i i i i  i i i i i i i i i i i i i  i i i i  i ii i ii ii i ii i i
3480 CAGCCGC-GAAATCCAGATAAAAAC-GAAGCCCCCGATGTAGACGGACCAGAAGCCACTACTGAGTGTTTAGACCACACCTACACCCAACAGACAAGCGGGGGTGATGGCCTAGATGCTA
3571 TAAAC
I I
3598 TCGAT
Figure 4.9 Alignment of the EHV-4 gB and EHV-1 gB DNA 
sequences. The upper sequence is that of EHV-4 gB, and the lower 
sequence that of EHV-1 gB. Identical residues are indicated with 
a vertical bar, and dashes denote spaces introduced to maximise 
homology between the two sequences. Salient features (TATA box, 
CAT box, mRNA initiation site, termination codon and 
polyadenylation signal) are indicated for each sequence. The 
EHV-1 gB DNA sequence is from Whalley et al. (1989) .
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F I G U R E  4.10
Alignment of the EHV-4 aB and HSV-1 gB Amino Acid Sequences
EHV-4 gB (-56 MSTCCRAICGPQRCYWRRDCGNLRQRRVLASIHRTPAAGSWLUSQLGNVNLPATSP -1)
EHV-4 gB 
HSV-1 gB
Signal sequence/
1 M S K D S T S L G V R - T I V I A C L V L - L G C C I V E A - - - V P T T P - -
I I I I  I I I I I I  I I I I
1 M H Q G A P S U G R R U F V V U A L L G L T L  G V L V A S A A P S S P G T P G V
34 S S Q P .................. S T P A S T Q S A K T V D - - - Q T L L P T E T P D P L
I l l l l l  I I
41 A R D P G G E R G P C H S G A A A L G A A P T G D P K P K K N K K P K N P T P P
63 R L A ...........V .................. R E - - S G I L A E - - O G D F Y T C P P P T G
I I  I I I  l l l l  I I I I I I I I
81 R P A G D N A T  V A A G H A T L R E H L R D I K A E N T D A N F Y V C P P P T G
87 S T V V R I E P P R S C P K F D L G R  N F T E G I A V I  F K E  N I A P Y K F R A
III I II II I I IIIIII llllllllll I
121 A T V V Q F E Q P R R C P T R P E G O  n y t E G I A V V F K E N I A P Y K F K A
127 N V Y Y K D I V V T K V W K G Y S H T S L S D R Y N D R V P V S V E E I F T L I
I I I  I I I I I  l l l l  I I  I
161 T M Y Y K D V T ' V S Q V W F G H R Y S Q F M G I  F E D R A P V P F E E V I  D K l
167 D S K G K C S S K A E Y L R D N I M H H A Y H D D E D E V E L D L V P S K F A T
I I I I I I I I  l l l l  I I  I I
201 N A K G V C R S T A K Y V R N N L E T T A F H R D D H E T D M E L K P A N A A T
207 P G A R A W Q T T  N O T  T S Y V G W M P W R H Y T S T S V N C I V E E V E A R S
l l l l l  I I I I I I I I I I I I I
241 R T S R G U H T T - D L K Y N P S R V E A F H R Y G T T V N C I V E E V D A R S
247 V Y P Y D S F A L S T G D I V Y T S P F Y G L R S A A Q L E H N S Y A Q E R F R
lllll I I I I I  I I  lllll I I I  I I  I I
280 V Y P Y D E F V L A T G D F V Y M S P F Y G Y R E G S H T E H T T Y A A D R F K
287 Q V E G Y Q P R D L D S K L Q A G E P V T K N  F I T T P H V T V S W  N W T E K K
I I I  I I I  I I I I I  I I I  l l l l  I
320 Q V D G F Y A R D L T T K A R A T A P T T R N L L T T P K F T V A U D W V P K R
327 I E A C T L T K U K E V D E L V R D E F R G S Y R F T  I R S I  S S T  F I S N T T
I I  I I I  l l l l  I I I I  I I  I I  I I  I I
360 P S V C T M T K W Q E V D E M L R S E Y G G S F R F S S D A I S T T F T T  N L T
367 Q F K L E D A P L T D C V S K E A K D A I D S I Y R K Q Y E S T H V F S G D V E
I I I I  I I I I I I  I I I  I
400 E Y P L S R V D L G D C I  G K D A R D A H D R  I F A R R Y  N A T  H I K V G Q P Q
407 F Y L A R G G F L I A F R P M I S N E L A R L Y L N E L V R S  N R T Y D L K N L
l l l l l l l l l  I I I I I I I  II I
440 Y Y L A N G G F L I A Y Q P L L S N T L A E L Y - - - - V R - - - - E H L - - -
*Cleavage
447 L N P N A N H N T  N R T R R S L L S  I P E P T P T Q E S L H R E Q I L H R L H K
I I l l l l
469  R - E Q S - R K P P N P T P ................................. P P P
487 R A V E A A N S T N S S N V T A K Q L E L  I K T T S S  I E F A M L Q F A Y O H  I
I I I I I I llllllllll III I II
484 G A .......... S A N A S  - V .......... E R  I K T T  S S  1 E F A R L Q F  T Y  N H  1
Figure 4.10- continued
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725 L H A L R F Y
II III
710 L H D L R F A
765 T L V L G A A G A V V S T V S G I A S F I N N P F G G L A I G L L V I A G L V A
I I I III III II llll II llll III I
750 K V V M G L V G G V V S A V S G V S S F M S N P F G A L A V G L L V I A G L A A
/Cytoplasmic domain
805 A F F A Y R Y V M Q L R S N P M K A L Y P I T T R S L K N - - K A K A S Y G Q N
llll llll I lllllllll II III II I
790 A F F A F R Y V M R L O S N P M K A L Y P L T T K E L K N P T N P D A S  - G - -
843 D D D D T S D F D E A K L E E A R E M I K Y M S M V S A L E K Q E K K A M K K N
IIIIIII IIIIII II III I I II II
827 E G E E G G D F D E A K L A E A R E M I R Y H A L V S A M E R T E H K A K K K G
883 K G V G L I A S N V S K L A L R - R R G P K Y T R L R E D D P H E S E K M V  (TERM)
I I I  I I I  II I I
867 T S R L L S A - K V T D M V M R K R R N T N Y T Q V P N K D G D A D E D D L  (TERM)
EHV-4 gB: 975 amino acids 
HSV-1 gB: 903 amino acids
Figure 4.10 Alignment of the predicted amino acid sequences of 
the EHV-4 gB and HSV-1 (KOS) gB proteins. The upper sequence is 
that of EHV-4 gB, and the lower sequence that of HSV-1 gB. 
Identical residues are indicated with a vertical bar, and dashes 
denote spaces introduced to maximise homology between the two 
sequences. The signal sequence, surface, transmembrane and 
cytoplasmic domains of the proteins are indicated. Potential N- 
1 inked glycosylation sites are underlined. The predicted 
internal proteolytic cleavage site of the EHV-4 gB protein 
(RR/S) , which is absent in HSV-1 gB, is indicated by an 
asterisk. The additional 56 amino acids that are hydrophilic in 
nature and which form the start of an unusually long 84 amino 
acid signal sequence for EHV-4 gB, and which are absent in HSV-1 
gB, are indicated in brackets above the alignment (residues -56 
to -1).
/Transmembrane domain
D I D S V V N V D N T A V I M Q G I A T F F K G L G K V G E A V G
l l l l  I I I l l l l  l l l l
D I D T V I H A D A N A A M F A G L G A F F E G H G D L G R A V G
Figure 4.11 Comparison of the predicted amino acid 
sequences of the EHV-4 gB and HSV-1 gB proteins. (a) 
Hydropathic plots determined by the method of Kyte and 
Doolittle (1982). Points above the horizontal line 
represent regions of above average hydrophilicity. In each 
plot, the hydrophobic signal sequence and transmembrane 
domains are indicated by shaded boxes. The additional 
hydrophilic amino acids prior to the true EHV-4 gB signal 
sequence are indicated by an unshaded box. (b) Plots of 
surface probability determined by the method of Emini et 
al. (1985). (c) Plots of chain flexibility determined by 
the Karplus-Schulz method, (d) Plots of antigenic index 
determined by the method of Jameson and Wolf (1988) . 
Antigenic index is a measure of the probability that a 
region is antigenic and is calculated by the summation of 
several weighted measures of secondary structure such as 
hydrophilicity, surface probability and chain flexibility, 
(e) Secondary structure analysis by the method of Chou and 
Fasman (1978) (CF) showing predicted turns (i), alpha 
helices (ii) and beta sheets (iii). (f) Secondary structure 
analysis by the method of Gamier et al. (1978) (GOR) 
showing predicted turns (i) , alpha helices (ii) and beta 
sheets (iii). (g) Potential N-linked glycosylation sites. 
Height of the vertical bar represents the probability of 
glycosylation.
All analyses were carried out using PEPTIDESTRUCTURE and 
PLOTSTRUCTURE from the University of Wisconsin Genetics 
Computer Group programmes (Devereux et al.. 1984).
F I G U R E  4.11
Comparison of the Predicted Secondary Structure 
of the EHV-4 gB and HSV-1 aB Proteins
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F I G U R E  4,12
Alignment of the EHV-4 aB and EHV-1 gB Amino Acid Sequences
EHV-4 gB 
EHV-1 gB
1
41
197
200
240
276
279
316
319
356
359
396
399
436
439
476
M S T C C R A  I C G P Q R C Y W R R D C G N L R Q R R V L A S  I H R T P A A G S
II II I l l l l l l l l l l l  lllll
- - • ■ ' ■ ■ ' " d G D G G D L R Q R R V L S P V C S A P A A G S1 m s s g c r s v g g s t w g n u r
41 W L W S Q L G M V - M L P A T - S P M S K D S T S L G V R T ' I V I A C L V L L G
I l l l l l l l l l l  I I I. l l l l l l l l l
W I G S Q L G N V G N L L A T P H  P L G I C - P A S S R V G T I V L A C L L L F G
Signal sequence / - - - - - - - - -  * S T Q S A K T V D Q T l .  L P T E T P D
  . . . I I  I I I I  l l l l l l l l l
S C V V R A V P T T P S P P T S T P T S M S  T H S H G T V D P T L L P T E T P D
79 C C 1 V E A V P T T P S S Q P S T P - - A - . - - - • - - . , , , , . . . .
| IIIIIII III 11 1 111 I I I I I I I ' 1
P L R L A V R E S G I L A E D G D F Y T C P P P T G S T V y R I E P P R S C P I C
117
I I  I I  I I I  I I M  I M  I I I I I120 P L R L A V R E S G I L A E D G D F Y T C P P P T G S T V V R I E P P R  T C P I C
F 0  L  G R N F T  E G I A V I  F K E N I A P Y K F R A  N V Y Y K D  I  V  V  T  K  V  U  K
I I I I I I II I I I I I I I I I I I I I I I I I | I | | | | | | | | | III
‘ .............................................................. ‘ P Y K F R A K V Y Y K O I V V T R V U K
157
160 F D L G R  N F T E G I A V I F I C E N I A
G Y S H T S t S D R Y N D R V P V S V E E  I F T L  I D S K G K C S S K A E Y L Rlllllllllllllllllllllll I I I I I I I I I I I I I I I I
G Y S H T S L S D R Y N D R V P V S V E E I F G L I D S K G K C S S K A E Y I R
237 D N I M H H A Y H D D E D E V E L D L - V P S K F A T P G A R A W Q T T  N O T  T
I I I I  I I  I I I  I I  I I  I I  I I  I I  I I  I I  I I  I I I I I I I I
D N I M H H A Y H D D E D E V E L D L C R P S -  L Q L R G A R A W Q T T  N O T  T
S Y V G W H P W R H Y T S T S V N C I V E E V E A R S V Y P Y D S F A L S T G D
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
S Y V G W M P W R H Y T S T S V N C I V E E V E A R S V Y P Y D S F A L S T G O  
I V Y T S P F Y G L R S A A O L E H N S Y A O E R F R O V E G Y Q P R D L O S I C
III IIIIIII II I I I I I I I I I I I I I I I I IIIIIII
I V Y A S P F Y G L R A A A R I E H N S Y A Q E R F R Q V E G Y R P R D L D S K  
L O A G E P V T K N F I T T P H V T V S W N W T E K I C I E A C T L T K W K E V D
I I I  l l l l l l l l l l l l l l l l l l l l l l l -  I I I I I I I  I I I I I
L O A E E P V T K N F I T T P H V T V S W N U T E t C K V E A C T l T K W I C E V D  
E L V R D E F R G S Y R F T I R S I S S T F I S  N T T  Q F K L E D A P L T D C V
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I llll II
E L V R D E F R G S Y R F T I R S I S S T F I S  N T T  Q F K L E S A P I T E C V  
S I C E A K D A I D S I Y R K Q Y E S T H V F S G D V E F Y L A R G G F L I A F R
l l l l l  I I I I I I  l l l l l l l l l l l l l l  I I I I I I I I  I I I I
S K E A K E A  I D S I  Y K K Q Y E S T H V F S G D V E Y Y L A R G G F  L I A F R
P H I  S N E L A R L Y L N E L V R S  N R T Y D L K N L L N P N A N H N T  N R T -
I I  I I  I I I I I I I I I I I I I I I I I I I  I I I  I I I  I I I  I I I
479 P M L S N E L A R L Y L N E L V R S  N R T Y D L K N L L N P N A N N N N  N T T  R
‘Cleavage
514 - R R S L L S  I P E P T P T Q E S L H R E Q  I L H R L H K R A V E A A  N S T N S
IIIIII III III I I I I I I I I I I I I I I I I I I
519 R R R S L L S V P E P Q P T Q D G V H R E Q I L H R L H K R A V E A T A G T D S
Ficrure 4.12- continued
554
559
754
874
879
914
954
959
e i i v T A I C O L E L I I C T T S S I E F A M L Q F A Y D H I Q S H V N E M l S R I
f  7“ H  I I I I I I I I  I I I I I I I  I M  I I I  I I I  I I  I I  I I I I I I] y ) I i c q l e l I I C T T S S I E F A M L Q F  A Y D H I Q S H V N E M L S R I
,Q, a T A U C T L Q N K E R T L W H E H V K V  N P _.S A I V S A T L O E R y A A R y L
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Figure 4.12 Alignment of the predicted amino acid sequences  ^of 
the EHV-4 gB and EHV-1 gB proteins. The upper sequence is that 
of EHV-4 gB, and the lower sequence that of EHV-1 gB. Identical 
residues are indicated with a vertical bar, and dashes denote 
spaces introduced to maximise homology between the two 
sequences. The signal sequence, surface, transmembrane and 
cytoplasmic domains of the proteins are indicated. Potential N 
linked glycosylation sites are underlined. The predicted 
internal proteolytic cleavage site of the proteins (RR/S) is 
indicated by an asterisk.
T A B L E  4,3
Composition of the EHV-4 aB Protein
Codon 
(amino acid)
Frequency % Of
total
Codon 
(amino acid)
Frequency % Of 
total
TTT (Phe) 27 2.8 TAT (Tyr) 10 1.0
TTC (Phe) 6 0.6 TAC (Tyr) 33 3.4
TTA (Leu) 10 1.0 TAA (End) 0 0.0
TTG (Leu) 10 1.0 TAG (End) 0 0.0
CTT (Leu) 16 1.6 CAT (His) 5 0.5
CTC (Leu) 14 1.4 . CAC (His) 12 1.2
CTA (Leu) 19 1.9 CAA (Gin) 16 1.6
CTG (Leu) 12 1.2 CAG (Gin) 13 1.3
ATT (He) 22 2.3 AAT (Asn) 13 1.3
ATC (lie) 9 0.9 AAC (Asn) 36 3.7
ATA (lie) 21 2.2 AAA (Lys) 36 3.7
ATG (Met) 18 1.8 AAG (Lys) 16 1.6
GTT (Val) 33 3.4 GAT (Asp) 17 1.7 •
GTC (Val) 10 1.0 GAC (Asp) 30 3.1
GTA (Val) 13 1.3 GAA (Glu) 31 3.2
GTG (Val) 17 1.7 GAG (Glu) 38 3.9
TCT (Ser) 21 2.2 TGT (Cys) 13 1.3
TCC (Ser) 17 1.7 TGC (Cys) 5 0.5
TCA (Ser) 11 1.1 TGA (End) 0 0.0
TCG (Ser) 6 0.6 TGG (Trp) 12 1.2
CCT (Pro) 5 0.5 CGT (Arg) 6 0.6
CCC (Pro) 11 1.1 CGC (Arg) 16 1.6
CCA (Pro) 19 1.9 CGA (Arg) 13 1.3
CCG (Pro) 10 1.0 CGG (Arg) 7 0.7
ACT (Thr) 22 2.3 AGT (Ser) 6 0.6
ACC (Thr) 23 2.4 AGC (Ser) 18 1.8
ACA (Thr) 17 1.7 AGA (Arg) 14 1.4
ACG (Thr) 14 1.4 AGG (Arg) 9 0.9
GCT (Ala) 21 2.2 GGT (Gly) 6 0.6
GCC (Ala) 20 2.1 GGC (Gly) 12 1.2
GCA (Ala) 19 1.9 GGA (Gly) 16 1.6
GCG (Ala) 11 1.1 GGG (Gly) 12 1.2
Table 4.3 Codon usage and predicted amino acid composition of 
EHV-4 gB (975 amino acids).
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F I G U R E  4.13
Alignment of the Amino Acid Sequences of the crB-T.i Tcp. 
Proteins of Eight Herpesviruses
EHV-4 mstccraicgpqrcywrrdcgnlrqrrvlasihrtpaagswlwsqlgnv-nlpatspmskdstslgvrtiviaclvllgcciveavpttpssqpstp--a 97
PRV mpaggglwrgprghrpghhggaglgrlwpaphhaaaargavalal11lalaaappcgaaavtraasasptpgtgatpndvsaea 84
BHV-1 maarggaeraagagdgrrgqrrhlrpgrvlaalrgpaapgaggaraalaaallwatwalllaapaagrpattppapppe-eaaspap 86
MDV irtiyfrrn 7
VZV mfvtawsvspssfyes 17
HSV-1 mhqgapswgrrwf w w a  11 g 111 gv I vasaapsspgtpgva rdpggergpchsgaaa-1 gaaptgdpkpkknkk 73
HCMV mesriwcLwcvnLcivclqaavsssstshatssthngshtsrttsaqtrsv 52
EBV mtrrrvlsv 9
Con
IV
EHV-4 stqsaktvdqtllptetpdplrlavresgilaedgd--FYtCPPPtGsTWRiEPpRsC-PkfdlGrNfTEGIAViFKENIAPYICFrAnvYYKdivVtkv 194
PRV sleei eafspgpseapdoevgdldartavraaaterdrFYVCPPPsGsTWRLEPeqaC-PeysqGrMf TEGI AVlFKENIAPhKFKAhi YYKnVi Vttv 183
BHV-1 paspsppgpdgddaaspcfcistdvraalrlaqaagensrFfVCPPPsGaTWRlaPaRpC-PeyglGrNyTEGIgViyKENIAPYtFKAyi-YKnViVttt 184
MDV ci f f I i vi lygtnsspstqnvtsrewssvqlseeestFYlCPPPvGsTViRlEPpRkC-PeprkatewgEGIAi iFKENIsPYKFKvtlYYKni iqttt 106
VZV IqveptqseditrsahlgdgdeireaihksqdaetkptFYVCPPPtGsTiVRlEPtRtC-PdyhlGkNfTEGIAVvyKENIAaYKFKAtvYYKcfViVsta 116
HSV-1 pknptpprpagdnatvaaghatl rehl rdikaentdanFYVCPPPtGaTWqf EqpRrC-PtrpeGqNyTEGIAVvFKENIAPYKFKAtmYYKdVtVsqv 172
HCMV ysqhvtsseavshranetiynttlkygdvvgvnttkypyrVCsrnaqGtdliRfErni iCtsmkpinedldEGIrtVvylCrNIvahtFKvrvYqKvltf rrs 152
EBV w l  laalacrlgaqtpeqpappattvqptatrqqtsfpFrVCelsshgdlfRfssdiqC-PsfgtreNHJEGl ImvFKdNI iPYsFKvrsYtKiVtni I i 108
Con------ FYVCPPP-G-TWR-EP-R-C-P--- G-N-TEGIAV-FKENIAPYKFKA--YYK-V-V— -
EHV-4 WkGyshts I sdRyrORVPVsveE I f 1 1 IDskGkCsSKAeY I RdN i mhhAyhcfie-deve IdLvPskf atpGaRaWqTTnDt tsyvGwmpwrhyT sTSVNC 293
PRV WsGstYaaiTNRftDRVPVpvqEITDvIDrrGkCvSKAeYvRnNhkvtAFdRDe-npvevdLrPsrlnalGtRgUHTTnDtYtkiGaagfYh-TGTSVNC 281
BHV-1 WaGstYaaiTNqytDRVPVgmgEITDlvDkkwrClSKAeYlRsgrkwAFdRDd-dpweaplkParlsapGvRgWHTTdDvYtalGsaglYR-TGTSVNC 282
MDV wtGttYrqiTNRytDRtPVsieEITDlIDgkGrCsSKArYlRnNvyveAFdRDa-gekqvlLkPskfntpesRaUHTTnetYtvwGspwiYR-TGTSVNC 204
VZV WaGssYtqiTNRyaDRVPipvsEITDtlDkfGkCsSKAtYvRnNhkveAFneOk-npqdmpLiaskynsvGskaUHTTnOtYmvaGtpgtYR-TGTSVNC 214
HSV-1 WfGhrYsqfmgifeDRaPVpfeEviDklnakGvCrStAkYvRnNlettAFhRDd-hetdmeLkPanaatrtsRgWHTTdlkYnpsrveafhR-yGTtVNC 270
HCMV yayiyttyl IgsnteyVappmwEI-hhlnkfaqCySsysrviggtvfvAyhRDsyenktmqLiPddysnthstryvTvkDqwhsrGstwlYR-etcnlNC 250
EBV ynGwyadsvTNRheekfsVdsyE-TDqriDtiyqCynavkmtkdgltrvyvdRDg-vnjtvnLkPtgglanGvRryasqtelYdapGwl iwtyrTrTtVNC 206
Con U - G - Y — TNR-DRVPV— EITD-ID--G-C-SICA-Y-R-N--- AF-RD....... L-P..... G-R-WHTT-D-Y— G--- YR-TGTSVNC
t m III m m m
EHV-4 IVEEVeARSVYPYDsFALSTGDIVYtSPFY-GLR-saaql-EHnsYAqeRFrQvegYqprDLDsklqA-gePvtkNFitTpHvTVsWnUteKkieaCtLt 389
PRV IVEEVeARSVYPYDsFALSTGDIVYMSPFY-GLR-egahg-EHigYApgRFqQvehYyptOLDsrlrA-sesvtRNFLrTpHfTVaWDWaPKtrrVCsLa 377
BHV-1 I VEEVeARSVYPYDs FALSTGDI i YMSPFY- GLR- egahr-EH tsYspeRFqQ i egYykrDmatgrr I - kePvsRNFLrTqHvTVaWDUvPKrknVCsLa 378
MDV IVEEmdARSVfPYsyFAmanGDIaniSPFY-GLs-ppeaaaEpmgYpqdnFkQldsYfsirDLDkrrkA-slPvkRNFLiTsHfTVgWDWaPKttrVCsmt 301
VZV I iEEVeARSifPYDsFgLSTGDI iYMSPFf-GLR-dgayr-EHsnYAmdRFhQfegYrqrDLDtral l--ePaaRNFLvTpHlTVgWrtUkPKrteVCsLv 309
HSV-1 IVEEVdARSVYPYDeFvLaTGDfVYMSPFY-GyR-egsht-EHttYAadRFkQvdgfyarOLttkarA-taPttRNlLtTpkfTVaWDWvPKrpsVCtmt 366
HCMV mTtittARSkYPYhfFAtSTGDvVYiSPFY-ngt-nrnas-yfgenAdkfFifpnytivsDfgrpnaApethrlvaFLeradsvisWDiqdeknvtCql.t 347
EBV I itdmAkSnsPfDf FvttTGqtVeMSPFYdGknketfh eradsFhvrtnYkivOyOnrgtn-pqgerRaFLdkgtyTlsW-klenrtayCpLq 298
Con IVEEV-ARSVYPYD- FALSTGD IVYMSPFY- GLR------ EH--YA--RF-Q— Y---DLD---A-— P--RNFL-T-H-TV-WDU-PK-— VC-L-
t
EHV-4 KUkEvdElvRdEfr-GSyRFtirsiSsTFiSntlqfkLedapLtDCVskEAkdAidsIYrkqYesTHVfsGd-vefYLArGGFliAFrPmiSNeLA-rLY 486
PRV KWrEaeEmtRdEtrdGSfRFtsralgasFvSdvTqldLqrvhLgDCVlrEAseAidalYrrrYNsTHVlaGdrpevYLArGGFWAFrPliSNeLA-qLY 476
BHV-1 KWrEacEmlRdEsr-GnfRFtarslSaTFvSdshtfaLqnvpLsDCVieEAeaAvervYrerYNaTHVlsGs-letYLArGGFvVAFrPmlSNeLA-kLY 475
MDV KMkEvtEml Ratvn- GrvRFmarel SaTF i Snt Tef dpnr i iLgqCikrEAeaAieqlf rtkYNdsHVkvGh-vqyf LAlGGFiVAyqPvlSksLA-hmY 398
VZV KWrEvedwRdEya-hnfRFtmkttStTFiSetnefnLnqihLsqCVkeEArai inrlYttrYNssHVrtGd- iqtYLArGGFWvFqPl ISNsLA- rLY 406
HSV-1 KWqEvdEmlRsEyg-GSfRFssdaiStTFttnlTeypLsrvdLgOCigkdArdAmdrlfarrYNaTHikvGq-pqyYLAnGGFliAyqPUSNtLA-eLY 463
HCMV fUeasertiRsEae-dSvtiFssaktntaTFlS-kkqevnmsdsalDCVrdEAinklqalfntsYHqTyekyGn-vsvfetsGGlvV-Fwqqik qks 438
EBV hWqtfdstiatEtg-kSihFvtdegtssFvtntT-vgielpdafkCieeqvnktmhekYeavqdrytkgqea-ityfitsGGlllAwlPttprsLAtvkn 395
Con KW-E--E--R-E---GS-RF S-TF-S--T---L L-DCV-EA--A- — IY---YN-THV--G YLA-GGF-VAF-P— SN-LA--LY
m/I * Cleavage
EHV-4 LnELvRsnrtydlknllnonanhntnrtrrs--llsipeptptqeslhreqiIhrlhkraveaanstnssnvtakqlelikTTSSiEFAntQFaYDHIQs 584
PRV arELeRlglagwgpaapaaarrarrs--------------- 542
BHV-1 LqELaRsnqtleg IfaaaaDkoqorrarr--........... 549
MDV L rELmRdnrtdemld I vnnkhai ykknats I sr I rrd.... -- 472
VZV LqELvRentnhspqkh-Dtrntrsrrs.......... .... 463
HSV-1 vrEh I Reqsrkppnptppppga-------- -------- — ...................... sanasveri kTTSS i EFArLQFTYnHIQr 514
HCMV LvELeRlanrsslnithrtrrs------------------- 492
EBV
Con
LtELttptssppsspsppapsaargstpaavlrrrrrd.....
L-EL-R................................. .............................. TTSS-EFA-LQFTYDHIQ-
470
r II
EHV-4 HVNeMLsRIAtAUCtLQNkErtLWnEmvtCvNPSAivSAtLdeRVAARvLGDViAithCVki-e-gnVylQNSMR-ssdsntCYSRPpVtFtitknaNsrg 681
PRV HVNcJIlgRIAaAUCeLONkdrtLWsEmsrlNPSAvAtAaLgqRVsARmLGDVmAiSrCVev-r-ggVyvQNSMRVpgergtCYSRPLVtF ehHqtg 636
BHV-1 HVNtMfsRIAtsWClLQNkEraLWaEaaKlNPSAaASAaLdrRaAARmLGDamAVtyChelge-grVfieNSMRapg— gvCYSRPpVsF---afgNese 643
MDV HiNcMfsRIAtAUCeLQNrElvLUhEgikiNPSAtASAtLgrRVAAkinLGDVaAVSsCtaida-esVtlQNSMRVitstntCYSRPLVlF— sygenqg 568
VZV HVNeMLaRIsssWCqLQNrEraLWsglfpiNPSAlAStiLdqRVkARiLGDVisVSnCpelgsdtriilQNSMRVsgsttrCYSRPLisi---vslN3 sg 560
HSV-1 HVNc«LgRvAiAWCelQNhEltLWnEarKlNPnAiASytvgrRVsARmLGDVmAVStCVpvaa-dnVivQNSMRissrpgaCYSRPLVsF-"ryedqgp 610
HCMV yiWraLaqlAeAWCvdOrrtlevfkElskiNPSAi ISAiynkpiAARfmGDVlqlasCVtinq-tsVkvlrcXnVkespqrCYSRPvVi F— nfaHssy 588
EBV qiNrMLgdlArAWCleQkrqnmvlrEltKiNPttvmSsiygkaVAAkrLGDVisVSqCVpvnq-atVtlrkSMRVpgsetmCYSRPUVsF---sf iNdtk 566
Con HVN-ML-RIA-AWC-LQN-E--LW-E--K-NPSA-ASA-L--RVAAR-LGDV-AVS-CV..... V--QNSMRV.... CYSRPLV-F..... N —  -
Figure 4.13- continued
EHV-4 tiEGQLGEeNEvyteRkh’EPCaiNqkRYFkFGkeYVYYEnYtYVRkvppteleviSTyVeLNLTLLEDREFlPLEVYTRaELeOtGLLDYsEIQRRNQL 781
PRV viEGOLGcDNEllisRdliEPCtgNHrRYFklGsgYVYYEdYnYVRmv--evpetiSTrVtLNLTLLEDREFlPLEVYTReELaOtGLLDYsEIQRRNQL 734
BHV-1 pvEGQLGEDNELlpgRelvEPCtaNHkRYFrFGadYVYYEnYaYVRrvplaeleviSTfVdLNLTvLEDREFlPLEVYTRaELaOtGLLDYsEIQRRNQL 743
MDV niqGQLGEnNELlptleavEPCsaNHrRYFlFGsgYalfEnYnfVkmvdaadlqiaSTfVeLNLTLLEDREilPLsVYTkeELrDvGvlDYaEvaRRNQL 668
VZV tvEGQLGtDNELimsRdlLEPCvaNHkRYFtFGhhYVYYEdYrYVReiavhdvgmiSTyVdlNLTLLkDREFmPLqVYTRdELrOtGLLDYsEIQRRNQm 660
HSV-1 t vEGOLGEnNELrItRda i EPCt vgHrRY FtFGggYVYfEeYaYshqIsradlttvSTf i dLHi TmLEDhEFvPLEVYTRhEikDsGLLDYtEvQRRNQL 710
HCMV vqyGQLGEDNEHlgnhrtEeCqIpslkiFiaGnsayeYvdYlfkRfflidlssIstvdsniiaLdidpLEntdFrvLElYsqkELrssnvfDleEIniRefns 688
EBV tyEGQLGtDNEifItkkmtEvCqatsqyYFqsGneihvYndYhhfktieldglatlqTfisLNtsLiEnidFasLElYsRdEqrasnvfDleglfReynf 666
Con --EGQLGEDNEL---R---EPC--NH-RYF-FG— YVYYE-Y-YVR..... I —  -ST-V-LNLTLLEDREF-PLEVYTR-EL-D-GLLDY-EIQRRNQL
[ Span 1 ] [ Span 2 ] [ Span 3 ]
EHV-4 HaLRFYDIDsWnvOntavimqGiAtFFkGLGkvGeAVGtlVlGAaGAVvStVSGiaSFinNPFGgLAiGLLViAGLVAAFfAYRYvmqLrsNPMKALYP 881
PRV HaLkFYDIDrWkvOhnwllrGiAnFFqGLGdvGaAVGkWlGAtGAViSaVgGmvSFlsNPFGALAiGLLVLAGLVAAFlAYRhisRLrrNPMICALYP 834
BHV-1 HeLRFYD IDrWktDgnmaimrG lAnF FqGLGavGqAVGtWl GAaGAa IStVSG i aSF i aNPFGALAtGLLVLAGLVAAF IAYRY i sRLrsNPMKALYP 843
MDV HeLkFYDlnkVievOtnyafmnGlAelFnGmGqvGqAiGkWvGAaGAivStiSGvsaFmsNPFGAl.AiGLiiiAGLVAAFlAYRYvnkLksNPMKAI.YP 768
VZV HsLRFYDIDkWqyOsgtaimqGmAqFFqGLGtaGqAVGhWlGAtGAllStVhGfttFlsNPFGALAvGLLVLAGLVAAFfAYRYvlkLktsPMKALYP 760
HSV-1 HdLRFaDIDtVihaDanaamfaGlgaFFeGmGdlGrAVGkWmGlvGgVvSaVSGvsSFmsNPFGALAvGLLVLAGLaAAFfAfRYvmRLqsNPMKALYP 810
HCMV ykqRvkyvedkVv-DplppylkGlddlmsGLGaaGkAVGvaigavgGAVaSvVeGvatFlkNPFGAfti iLvaiAwiityliYtrqrRLctqPlqnLfP 78 7
EBV qaqniaglrkdldnavsngrnqfvdglgelmdslG-sVGqsitnlvstVgglfSslvSgfisfFknpfgGmLiLvlvagwilvisltRrtrqmsqqpvq 765
Con H-LRFYDID-W--D......G-A-FF-GLG— G-AVG-W-GA-GAV-S-VSG--SF— NPFGALA-GLLVLAGLVAAF-AYRY--RL--NPMKALYP
S
EHV-4 iTTrsLKnkakasygqnddddtsdf--DEaKLe  eAREMIkYMsmVSAlEkqEkKAmKKNkgvgLiasnvsklalR-RRgpk 959
PRV vTTktLK....... edgvdegdv--DEaKLd................ qARnMIrYMsiVSAlEqqEhKArKKNsgpaLlasrvgamatR-RR--h 901
BHV-1 i TT raLKd- -dargatapgeeeeef- -DaaKLe................ qAREMI kYHsLVSAvErqEhKAkKsNkggpL latr I tql a IRrRappe 920
MDV mTTevLKaqatrelhgeesddlertsiDErKLe...... ... ......eAREM I kYMaLVSAeErhEkk I r rkrrgt tavl sdh t akmr i knsnpk 849
VZV lTTkgLKqlpegmcfcfaekpnatdt--pieeigdsqntepsvnsgfdpdkfreAqEMIkYMtLVSAaErqEsKArKKNktsaLltsrltglalRnRRgys 858
HSV-1 I TTkeLKn- ptnpdasgegeeggdf --DEaKLa.................eAREMIrYMaLVSAmErtEhKAkKK-gtsrLlsakvtdnvmRkRRntn 887
HCMV ylvsadgttvtsgstkdtslqapps— yEesvynsgrkgpgppssdastaappytneqaYqmLlalarldaeqraqqNgtdsLdgqtgtqdkgqkpnlld 885
EBV mlypgidelaqqh-asgegpginpi --skteLq----------------- AimtalheqnqeqkraaqraAgpsvasraLqaardrfpglRrRRyhd 842
Con -TT--LK................ -DE-KL................. AREMI-YM-LVSA-E— E-KA-KKM.... 1........ R-RR— -
EHV-4 Ytrlredctmesekmv 975
PRV Yqrlesedpdal 913
BHV-1 Yqqlpmadvgga 932
MDV Ydklpttysdseddav 865
VZV rvrtenvtgv 868
HSV-1 Ytqvpnkdgdadeddl 903
HCMV rlrhrkngyrhlkdsdeeenv 906
EBV petaaallgeaetef 857
Con Y.................
Figure 4.13 Alignment of the amino acid sequences of the gB- 
like proteins of EHV-4, PRV, BHV-1, MDV, VZV, HSV-1, HCMV and 
EBV. Dashes denote spaces introduced to maximise homology 
between the sequences. The consensus sequence (Con) denotes 
residues that are identical in at least five of the eight 
proteins, and such residues are shown in capital letters. 
Potential N-linked glycosylation sites are underlined. Spans 1, 
2 and 3 of the HSV-1 gB hydrophobic transmembrane domain are 
indicated. An asterisk denotes the internal proteolytic cleavage 
site of the VZV protein. HSV-1 gB mutants are indicated: rate of 
entry (r) (Bzik et_al., 1984b), syncytial (s) (Bzik et al.. 
1984b), temperature-sensitive (t) (Bzik et al., 1984a) and
monoclonal antibody-resistant mutants I, II, III, IV 
(Highlander et al. . 1989) and (m) (Pellett et al. . 1985b).
The sources of the sequences were as follows: PRV (Robbins et 
al., 1987), BHV-1 (Lawrence et al. . 1988), MDV (Ross et al..
1989), VZV (Keller et al.. 1986), HSV-1 (Bzik et al., 1984a),
HCMV (Cranage et al.. 1986), EBV (Pellett et al.. 1985a).
T A B L E  4,4 
Main Features of the Herpesvirus gB-Like Proteins
Herpesvirus 
gB homologue
Total size 
(a.a)
Signal 
sequence 
(a.a)
Mature 
form 
(a.a)
Number
of
NGS
Internal
cleavage
EHV-4 975 84 891 11 Yes
EHV-1 980 85 895 9 Yes
PRV 913 53 860 6 Yes
BHV-1 932 67 865 6 Yes
MDV 865 21 844 9 Yes
VZV 868 8 860 7 Yes
HSV-1 903 *30 873 6 No
HCMV 906 24 882 18 Yes
EBV 857 22 835 9 No
Table 4.4 Sources of the gB sequences are as in Figure 4.13. 
The signal sequence of HSV-1 (strain F) gB (Pellett et al.. 
1985b) is 29 amino acids, yielding a mature form of 874 amino 
acids. NGS, N-linked glycosylation sites (in external domain)? 
a.a., amino acids.
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F I G U R E  4.14
Dot Matrix Similarity Analysis of the EHV-4 gB Amino Acid 
Sequence Against Those of Other Herpesvirus qB-Like Proteins
(a) E H V - 4 200
I i i i i I
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Figure 4.14- continued
Figure 4.14- continued
(e) E H V - 4
i i i . i i
4 0 0I 60 0I 8 0 0I
Figure 4.14 Dot matrix similarity analysis of the EHV-4 gB 
amino acid sequence against those of the gB-like proteins of 
five other herpesviruses. Analysis was carried out using COMPARE 
and DOTPLOT from the University of Wisconsin Genetics Computer 
Group programmes (Devereux et_al., 1984). In each plot, the 
horizontal axis is the EHV-4 gB amino acid sequence numbered as 
in Figures 4.12 and 4.13. Vertical axes represent the amino acid 
sequences of the gB-like proteins of EHV-1 (a), PRV (b) , HSV-1 
(c) , HCMV (d) and EBV (e) . Points are plotted when at least 15 
amino acids in a moving window of 30 are identical. Large 
regions of similarity are indicated by uninterrupted diagonal 
lines from lower left to upper right.
Homology Between the Herpesvirus qB-Like Proteins
EHV-4 EHV-1 PRV BHV-1 MDV VZV HSV-1 HCMV EBV
EHV-4 88.6 53.1 53.0 46.8 49.7 46.0 28.2 30.1
EHV-1 - 53.4 52.7 45.8 49.7 46.2 28.0 29.5
PRV - 60.7 48.0 50.9 50.7 29.3 30.5
EHV-1 - 46.6 51.6 48.8 28.3 29.4
MDV - 48.7 46.4 29.3 29.5
VZV - 46.1 29.2 28.5
HSV-1 - 29.5 30.3
HCMV _ 31.4
EBV
Table 4.5 Percentage amino acid homologies for pairwise 
comparisons of the herpesvirus gB-like proteins.
Alignment of the Carboxvl-Terminal Amino Acids of 
the ICP18.5-Like Proteins of Eight Herpesviruses
EHV-4 E L A r F - M V t - a a k 9 - D U s i S e F q r F Y C F e G V - - t G V T a t 0 R I A U k y :I 9 E L 45
EHV-1 E L A r F - M i t - a a k 9 - D U s i S e F q r F Y C F e G V - - t G V T a t 0 R t A W k y :I 9 E L 45
PRV 9 L A r F - M v - - a r - - - D U c V s e F r g F Y r F q t a - - - G V T a t Q R q A U r y :I R E L 41
BHV-1 E L A a F - M I - a a a 9 9 - g U a v S d F q q F f C F a s a r a r G V T a a Q R I A U q Y 1I R E L 47
MDV
VZV E L A k F - M g g v v g s - - n W I I s P F r g' F Y C F s G V - - e G V T f a 0 R I A U k Y ][ R E L 668
HSV-1 E L A r F i M 9 a - 9 9 s 9 a D U a V s e F q I* F Y c F d G i - - s G i T P t Q R a A W r Y 1 R E L 684
EBV f 1 t s I i w - P - 9 i e p s D U i e t s F n s F Y s V p G g - - s I a s s q 0 - i I c r a 1 R E a 612
Con E L A - F - M - - - - - - - D U - - s - F - - F Y c F - G - - - - G V T - - 0 R - A W - Y 1[ R E L
EHV-4 i L A a a V F s S V F H C G E V r L I R A D r t y P n t n G - qr c a s G i Y i 85
EHV-1 i L A a a V F s S V F H C G E V r L I R A D r t y P d s s G - q r c v s G i Y i 85
PRV v L A V a V F r S V F H C G d V e V I R A D - - r f a - - G - . . . . . . . - - - - r d - - G I Y L 73
BHV-1 v L A r a V F a S V F H C G r V P L I R A D r t a P g p d G - qs c P s G V Y L 87
MDV V F k C G E t h i c R A D s I q i n s n G - . . . . . . . - - d yv w k n G i Y i 31
VZV v f A t t I F t S V F H C G E V r L c R v D r I g k d p r G c t s q p k g i 9 s s h 9 P I d G i Y L 718
HSV-1 i i A t t I F a S V y r C G E l e L r R p D c s r P t s e G - - - - - - - - - - r yrypp G v Y L 724
EBV v L t V s I y n k t - w g r s I i L r R A D a v s P - - - G - . . . . . . . - - qa I p p d G t Y L 648
Con - L A - - - F - S V F H C G E V - L - R A D - - - P - - - G - ...... - - - - - - - - G - Y L
EHV-4 T Y E t S C P L V A v l f v A p n G v I - - G e e t V V I Y D s D V F S L L Y t V L Q qL A P 9 s 9 133
EHV-1 T Y E a S C P L V A v l s a A p h G a I - - G a e t V V I Y D s D V F S L L Y a v L Q qL A P 9 s 9 133
PRV T Y E a s C P L V A - v f g A g p G g I - - G p g t t a v i a s D V F 9 L L h t t L Q - L r 9 a P S 119
BHV-1 T Y E e s w P L a A - v l n A p r a p e t v G e d s V V I Y D r D V F S L L Y a V I Q r L A P a 9 r 136
MDV T Y E t e y P L i m i l g s e s s t s e - - t q n m t a I i D t D V F S L L Y s i L Q ym A P V t a 79
VZV T Y E e t C P L V A i  i q s g e t G  - 1 - - d q n t V V I Y D s D V F S L L Y t I m 0 r L A P d s t 765
HSV-1 T Y d s d C P L V *  i v e s A p d C c  1 • - G p r s V V v Y D r D V F S i L Y s V L Q h L A P r I P 772
EBV T Y d s d r P L i I l y k g r g w v f k - - d l y a I I y I h I qm r d d s a * 685
Con T Y E - - C P L V A - - - - A - - G - I - - G - - - V V I Y D - D V F S L t Y - - L 0 - I A P - - -
EHV-4 a n * 135
EHV-1 a n * 135
PRV r * 120
BHV-1 a p r * 139
MDV d q v r v e q i t n s h a p i * 94
VZV d p a f s * 770
HSV-1 d g g h d g p p * 780
EBV 685
Con
Figure 4.15 Alignment of the carboxyl-terminal amino acids of 
the ICP18.5-like proteins of EHV-4, EHV-1, PRV, BHV-1, MDV, VZV, 
HSV-1 and EBV. Dashes denote spaces introduced to maximise 
homology between the sequences. The consensus sequence (Con) 
denotes residues that are identical in at least five of the 
eight proteins, and such residues are shown in capital letters. 
Residue 1 of the EHV-4 protein is aligned with residue 1 of the 
EHV-1, PRV, BHV-1 and MDV proteins for which complete sequence 
data are not available, and with residues 624, 638 and 568 of 
the VZV, HSV-1 and EBV proteins, respectively, for which 
complete sequence data are available. The sources of the 
sequences were as in Figure 4.13 except for VZV (Davison and 
Scott, 1986a), HSV-1 (Pellett et_al., 1986) and EBV (Pellett et 
al.. 1986). The EHV-1 sequence is from Whalley et al. (1989).
D I S C U S S I O N
The DNA sequence of the gB gene of EHV-4 has been
determined and its gene product compared with the gB-like 
proteins of several other herpesviruses. Alignment of these
proteins identified gB as a highly conserved species across the 
herpesviruses with regions of particularly homologous amino 
acids which may be of functional importance. The conservation of 
all ten cysteine residues and several N-linked glycosylation 
sites in the external domain of the molecules indicates that 
they probably share very similar secondary and tertiary 
structures. Taken together with their remarkably similar
hydropathic profiles, the gB proteins probably adopt an
orientation in membranes similar to that predicted for HSV-1 gB 
(Pellett et al.. 1985b). This model predicts a cleavable signal 
sequence, a hydrophilic surface domain oriented to the 
extracellular environment, a membrane-spanning domain that 
traverses the membrane three times and a short cytoplasmic 
anchor domain that projects into the cytoplasm or virion 
envelope interior. This generally accepted model was supported 
by the studies of Claesson-Welsh and Spear (1987). By comparing 
the amino acid sequence at the amino-terminus of gB purified 
from cells infected with HSV-1 strains KOS and F with that 
deduced from DNA sequence analysis they confirmed that gB was 
synthesised with a cleavable signal sequence of 29 (strain F) or 
30 (strain KOS) amino acids. HSV-1 gB synthesised from in vitro 
translation of gB mRNA in the presence of membranes was shown to 
be inserted into membranes and glycosylated cotranslationally 
but not able to be inserted after most of the protein had been
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synthesised. A large fragment of gB synthesised in this way, 
which carried all the N-linked glycosylation sites of intact gB, 
was protected from proteolysis by membranes. Since the deduced 
amino acid sequence of HSV-1 gB indicated that all the N-linked 
glycosylation sites were on the amino-terminal side of the 
proposed transmembrane domain, these findings supported the
orientation of gB in membranes as previously proposed. The 
pattern of fragments produced by trypsin cleavage of gB 
supported the theory that gB traverses the membrane three times. 
The conservation of orientation in membranes for other gB-like 
proteins was reinforced by analysis and comparison of the
secondary structure of the HSV-1 gB and EBV gB proteins (Pellett 
et al.. 1985a). The surface, transmembrane and, in particular, 
cytoplasmic domains were near identical in structure despite 
their relatively extensive divergence of amino acid sequence. 
Further detailed analysis of EHV-4 gB and other herpesvirus gB- 
like proteins should confirm these predictions.
The prediction of an internal proteolytic cleavage site for 
EHV-1 gB and EHV-4 gB from sequence data was confirmed by
Meredith et al. (1989) who were the first workers to
unequivocally identify EHV-1 gB and EHV-4 gB as disulphide- 
linked heterodimers. Using one- and two-dimensional gel 
electrophoresis techniques to compare the major structural 
proteins of EHV-1 strain Abl and EHV-4 strain MD, in addition 
to Western blotting and immunoprecipitation with monoclonal 
antibodies to EHV-1, they identified EHV-1 gB as migrating as a 
108kDa glycoprotein (140kDa under non-reducing conditions) that 
was cleaved to give two glycoprotein species of 76kDa and 58kDa 
held together by disulphide bonds. EHV-4 gB was demonstrated to
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exist as a 112kDa glycoprotein that was cleaved into 74kDa and 
61kDa species linked by disulphide bonds. Internal proteolytic 
cleavage at the site predicted on the basis of sequence data 
would yield two unglycosylated protein species of a similar size 
(50kDa and 51kDa) for EHV-4 gB, identical in size to those 
predicted for EHV-1 gB (Whalley et__al., 1989). Since the
majority of N-linked glycosylation sites reside in the amino- 
terminal half of the gB molecules, this region probably 
corresponds to the higher molecular mass species and the 
carboxyl-terminal half to the lower molecular mass species of 
the disulphide-linked complexes. A separate study confirmed the 
existence of EHV-1 gB and EHV-4 gB as disulphide-linked 
complexes (Sullivan et al., 1989). A particularly interesting 
observation made by Meredith et al. (1989) was that one EHV-1 
monoclonal antibody (9o<C2) reacted with the 58kDa and 108kDa, 
but not the 76kDa, species of EHV-1 in Western blotting or 
immunoprecipitations, and cross-reacted with only the 112kDa 
species of EHV-4. This suggested that 9o<C2 reacted with an 
epitope present on both the 58kDa and 108kDa species of EHV-1, 
which is therefore conserved during proteolytic cleavage of the 
108kDa species but destroyed during cleavage of the 112kDa EHV-4 
species. This led the authors to suggest that the proteolytic 
cleavage sites of EHV-1 gB and EHV-4 gB may be in different 
locations. However, alignment of the EHV-1 gB and EHV-4 gB amino 
acid sequences demonstrated that the proposed cleavage sites are 
in identical positions (Figure 4.12). An interesting finding was 
that EHV-1 gB contains an additional two consecutive arginine 
residues immediately prior to the proposed cleavage site which 
are absent in EHV-4 gB. It could be possible that EHV-1 gB is
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cleaved after these two additional arginine residues and not at 
the proposed R-R/S sequence which remains the only possible 
cleavage site for EHV-4 gB. This may represent the differential 
cleavage of the EHV-1 gB and EHV-4 gB proteins suggested by 
Meredith et al. (1989) which could account for the reactivity 
pattern of 9oCC2 and, if proved correct, the epitope for 9©<C2 
would be expected to encompass the R-R/S sequence. The exact 
location at which EHV-1 gB and EHV-4 gB are cleaved awaits 
determination by amino-terminal sequencing of the purified 
components of the disulphide-linked complexes, a procedure that 
would also identify the signal peptidase cleavage site of the gB 
proteins.
The fast-entry phenotype of HSV-1 mutant tsB5 relative to 
wild-type KOS was shown to be the result of a Val-to-Ala 
substitution at position 552 of gB (Bzik et al., 1984b). It may 
be of significance that the amino acid in the corresponding 
position of the gB homologues of EHV-4, PRV, BHV-1, MDV, HCMV 
and EBV is also an Ala (Figure 4.13). Interestingly, this Val 
residue is also replaced by an Ala residue in the gB protein of 
HSV-1 strain F. The rate of entry mutation lies within a domain 
that is well conserved across the herpesvirus gB-like proteins, 
which accentuates the probable important conserved role played 
by this domain in the entry of virus into infected cells.
The HSV-1 mutants tsJ12 and tsJ20 which are temperature- 
sensitive for the accumulation of gB and viral growth are 
associated with amino acid changes at positions 376 (Arg-to-Cys) 
and 272 (Val-to-Ile), relative to wild-type KOS, respectively 
(Bzik et al.. 1984a). Inspection of the amino acid sequences of 
herpesvirus gB-like proteins revealed that an Arg residue is
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also present in a position equivalent to HSV-1 gB residue 376 in 
all cases apart from EBV. A Val residue is also present in a 
position aligning with HSV-1 gB residue 272 for EHV-4, PRV, 
BHV-1 and MDV; VZV and EBV contain an lie in this position, the 
substituting amino acid which confers the temperature-sensitive 
phenotype to HSV-1 tsJ20. Since the sites of these temperature- 
sensitive mutations lie within well conserved regions of the 
HSV-1 gB protein, it seems likely that temperature-sensitive 
mutations for other herpesviruses may also map to this region.
It has been proposed that HSV-1 gB is part of a 
multiprotein complex which determines the social behaviour of 
infected cells (Ruyechan et_al., 1979). The cytoplasmic domain 
of gB is thought to interact with the virion tegument proteins 
and other membrane proteins to affect the social behaviour of 
infected cells (Pellett et al.. 1985a), since a syncytial
mutation has been mapped to this domain in HSV-1 gB (Bzik et
al., 1984b ). A single amino acid substitution at position 857
(Arg-to-His) in mutant tsB5, relative to wild-type KOS, is 
associated with the syncytial phenotype, characterised by 
extensive cell fusion (Bzik et al.. 1984b). An Arg residue was 
also found to be present in this position in the gB-like 
proteins of BHV-1, MDV and VZV (Figure 4.13). It has been
predicted that residues 841 to 858 of HSV-1 gB are amphipathic, 
adopting both a hydrophilic and a hydrophobic face, and that
this region may interact with other proteins (Pellett et al.. 
1985a). The highly conserved nature of this region between all 
the alphaherpesvirus gB homologues indicates a common, conserved 
function.
Cai et al. (1988) identified two syncytial mutations in the
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cytoplasmic domain of HSV-1 (KOS) gB, one of which was that 
previously described in tsB5. The second site which could be 
altered to induce extensive cell fusion was located between 
residues 816 (leucine) and 817 (lysine). Mutations in gB that 
decreased cell fusion activity were shown to be located both 
inside and outside the cytoplasmic domain, suggesting that gB 
may contain separate functional regions responsible for the 
induction and inhibition of cell fusion. It is of interest 
that residues 816 and 817 of HSV-1 gB are aligned with identical 
residues in all the alphaherpesvirus gB-like proteins (Figure 
4.13).
Huff et al. (1988) demonstrated that the carboxyl-terminal 
41 amino acids of HSV-1 gB are not essential for the production 
of infectious virus particles and for gB function. It can be 
seen from Figure 4.13 that the 40 or so amino acids at the 
carboxyl-terminal of all the herpesvirus gB-like proteins are 
poorly conserved and, as such, may also be dispensable for 
protein function.
Truncation of the 194 carboxyl-terminal amino acids of 
HSV-1 gB resulted in secretion of the product from transfected 
cells due to deletion of the transmembrane and cytoplasmic 
domains which contain sequences essential for a membrane 
anchoring function (Pachl et al., 1987) . Analysis of the EHV-1 
gB and HSV-1 gB amino acid sequences led Whalley et al. (1989) 
to speculate that a hydrophobic stretch of amino acids (EHV-1 gB 
residues 853 to 868 and EHV-4 gB residues 848 to 863, Figure 
4.12) could serve to anchor the protein into the membrane in 
accordance with the criteria defined by Engelman et al. (1986). 
The general conservation of amino acid sequence in this region
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of all herpesvirus gB-like proteins suggests a common anchoring 
function.
Domains within HSV-1 (strain KOS-321) gB that are involved 
in virus penetration of cells have been studied using monoclonal 
antibody-resistant (mar) mutants. Five distinct epitopes for 
monoclonal antibodies on gB (antigenic sites I to V) have been 
identified using virus neutralising monoclonal antibodies and 
mar mutants (Marlin et al.. 1986). Mutations affecting either 
site II or site III caused temperature-sensitive defects in gB 
glycosylation at the non-permissive temperature (39°C), whereas 
variants altered in both sites produced no mature gB and showed 
reduced titres when grown at 39°C. Since other HSV-1 strains 
carrying temperature-sensitive mutations in the gB gene produced 
a gB precursor at 39°C that was not recognised by antibodies to 
sites II and III, it was suggested that sites II and III are 
linked with gB structures that are antigenic and essential for 
the processing of gB and its function in virus infectivity 
(Marlin et al., 1986). Highlander et al. (1988) demonstrated 
that gB-specific monoclonal antibodies recognised two major 
antigenic sites located in separate regions of the surface 
domain. The residues critical to recognition by monoclonal 
antibodies to sites I, III and XV, which neutralised virus 
infectivity by inhibiting penetration, were mapped to the centre 
of the surface domain (residues 241 to 441). Antibodies specific 
for site II and which had no effect on viral penetration 
recognised residues near the transmembrane domain (residues 596 
to 737) . Only the antibody to site III could neutralise 
infectivity in the absence of complement. In the absence of 
complement, antibodies to sites I and IV slowed the rate of
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virus entry into cells. Antibodies that bind to gB were 
therefore shown to inhibit viral penetration by binding to a 
domain that is directly involved in this process. The authors 
concluded that sites I, III and IV comprise a major antigenic 
site associated with structures which contribute to virus 
infectivity. This analysis of the antigenic structure of HSV-1 
gB was further extended by the studies of Highlander et al. 
(1989). Mutations affecting antibody neutralisation at sites I 
to XV were identified as single amino acid changes at residues 
473 (Ser-to-Asn), 594 (Gly-to-Arg), 305 (Glu-to-Lys) and 85
(Gly-to-Asp) , respectively. Additionally, two distinct site II 
antibodies selected mar mutants which demonstrated a decreased 
rate of entry into host cells (residue 594, Gly-to-Arg) , the mar 
and rate of entry phenotypes thus being due to a single 
mutation. Insertion of amino acids throughout the surface domain 
of gB produced proteins that were not recognised by antibodies 
to sites II and III but which were still recognised by 
antibodies to sites I and XV. Since mar mutations in sites II or 
III could cause temperature-sensitive defects in gB 
glycosylation and variants in both sites were temperature- 
sensitive for virus production (Marlin et al.. 1986), these new 
data confirmed that sites II and III contain structures 
important for gB function in virus infectivity. Since antibodies 
to site II did not inhibit penetration but selected mutants 
showing altered rate of entry kinetics, it was suggested that 
this site does not contribute to gB function to the same extent 
as site III but still remains important in the infectious 
process (Highlander et al., 1989).
Pellett et al. (1985b) also reported several mutations that
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result in resistance to neutralisation by monoclonal antibodies 
in HSV-1 (strain F) gB at residues 302 (Tyr-to-Asn), 312 (Ser- 
to-Thr), 314 (Ala-to-Thr), 334 (Arg-to-Gln) and 472 (Ser-to-
Asn) . Most of these mutations were close to the site III 
mutation described previously. All these mutations are indicated 
in Figure 4.13. It can be seen that the site I mutation is
located within a very poorly conserved region of the gB molecule 
and, as such, little conservation of function can be expected. 
This site I mutation is located in a part of the molecule which 
closely aligns with the predicted proteolytic cleavage site of 
the other herpesvirus gB-like proteins. The very divergent
nature of this region suggests that epitopes in this area are
likely to show no cross-reactivity. This site I mutation is
located close to the region where a putative epitope for the 
EHV-1 monoclonal antibody 9©<C2 may reside, as discussed 
earlier. HSV-1 gB antigenic site IV is located near the amino- 
terminus in a region displaying little amino acid conservation 
with other herpesvirus gB-like proteins, and represents an 
epitope unique to HSV-1; the Gly residue at position 85 is type- 
specific, being replaced by an Arg in HSV-2 gB. An epitope for 
the EHV-1 gB monoclonal antibody 3F6 (Allen and Yeargan, 1987) 
has been identified as the sequence ETPDPLR at EHV-1 gB residues 
116 to 122 (G. Allen, Equine Virology Research Foundation
Grantholders Meeting, Newmarket, October 1989), which is 
conserved with EHV-4 gB residues 113 to 119 (Figure 4.12), 
representing a gB type-common epitope. This epitope aligns with 
a region adj acent to the HSV-1 gB antigenic site IV mutation 
(Figure 4.13). The HSV-1 gB antigenic site II mutation maps 
near a region that is highly conserved between the herpesvirus
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gB-like proteins, suggesting conservation of high order 
structure and function. This HSV-1 gB epitope may share cross­
reacting determinants with other gB-like proteins. The region in 
which the HSV-1 gB antigenic site III mutation maps is highly 
conserved with the other gB-like proteins, with a predicted 
conservation of secondary as well as primary structure and a 
predicted similar important function in the gB-like proteins. 
That this region can affect gB processing and viral infectivity 
was supported by studies on the mutants tsJ12 and tsJ20, which 
contain mutations close to the site III mutation as described 
earlier.
Further detailed studies on EHV-4 gB and the gB-like 
proteins of other herpesviruses will provide a more accurate 
overview of the precise functions and antigenic structure of 
each protein which, on the basis of sequence data, can be 
expected to be very similar.
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CHAPTER 5
Expression of the EHV-4 Glycoprotein gB Gene in Prokaryotic 
Vector Systems and Evaluation of the Immunogenicity of the 
Purified Recombinant Proteins and of Peptides Derived 
From the EHV-4 gB Amino Acid Sequence
I N T R O D U C T I O N
Two commercial vaccines are currently available in the U.K. 
which offer protection against EHV-induced abortigenic and 
respiratory diseases. Rhinomune contains a live attenuated EHV-1 
strain and is licensed to protect against respiratory disease. 
Pneumabort-K is a formalin-inactivated EHV-1 Army 183 strain and 
is licensed to protect against abortion. Initial challenge 
studies with the latter vaccine in both young horses and
pregnant mares demonstrated that it could protect against 
abortion. Two vaccinations, three weeks apart, protected 11 
pregnant mares following challenge eight weeks later with
virulent EHV-1 (Bryans, 1978). In other trials, two 
vaccinations 62 days apart resulted in only two out of 11 
mares aborting following challenge with EHV-1 Army 183 15
days after the second vaccination (Moore and Koonse, 1977). 
These studies demonstrated that the vaccine preparation was 
immunogenic in as much as it could induce virus neutralising
antibody levels comparable to those resulting from infection 
with virulent virus. Use of the vaccine in Kentucky between 1977
and 1980 was reported to be associated with a significant
reduction in the incidence of abortion due to EHV-1 from 6.8 per
1000 in an unvaccinated population to 1.8 per 1000 in a
vaccinated population (Bryans, 1981; Bryans and Allen, 1982). 
Further use of the vaccine in Kentucky during the four year 
period following its commercial introduction in 1980 resulted in 
a decrease in the incidence of abortion induced by EHV-1 to the 
lowest level ever recorded in the breeding population (Allen and 
Bryans, 1986). Despite such initial promise, more recent trials
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have, placed doubt on the efficacy and safety of this vaccine. In 
studies to establish the nature and longevity of the immunity 
established by Pneumabort-K, it was demonstrated that the 
vaccine could not protect against an aerosol infection with EHV- 
1, even in ponies that had previously been exposed to EHV-1 on 
many occasions, although the incidence and duration of clinical 
signs and the amounts and duration of virus shedding were 
reduced (Burrows et al.. 1984). Of particular concern was the 
inability to prevent the cell-associated viraemia caused by EHV- 
1 infection, and the probable subsequent infection of the 
foetus. However, protection was afforded against challenge with 
EHV-4 (Mumford and Bates, 1984).
Commercially available vaccines based on EHV-1 strains are 
still capable of stimulating the production of antibodies cross­
reactive with EHV-4 by virtue of shared antigens. In recent 
years much emphasis has been placed on the development of more 
effective and safer vaccines to protect horses against 
abortigenic and respiratory diseases. Any such new vaccines must 
be capable of eliciting an effective immune response against the 
envelope glycoproteins, especially those directly involved in 
cell fusion and viral infectivity. The EHV-1 envelope 
glycoproteins have been specifically identified as the virion 
components to which antibodies that inhibit virus infectivity 
bind (Papp-Vid and Derbyshire, 1978, 1979) . Although it has been 
suggested that monovalent vaccines based on EHV-1 (Edington and 
Bridges, 1990) and EHV-4 (Fitzpatrick and Studdert, 1984) could 
elicit antibody and cellular immune responses to both virus 
types, a bivalent vaccine incorporating the appropriate 
immunogenic antigens from both EHV-1 and EHV-4 should prove to
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be most effective. By analogy with HSV-1, glycoproteins gB and 
gC of EHV-1 and EHV-4 would be the best antigens for development 
as novel vaccines. Indeed, the gp2, gplO, gpl3 (gC) and gpl4 
(gB) glycoproteins of EHV-1 and EHV-4 have been shown to be the 
most immunogenic viral antigens, whilst gp2 and gpl4 (gB) were 
the most cross-reactive antigens between the two viruses (Allen 
and Bryans, 1986). The recombinant DNA technology currently 
available greatly facilitates the development of more effective 
and safer novel vaccines. Strategies for vaccine development 
include the construction of recombinant viruses which express 
all the necessary immunogenic antigens of both EHV-1 and EHV-4 
and the production of individual immunogenic glycoproteins by 
expression of their genes in bacterial expression systems for 
direct use as subunit vaccines. The bivalent vaccine approach 
and other strategies will be more fully discussed in Chapter 7 
of this thesis. This chapter is concerned with the evaluation of 
EHV-4 gB as a subunit vaccine.
Knowledge of the DNA sequence of the EHV-4 gB gene (Chapter 
4) permitted selected segments of the gene to be expressed as 
fusion proteins by cloning in-frame with bacterial coding 
sequences in bacterial expression vector systems. Many vectors 
have been constructed which simplify the expression and 
subsequent purification of foreign proteins expressed in E.coli 
(Marston, 1987) . Probably the most widely used are those which 
direct the intracellular synthesis of proteins as soluble fusion 
products with |3-galactosidase (Koenen et al.. 1982; Ruther and 
Muller-Hill, 1983), which can then be directly purified from 
crude cell lysates by immunoaffinity chromatography or 
electroelution from polyacrylamide gels. Cloned DNA fragments
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can also be expressed as fusion proteins with staphylococcal 
protein A and purified from crude cell lysates by immunoaffinity 
chromatography on IgG-sepharose (Uhlen et al., 1983; Nilsson et 
al.. 1985). Alternatively, fusion proteins can be secreted into 
the periplasmic space or culture medium, leading to rapid 
purification (Abrahmsen et al.. 1986; Kato et al.. 1987;
Marston, 1987).
Segments of EHV-4 gB were expressed intracellularly as (3- 
galactosidase fusion proteins using the pUR vector system 
(Ruther and Muller-Hill, 1983) which were then purified by 
electroelution from polyacrylamide gels. The pUR series of 
plasmids contain four unique cloning sites at the 3' end of the 
lacZ coding region and since the positions of the inserted 
restriction sites have been shifted relative to the lacZ coding 
region in each of the six vectors, any foreign coding region can 
be inserted into one of the vectors in the same reading frame as 
lacZ to allow expression as a (3-galactosidase fusion product. 
LacZ expression is repressed by maintaining the plasmids in the 
E.coli JM101 host, which overproduces the lac repressor due to 
the lacl^ allele. Fusion protein synthesis is induced with 
isopropyl- (3 -D-thiogalactopyranoside (IPTG). Another, more 
efficient, expression system was also used which directed the 
intracellular synthesis of gB as a fusion product with the 
carboxyl-terminus of Sj26, a 26kDa glutathione-S-transferase 
(GST) encoded by the parasitic helminth Schistosoma iaponicum. 
and fusion protein was rapidly purified by affinity 
chromatography on glutathione-agarose beads (Smith and Johnson, 
1988). The pGEX series of plasmids contain a tac promoter 
followed by the complete coding sequence of GST in which the
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normal termination codon has been replaced by a polylinker 
containing unique restriction sites for BamHI, Smal and EcoRI, 
closely followed by a termination codon in all three reading 
frames. These plasmids contain a fragment of the lac operon 
carrying the overexpressed lacl^ allele of the lac repressor and 
a portion of lacZ. Under uninduced conditions the lacl^ allele 
efficiently inhibits transcription from the strong tac promoter, 
regardless of the lacl status of the host, until induction with 
IPTG.
The immunogenicity of purified gB fusion proteins was 
evaluated by analysing the nature of the immune response induced 
in hamsters, and by subsequent challenge studies on immunised 
animals. Additionally, the immunogenicity of several synthetic 
peptides derived from the primary amino acid sequence of EHV-4 
gB was evaluated in a similar manner.
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M A T E R I A L S  A N D  M E T H O D S
Construction of Recombinant Plasmids
The plasmid pBSgB (Figure 4.2) was double-digested with 
BamHI and Hindlll and the 1674bp fragment released 
directionally cloned between the BamHI and Hindlll sites of the 
expression vector pUR288 to generate the recombinant plasmid 
pUR1.7gB. The 624bp fragment released by double-digestion of 
pBSgB with Bglll and Hindlll was directionally cloned between 
the BamHI and Hindlll sites of pUR288 to generate the 
recombinant plasmid pUR0.6gB. Finally, the 1056bp fragment 
released by double-digestion of pBSgB wi-th-BamHI—and~BglII- was 
cloned into the BamHI site of both pUR288 and the GST expression 
vector pGEX-2T to generate the recombinant plasmids pURl.OgB and 
pGEXl.OgB, respectively. Each of these plasmids contained gB 
coding sequences cloned in-frame with (3 -galactosidase 
(pUR1.7gB, pURl.OgB, pUR0.6gB) or GST (pGEXl.OgB) coding 
sequences. Insertion of the DNA insert in the correct 
orientation in plasmids pURl.OgB and pGEXl.OgB was confirmed by 
restriction endonuclease analysis.
Induction of Fusion Protein Synthesis
E.coli strain JM101 carrying the recombinant plasmid was 
inoculated into 10ml of L broth containing ampicillin at 
lOOug/ml and grown at 37°C for 16 to 20hr with vigorous shaking 
in an orbital incubator. 1ml of this culture was diluted into 
100ml of L broth containing lOOug/ml ampicillin and grown at 
37°C with vigorous shaking until the OD reading at 600nm was 
approximately 0.5 (took 2.5 to 3hr) . The culture was then
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induced for fusion protein production by the addition of IPTG 
(Table 5.1) to a final concentration of 0.5mM and incubation at 
37°C with vigorous shaking for a further 2hr. For each 
recombinant plasmid, a time-course study was initially carried 
out in order to determine the induction time with IPTG that 
gives optimum levels of fusion protein synthesis. In this case, 
bacterial cells were grown to an OD reading of 0.5 as above, and 
then individual aliquots of culture were induced with 0.5mM IPTG 
for varying lengths of time, typically Ohr, 0.5hr, lhr, 1.5hr, 
2hr, 2.5hr, 3hr, 3.5hr and 4hr.
Preparation of Cell Extracts (Small Scale)
2ml of each induced bacterial culture was spun in a 
benchtop microcentrifuge (13000rpm/lmin), pelleted cells were 
washed by resuspending in 1ml of dH20 and recovered by 
centrifugation once more. Cells were lysed in 200ul of SDS-PAGE 
sample buffer (Table 5.1) by vigorous pipetting and cell debris 
removed by centrifugation as above for 5min. 20ul of each 
supernatant was analysed for fusion protein production by SDS- 
polyacrylamide gel electrophoresis.
SDS-Polvacrvlamide Gel Electrophoresis (SDS-PAGE)
Cell extracts were fractionated by SDS-PAGE as previously 
described (Laemmli, 1970). Gels contained 10% acrylamide with a 
5% stacking gel. The composition of the gel mixes is shown in 
Table 5.1. SDS-PAGE was conducted on a vertical gel set (BRL) 
used according to the suppliers instructions. Following pouring 
of the running gel, leaving a 4cm space above for application of 
the stacking gel, lOOul of water-saturated butanol was applied
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to the top of the gel to ensure a smooth surface and the gel 
left to polymerise for at least 30min. Following removal of the 
butanol by rinsing with dH20, the stacking gel was poured, the 
well-forming comb inserted and the gel left to polymerise for at 
least 30min. Samples were boiled in SDS-PAGE sample buffer for 
3min and then loaded onto the gel. All gels were electrophoresed 
at a constant voltage of 200V for 3 to 4hr at room temperature 
in SDS-PAGE running buffer (Table 5.1). Gels were stained with 
Coomassie blue (Table 5.1) for 2hr with gentle agitation. 
Protein bands were visualised by gentle agitation in destaining 
solution (Table 5.1) for 4 x 45min. Finally, gels were dried 
under vacuum at 80°C for 2hr.
Purification of 3 -Galactosidase Fusion Proteins
Fusion proteins were isolated by electroelution (Maniatis 
et al. . 1982) from preparative 3mm SDS-PAGE gels. The cell
extract from 50ml of induced bacterial culture, prepared by 
lysis of cells in 5ml of SDS-PAGE sample buffer as previously 
described, was electrophoresed on each gel as previously 
described. Only a small strip of gel was stained with Coomassie 
blue and this was aligned with the unstained master gel so that 
the location of the fusion protein on the unstained gel could be 
located and excised. Excised gel slices were placed in sterile 
dialysis tubing (3cm wide) sealed at one end with a clip, 30ml 
of SDS-PAGE running buffer added, air bubbles removed and the 
tubing sealed with another clip. The dialysis bag was placed in 
a hprizontal gel electrophoresis tank containing SDS-PAGE 
running buffer, ensuring that the bag was fully submerged. A 
constant voltage of 100V was applied for 14 to 16hr, then the
147
polarity was reversed for lOmin to remove any protein from the 
side walls of the dialysis bag. The buffer was removed from the 
bag and protein precipitated by adding 5 volumes of ice cold 
acetone and incubation at -20°C for 2hr. Protein was recovered 
by centrifugation in a Beckman JS7.5 rotor (7000rpm/15min/4°C). 
The pellet was washed by resuspending in 20ml of dH20 and the 
protein recovered by centrifugation. This washing step was 
repeated twice more. Finally, the pellet was resuspended in 1ml 
of PBS buffer (Table 5.1) and lOul was analysed by SDS-PAGE.
Purification of GST Fusion Proteins
A 500ml induced bacterial culture was centrifuged 
(7000rpm/15min/4°C) in a Beckman JS7.5 rotor. Pelleted cells 
were resuspended in 10ml of MTPBS (Table 5.1) containing 1% 
Triton X-100 and lysed by mild sonication (6 x 30 second bursts) 
on ice. Lysed cells were centrifuged in a Beckman JA20 rotor 
(10000rpm/10min/4°C). Fusion protein was absorbed onto 
glutathione-agarose beads by mixing the supernatant with 2ml of 
50% glutathione-agarose beads (sulphur linkage, Sigma) in a 20ml 
polypropylene tube with gentle agitation on a rotating platform 
for lOmin. Beads were previously pre-swollen in MTPBS, washed 
twice in the same buffer and stored as a 50% suspension in MTPBS 
at 4°C. Following absorption, beads were collected by 
centrifugation at lOOOrpm for 3min in a benchtop centrifuge and 
washed by resuspending in 50ml of MTPBS. Beads were collected by 
centrifugation and the washing procedure repeated twice more. 
Finally, fusion protein was eluted from the beads by competition 
with reduced glutathione using 2 x lOmin washes with 1 bead 
volume (2ml) of 50mM TrisHCl (pH 8.0) containing freshly
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prepared 20mM reduced glutathione. The eluates were combined and 
20ul was analysed by SDS-PAGE.
Peptide Synthesis
Peptides corresponding to EHV-4 gB amino acid sequences 
QESLHREQILHRIHKRAVEAANS (peptide 24; residues 528 to 550, Figure
5.3), VELDLVPSKFATPGARA (peptide 25; residues 251 to 267, Figure
5.3) and HTSLSDRYNDRVPVSVEEIF (peptide 27; residues 200 to 219, 
Figure 5.3) were prepared using solid-phase synthetic methods as 
previously described (Stokes et al., 1990). An additional 
cysteine residue was added at the terminus of each peptide in 
order to promote the formation of cross-links between peptides 
and thus eliminating the requirement for a carrier protein. 
These peptides were selected on the basis of predicted 
immunogenicity from criteria such as hydrophilicity (Kyte and 
Doolittle, 1982) and predicted secondary structure (Chou and 
Fasman, 1978). Peptide 24 was predicted to be alpha-helical, 
peptide 25 to be strongly alpha-helical and hydrophilic and 
probably situated close to the surface of the gB molecule since 
it is located near a potential N-linked glycosylation site, 
whilst peptide 27 was predicted to be very hydrophilic. In 
addition, peptides 24 and 25 demonstrated some divergence of 
sequence with the corresponding regions of EHV-1 gB and, as 
such, may represent type-specific antigenic sites. All peptides 
showed divergence of sequence with HSV-1 gB.
In Vitro and In Vivo Immunogenicity Studies
Studies on the immunogenicity of EHV-4 gB fusion proteins 
and peptides were carried out by Dr. Anne Stokes, AFRC Institute
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for Animal Health, Pirbright Laboratory, Pirbright, Surrey. All 
procedures with experimental animals, ELISA assays, virus 
neutralisation assays, immunisation of hamsters with peptides 
and challenge experiments were carried out as previously 
described (Stokes et_al., 1989, 1990). For immunisation with 
fusion proteins, 5ug of purified fusion protein emulsified in an 
equal volume of complete Freunds adjuvant was administered to 
each hamster. Further immunisations with 5ug of fusion protein 
in incomplete Freunds adjuvant were given on days 14 and 28 and 
hamsters were challenged with EHV-1 12 days after the final 
immunisation.
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T A B L E  5.1
Stock Solutions, SPS-PAGE Buffers and Gel Mixes
Stock Acrvlamide
acrylamide
methylene-bisacrylamide
dH20
SDS-PAGE Running Gel
stock acrylamide
1M TrisHCl (pH 8.8)
dH20
10% SDS
10% APS
TEMED
29g
ig
to 100ml
10.0ml
11.2ml
8.5ml
0.3ml
75ul
20ul
SDS-PAGE Stacking Gel
stock acrylamide
1M TrisHCl (pH 6.8)
dH20
10% SDS
10% APS
TEMED
1.7ml
1.2ml
7.0ml
0.1ml
75ul
8ul
SDS-PAGE Running Buffer 
glycine 
Tris base 
SDS 
dH20
SDS-PAGE Sample Buffer 
2.5% SDS
2.5% 0 -mercaptoethanol 
0.IM TrisHCl (pH 6.8) 
10% glycerol 
0.01% bromophenol blue
Coomassie Blue Staining Solution 
Coomassie blue 
methanol
glacial acetic acid 
dH20
Destainina Solution 
methanol
glacial acetic acid 
dH20
14.4g 
3. lg 
l.Og 
to 1 litre
0.5g 
300ml 
100ml 
to 1 litre
300ml
100ml
600ml
IPTG
IPTG at lOOmM in dH20. Store at -20°C. Use 
concentration of 0.5mM.
at final
PBS
Dissolve PBS tablet in 100ml dH20. Sterilise by
autoclaving.
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MTPBS
5M NaCl 
1M Na2HP04 
1M NaHoPO. 
dH20
Sterilise by autoclaving.
30ml
16ml
4ml
to 1 litre
152
R E S U L T S
Construction. Structure and Restriction Endonuclease Analysis of 
Recombinant Plasmids
The construction, structure and restriction endonuclease 
analysis of the recombinant plasmids used to express segments of 
the EHV-4 gB protein as fusions with (3 -galactosidase are shown 
in Figure 5.1. The structure of the pUR series of plasmids is 
shown in Figure 5.1a,b. The fortuitous location of restriction 
endonuclease cleavage sites in the EHV-4 gB gene permitted 
expression of segments of this gene in-frame with lacZ in a 
single vector, pUR288. Three segments of EHV-4 gB DNA were 
separately expressed in pUR288 (Figure 5.1c). The 1674bp 
BamHI/Hindlll fragment corresponds to amino acid residues 142 to 
699, the 1056bp BamHI/Bglllfragment to residues 142 to 493 and 
the 624bp Bglll/Hindlll fragment to residues 492 to 699, of the 
EHV-4 gB protein (Figure 5.3). The structure of these 
recombinant plasmids is shown in Figure 5.Id and these were 
confirmed by restriction endonuclease analysis (Figure 5.1e).
The construction, structure and restriction endonuclease 
analysis of recombinant plasmid pGEXl.OgB is shown in Figure
5.2. The structure of the pGEX series of plasmids is shown in 
Figure 5.2a,b. The 1056bp BamHI/Bglll fragment described above 
(Figure 5.2c) was cloned in-frame with GST coding sequences to 
generate the plasmid pGEXl.OgB (Figure 5.2d). Insertion of the 
EHV-4 gB DNA in the correct orientation was confirmed by 
restriction endonuclease analysis (Figure 5.2e).
As can be seen from Figure 5.3, the regions of EHV-4 gB 
expressed represent 558 amino acids from the hydrophilic surface
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domain and correspond to 78% of the total amino acids in this 
domain.
Expression and Purification of Fusion Proteins
The fusion product of pUR1.7gB was expected to be 184kDa, 
comprising 116kDa 3 -galactosidase and 68kDa gB moieties. For 
each of four clones expressing pUR1.7gB, the level of expression 
of fusion protein was very low (Figure 5.4a). To determine 
whether this low yield was due to the induction time with IPTG 
being too long or too short, a time-course study was carried out 
(Figure 5.4b) . This confirmed that there was a constant low 
level of fusion protein accumulation, probably due to 
degradation of the protein soon after its synthesis. Although 
the fusion of a protein to 3 -galactosidase greatly increases 
its stability and prevents it being recognised as foreign and 
degraded, there is obviously a limit to the size of the 
exogenous protein that can be expressed. As has been 
demonstrated here, the fusion protein is degraded soon after its 
synthesis. Protein stability, rather than the strength of the 
promoter driving protein expression, is the most important 
consideration when expressing proteins as fusion products. 
However, high levels of fusion protein expression were obtained 
with pURl.OgB and pUR0.6gB. The fusion product of pURl.OgB was 
predicted to be 159kDa (p-galactosidase, 116kDa; gB, 43kDa). As 
can be seen from Figure 5.5a, three separate clones successfully 
expressed pURl.OgB to a level representing 2 to 5% of total 
cellular protein (lanes 4, 6 and 8). In contrast, a clone 
containing gB DNA inserted in the opposite, incorrect 
orientation expressed only the 3 -galactosidase product (lane
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10). A time-course study indicated that fusion protein 
accumulation reaches its highest level between 2 and 3hr after 
induction prior to decreasing once more (Figure 5.5b) . The 
fusion product of pUR0.6gB was predicted to be 141kDa ( (3 -  
galactosidase, 116kDa; gB, 25kDa). Four separate clones were 
demonstrated to successfully express pUR0.6gB to high levels 
(Figure 5.6a? lanes 4, 6, 8 and 10). In addition to full length 
fusion protein, small amounts of another product slightly larger 
than (3 -galactosidase were also synthesised by each induced 
clone. This truncated product was probably a result of in vivo 
cleavage by E.coli at the proposed internal proteolytic cleavage 
site of EHV-4 gB, RR/S, which occurs 25 amino acids from the 
amino-terminus of the gB segment expressed (Figure 5.3) . The 
fusion product following proteolytic cleavage at this site would 
contain (2 -galactosidase fused to 25 amino acids from gB and be 
119kDa. This is consistent with the observed size of the 
truncated product. A time-course study demonstrated that maximum 
accumulation of pURO. 6gB occurs between 2.5 and 3hr after 
induction prior to levels decreasing once more- the levels of 
the truncated product also increased and decreased in direct 
parallel with the full length product (Figure 5.6b).
The pGEXl.OgB fusion product was predicted to be 70.5kDa 
(GST, 27.5kDa? gB, 43kDa). Three separate clones were 
demonstrated to successfully express pGEXl.OgB to high levels, 
and certainly equal to or better than those achieved for the (3 - 
galactosidase fusion proteins (Figure 5.7a; lanes 4, 6 and 8). 
Induction of pGEX-2T alone produced a similar amount of native 
GST (lane 2) . A time-course study demonstrated that the 
induction time which gave maximum levels of fusion protein
155
accumulation was 2hr, after which fusion protein levels 
decreased once more (Figure 5.7b).
The purity of purified fusion proteins was determined by 
SDS-PAGE. An aliquot of pUR0.6gB purified by electroelution from 
gels is shown in Figure 5.8a. Generally, fusion protein purified 
in this manner was consistently over 95% pure, with typical 
yields of 200 to 300ug/100ml of culture. The results of 
purification of pGEXl.OgB by affinity chromatography on 
glutathione-agarose beads are shown in Figure 5.8b. They 
demonstrate that the fusion protein readily bound to the beads 
and was efficiently eluted from beads with reduced glutathione. 
Eluted material contained two protein species present in equal 
amounts, the larger species corresponding to the full length 
pGEXl.OgB fusion product. Despite several separate purifications 
of fusion protein, the same two protein species were 
consistently purified. How the smaller species arose is unclear 
but several explanations exist. These include partial 
degradation of the full length product or premature termination 
of translation during protein synthesis.
Evaluation of the Immunogenicity of EHV-4 gB Fusion Proteins and 
Synthetic Peptides
The immunogenicity of fusion proteins pUR0.6gB and 
pGEXl.OgB, and peptides 24, 25 and 27 from the EHV-4 gB
sequence, was evaluated in hamsters. As can be seen from Figure
5.3, pURO.6gB contains the sequence of peptide 24 whilst 
pGEXl.OgB encompasses the sequences of both peptides 25 and 27. 
The results of in vitro and in vivo studies with EHV-4 gB fusion 
proteins and peptides are summarised in Table 5.2. Antibodies
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raised against each peptide in vivo reacted well with that 
peptide in vitro. Similarly, antibodies raised against peptide 
24 also reacted with pUR0.6gB and antibodies raised against 
peptides 25 and 27 both reacted with pGEXl.OgB, demonstrating 
the integrity of the purified fusion proteins. Antibodies raised 
against each fusion protein in vivo reacted with that fusion 
protein in vitro. A monoclonal antibody to EHV-1 gpl7/18 reacted 
strongly with peptide 24, which is consistent with the fact that 
peptide 24 is predicted, on the basis of sequence data, to 
reside on the small subunit of gB, gpl8. Somewhat surprisingly, 
a monoclonal antibody specific for EHV-1 gp2 demonstrated strong 
reactivity with peptides 24 and 27. Serum from a horse 
vaccinated with Pneumabort-K reacted with all three peptides 
whereas serum from a hamster taken at 10 days p.i. only reacted 
with peptide 24. The most crucial findings of these studies were 
as follows. Firstly, no peptide could stimulate the production 
of virus neutralising antibodies or confer protective immunity 
in hamsters, although antibodies against peptide 25 reacted 
against whole EHV-4 virus in an ELISA assay. Secondly, no fusion 
protein -could stimulate the production of virus neutralising 
antibodies in hamsters, although 1 out of 3 hamsters immunised 
with pUR0.6gB was protected from a lethal EHV-1 challenge. 
Thirdly, an additional observation not shown in Table 5.2 was 
that immunisation of hamsters with all three peptides induced 
lymphocytes to proliferate in response to whole virus antigen in 
vitro.
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Figure 5.1 Construction, structure and restriction 
endonuclease analysis of pUR recombinant plasmids, (a) 
Physical map of the pUR series of plasmid expression 
vectors. (b) Polylinkers of the pUR vectors, (c) EHV-4 gB 
fragments ejqpressed in pUR288. (d) Physical maps of the 
plasmids pUR1.7gB, pURl.OgB and pUR0.6gB. The broken lines 
represent pUR288 DNA and the solid lines represent EHV-4 gB 
DNA. Sizes are shown in kilobases. The sites for BamHI (B), 
EcoRI (E), Hindlll (H), PstI (P), Sail (Sa), SstI (Ss) and 
Xbal (Xb) are shown. (*) indicates a destroyed BamHI site 
as a result of insertion of a Bglll end. The direction of 
transcription of the EHV-4 gB gene is denoted by an arrow, 
(e) Restriction endonuclease analysis of plasmids pUR1.7gB, 
pURl.OgB and pUR0.6gB. Plasmid pUR1.7gB was digested with 
EcoRI (lane 1), Hindlll (lane 2) and SstI (lane 3), plasmid 
pURl.OgB was digested with EcoRI (lane 4), Hindlll (lane 5) 
and SstI (lane 6), and plasmid pUR0.6gB was digested with 
EcoRI (lane 7), Hindlll (lane 8) and SstI (lane 9). Hindlll 
digested X  DNA fragments were used as size markers.
Diagrams (a) and (b) are taken from Ruther and Muller-Hill 
(1983) .
F I G U R E  5,1
Construction, Structure and Restriction Endonuclease 
Analysis of pUR Recombinant Plasmids
(a) EcoRI
EcoRI
pUR 278  
2 88  
289  
S200bp
EcoRI
EcoRI
pUR 290
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292  
5200bp
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La c  Z 1010 1020
EcoRI Ha e I I I
GAA TTC CAG CTG AGC GCC GOT COC TAC CAT TAC CAG n G  GTC TGG TGT CAA AAA TAA TAA TAA CCGGGCAGGCCATGTCTGCCCG.
1020 HI J l I  J J a I Hi  m l  11 Cu^I
EcoR I. . . . . . . . TGG TGT CAA AAA GGG GAT CCG TGG ACTCTA GAA’ AGC n A  TOG ATG A T A   rtJR 278
EcoR I. . . . . . . . TGG TGT C GG GGA TCC GTC GAC TCT AGA AAG CTT ATC GAT GAT  . . . . . . .  riJR 288
E c o R I.. . . . . . . TGG TGT CA G GGG ATC CGT CGA CTC TAG AAA GOT TAT CGA T G A   pUR 289
BapH I Sa l I  Ps t I  ^ H i r c I I I  Cl a I 
EcoR I. . . . . . . . . TGG TGT CAA AAA GGG GAT CCG TCG ACC TGC AGC CAA GCT TAT CGA T G A   fOR 290
E coR I. . . . . . . . . TGG TGT C GG GGA TCC GTC GAC CTG CAG CCA AGC H A  TOG ATG . . . . . . . . .  rtJR 291
EcoR I. . . . . . . . . TGG TGT CA G GGG ATC CGT CGA CCT GCA GCC AAG CTT ATC GAT . . . . . . . . . . .  rtJR 292
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Figure 5.2 Construction, structure and restriction 
endonuclease analysis of plasmid pGEXl.OgB. (a) Physical 
map of the pGEX plasmids, (b) Polylinker of the pGEX 
plasmids. Thrombin and factor X cleavage sites are 
indicated, (c) EHV-4 gB fragment expressed in pGEX-2T. (d) 
Physical map of plasmid pGEXl.OgB. The broken line 
represents pGEX-2T DNA and the solid line represents EHV-4 
gB DNA. Sizes are shown in kilobases. The sites for BamHI 
(B), EcoRI (E), Smal (Sm) and SstI (Ss) are shown. (*) 
indicates a destroyed BamHI site as a result of insertion 
of a Bglll end. The direction of transcription of the EHV-4 
gB gene is denoted by an arrow. (e) Restriction 
endonuclease analysis of plasmid pGEXl.OgB. The plasmid was 
digested with BamHI (lane 1), BamHI/EcoRI (lane 2) and SstI 
(lane 3). Hindlll digested \  DNA fragments were used as 
size markers.
Diagrams (a) and (b) are taken from Smith and Johnson 
(1988) .
F I G U R E  5.2
Construction. Structure and Restriction Endonuclease 
Analysis of Plasmid pGEXl.OgB
(a) EcoRISTOP
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Pro Lys Ser Asp Leu H e  Clu Gly Arg1, Gly lie Pro Gly Asn Ser Ser ***
pGEX-3X CCA AAA TCC GAT CTG ATC CAA CGT CGT GGG ATC CCC GGG AAT TCA TCC TGA CTG ACT CAC CAT CTG
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Figure 5.3 Summary of the regions of the EHV-4 gB protein 
expressed as fusion products and from which peptides were 
prepared. The DNA sequence of the EHV-4 gB gene and the 
predicted amino acid sequence of its gene product are 
shown. Potential N-linked glycosylation sites are boxed and 
the internal proteolytic cleavage site is indicated by an 
arrow. The restriction endonuclease cleavage sites for 
BamHI, Bglll and Hindlll, which were utilised in cloning 
segments of the gene into expression vectors, are 
indicated. The three EHV-4 gB peptides whose immunogenicity 
was evaluated in hamsters (peptides 24, 25 and 27) are 
underlined.
F I G U R E  5.3
Derivation of EHV-4 gB Fusion Proteins and Peptides
EHV-4 gB
nAACTAGCTCGGTTTATGGTTACTGCGGCTAAAGGTGATTGGTCAATTAGCGAGTTTCAAAGGTTTTATTGCTTTGAGGGTGTGACAGGTGTGACCGCCACGCAACGGCTGGCGTCGAAA 120
TATATCGGGGAGCTCATTCTAGCTGCCCCAGTATTCTCTTCGGTTTTCCACTGCGGAGAGGTGCGCCTTCTGCCCCCACATCGTACATATCCAAACACCAACGGCGCACAGCCCTGCGCT 240
M S T C C R A I C G P Q R C Y W R R D C G N L R Q R R V L A  30
AGCGGCATTTACAIAACATACGAGACGTCATGTCCACTTGTTGCCGTGCTATTTGTGGCCCCCAACGGTGTTATTGGCGAAGAGACTGTGGTAATTTACGACAGCGACGTGTTCTCGCTT 360
S I  H R T P A A G S W L W S Q L G N V N L P A T S P M S K D S T S L G V R T  I V  70
CTATACACCGTACTCCAGCAGCTGGCTCCTGGCTCTGGAGCCAATTAGGAAATGTAAACTTGCCAGCTACCTCCCCCATGTCTAAAGACTCGACATCTCTGGGGGTGAGAACAATAGTCA 480
Signal sequence/
I A C L V L L G C C I V E A V P T T P S S Q P S T P A S T Q S A I C T V D Q T L L .  110 
TTGCGTGTTTGGTTCTCTTGGGATGTTGTATTGTGGAAGCTGTACCAACCACGCCAAGTTCTCAGCCCAGTACTCCCGCGTCAACCCAGTCCGCTAAAACCGTTGACCAAACGCTTCTAC 600
P T E T P D P L R L A V R E S G I L A E O G D F Y T C P P P T G S T V V R  I E P  150 
CAACTGAAACACCAGACCCGCTCAGACTGGCTGTACGCGAGTCCGGTATACTCGCAGAGGATGGAGACTTTTACACCTGCCCGCCGCCTACTGGATCCACAGTTGTACGCATTGAACCCC 720
BamHI
P R S C P K F D L G R  fN F t | E G I A V I F K E N I A P Y K F R A N V Y Y K D I  V 190 
CACGGTCATGTCCCAAGTTTGATCTGGGGAGGAACTTCACGGAGGGCATTGCTGTTATTTTCAAGGAAAACATAGCCCCGTACAAATTTAGAGCAAACGTCTACTACAAAGACATTGTAG 840
peptide 27
V T K V W K G Y S  H T S L S D R Y N D R V P V S  V E  E I F T ' L I D S K G K C S S  230
TGACAAAGGTTTGGAAAGGATACAGCCACACCTCTTTATCCGATAGATACAATGACAGAGTGCCAGTTTCAGTGGAGGAGATATTCACTCTCATCGATAGCAAAGGAAAATGTTCTTCTA 960
peptide 25
K A E Y L R D N  I H H H A Y H D D E O E  V E L D L V P S K F A T P G A R A  W Q T 270
AGGCAGAGTACCTCCGAGATAACATTATGCATCACGCTTACCACGACGACGAAGACGAGGTGGAGCTCGACCTGGTTCCGTCTAAGTTTGCTACTCCTGGGGCCAGAGCATGGCAAACCA 1080
T In D tl T S Y V G W M P W R H Y T S T S V N C I  V E E V E A R S V Y P Y D  S F A  310
CTAACGACACCACGTCTTATGTCGGATGGATGCCATGGAGGCACTACACATCAACCTCTGTCAACTGCATTGTCGAAGAGGTAGAAGCGCGGTCTGTTTACCCATACGACTCCTTTGCCC 1200
L S T G D  I V Y T S P F Y G L R S A A Q L E H  N S Y  A Q E R F R Q V E  G Y Q P R  350
TATCGACCGGTGATATTGTGTACACCTCACCGTTTTACGGCCTTCGGTCAGCTGCTCAGTTAGAACACAATAGCTACGCACAGGAGCGCTTTAGACAAGTTGAAGGATACCAACCAAGAG 1320
O L D S K L Q A G E P V T K  N F  I T T P H V  T V S W  U t| E I C K I E A C T L T K  390 
ACTTGGACAGTAAATTACAGGCCGGAGAGCCAGTTACCAAAAACTTTATTACTACACCTCATGTTACAGTCAGCTGGAACTGGACTGAAAAAAAGATAGAGGCGTGTACACTAACTAAAT 1440
W K E V  D E L V R D E F R  G S Y R F T I R S I S S T F I  S T fl O f ’k L E D A P  430 
GGAAGGAGGTTGACGAACTTGTCAGAGATGAGTTTCGGGGGTCCTACAGGTTTACTATTCGATCCATTTCGTCCACGTTTATTAGCAACACTACTCAATTTAAGCTAGAAGATGCCCCAC 1560
L T D C V S K E A K D A I D S I Y R K O Y E S T H V F S G D V  E F Y L A R G G F  470
TCACCGACTGTGTGTCAAAAGAAGCCAAAGATGCCATAGACTCTATATACCGAAAACAGTATGAGTCTACACACGTTTTTAGTGGGGATGTGGAATTTTACTTGGCACGTGGAGGGTTCT 1680
I I A F  R P H  I S N E L A R L Y L N E L V R S  |H R t I Y D L t C N L L N P N A N H N  510
TAATCGCATTTAGACCGATGATTTCTAACGAACTTGCCAGGCTGTACCTAAACGAGCTTGTGAGATCTAACCGCACCTATGACCTAAAAAATCTGTTAAACCCCAACGCAAACCATAATA 1800 
^  Bglll peptide 24
T IN R t| R R S L L S I P E P  T P T  Q E S L H R E O I  L H R L H I C R A V E A A f N S  550
CCAATCGAACACGCAGGTCGCTACTATCAATACCAGAACCTACTCCAACCCAAGAGAGCCTCCACAGAGAACAAATACTACATCGCCTACACAAACGAGCAGTGGAGGCTGCGAATAGTA 1920
71 |H S si In V Tl A K Q L E L I K T T S S I E F A M L Q F A Y D H I Q S H V N E M L  590 
CAAACICTTCCAACGTCACCGCCAAACAACTAGAGCTAATCAAAACAACGTCCTCTATTGAGTTTGCTATGCTACAGTTTGCATACGATCACATCCAATCCCACGTTAATGAGATGCTAA 2040
S R  I A T A U C T L Q N K E R T I W N E M V K V N P S A  I V S A T L D E R V A A  630
GTAGGATAGCAACTGCGTGGTGTACACTACAAAACAAAGAGCGGACCCTCTGGAATGAGATGGTAAAGGTTAACCCAAGCGCTATTGTTTCCGCCACTCTTGACGAGCGAGTTGCGGCAA 2160
R V I G O V I A I T H C V I C I E G N V Y L Q N S H R S S D S N T C Y S R P P V T  670
GGGTTTTGGGAGACGTTATAGCCATAACACATTGTGTAAAAATAGAGGGCAATGTGTACTTACAAAACTCTATGCGCTCCTCGGACAGCAACACGTGCTACTCCCGCCCACCTGTAACGT 2280
F T  I T K N A  N S R G T  I E G Q L G E E N E V Y T E R K L  I E P C A  I N Q I C R  Y 710
TTACCATTACTAAAAATGCAAACAGCAGAGGGACGATAGAGGGCCAGTTGGGAGAAGAAAACGAGGTTTATACGGAGCGCAAGCTTATCGAGCCGTGCGCTATCAATCAAAAACGATACT 2400
Hindlll
F K  F G K E Y V Y Y E  In Y Tl Y V R K V P P T E I E V I S T Y V E l  |H I t| L L E D 750
TTAAGTTTGGCAAAGAGTATGTTTACTATGAGAACTACACGTACGTTCGCAAAGTGCCCCCGACTGAAATCGAAGTGATCAGCACCTACGTTGAACTAAACTTAACTCTTTTGGAAGACC 2520
R E F L P L E V Y T R A E L E D T G L L D Y S E I Q R  R N Q L H A L R F Y D I D  790
GCGAGTTTCTACCCCTGGAGGTTTACACGCGAGCTGAGCTTGAAGACACGGGGCTATTGGATTACAGCGAGATACAGCGCCGTAACCAGCTTCACGCCCTCCGATTCTACGATATAGACA 2640
/Transmembrane domain
S V V H V D N T A V I M Q G I A T F F K G I G I C V G E A V G T L V L G A A G A V  830 
GCGTTGTCAACGTGGACAACACTGCTGTCATTATGCAGGGAATTGCCACCTTTTTTAAAGGCCTTGGTAAGGTGGGAGAGGCAGTTGGGACGCTTGTACTTGGAGCGGCTGGCGCGGTTG 2760
V S T V S G  I A S F  I H N P F G G L A I  G L  L V I  A G  L V A A F  F A Y R Y V M Q  870
TTTCTACAGTATCGGGTATAGCCTCATTTATAAACAACCCATTTGGGGGGCTCGCAATAGGCCTGTTGGTAATTGCGGGCTTAGTGGCTGCGTTTTTTGCCTACCGGTATGTAATGCAAC 2880
domain
L R  S N P  M K A L Y P I T T R S L K N K A K A S Y G Q H D D D D T S D F D E A K  910
TGCGCAGCAACCCCATGAAAGCTCTATACCCAATAACAACCAGGAGCCTTAAAAACAAAGCCAAAGCCTCATACGGCCAAAACGACGATGATGACACTAGCGACTTCGATGAAGCCAAGC 3000
l E E A R E M I K Y M S H V S A L E K Q E K K A H K K N K G V G L I A S  N V S K  950
TGGAGGAGGCACGCGAAATGATCAAATATATGTCTATGGTTTCTGCCCTGGAAAAACAGGAAAAAAAGGCAATGAAGAAAAACAAGGGGGTTGGACTTATTGCCAGCAACGTTTCAAAAC 3120
L A L R R R G P K Y T R  L R E D D P M E S E I C M V -  975
TCGCACTGCGCAGGCGCGGTCCGAAATATACCCGTCTTCGAGAAGACGATCCCATGGAAAGCGAAAAAATGGTTTAAAAATGTTAAATAAATATTTTGACACGTACTTGTGGGTTGACTC 3240
ATATTTGCATAACATCTTTCTAGTTCCGGCTATAAGCCTATTTAAGCCTAGTATTTTTGCCAAAAGTTTATCATCCTCTACAAGCGCACATCCTCTCAAAAGAGTTGAATTTTGCTGTTT 3360 
ATTACGCTATCCTAAAGCTAAACGCCTGTAATGGAATCTCAATGCAAAACTTCTACATCAGCCGCTGATGAAACTCTGTTGGCTGCATCGCTACCGCGGCGGAAATCCAAATAAAAACAG 3480 
AAGCACCCGATTCAGACACGCCCGCTGCCACGGGGTGTCAAGACCACACCTACGCTCGCCGGCTCACCGAGAATGGTGCAATCGAAGAGATAAACACGGCTGATCTACTGGAAATGGTGC 3600
TGGCTTCTGAAAACGCTCAAAGCGAACCCGGAATTC
EcoRI
3636
Figure 5.4 Analysis of expression of the fusion protein 
pURl.7gB by SDS-PAGE.
(a) Four clones (1 to 4) containing the 1674bp
BamHI/Hindlll EHV-4 gB DNA fragment cloned in plasmid 
pUR288 were analysed for egression of the pUR1.7gB 3 - 
galactosidase/EHV-4 gB fusion protein following induction 
with IPTG for 2hr. The samples shown on the gel are as
follows:-
clone 1, uninduced (lane 1) and induced (lane 2); clone 2, 
uninduced (lane 3) and induced (lane 4); clone 3, uninduced 
(lane 5) and induced (lane 6); clone 4, uninduced (lane 7) 
and induced (lane 8).
(b) Time-course study to determine induction time required 
for optimum yield of fusion protein. The samples shown on 
the gel are as follows:-
pUR288, uninduced (lane 1) and induced (lane 2); pURl.7gB, 
uninduced (lane 3) and induced for 0.5hr (lane 4), lhr 
(lane 5), 1.5hr (lane 6), 2hr (lane 7), 2.5hr (lane 8), 3hr
(lane 9), 3.5hr (lane 10) and 4hr (lane 11).
For each gel, an arrow indicates the position of the 
induced 184kDa fusion protein. Sizes of the protein markers 
(M) are shown in kDa.
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Figure 5.5 Analysis of expression of the fusion protein 
pURl.OgB by SDS-PAGE.
(a) Three clones (1 to 3) containing the 1056bp BamHI/Bglll 
EHV-4 gB DNA fragment cloned in the correct orientation in 
pUR288 were analysed for expression of the pURl.OgB 0 - 
galactosidase/EHV-4 gB fusion protein following induction 
with IPTG for 2hr. Clone 4, which contains the EHV-4 gB DNA 
inserted in the incorrect orientation in pUR288 was used as 
a . negative control. The samples shown on the gel are as 
follows:-
pUR288, uninduced (lane 1) and induced (lane 2); clone 1, 
uninduced (lane 3) and induced (lane 4); clone 2, uninduced 
(lane 5) and induced (lane 6); clone 3, uninduced (lane 7) 
and induced (lane 8); clone 4, uninduced (lane 9) and 
induced (lane 10).
(b) Time-course study to determine induction time required 
for optimum yield of fusion protein. The samples shown on 
the gel are as follows:-
pUR288, uninduced (lane 1) and induced (lane 2); pURl.OgB, 
uninduced (lane 3) and induced for 0.5hr (lane 4), lhr 
(lane 5), 1.5hr (lane 6), 2hr (lane 7), 2.5hr (lane 8), 3hr 
(lane 9), 3.5hr (lane 10) and 4hr (lane 11).
For each gel, an arrow indicates the position of the 
induced 159kDa fusion protein. Sizes of the protein markers 
(M) are shown in kDa.
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Ficrure 5.6 Analysis of expression of the fusion protein 
pURO.6gB by SDS-PAGE.
(a) Four clones (1 to 4) containing the 624bp Bglll/Hindlll 
EHV-4 gB DNA fragment cloned in pUR288 were analysed for 
expression of the pURO. 6gB (3 -galactosidase/EHV-4 gB fusion 
protein following induction with IPTG for 2hr. The samples 
shown on the gel are as follows
pUR288, uninduced (lane 1) and induced (lane 2); clone 1, 
uninduced (lane 3) and induced (lane 4); clone 2, uninduced 
(lane 5) and induced (lane 6); clone 3, uninduced (lane 7) 
and induced (lane 8); clone 4, uninduced (lane 9) and 
induced (lane 10).
(b) Time-course study to determine induction time required 
for optimum yield of fusion protein. The samples shown on 
the gel are as follows
pUR288, uninduced (lane 1) and induced (lane 2); pURO.6gB, 
uninduced (lane 3) and induced for 0.5hr (lane 4), lhr 
(lane 5), 1.5hr (lane 6) , 2hr (lane 7), 2.5hr (lane 8), 3hr 
(lane 9), 3.5hr (lane 10) and 4hr (lane 11).
For each gel, an arrow indicates the position of the 
induced 141kDa fusion protein. Sizes of the protein markers 
(M) are shown in kDa.
F I G U R E  5.6
Expression of the Fusion Protein pUR0.6gB
(a) M 1  2 3 4 5 6 7 8 9  10 M 
180- 
116- 
84-  
58- 
48-  
36-
Ficrure 5.6- continued
(b) M 1 2 3 4  5 6  7 8 9  10 11 M
180-
116-
84-
58-
48-
Figure 5.7 Analysis of expression of the fusion protein 
pGEXl.OgB by SDS-PAGE.
(a) Three clones (1 to 3) containing the 1056bp BamHI/Bglll 
EHV-4 gB DNA fragment cloned in the correct orientation in 
pGEX-2T were analysed for expression of the pGEXl.OgB 
glutathione-S-transferase/EHV-4 gB fusion protein following 
induction with IPTG for 2hr. The samples shown on the gel 
are as follows
pGEX-2T, uninduced (lane 1) and induced (lane 2); clone 1, 
uninduced (lane 3) and induced (lane 4); clone 2, uninduced 
(lane 5) and induced (lane 6); clone 3, uninduced (lane 7) 
and induced (lane 8).
(b) Time-course study to determine induction time required 
for optimum yield of fusion protein. The samples shown on 
the gel are as follows
pGEXl.OgB, uninduced (lane 1) and induced for 0.5hr (lane 
2), lhr (lane 3), 1.5hr (lane 4), 2hr (lane 5), 2.5hr (lane 
6), 3hr (lane 7) and 4hr (lane 8).
For each gel, an arrow indicates the position of the 
induced 70.5kDa fusion protein. Sizes of the protein 
markers (M) are shown in kDa.
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Figure 5.8 Analysis of purified fusion proteins by SDS- 
PAGE.
(a) pUR0.6gB fusion protein purified by electroelution from 
gels.
(b) Purification of pGEXl.OgB fusion protein by 
immunoaffinity chromatography on glutathione-agarose beads. 
The samples shown on the gel are as. follows:-
whole induced cell extract (lane 1); unbound material after 
incubation of supernatant from a lysed, induced cell 
extract with glutathione-agarose beads (lane 2)? purified 
material eluted from beads (lanes 3 and 4).
The sizes of the protein markers (M) are shown in kDa.
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T A B L E  5.2
Summary of In Vitro and In Vivo Studies With 
EHV-4 gB Fusion Proteins and Peptides
ANTIBODY ANTIGEN
Virus (EHV-1/4) gB Fusions Peptides Protection
Elisa Neut pUR0.6 pGEXl.O 24 25 27 in hamsters
24 — — + — + - — —
25 + - - + - + - -
27 - - - ' + - + -
pURO.6gB - - + - + - - 1/3
pGEXl.OgB — — — + - + + —
MAb 17/18 + — ND ND ++ - — +
MAb 14(gB) + - ND ND - - - +
MAb 21/22a + - ND ND - - - -
MAb 13(gC) + - ND ND - - - +
MAb 2 + - ND ND ++ - ++ -
MAb 10 + - ' ND ND - - - -
Horse
Serum + + ND ND + ++ ++ NA
Hamster 
(10 days 
p.i.) + + ND ND + - — NA
Table 5.2 Summary of in vitro and in vivo studies with EHV-4 gB 
fusion proteins and peptides. The key to this table is shown 
below.
Elisa:- reactivity of antibodies against whole virus.
Neut:- denotes if antibodies have virus neutralising activity. 
Horse Serum:- from horses vaccinated with Pneumabort-K.
Hamster (10 days p.i.):- serum from hamster 10 days after
infection with EHV-1.
MAb:- monoclonal antibodies against EHV-1 glycoproteins (Allen 
and Yeargan, 1987).
ND:- not determined.
NA:- not applicable.
158
D I S C U S S I O N
The glycoprotein gB of EHV-4 has been evaluated as a 
potential candidate for vaccine development. Studies carried out 
in hamsters seeked to identify the nature of the immune response 
elicited to purified preparations of EHV-4 gB fusion proteins 
and to several synthetic peptides derived from the primary amino 
acid sequence of this glycoprotein. Hamsters immunised with 
purified fusion proteins seroconverted but failed to produce 
antibodies capable of neutralising virus infectivity in vitro. 
Identical results were obtained using synthetic peptides. 
Generally, hamsters immunised with purified fusion proteins or 
peptides were not protected from a lethal challenge with 
virulent EHV-1, although one out of three hamsters immunised 
with pUR0.6gB survived a lethal virus challenge.
The general failure of recombinant EHV-4 gB and synthetic 
peptides to stimulate the production of virus neutralising 
antibodies and to confer protective immunity in hamsters is 
somewhat at odds with similar studies using recombinant gB-like 
proteins produced by several methods for other herpesviruses. 
Expression of HCMV gB in vaccinia virus and immunisation of 
rabbits with the live recombinant vaccinia virus elicited the 
production of antibodies which neutralised virus infectivity in 
vitro (Cranage et al.. 1986). Cattle immunised with BHV-1 gl, 
purified using a monoclonal antibody to gl, produced antibodies 
which neutralised virus infectivity in vitro and participated in 
ADCC of BHV-l-infected cells, and were also protected from 
challenge with virulent BHV-1 (Babiuk et al. . 1987). Similarly, 
immunisation of cattle with a recombinant vaccinia virus
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expressing BHV-1 gl elicited virus neutralising antibody 
production (van Drunen Littel-van den Hurk et al.. 1989) and 
immunisation of mice with transfected cells expressing gl also 
stimulated the production of BHV-1-specific virus neutralising 
antibodies (Fitzpatrick et al.. 1988). The use of these
transfected cells as targets in immune-mediated cytotoxicity 
assays demonstrated that BHV-1 gl was recognised by murine 
antibody and CTLs. There is a wide body of literature concerned 
with the expression of, and immune response to, HSV-1 gB. Mice 
immunised with a recombinant vaccinia virus expressing HSV-1 gB 
produced virus neutralising antibodies and were protected from a 
lethal HSV-1 challenge (Cantin et al.. 1987). The construction 
of a recombinant adenovirus expressing HSV-1 gB to high levels 
has been reported (Johnson et al.. 1988b). Immunisation of mice 
with this recombinant adenovirus produced neutralising 
antibodies to HSV-1 and HSV-2 and protected mice from a 
subsequent lethal challenge with HSV-2 (McDermott et al., 
1989). Secreted recombinant HSV-1 gB expressed in human cells 
was demonstrated to induce neutralising antibodies specific for 
HSV-1 and HSV-2 in mice, and protected animals against a lethal 
HSV-1 challenge (Manservigi et al.. 1990). In addition, a
recombinant vaccinia virus expressing HSV-1 gB was shown to 
induce gB-specific CTLs in mice (McLaughlin-Taylor et al., 
1988). In a separate study, a mouse L cell line expressing HSV-1 
gB was shown to induce CTLs in mice and virus-specific CTLs also 
recognised the gB expressed by this cell line (Blacklaws et al., 
1987). Furthermore, immunisation of mice with this cell line 
provided protection from a lethal HSV-1 challenge.
The most extensive characterisation of EHV-1 gB as an
160
antigen for stimulating antibody production in the horse was 
carried out by George Allen (Equine Virology Research Foundation 
Grantholders Meeting, Newmarket, October 1989). His studies 
demonstrated that the vast majority of the antibody response in 
the serum of foals experimentally vaccinated with EHV-1 or EHV-4 
was directed against gB. Conversely, the antibody response was 
directed predominantly against gC in foals vaccinated with an 
inactivated EHV-1 vaccine although a significant antibody 
response to all the other major glycoproteins (gp2, gplO and 
gp22a) was also observed in these animals. During these studies 
a panel of 37 monoclonal antibodies to EHV-1 gB were generated, 
of which nine were directed against epitopes on the large 
subunit of the gB dimer (gpl4) and 18 against epitopes on the 
smaller gpl8 subunit. The type-common nature of the gB epitopes 
was demonstrated by the ability of 33 out of 37 monoclonal 
antibodies to recognise epitopes present on EHV-4 gB. However, 
only two monoclonal antibodies possessed virus neutralising 
activity and only two were directed against linear (continuous) 
epitopes. The fact’ that only two out of a panel of 37 monoclonal 
antibodies specific for EHV-1 gB could neutralise virus 
infectivity, taken together with the results presented in this 
chapter, suggests that EHV-1 gB and EHV-4 gB may not be such 
important targets for virus neutralising antibodies as are the 
gB-like proteins of other herpesviruses. It therefore seems 
likely that EHV-1 gB and EHV-4 gB may play more important roles 
in stimulating immune mechanisms other than virus 
neutralisation. Further support for such a role in immunity was 
provided by the observation that a recombinant vaccinia virus 
expressing EHV-1 gB was unable to stimulate the production of
161
virus neutralising antibodies following immunisation of mice 
(Bell et al., 1990) . However, in a separate study EHV-1 gB
expressed in vaccinia virus was successful in stimulating the 
production of virus neutralising antibodies in guinea pigs and 
in protecting hamsters from a lethal EHV-1 challenge (Guo et 
al., 1990). CDL of infected cells has been proposed to be
important for protection in the hamster model of EHV-1 
infection, since the appearance of virus-specific antibodies 
which could lyse infected cells in vitro in the presence of 
complement following EHV-1 infection resulted in the clearance 
of virus (Stokes et al.. 1989). Such antibodies were apparent 10 
days after infection of the horse with EHV-1 and correlated with 
the time at which virus was beginning to be cleared from the 
system (Stokes and Wardley, 1988). The spleen of hamsters 
infected with EHV-1 contained virus-specific CTLs at 6 days p.i. 
which could lyse EHV-l-infected cells (Stokes et al.. 1989).
Such' a CTL response has also been observed following infection 
of horses with EHV-4 (Bridges and Edington, 1987) . CTLs have 
often been regarded as forming the first line of defence 
following infection. A role for EHV-1 gB and EHV-4 gB in 
stimulating ADCC, CDL and CTL responses is consistent with 
similar roles reported for HSV-1 gB and BHV-1 gl. Furthermore, 
gB has been shown to be one of several glycoproteins recognised 
by equine lymphocytes following an EHV-4 infection (Bridges et 
al.. 1988). It seems likely that an immune mechanism such as CTL 
activity may account for the protection afforded one hamster in 
the absence of virus neutralising antibodies following 
immunisation with pUR0.6gB (Table 5.2). The role of EHV-4 gB in 
cell-mediated immunity is further reinforced by the finding
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that immunisation of hamsters with three EHV-4 gB synthetic 
peptides could stimulate the proliferation of lymphocytes in 
response to whole virus antigen in vitro.
Antigenic determinants of proteins have been classified as 
continuous (linear) or discontinuous (conformation-dependent). 
Continuous epitopes comprise local amino acids whereas 
discontinuous epitopes are composed of amino acids from 
different parts of the molecule which are brought together to 
form the epitope by folding of the protein into its native 
structure (Barlow et al.. 1986). One of the two continuous 
epitopes of EHV-1 gB recognised by EHV-1 gB-specific monoclonal 
antibodies has been characterised (G. Allen, EVRF Grantholders 
Meeting, Newmarket, October 1989). The epitope recognised by the 
non-neutralising monoclonal antibody 3F6 was initially localised 
to a 60 amino acid sequence near the amino-terminus of the 
molecule by determination of the sequence of the EHV-1 DNA 
inserts contained within a library of Agtll recombinants that 
expressed the 3F6 epitope (Allen and Yeargan, 1987) . By testing 
the ability of truncated peptides from this region to bind 3F6, 
the 3F6 epitope was identified as the amino acid sequence 
ETPDPLR between residues 116 to 122 of the EHV-1 gB protein. 
This epitope was found to be conserved with EHV-4 gB but not 
other herpesvirus gB-like proteins. This is an important 
protective epitope on EHV-1 gB since hamsters immunised with 3F6 
were protected against a subsequent lethal EHV-1 challenge 
(Stokes et al., 1989). This particular epitope seems especially 
important in EHV-4 gB since 15% of total equine antibody was 
specifically directed against this epitope in EHV-4-infected 
foals, a higher proportion than was seen in EHV-l-infected and
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EHV-l-vaccinated foals (G. Allen, EVRF Grantholders Meeting, 
Newmarket, October 1989).
An obvious problem when expressing any protein as a fusion 
product with, for example, (3 -galactosidase in E.coli is that 
the conformation of the |3 -galactosidase moiety influences the 
folding of the foreign protein. Since the foreign protein is 
consequently not presented in its native conformation, 
disruption of discontinuous epitopes will inevitably occur. 
Furthermore, the inability of E.coli to glycosylate proteins and 
the limitation on the size of the foreign protein that can be 
expressed as a fusion product in E.coli results in altered 
tertiary protein structure and, concomitant with this, the loss 
of discontinuous epitopes. These limitations should be borne in 
mind when expressing proteins in E.coli. Such problems can be 
partially overcome by cleavage of the desired protein from the 
carrier protein. The pGEX vector system has been designed for 
this purpose. The pGEX-2T and pGEX-3X vectors possess protease 
cleavage sites specific for thrombin and factor X, respectively 
(Figure 5.2b). The GST fusion protein could be cleaved to remove 
the GST carrier from the desired protein and both the carrier 
and any uncleaved fusion protein removed by absorption on 
glutathione-agarose beads to leave the pure, desired protein 
product. Alternatively, several other expression systems are 
available which would permit the synthesis of proteins in their 
naturally glycosylated and conformational state with retention 
of their biological properties. These include mammalian cell 
expression systems (Seidel-Dugan et al.. 1988; Su and Courtney, 
1988? Manservigi et al.. 1988), murine cell expression systems 
(Blacklaws et al.. 1987; Fitzpatrick et al.. 1988) and the use
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of live virus vectors such as vaccinia virus and human 
adenovirus. The use of live virus vectors will be described in 
Chapter 7 of this thesis. The purification of EHV-4 gB from 
viral extracts by immunoaffinity chromatography using monoclonal 
antibodies is a particularly appealing approach. Despite the 
problems associated with protein expression in E.coli. an 
immunoreactive HSV-1 gD protein has been successfully 
synthesised using this method (Watson et al.. 1982). Fusion of 
HSV-1 gD with P-galactosidase gave a fusion product that 
stimulated the production of virus neutralising antibodies to 
HSV-1 and HSV-2 in rabbits (Weis et al., 1983). Although
prokaryotic expression systems do have limitations, they cannot 
be dismissed as a simple, cheap and safe method for the 
production of large amounts of recombinant proteins.
Synthetic peptides have recently been employed in vaccine 
development strategies. The rationale for this is that antigenic 
peptides representing surface regions of viral proteins can 
induce the production of specific antibodies that confer humoral 
immunity to that virus. Immunisation of hamsters with several 
EHV-4 gB peptides did not stimulate the production of virus 
neutralising antibodies or protect animals from a lethal EHV-1 
challenge, although it induced the proliferation of lymphocytes 
in response to whole virus antigen in vitro. The inability of 
EHV-4 gB peptides to stimulate the production of virus 
neutralising antibodies may be attributed to both the lesser 
role of EHV-4 gB as a maj or target for virus neutralising 
antibodies, as predicted earlier, and the fact that the bulk of 
the antibodies to EHV-4 gB are probably directed against 
conformational epitopes. Similarly, synthetic peptides from the
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MDV gB sequence raised anti-peptide antibodies in rabbits which 
could not neutralise virus infectivity in vitro (Ross et al..
1989). However, synthetic peptides from the HSV-1 gD sequence 
have been successfully used to elicit the production of virus 
neutralising antibodies in rabbits and mice (Cohen et al.. 1984; 
Weijer et al.. 1988) and to protect mice from a lethal challenge 
with HSV-2 (Eisenberg et al., 1985). A 23 amino acid B cell 
determinant from HSV-1 gD has been shown to be antigenic for 
proliferating T cells (Heber-Katz et al., 1988) and a T cell 
epitope has been identified in HSV-1 gD by the use of synthetic 
peptides (DeFreitas et al., 1985). Peptides with predicted 
amphipathic properties (Margalit et al.. 1987) from the VZV gll 
and gXV sequences were demonstrated to elicit T cell responses 
as measured by proliferation and cytotoxicity assays (Hayward,
1990). The algorithm of Margalit et al. (1987) therefore 
successfully predicted T cell epitopes on the basis of a 
potential amphipathic helical structure in this case. Other 
structures can also elicit T cell responses since the peptide 
containing the T cell epitope identified for HSV-1 gD by 
DeFreitas et al. (1985) was not particularly amphipathic but 
possessed hydrophobic residues which contribute to an 
alternative structural model proposed for a T cell antigenic 
site (Rothbard et al.. 1988). Such structural models should 
prove useful in identifying T cell epitopes on EHV-4 gB.
The construction of an antigenic map of EHV-4 gB is a 
prerequisite for fully understanding the contribution it makes 
in immunity. Our knowledge of the HSV-1 gB protein has permitted 
the construction of such a map to be initiated for this protein. 
The most widely employed approach to map functional epitopes has
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been by analysis of several mutants resistant to potent 
neutralising antibodies (mar mutants) (Kousoulas et al.. 1984,
1988? Pellett et al.. 1985b). These studies demonstrated that 
epitopes clustered in two distinct regions of the surface domain 
of the HSV-1 gB molecule. Another approach involved the 
construction of truncated derivatives, internal deletion mutants 
and oligopeptides of HSV-1 gB to map epitopes for a panel of 
monoclonal antibodies to HSV-1 gB (Pereira et al.. 1989). Using 
this strategy, seven neutralising epitopes were localised to a 
segment of continuous residues between positions 1 and 47 of the 
molecule, five of which were specific for HSV-1 but not HSV-2. A 
further eleven neutralising epitopes mapped to a discontinuous 
domain composed of residues from the amino-terminal half of the 
molecule, of which four (between residues 273 and 298) 
corresponded to sites recognised by neutralising antibodies used 
in mapping studies with mar mutants (Kousoulas et al.. 1984,
1988; Pellett et al.. 1985b). Comparison of the reactivity of 
parental HSV-1 gB and a recombinant HSV containing a HSV-l/HSV-2 
gB hybrid with type-specific monoclonal antibodies identified a 
subset of type-specific epitopes mapping in the amino-terminal 
half of the HSV-1 gB molecule (Kousoulas et al.. 1989).
The mapping of epitopes on HCMV gB has also progressed. By 
testing the reactivity of truncated derivatives of the HCMV gB 
molecule expressed in COS cells and in a CHO cell line with a 
panel of neutralising antibodies, neutralising epitopes were 
demonstrated to map in at least two domains located in a 
discontinuous region of amino acids from residues 461 to 680 of 
the molecule (Banks et al., 1989). Two linear epitopes have been 
mapped on HCMV gB, one for a neutralising and the other for a
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non-neutralising monoclonal antibody, by expressing overlapping 
fragments of the carboxyl-terminal part of the molecule in 
E.coli as (3-galactosidase fusion products and testing their 
reactivity with these monoclonal antibodies? both antibodies 
recognised sequences between residues 608 and 625 of the 
molecule (Utz et al.. 1989). It was also found that the non­
neutralising monoclonal antibody could inhibit the neutralising 
activity of the other monoclonal antibody, which led the authors 
to suggest that future vaccine preparations would be less 
detrimental to the host if they were to include only the 
immunogenic regions eliciting protective responses and not 
entire virion glycoprotein components. In this way, the 
possibility of antibody inhibition of neutralising antibodies to 
that virion component would be minimised.
Although a panel of monoclonal antibodies to EHV-1 gB have 
been generated, there is a great need for the generation of 
monoclonal antibodies to EHV-4 gB if accurate epitope mapping of 
the molecule is to be accomplished using approaches such as 
those described for HSV-1 gB and HCMV gB. In the meantime, 
prediction of the best antigenic regions of the molecule can be 
accomplished by using quantities such as protein hydrophilicity 
(Hopp and Woods, 1981? Kyte and Doolittle, 1982), mobility 
(Westhof et al.. 1984), antibody accessibility (Novotny et al.. 
1986) and protrusion (Thornton et al.. 1986).
The accuracy of predictive algorithms is well proven. The 
prediction of amino acid residues likely to be exposed on the 
molecule surface using the Surfaceplot algorithm (Parker et al.,
1986) permitted the synthesis of twelve peptides, containing 
thirteen predicted surface sites, from the HSV-1 gD sequence
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which all produced positive immune responses in rabbits; eight 
of the peptides produced anti-peptide antibodies that reacted 
with intact virions, which suggested the presence of the peptide 
sequences on the surface of the gD molecule in the virion, and 
five antisera contained virus neutralising activity (Strynadka 
et al., 1988). It is noteworthy that seven of the predicted
surface sites were not predicted by the parameters of Hopp and 
Woods (1981), of which three generated virus neutralising 
antibodies and all produced anti-peptide antibodies that bound 
to HSV-1 virions.
A predicted antigenic map of the EHV-4 gB protein is shown 
in Figure 5.9. Peptides corresponding to some of these predicted 
antigenic regions could be synthesised and further evaluation of 
their immunogenicity carried out in hamsters. Ultimately, 
important epitopes of the EHV-4 gB molecule could be 
characterised by the Pepscan method (Geysen et al. . 1984, 1985)
using horse neutralising antiserum or, when available, 
neutralising monoclonal antibodies to EHV-4 gB.
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Figure 5.9 Prediction of the most antigenic sites of the 
EHV-4 gB protein. Antigenic sites were predicted by the 
method of Jameson and Wolf (1988) using PEPTIDESTRUCTURE 
and PLOTSTRUCTURE from the University of Wisconsin Genetics 
Computer Group programmes (Devereux et al.. 1984). Octagons 
represent sites with an antigenic index of at least 1.6. 
Predicted antigenic sites are superimposed on a two- 
dimensional plot representing secondary structure predicted 
by the method of Chou and Fasman (1978). Potential N-linked 
glycosylation sites are denoted by ball-and-stem 
structures.

CHAPTER 6
DNA Sequence of the EHV-4 Genome Between 0.067 and 0.122 Map 
Units and Analysis of the Predicted Gene Products
I N T R O D U C T I O N
The genetic relatedness of several alphaherpesviruses has 
been established by the utilisation of molecular hybridisation 
techniques. Using this approach the genomes of HSV-1 and HSV-2 
were shown to share a directly col inear arrangement and those of 
EHV-1 and VZV demonstrated colinearity with the ^i/^sL 
arrangement of HSV (Davison and Wilkie, 1983). The genome of PRV 
has also been shown to be grossly colinear with the 
arrangement of HSV with the exception of a region between 0.07 
and 0.39 m.u. which appears to be inverted relative to HSV (Ben- 
Porat et al.. 1983; Davison and Wilkie, 1983). The most highly 
conserved genes were those encoding the major DNA binding 
protein, major capsid protein, DNA polymerase, immediate-early 
protein VmwIE175 and one or both of the two subunits of 
ribonucleotide reductase. However, the close linear relationship 
shared by these herpesvirus genomes applied only to the L 
segment; the only detectable homology in the S segment was in 
IRcj/TRs and was due to the presence of the highly conserved 
VmwIE175 gene. The S segment was thus demonstrated to be the 
most heterologous region of the alphaherpesvirus genomes.
The first alphaherpesvirus genome for which the complete 
DNA sequence was elucidated was that of VZV (Davison and Scott, 
1986a) . Comparison of amino acid sequences of the predicted gene 
products with those available for HSV-1 permitted the 
establishment of a clearly defined genetic relationship between 
these viruses. These analyses confirmed the highly conserved 
nature of the genes reported by Davison and Wilkie (1983) and 
demonstrated that many other genes were located in similar
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genomic positions and that their genomes were generally 
colinear, at least within UL.
However, gene conservation is not limited to the 
alphaherpesvirus genomes. The available DNA sequence of the 
genome of the gammaherpesvirus EBV (Baer et al.. 1984) permitted 
the identification of several genes whose products had 
counterparts in HSV-1. These included the genes encoding the 
major DNA binding protein and DNA polymerase (Quinn and McGeoch, 
1985), major capsid protein (Davison and Scott, 1986b), 
ribonucleotide reductase (Gibson et al., 1984), exonuclease
(McGeoch et al.. 1986b), glycoproteins gB (Pellett et al.,
1985b) and gH (McGeoch and Davison, 1986), thymidine kinase
(Honess et al.. 1989), homologues of HSV-1 genes UL5 and UL52 
which are involved in DNA replication (McGeoch et al.. 1988b), 
and another gene of unknown function comprising a spliced mRNA 
(Costa et al.. 1985). In a similar vein, investigations into the 
genetic relatedness of VZV and EBV identified EBV counterparts 
to 29 of the 67 genes specified by VZV (Davison and Taylor,
1987). Conserved genes were grossly colinear and detected only
within the UL region of each genome. These included the genes of 
known function conserved between HSV-1 and EBV as described 
above and also homologues of the virus-specified enzyme
deoxyuridine-5'-triphosphate nucleotidohydrolase (dUTPase) 
(Preston and Fisher, 1984) and the immediate-early protein IE63 
(Sacks et al.. 1985; Perry and McGeoch, 1988).
In contrast, very little is known regarding gene 
organisation in the genomes of EHV-1 and EHV-4. Their genomes 
are directly colinear with each other and with the Ii/Isl 
arrangement of the HSV genomes (Davison and Wilkie, 1983;
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Cullinane et al.. 1988). Insufficient sequence data is available 
for EHV-1 and EHV-4 to enable precise comparisons to be made 
regarding genetic structure with the genomes of HSV-1, VZV and 
EBV. The only data available for EHV-4, apart from the DNA 
sequence of the gB gene as presented in Chapter 4 of this 
thesis, is that of the BamHI-L genomic fragment (Cullinane et 
al., 1988). This fragment spans the junction between Ug and TRg 
and contains four ORFs, all of which have counterparts in HSV-1 
and VZV. The gene products of ORFs 1, 2, 3 and 4 were
demonstrated to be homologous to those of HSV-1 US8 (gE) /VZV 
gene 68 (gpl), HSV-1 US9/VZV gene 65, HSV-1 US10/VZV gene 64 and 
HSV-1 US1/VZV gene 63, respectively. The arrangement of the 
EHV-4 genes was intermediate between that observed for HSV-1 and 
VZV; ORFs 1 and 2 were similar in genomic location and 
orientation to their HSV-1 counterparts whereas ORFs 3 and 4 
more closely resembled their VZV counterparts in these respects.
Derivation of a precise genetic relationship between EHV-4 
and other herpesviruses awaits determination of the DNA sequence 
of its genome. The studies presented in this chapter represent 
the first step of such an objective. Gene arrangement in a
selected region of the UL region of the EHV-4 genome was
investigated and compared with the gene arrangement in the 
corresponding region of the HSV-1 and VZV genomes and their gene 
products analysed. The genomic region to be studied was selected 
in light of the studies of Allen and Yeargan (1987) who mapped 
the genes for the six major glycoproteins of EHV-1 (Figure
3 .18). The genomic location within the UL region of three of 
these genes indicated that EHV-1 specifies three glycoprotein 
species (gp2, gplO and gp21/22a) for which no genetic homologues
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had been detected in other herpesviruses. These regions of the 
EHV-1 genome are prime candidates for containing a gene 
arrangement divergent from that seen in HSV-1 and VZV. The 
genomes of EHV-1 and EHV-4 are col inear and therefore likely to 
share a similar genetic organisation. Furthermore, the 
structural protein profiles of EHV-1 and EHV-4 virions clearly 
show that both viruses specify the gp2, gplO and gp21/22a 
species (Table 1.2). Taken together, these findings clearly 
suggest that EHV-4 will also specify these glycoprotein species 
and that their genes would be expected to map in a similar 
position to their EHV-1 counterparts.
It was decided to investigate the gene arrangement around 
the predicted genetic locus for gplO, an epitope of which mapped 
to between 0.093 and 0.114 m.u. on the EHV-1 genome (Allen and 
Yeargan, 1987) . The corresponding region of the EHV-4 genome was 
identified by virtue of colinearity and analysed by DNA 
sequencing. Additional DNA sequence data for EHV-4 BamHI-Q is 
also presented in this chapter.
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M A T E R I A L S  A N D  M E T H O D S
Subclonincr of EHV-4 DNA
The plasmid containing the 14.lkb BamHI-B genomic fragment 
cloned in pUC9 was digested with Smal and the two fragments 
generated (9.7kb and 7.lkb) were separated by electrophoresis. 
The 7. lkb fragment was purified as previously described and 
self-ligated to generate the recombinant plasmid pUC4S, which 
contained the rightmost 4.4kb of BamHI-B in the form of a 
BamHI/Smal fragment attached to pUC9 sequences. The plasmid 
containing the 9.5kb BamHI-G genomic fragment cloned in pUC9 
was digested with Sail and the resulting 1.9kb Sail fragment 
(which contained the 1.9kb BamHI/Sall left-terminal subfragment 
of BamHI-G), and the adjacent 0.9kb Sail subfragment of 
BamHI-G, were separately cloned into the Sail site of plasmid 
vectors Bluescript M13+ and pUC8, respectively. The recombinant 
plasmids generated were named pBS1.9G and pUC0.9G, respectively.
DNA Sequencing
The EHV-4 DNA inserts in plasmids pUC4S, pBS1.9G and 
pUCO.9G were sequenced by the dideoxy chain termination method 
using the double-stranded DNA method for template preparation 
as described in Chapter 4 and both commercially available and 
custom made primers. The DNA sequences of EHV-4 BamHI-Q and the 
left-terminal region of EHV-4 BamHI-M were determined by 
sequencing of the plasmids containing these genomic fragments 
as described above. All computer analyses of DNA sequences were 
performed as described in Chapter 4.
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Purification of Recombinant Acrfcll Bacteriophage
A single colony of E.coli Y1090 was inoculated into 100ml 
of NZCYM medium (Table 2.1) containing ampicillin at lOOug/ml 
and 0.2% maltose, and grown overnight at 37°C with vigorous 
shaking in an orbital incubator. Cells were collected by 
centrifugation (2000rpm/10min) and suspended in an equal volume 
of lOmM MgS04 to give an OD (600nm) reading of about 0.5. This 
suspension was kept on ice until required and used the same day. 
108 plaque forming units (lOul) of recombinant X  gtll 
bacteriophage carrying a putative EHV-1 gplO DNA insert (kindly 
provided by Professor G. Allen, University of Kentucky, USA) was 
mixed with 1010 pelleted E.coli Y1090 cells, prepared as 
described above (OD of 0.5 at 600nm = 4xl08 cells/ml; 25ml of 
E.coli Y1090 represents 1010 cells), in 3ml of SM (Table 2.1). 
The mixture was incubated at 37°C for 20min to allow bacteria to 
absorb bacteriophage particles and then used to infect 500ml of 
NZCYM medium containing lOOug/ml ampicillin and 0.2% maltose. 
This was incubated overnight at 37°C with vigorous shaking until 
complete lysis of bacteria had occurred, which was evident from 
the considerable amount of bacterial cell debris in the culture. 
Following chilling of the lysed culture to room temperature, 
pancreatic DNase and RNase (Table 2.1) were each added to a 
final concentration of lug/ml and the culture incubated at room 
temperature for 30min. Solid sodium chloride was added to a 
final concentration of 1M (29.2g/500ml), dissolved by gentle 
mixing and incubated on ice for lhr. Debris was removed by 
centrifugation (7000rpm/10min/4°C) in a Beckman JS7.5 rotor. 
Solid PEG-6000 was added to a final concentration of 10% (50g)
and dissolved by stirring. The solution was left to stand on ice
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for lhr and the precipitated bacteriophage particles were 
collected by centrifugation (7000rpm/10min/4°C) in a Beckman 
JS7.5 rotor. The bacteriophage pellet was resuspended in 8ml of 
SM. An equal volume of chloroform was added to the bacteriophage 
suspension, mixed thoroughly and the phases separated by 
centrifugation (2000rpm/5min) in a benchtop centrifuge. Caesium 
chloride (0.75g/ml) was added to the upper aqueous phase 
containing the bacteriophage and dissolved by mixing. The 
contents were transferred to a 12ml Beckman 'Quick-Seal' 
centrifuge tube, sealed and bacteriophage particles banded by 
centrifugation (40000rpm/24hr/4°C) in a Beckman 50Ti rotor. The 
bacteriophage particles, visible as a bluish-grey band, were 
collected by puncturing the side of the tube with a 19-gauge 
needle and withdrawal into a 2ml syringe. Bacteriophage 
particles were dialysed for 2 x lhr at room temperature against 
2 litres of lOmM NaCl/50mM TrisHCl pH8.0/10mM MgCl2 to remove 
caesium chloride.
Extraction of Recombinant Bacteriophage DNA
To the dialysed bacteriophage suspension were added EDTA, 
proteinase K and SDS (Table 2.1) to final concentrations of 
20mM, 50ug/ml and 0.5%, respectively. The contents were mixed by 
gentle inversion, incubated at 65°C for lhr and extracted once 
with phenol, once with phenol/chloroform and once with 
chloroform as previously described. The aqueous phase was 
dialysed for 3 x 2hr against 2 litres of TE and bacteriophage 
DNA precipitated with two volumes of ethanol in the presence of 
0.3M sodium acetate (pH 6.0) at -70°C for 30min. DNA was 
pelleted by centrifugation (13000rpm/10min) in a benchtop
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microcentrifuge, washed with 70% ethanol, dried in a vacuum 
dessicator and resuspended in TE. Purity of the DNA was 
determined by gel electrophoresis as previously described. Over 
lmg of bacteriophage DNA was obtained.
Subcloning of Recombinant Bacteriophage DNA Containing EHV-1 
Sequences
Purified recombinant \  gtll bacteriophage DNA was double­
digested with Kpnl and Xbal and a resulting 6.5kb fragment 
(containing the EHV-1 DNA insert in the EcoRI site) purified and 
cloned between the Kpnl and Xbal sites of Bluescript M13+ using 
standard techniques. The EHV-1 DNA insert was sequenced using a 
Xgtll-specific primer close to the EcoRI site as previously 
described.
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R E S U L T S
Structure of Recombinant Plasmids
The structure of the recombinant plasmids pUC4S, pBS1.9G 
and pUCO. 9G, which contain the rightmost 4.4kb BamHI/Smal 
subfragment of BamHI-B, the leftmost 1.9kb BamHI/Sall and 
adjacent ‘0.9kb Sail subfragments of BamHI-G, respectively, is 
shown in Figure 6.1. Their structure was confirmed by 
restriction endonuclease analysis (Figure 6.2).
Determination of the EHV-4 DNA Sequence
Sequencing of the DNA inserts in the above plasmids was 
initiated using commercially available primers (M13, Reverse, 
T7, KS) and then completed using custom made primers to rapidly 
generate sequence data for both strands. Each nucleotide was 
sequenced at least three times until all ambiguities were 
removed. Sequencing was extended for a further 0.6kb downstream 
of the subcloned region of BamHI-G by priming on intact BamHI-G 
using custom made primers. The data were compiled and analysed 
as previously described. An autoradiograph of one of the 
sequencing gels for this region is shown in Figure 6.3. The 
region sequenced consisted of 7868 nucleotides, extending 
rightwards from a few nucleotides downstream of the Smal site in 
BamHI-B to a region approximately 3.4kb downstream of the left 
terminus of BamHI-G (Figure 6.4).
Analysis of the EHV-4 DNA Sequence
Sequence data was analysed for ORFs by identifying 
potential ATG initiation codons (Kozak, 1984, 1986) and
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polyadenylation signals (Berget, 1984). The ORFs identified were 
designated B1 to B7 and their arrangement and genomic location 
are shown in Figure 6.4. The complete DNA sequence of this 
region, the gene layout and the amino acid sequence of the 
predicted gene products are shown in Figure 6.5, and a summary 
of the salient features of these genes is presented in Table 
6.1. In the analyses which follow, the DNA sequences of the VZV 
genome (Davison and Scott, 1986a) and the UL region of the HSV-1 
genome (McGeoch et al., 1988a) are the reference sources against 
which the EHV-4 sequence is compared.
The sequences surrounding each predicted initiation codon 
suggest that they could all function as efficient initiation 
sites, conforming well with the optimal sequence ACCATGG 
identified for translation initiation (Kozak, 1984, 1986). The 
initiation codon for ORF B1 was identified at nucleotide 592 and 
this ORF extends back to nucleotide 1 in a leftward direction. 
This partial ORF is analogous to HSV-1 UL52/VZV gene 6. ORF B2 
extends for 732 nucleotides from nucleotide 591 to the 
termination codon at nucleotide 1323 in a rightward direction, 
with a polyadenylation signal at nucleotide 1338. The initiation 
codon for this gene overlaps with the initiation codon of ORF B1 
on the opposite strand. A second in-frame ATG in ORF B2 occurs 
at nucleotide 606, but the sequences surrounding it suggest that 
it could not function as an efficient initiation site. ORF B2 is 
analogous and similar in size to HSV-1 UL51 (732 nucleotides) 
and VZV gene 7 (777 nucleotides). ORF B3 is 978 nucleotides in 
length and extends leftwards from nucleotide 2394 to the 
termination codon at nucleotide 1416, with a polyadenylation 
signal at nucleotide 1375. This ORF is analogous to HSV-1
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UL50/VZV gene 8, although it is significantly smaller than HSV-1 
UL50 (1113 nucleotides) and VZV gene 8 (1188 nucleotides) . The 
remaining ORFs in the EHV-4 sequence extend in a rightward 
direction. ORF B4 comprises 870 nucleotides, initiating at 
nucleotide 2860 and terminating at nucleotide 3730, 36
nucleotides downstream of which lies a polyadenylation signal. 
This ORF is analogous and similar in size to HSV-1 UL49 (903 
nucleotides) and VZV gene 9 (906 nucleotides) . ORF B5 extends 
from nucleotide 3845, continues into BamHI-G and would appear to 
terminate at nucleotide 4514. However, this would yield an ORF 
much smaller than the analogous gene in HSV-1 (UL48, 1470
nucleotides) and' VZV (gene 10, 1230 nucleotides). A feasible 
explanation for this is that a small BamHI fragment (0.6 to 
0.8kb) has been omitted from the original restriction map of the 
EHV-4 genome between BamHI-B' and BamHI-G (Figure 1.3). The most 
likely termination codon for this ORF is at nucleotide 4620, six 
nucleotides prior to a polyadenylation signal. Furthermore, an 
ORF extends back to the start of BamHI-G from this termination 
codon, and the predicted amino acid sequence of this region is 
indicated in brackets in Figure 6.5. B6 is the largest ORF in 
the EHV-4 sequence presented here, initiating at nucleotide 4993 
and terminating at nucleotide 7609. This 2616 nucleotide ORF is 
considerably larger than the corresponding ORF in HSV-1 (UL47, 
2079 nucleotides) and VZV (gene 11, 2457 nucleotides) . The
likely initiation codon of ORF B7, the EHV-4 homologue of HSV-1 
UL46 and VZV gene 12, is at nucleotide 7734, although the 
sequence has only been extended for 135 nucleotides. Since no 
polyadenylation signal is present for ORF B6 in the region 
sequenced, it seems probable that the 3' end of its mRNA is
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coterminal with that of ORF B7, an arrangement that has also 
been reported for the corresponding genes of HSV-1 (McKnight et 
al., 1987).
It is difficult to assign transcriptional regulatory 
elements to EHV-4 genes B1 to B7 shown in Figure 6.5 with any 
certainty on the basis of DNA sequence data alone. The sequence 
TATAAAA at nucleotide 2712, 148 nucleotides prior to the
initiation codon, could tentatively be assigned as the TATA box 
for ORF B4, with a putative mRNA initiation site at nucleotide 
2745 within the sequence TCATTC. The analogous VZV gene 9 also 
has the potential TATA box TATAAAA in a similar position, 92 
nucleotides prior to the initiation codon. The sequence TATAAAA 
at nucleotide 4882, 111 nucleotides prior to the initiation 
codon, could be the functional TATA box for ORF B6, with a 
putative mRNA initiation site at nucleotide 4922 within the 
sequence CTATCTA. The TATAAAA sequence occurs in the analogous 
VZV gene 11, 89 nucleotides prior to the initiation codon, and 
also in the HSV-1 homologue UL47, 223 nucleotides prior to the 
initiation codon. Additionally, the variant sequence TATAACA at 
nucleotide 473 may represent the TATA box of ORF B2.
The ORFs are compactly arranged in the EHV-4 sequence, the 
largest non-coding region being 465 nucleotides long and located 
between ORFs B3 and B4. The corresponding genes in HSV-1 and VZV 
show a similar compact arrangement. An overall G+C content of 
49% is reported for the EHV-4 sequence, a value similar to the 
47% G+C content of the genomic region encoding the glycoprotein 
gB gene of EHV-4.
These EHV-4 sequence data demonstrate that the EHV-4 genome 
has an identical gene arrangement between 0.067 and 0.122 m.u.
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as the HSV-1 (1-^) and VZV genomes.
Analysis of Amino Acid Sequences
The amino acid sequences of the predicted gene products of 
EHV-4 ORFs B1 to B7 were analysed and compared with the 
corresponding gene products of HSV-1 and VZV. Analyses employed 
were protein alignment, hydropathic analysis and dot matrix 
similarity comparisons, all of which were carried out as 
described in Chapter 4. Percentage amino acid homology values 
for pairwise comparisons of analogous gene products of EHV-4, 
HSV-1 and VZV are shown in Table 6.2.
i) EHV-4 Bl/HSV-1 UL52/VZV Gene 6
Of the 197 amino acids available for analysis for EHV-4 Bl, 
42 residues are shared by all three proteins over a total length 
of 220 residues (Figure 6.6a). This is indicative of a moderate 
level of conservation of this protein in all three viruses. The 
HSV-1 and VZV proteins show a 37% amino acid identity over their 
entire length and the HSV-1 protein is one of several proteins 
identified as being required for the replication of viral DNA 
(McGeoch et_al., 1988b; Wu et al. . 1988). A homologous protein 
is also specified by EBV BSLF1, which accentuates the important 
conserved role of these species in the DNA replication process.
ii) EHV-4 B2/HSV-1 UL51/VZV Gene 7
EHV-4 B2 is predicted to be 244 amino acids long with a 
molecular mass of 26.2kDa, which compares favourably with the 
predicted sizes of the homologous proteins of HSV-1 (244 amino 
acids; 25.5kDa) and VZV (259 amino acids; 28.2kDa). The codon 
usage and amino acid composition of EHV-4 B2 are shown in Table 
6.3. Alignment of EHV-4 B2 with the analogous proteins of HSV-1
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and VZV reveals that they are quite well conserved with 67 of 
the amino acids being shared by all three proteins over a total 
length of 262 residues, corresponding to an overall identity of 
26% (Figure 6.7). The amino-terminal portion is the best 
conserved region, with 32 residues being identically matched in 
all three proteins in a region of 55 amino acids corresponding 
to residues 36 to 90 of EHV-4 B2. The centre of the molecules 
show moderate conservation of amino acid sequence, with 36% of 
the residues being shared in a region stretching from residues 
91 to 164 in EHV-4 B2. Of the remaining amino acids towards the 
carboxyl-terminus of the molecules, only one is shared by all 
three proteins. Thus, an important and conserved function can be 
predicted for the amino-terminal region of the molecules whilst 
the carboxyl-terminal region may be divergent in function. Most 
highly conserved regions include the sequences TRRLV (residues 
64 to 68) and IARTY (residues 73 to 77) in the EHV-4 protein 
which are totally conserved with the HSV-1 and VZV proteins. The 
quite high amino acid homology between EHV-4 B2 and the 
analogous proteins of HSV-1 and VZV is summarised in dot matrix 
similarity comparisons (Figure 6.8). The hydropathic profiles 
of these proteins are very similar and show that the proteins do 
not possess extreme properties, although their carboxyl-terminal 
regions are generally hydrophilic (Figure 6.9). However, the 
function of these proteins is unknown,
iii) EHV-4 B3/HSV-1 UL50/VZV Gene 8
The codon usage and amino acid composition of EHV-4 B3 are 
shown in Table 6.4, and an alignment of this protein with its 
HSV-1 and VZV homologues is shown in Figure 6.10. EHV-4 B3 is 
326 amino acids long with a predicted molecular mass of 35.2kDa,
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which is somewhat smaller than the sizes predicted for the 
analogous proteins of HSV-1 (371 amino acids; 39.1kDa ) and VZV 
(396 amino acids; 44.8kDa). The proteins possess highly 
divergent amino acid sequences, with only 49 amino acids being 
shared by all three proteins over a total length of 453 residues 
(11% identity). Generally, the amino acid homology is patchy and 
distributed over the whole length of the molecules. The best 
conserved region is towards the carboxyl-terminus where 39 amino 
acids are shared by all three proteins in a region corresponding 
to the carboxyl-terminal 155 amino acids of the EHV-4 protein. 
In particular, the sequences GFGST (residues 320 to 324) and 
GRSS (residues 217 to 220) in the EHV-4 protein are shared by 
all three proteins. The central region of the molecules are most 
divergent, with the VZV protein containing multiple insertions 
relative to the EHV-4 and HSV-1 proteins between residues 169 
and 229. In a similar vein, the HSV-1 protein contains a 15 
amino acid insertion between residues 96 and 110. The dot matrix 
similarity analysis in Figure 6.11 demonstrates the generally 
low level of amino acid conservation between these proteins. The 
hydropathic profiles of these proteins demonstrate that they 
possess no extreme features (Figure 6.12). However, a very 
hydrophilic peak is observed in their hydropathic profiles, 
which is indicated by a shaded box. These regions correspond to 
amino acid residues 171 to 181, 212 to 222 and 231 to 241 of the 
EHV-4, HSV-1 and VZV proteins, respectively, which are 
particularly well conserved between the proteins (Figure 6.10). 
Additionally, the HSV-1 protein contains a very hydrophilic 
short stretch of amino acids (residues 181 to 187) of which four 
residues are arginine. The gene product of HSV-1 UL50, first
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identified by Preston and Fisher (1984), is known to be the 
enzyme dUTPase which has an important role in viral DNA 
metabolism. dUTPase catalyses the hydrolysis of dUTP to dUMP and 
pyrophosphate and serves to provide the cell with a supply of 
dUMP which can be converted to IMP by thymidylate synthetase, 
and also serves to reduce the intracellular concentration of 
dUTP (Preston and Fisher, 1984).
iv) EHV-4 B4/HSV-1 UL49/VZV Gene 9
The EHV-4 B4 protein is predicted to be 290 amino acids 
long (31.5kDa), which compares favourably with the predicted
size of the analogous proteins of HSV-1 (301 amino acids; 
32.2kDa) and VZV (302 amino acids; 32.2kDa). The codon usage and 
amino acid composition of the EHV-4 B4 protein are shown in 
Table 6.5. The alignment of these proteins (Figure 6.13) reveals 
that 40 amino acids are shared by all three proteins over a 
total length of 344 residues. The amino-terminal half of the 
molecules display the greatest level of divergence, with limited 
and patchy amino acid conservation. Conversely, the carboxyl- 
terminal half of the molecules is the best conserved region and 
a stretch of 79 amino acids between residues 165 and 243 of EHV- 
4 B4 shares 36% of its residues with both the HSV-1 and VZV
proteins. In particular, the sequence FNKNVFCAAV at residues 183 
to 192 of the EHV-4 protein shares nine out of ten residues 
with the HSV-1 protein and eight out of ten residues with the 
VZV protein. The extent of amino acid homology between EHV-4 B4 
and its HSV-1 and VZV homologues is summarised by means of dot
matrix similarity comparisons in Figure 6.14. The hydropathic
profiles of the proteins demonstrate their hydrophilic nature 
(Figure 6.15). Analysis of the amino acid composition of EHV-4
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B4 (Table 6.5) shows that the protein is highly charged, with 
the acidic residues Asp and Glu accounting for 10% of the total 
amino acids. Strongly basic amino acids, Arg and Lys, further 
account for 13% of the total amino acids, giving the protein a 
net basic character. The HSV-1 and VZV proteins show a very 
similar composition of acidic and basic residues, with 
acidic/basic compositions of 10%/14% and 12%/14%, respectively. 
The function of these proteins is still unknown,
v) EHV-4 B5/HSV-1 UL48/VZV Gene 10
An alignment of the predicted gene products of EHV-4 B5, 
HSV-1 UL48 and VZV gene 10 is shown in Figure 6.16. Only the 
first 211 amino acids of the EHV-4 protein were available for 
comparison and the complete HSV-1 and VZV protein sequences are 
shown. Alignment of the sequences shows that 43 amino acids are 
totally conserved between the three proteins over a total length 
of 219 residues in the amino-terminal half of the molecules. 
Conserved amino acids are distributed over this region in small 
blocks. The hydrophilic sequence ELRAREE at residues 175 to 181 
of the EHV-4 protein is perfectly conserved with residues 160 to 
166 of the HSV-1 protein and residues 164 to 170 of the VZV 
protein. Similarly, the sequence TWNEDLFS at residues 83 to 90 
of the HSV-1 protein aligns with identical residues at position 
88 to 95 in the VZV protein and shares six of these residues 
with the sequence KWNEDMFS at residues 94 to 101 in the EHV-4 
protein. Since homology is evenly distributed in small patches 
no larger than five amino acids over the remaining length of the 
HSV-1 and VZV proteins, it seems likely that these two well 
conserved regions may have an important role in protein 
function. Dot matrix similarity comparisons of the, amino-
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terminal 211 amino acids of the EHV-4 B5 protein with the 
corresponding region of the HSV-1 and VZV proteins are shown in 
Figure 6.17 and serve to illustrate the well conserved nature of 
the amino acid sequences in this region. The gene product of 
HSV-1 UL48 has a role in the transactivation of IE genes 
(Campbell et al.. 1984; Pellett et al. . 1985c). Analysis of the 
gene product of HSV-1 UL48, also known as the C< -trans-inducincr 
factor (o<-TIF), has revealed that it is highly charged, 
consisting of large proportions of acidic (14%) and basic (9%) 
residues (Dalrymple et al.. 1985). The amino acid composition of 
the amino-terminal half of the EHV-4 B5 protein (Table 6.6) 
identifies it as also being of highly charged and acidic 
character, with acidic and basic amino acid contents of 15% and 
7%, respectively. This compares well with acidic/basic amino 
acid compositions of 12%/8% and 15%/8% for the corresponding 
region of the HSV-1 and VZV proteins, respectively. In common 
with the relatively high leucine content reported for the HSV-1 
C5<-TIF protein (Dalrymple et_al., 1985), this amino acid is the 
most abundant residue in the region of the EHV-4 B5 protein 
analysed (Table 6.6). This suggests that these proteins may have 
a well defined and conserved secondary structure. The 
hydropathic profiles of the proteins (Figure 6.18) demonstrate 
that they do not possess extreme features. The peak 
corresponding to the strongly hydrophilic sequence ELRAREE 
conserved in all three proteins is indicated by a shaded box in 
each hydropathic profile,
vi) EHV-4 B6/HSV-1 UL47/VZV Gene 11
The EHV-4 B6 gene product is predicted to be 872 amino 
acids long with a molecular mass of 97.4kDa, which is
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significantly larger than the analogous proteins of HSV-1 (693 
amino acids; 73.8kDa) and VZV (819 amino acids; 91.8kDa). It is 
also the least well conserved of the proteins analysed in this 
chapter (Table 6.2). The codon usage and amino acid composition 
of the EHV-4 B6 protein are shown in Table 6.7 and an alignment 
of the proteins encoded by EHV-4 B6, HSV-1 UL47 and VZV gene 11 
is presented in Figure 6.19. Only 66 amino acids are shared by 
all three proteins over a total length of 920 residues, 
emphasising the highly divergent nature of these species. A 
significant point, however, is that the EHV-4 B6 protein is more 
closely related to its VZV homologue (27% homology) than to its 
HSV-1 homologue (17% homology), whilst the HSV-1 and VZV 
proteins share only 18% of their sequences (Table 6.2). 
Comparison of the EHV-4 protein with its HSV-1 and VZV 
counterparts by the dot matrix method (Figure 6.20) clearly 
shows that the carboxyl-terminal half of these proteins is 
better conserved than the amino-terminal half, which exhibits 
particular divergence of amino acid sequence. Despite their 
extensive divergence of amino acid sequence, the proteins still 
share some similar features. Their hydropathic profiles display 
a conserved, strongly hydrophilic region corresponding to about 
the first 200 amino acids of each protein (Figure 6.21). This 
region is highly charged and acidic in character in each 
protein. In the case of the EHV-4 protein, 30% of the amino 
acids in this region are charged and compares with a value of 
21% for the remainder of the molecule. A similar distribution of 
charged residues is predicted for the HSV-1 protein (36% and 
19%) and the VZV protein (40% and 19%). Of particular note is 
the clustering of glutamic acid residues in the amino-terminal
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region of the EHV-4 and VZV proteins. A region between residues 
111 and 201 of the EHV-4 protein contains 26 glutamic acid 
residues and the corresponding region of the VZV protein 
contains 40 glutamic acid residues. In contrast, the HSV-1 
protein contains only 10 glutamic acid residues in this region. 
The HSV-1 protein is unique in possessing an arginine-rich 
domain (residues 63 to 75) in which nine out of thirteen 
residues are arginine. The VZV protein contains multiple 
reiterations of the sequences DAIDDE and GEAEE between residues 
117 and 217. No such reiterated sequences occur in the EHV-4 and 
HSV-1 proteins. Overall, acidic residues account for 14.2%, and 
basic residues for 9.4%, of the total amino acids in the EHV-4 
protein. The VZV protein is even more acidic with an 
acidic/basic amino acid composition of 17.5%/7.3%. In contrast, 
the HSV-1 protein shows no overall acidic character (11.1% 
acidic, 12.4% basic residues). The HSV-1 protein has a high 
alanine (16.2%) and arginine (11.5%) content compared to the 
EHV-4 (alanine 8.8%, arginine 7.3%) and VZV (alanine 9.3%, 
arginine 5.7%) proteins. The gene product of HSV-1 UL47 has been 
shown to reduce the -TIF-dependent induction of IE gene 
expression (McKnight et al., 1987).
vii) EHV-4 B7/HSV-1 UL46/VZV Gene 12
Although little data is presented for the EHV-4 B7 protein, 
alignment of the amino-terminal residues of the three proteins 
clearly shows that EHV-4 ORF B7 does indeed encode a protein 
with detectable homology to the gene products of HSV-1 UL46 and 
VZV gene 12, with 14 residues being shared by all three proteins 
over a total length of 76 residues (Figure 6.6b). Of particular 
note is a block of amino acids GCLLPTP at residues 24 to 30 in
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the EHV-4 protein which is perfectly conserved with residues 38 
to 44 of the HSV-1 protein and with six of seven residues in the 
VZV protein. The gene product of HSV-1 UL46 has been shown to 
increase the o<-TIF-dependent activation of IE gene expression 
(McKnight et al., 1987).
Characterisation of the EHV-1 o p 10 Epitope Sequence Contained 
Within a Recombinant \  gtll Bacteriophage
Since DNA sequence analysis of the EHV-4 genome between 
0.067 and 0.122 m.u., a region to which the EHV-4 gplO gene was 
expected to map, demonstrated that none of the genes in this 
region encode a species with features typical of envelope 
glycoproteins ie. a hydrophobic signal sequence at the amino 
terminus and a hydrophobic transmembrane domain towards the 
carboxyl terminus, it was necessary to profer an explanation for 
these somewhat unexpected data. This was achieved by determining 
the DNA sequence of the EHV-1 insert in the recombinant 
bacteriophage expressing a gplO epitope. The DNA sequence of the 
EHV-1 insert and the amino acids encoded by the partial ORF it 
specifies are shown in Figure 6.22a. The EHV-1 gplO sequence is 
actually part of an ORF encoding the EHV-1 protein analogous to 
the gene products of HSV-1 UL47/VZV gene ll/EHV-4 B6, and an 
alignment of the 71 amino acids available for the EHV-1 protein 
with the corresponding amino acids of the protein specified by 
EHV-4 ORF B6 is presented in Figure 6.22b. The two sequences 
share amino acid homology of 75%. The map position of EHV-4 ORF 
B6 corresponds to the region to which Allen and Yeargan (1987) 
mapped the EHV-1 gplO gene. It is concluded that ORF B6 is the 
EHV-4 gplO gene, but its predicted gene product does not possess
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features typical of envelope glycoproteins.
DNA Sequence of a Region of the EHV-4 Genome Containing Part of 
the Gene Encoding the Major DNA Binding Protein
The DNA sequence of EHV-4 BamHI-Q and the left terminus of 
BamHI-M, and the amino acid sequence of the partial ORF it 
specifies, are presented in Figure 6.23a. This partial ORF 
encodes part of the major DNA blinding protein. An alignment of 
the amino acid sequence available for the EHV-4 protein with its 
HSV-1 (UL29) and VZV (gene 29) homologues is shown in Figure 
6.23b. This demonstrates that the proteins are highly conserved 
between these three alphaherpesviruses, with 117 amino acids 
being shared by all three proteins over a total length of 271 
residues, and is consistent with the finding that this is one of 
the most highly conserved proteins between HSV-1 and VZV 
(McGeoch et_al., 1988a).
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Figure 6.1 Physical maps of plasmids pBS1.9G, pUC0.9G and 
pUC4S. The broken lines represent vector DNA and the solid 
lines represent EHV-4 DNA. Sizes are shown in kilobases. 
Sites shown are those for BamHI (B), EcoRI (E), Hindlll 
(H), Kpnl (K), PstI (P), Sail (Sa), Smal (Sm) and Xhol 
(X). The orientation of EHV-4 DNA is denoted by an arrow.
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Figure 6.2 Restriction endonuclease analysis of plasmids 
pBS1.9G, pUCO.9G and pUC4S. Plasmid pBS1.9G was digested with 
BamHI (lane 1), Sail (lane 2) and Smal (lane 3), plasmid pUC0.9G 
with BamHI (lane 4) , Sail (lane 5) and Smal (lane 6) , and 
plasmid pUC4S with BamHI (lane 7) and BamHI/EcoRI (lane 8). 
Hindlll digested A  DNA fragments were used as size markers.
Figure 6.3 Autoradiograph of a typical sequencing gel 
obtained in determining the DNA sequence of the EHV-4 
genome between 0.067 and 0.122 map units. The primers used 
were Ml 3 on the upper strand and Reverse on the lower 
strand. These primers were annealed to single-stranded DNA 
template generated from plasmid pUC4S and sequencing 
reactions then carried out. The samples shown on the gel 
are as follows:-
M13 primer (long run)- A track (lane 1), C track (lane 2), 
G track (lane 3) and T track (lane 4); Reverse primer (long 
run)- A track (lane 5), C track (lane 6), G track (lane 7) 
and T track (lane 8) ; M13 primer (short run)- A track (lane 
9), C track (lane 10), G track (lane 11) and T track (lane 
12); Reverse primer (short man)- A track (lane 13), C track 
(lane 14), G track (lane 15) and T track (lane 16).
Sequence data generated from the M13 primer reaction 
corresponds to that in a rightward direction from 
nucleotide 1 in Figure 6.5, and that from the Reverse 
primer reaction corresponds to that in a leftward direction 
on the opposite strand from the BamHI site in Figure 6.5.
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Figure 6.4 Map of the EHV-4 genome showing the restriction 
endonuclease sites and DNA fragments used in studying gene 
arrangement between 0.067 and 0.122 map units, 
(a) Structure of the EHV-4 genome, (b) Location of BamHI 
sites in the viral genome, (c) Genomic location of DNA 
fragments sequenced during this study. The 7868bp region 
sequenced is indicated by a thick bar. (d) Gene arrangement 
in the region of the genome sequenced. Complete ORFs B2, 
B3, B4 and B6 are indicated by arrows. Broken arrows 
indicate the location of partial ORFs Bl, B5 and B7. Dots 
represent the 5' end and arrowheads the 3' end of each ORF.
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Figure 6.5 DNA sequence of the rightmost 4477bp of EHV-4 
BamHI-B and leftmost 3397bp of BamHI-G. The amino acid 
sequences of the gene products of ORFs B1 to B7 are shown 
below (leftward encoded) or above (rightward encoded) the 
sequence. Potential polyadenylation signals are underlined 
and tentative TATA elements are shown in bold type. Since a 
small BamHI fragment appears to have been omitted from the 
EHV-4 library between BamHI-B and BamHI-G, only the first 
211 amino acids of the gene product of ORF B5 are shown and 
the most likely carboxyl-terminal amino acids of this 
protein are shown in brackets.
F I G U R E  6.5
DNA Sequence of the EHV-4 Genome Between 
0.067 and 0.122 Map Units
CAGTACTGTGACCGAGAATAGCAGCCTTTACGGAACCTCGCTGGGGGTCGTACTTTGCGGCGGCTGCCGTTCGTCCTGTTCTCGCTGT'AGCGTTGT'CCAGAGT'TATAGCCAGAGCCAGTA 120
T S H G L I A A K V S G R Q P D Y K A A A A T R G T R A T A N D L T I A L A L I  158
TCAAGTCATTGTGGAGCTGGAAGGTATCTCCGTCTACAAGCGCCTGAAGCAGTATCTTAGACGATATTGGGTGACCGTGTAACAAAGTCTTGGTTAACGCTCTTGCTCCTGTTAAAGTTA 240
L D N H L O F T D G D V L A Q I L I K S S I P H G H L L T K T L A R A G T L T L  118
AAAACGCACACACAAACATTGGGCGTATGCGTTCTTGCGGCTCGTCACTAGCACCTCCCACAATACCGCTTAACAAACAAAAGCTTACTGATGGTTTTCGCTCTAAAAGAGCAGCCGCCA 360
F A C V F M P R I R E C J P E O S A G G V I G S L L C F S V S P K R E L L A A A L  78
ACAGCTCCTCGTCTGACTGATCAGTTGTGTCCCAGCTGTCACCAACATCAGCGTCCAATACGCGAGGCTGGGAGCCAAAAAGATCATCGAGCTCAGAACTCCAGTCGTAGCTTATAACAT 480
L E E D S Q O T T O U S O G V D A D L V R P Q S G F L D O L E S S U O Y  S I  V Y  38
(ORF B2) M F K 3
AAGCATCCTCAGAGCTCTCCTGGCCAGTTAGAAGCATCAGCGAATAAGTGATAACGCAGCTATCCGTAGCATAAAGAACCCTAATAGTGGGATTTGGGTTGTTTAACGCCATGTTTAAGT 600
A D E S S E Q G T L L H L S Y T I V C S D T A Y L V R 1 T P N P N N L A M  (ORF B1) 1
U L M S S L C G T K N P A S L E E V Y E P I H G G K N P A T M L R L Q S A L A A  43
GGCTAATGTCCAGTCTATGTGGAACTAAAAACCCCGCATCCCTAGAAGAAGTTTATGAGCCAATTATGGGTGGGAAGAACCCAGCCACCATGCTCCGCCTACAGTCCGCCCTGGCTGCAG 720
V N A L L P A T L T I E D V I S S  A D M T R R L V K A O T L A R T Y O A C Q H N  83
TTAATGCACTTTTGCCAGCAACCCTCACTATAGAGGATGTGATTTCATCGGCAGACAACACACGGCGCTTGGTTAAAGCCCAGACCCTGGCTCGTACCTATCAAGCGTGCCAGCATAACA 840
I E C L S R H R A S S D N P N L N A V V A T H M A N A K R L S D T C L A A L M H  123
TAGAGTGTTTATCCAGACATAGGGCCAGTTCCGACAACCCAAATTTGAATGCCGTGGTGGCTACGCACATGGCCAATGCTAAGCGCCTTTCGGATACCTGCCTCGCTGCTCTAATGCACC 960
L Y L S V G A V D A T T D T M V D H A I R M T A E N S V V H A D V A V L E K T L  163
TCTACCTGTCGGTTGGGGCAGTGGATGCCACTACGGACACTATGGTAGATCACGCCATTCGCATGACTGCTGAAAATAGCGTGGTAATGGCCGATGTTGCTGTTTTGGAGAAGACTCTTG 1080
G L E P Q P S  V M A H D L L A L E S S V Y M S G N S V P V  N D Y P A E D V E S T  203
GACTGGAGCCCCAGCCATCAGTAATGGCACATGACTTACTGGCCCTCGAAAGCAGTGTGTATAATTCTGGCAATTCCGTGCCAGTAAATGACTATCCAGCGGAAGATGTTGAGTCTACCC 1200
Q S V H S P L L S K R P S N T E V V C S S I P V  K S N L K S K P R R K P S L V A  243
AGAGTGTACACAGCCCTTTGCTGTCCAAGCGGCCTAGCAACACCGAGGTTGTTTGTAGCTCCATCCCAGTGAAATCAAACCTCAAATCCAAGCCCAGACGCAAACCCAGTTTGGTAGCGG 1320
A - 244
CGTAAAATTTAAAAACCAATAAACGATTTAAAGCTTTTAAAGGACTATGTTTATTTTATATCTTCATAACACGTATAGTGAAACCAGGGGCAGTTATAGTCCTGTTGAACCAAAGCCCCC 1440
- L G T S G F G G  319
CTCAGAGCGGGCACTCGAGGGTGCGTCGTGATCAAATGCTTCTGTAAACTTCCAAAGGATGGGCGTCGGGTTATGTTTGACAGCTCCGGTGGGCGAATAGGTAGGAAAGGGGGTGTTATA 1560
E S R A S S P A D H D F A E T F K H L I P T P N H K V A G T P S Y T P F P T N Y  279
GTTTACGTTGGTGGGTATCAGCGCCTCGTCAATATCTTCCGTTAACACTAGCTGAGCAACACGCTGACCCTTGGTGATATATACGGGATACTTATTGATATTAAGGATAAAAAAGCAACA 1680
H V N T P I L A E D I O E T L V L Q A V R Q G K T I Y V P Y K N I N L I F F C C  239
CGTTCTCCCGGTTACCCACCTAGTTGGTAGCACTATTAAACCCCTTCGATTCATAGACGAGCGTCCAAATATACACGGAGTAACCGCTGGGTTAGAGGAAGAAAACACAATTGGCAGTTC 1800
T R G T V W R T P L V  I L G R R N H  S S R G F  I C P T V A P N S S S F V I  P L E  199
CACAAAGTAGCTCTCATCAGGTTCTATAGTGGCGTTTGTTTGTGCGCTGATGTCATATCCTGCGTCTTCGTCGCGTTTTGGAGCAAAGTAATCGTAAAATATGTTAACTCTTGGTGACCG 1920
V F Y S E D P E I T A N T Q A S I D Y G A D E D R K P A F Y D Y F I N V R P S R  159
CCCATTTTCAGTTAAGTTAATGTTAGTCACGTTTATGGTCTCCGTGCTGAGTTTTACTAGCACGAGCCCCAAACTCATACATCCAGGGGGCACTACCGTATTTACTCCGTTGGCAAATTG 2040
G N E T L N  I M T V M  I T E T S L K V L V  L G L S M C G P P V  V T N V G N A F O  119
TACCGCTTTCACGACGCCGCGATATCCCGAGTCTACTATACCGTAGGCGGTGTAGTAGTTGGCTAGATTCCCAGTAAACGTTATGTTGCTAAAATTCCCTGGCTCACGTCCAACATGCGG 2160
V A K V V G R Y G S D V I G Y A T Y Y N A L N G T F T I N S F N G P E R G V H P  79
CAAACCGCTAATTTGCGCGAGAACAATGGCATATCCGCTGGAGCAGGCAACCCGTACACCTACGTCAGTGAGCACACTATAAAATTCGCCCGCACTTCCAAGCCCGGCACTCAGCTCGAC 2280
L G S I O A L V I A Y G S S C A V R V G V D T L V S Y F E G A S G L G A S L E V  39
TGTGTGGTTGTTGATTAACACCAACAATCTTCCATCAGCTTCTGCTCGCGCTTCCCATCCATTACTACATTCAACCACCACGATGTTGTCAGCGAGATTAGTGGCGCTGGCCATTTTAAC 2400
T H N N I L V L L R G O A E A R A E U G N S C E V V V I N D A L N T A S A H  (ORF 1
CTGCCTTTTGGTGGTGTTTGGTTTGACCAGAGGGGCTAGCGGCGACCTTGAAGCAAAGCAACGACTCGACGTTGCAAGAGAAGAAGAGAGGCGCGACTTTTGGCATGCAGCCTGCTCCGG 2520
B3)
ACACGGATTTCCAATTACCACCCCGAGCACTGCAGCTATTCTATTTTATGTGTCTTTGCTTGCAGTAGGCGTGGCCGTTGCTTGCCAGGCATACCGCGCCTTCCTACGAATTGTGACGCT 2640
GGAGATGTTGCGACACCTACACTGAGCAACATTGTATGTATAATCCCGGATATGTTGCAACCGTTTGACTGTATAAAAGGACTAGCGCTAAACCTACTAGAATCATTCGTGCTGAAAGTT 2760
(ORF B 4 ) H L T P Q R S  7
CCTTTCTAGTCrACAGCACTTCCATTAGAGTTTGTAGAGGTTTTTACTAGTGAGTAAATATGTCCGATACGTGGCGTAGACGTCGTAGTGGCGGTGGTGATGTTAACGCCACAGAGGAGT 2880
S Y T L Q F V T K I G K D D L L A E A L L C E K T N F T I H S V Y L G K M I C M  47
TCGTATACTCTACAATTCGTAACGAAAATAGGCAAAGACGACCTTCTCGCGGAAGCTTTGTTGTGCGAGAAAACGAACTTTACGATAAACAGCGTGTATCTAGGGAAAATGATTTGTATG 3000
T V H A V T M T K F T P D K A E R A A H Y N P Q  E H I Y E T C P G D E F Y D A C  87
ACAGTGCATGCCGTAACGATGACGAAGTTTACACCAGACAAAGCAGAGCGTGCCGCTCACTACAACCCCCAAGAACACATATACGAGACGTGTCCAGGAGATGAATTTTACGATGCCTGT 3120
E Y S L V G G G K L S T S H G R L S P T K T T P H P K S A G V T P P Q R V P A R  127
GAATATTCTCTCGTTGGAGGTGGTAAATTATCTACCTCCCATGGCCGTTTGAGCCCCACAAAAACCACACCCCACCCAAAGAGCGCGGGTGTAACCCCACCCCAACGTGTACCAGCGCGA 3240
P A T R A A A P S A T P T Q P D C V A K Q R T ' S P G V N S I K S G K S L A F S C  167
CCAGCTACTCGTGCGGCGGCACCGTCTGCAACACCAACCCAGCCGGATTGTGTTGCAAAACAACGCACTTCGCCAGGTGTAAACTCCATAAAGAGCGGTAAAAGCCTTGCGTTTAGCTGC 3360
T P K T P K T P U Y G A T H L F N K H V F C A A V S R V A A A H A S D A A S A L  207
ACCCCCAAAACGCCAAAGACGCCATGGTACGGTGCAACTCACCTGTTCAACAAAAACGTGTTTTGTGCCGCAGTGAGTCGCGTAGCCGCCGCACATGCAAGCGACGCAGCATCAGCACTA 3480
U D L D P P K T N E D L O R F L K A A A I R I L V C E G S K L ’L E M A N A T M E  247
TGGGACCTAGACCCTCCAAAAACGAACGAGGACTTGGACAGGTTTTTGAAGGCTGCAGCAATTCGCATTTTGGTTTGCGAGGGATCTAAACTCCTCGAAATGGCAAACGCAACAATGGAA 3600
Figure 6.5- continued
R S P D G A A A V A P I G Y D R R P R L A S R R R S I K C K P P A D D F F D D T  287 
AGATCCCCAGATGGGGCTGCAGCGGTCGCCCCCATCGGTTACGATCGCCGTCCTCGGTTAGCTTCTAGGAGGCGATCAATAAAATGTAAACCTCCAGCGGATGATTTTTTCGACGACACA- 3720
D S R - (ORF 290
GATTCCAGATAACGCATTTGCATAAATTTATAGCATTACAATCTCAATAAAATGTACCACTTGCTTATTCCTTTACCTTATTTGTCGTGTGCTCTGTTACTCTGCTGGTATTCAACGCGC 3840
B5) M A A N I A M F A D l E D Y D D T R S C E Y G Y G T C E L M D V D G V V A S F  39 
TACCATGGCGGCTAACATAGCCATGTTTGCCGACATAGAAGATTACGATGACACCCGCTCTTGTGAATATGGCTATGGTACCTGTGAGCTTATGGATGTTGATGGTGTGGTTGCTAGCTT 3960
D E G M L S A S E S I  Y S S P A O K R L A L P P P K A T S P T A L Y Q R L Q A E  79 
CGACGAGGGAATGTTAAGTGCCAGCGAGTCCATTTATTCTAGCCCAGCCCAAAAGCGTTTGGCGCTACCACCACCCAAAGCAACTAGCCCCACCGCATTATACCAGCGGCTACAAGCCGA 4080
L G F P E G Q A H L F A M E K W M E D M F S A I P V H V D L Y T E I A L L S T S  119
GCTGGGCTTTCCAGAGGGCCAGGCAATGCTGTTTGCTATGGAAAAGTGGAACGAGGACATGTTCTCGGCAATACCGGTACATGTAGATTTGTACACAGAAATCGCCCTGCTATCAACCTC 4200
V N E V V K A G L D S L P I P T N Y I P E V D L N A H G S E P F P E V P A L E D  159
GGTAAACGAGGTAGTTAAAGCGGGGCTCGATAGCCTGCCCATACCCACCAACTATATTCCAGAGGTAGACTTAAACGCACACGGAAGCGAGCCCTTTCCGGAGGTGCCCGCTCTGGAGGA 4320
E L E T Y V J S A Q R F Y L S E L R A R E E H Y S R L L R G Y C V A L L H Y L Y  199 
CGAACTAGAAACCTACGTAATATCGGCTCAGCGATTTTACCTATCAGAGTTACGCGCACGCGAAGAGCACTATTCGCGGCTGCTTAGAGGCTACTGTGTAGCGCTATTGCATTACCTGTA 4440
( D P V P P L T V G I R Q T A E T L A L P S N L T L Q S M E
G S A K R Q L R G A G S ..........  211
CGGCAGCGCTAAGCGGCAACTGCGCGGAGCCGGATCCAGTTCCACCGCTTACCGTAGGGATTCGTCAGACTGCTGAAACGCTTGCTCTTCCGTCTAACCTCACCCTACAGAGCATGGAAA 4560 
BamHI
T D V L D Y S S I S G D E L H O M F D I ) -
CTGACGTTCTTGACTACTCATCTATTTCAGGCGACGAGCTCAACCAGATGTTTGACATTTAATACAATAAAGCACGTTTCCAAACTTAACATAATGGCCGTATTTTCCGTCGATACGCTG 4680
CGTGAATAGAACGTAATGGGGGGAGGTGGGCGTGGTCTGCGGGTGGTGTATGTTTAAATTGGGCCCGGAGGTCTATAGGCAAGTTTTGTTTGCATTCGTGATCTGCTGCAACAAACGACA 4800
ATTAACTACCAATCTTCAAATATCGCCCATTTAACAGTACAAAACTAGGGGGTATGGCGGTTTTGAAGCTCGTAGCTTGCCTATAAAACTCGCGCGCCTTTGCCGCGAGATGGATGTTGC 4920
(ORF B6) H D Q H H G V R G G A P I  R R P  16
TATCTAGCGTAGATAGCGGGCGTTTGCCGTCAAAACTGACGGTTGTACTACAGCGATACGGAAGTAGTTAGCATGGACCAACATCACGGCGTTCGCGGTGGGGCGCCTATACGCAGGCCT 5040
R R S I E T R S H P F R A A G N T Q R T Y S T P R L S Y R D G L S G R A S S L E  56 
CGCAGATCAATAGAAACGCGCTCCCATCCATTTAGAGCCGCAGGAAATACACAGCGCACATACAGCACGCCAAGACTTAGTTATAGAGATGGATTGTCTGGCAGAGCCTCTTCACTTGAA 5160
P G G Q A H O O M E S S T Q S T S N M O P S T S F W G Y L R R V F S O D A P A Q  96
CCCGGGGGCCAAGCTCACGATCAAAATGAGAGCTCTACACAAAGTACTTCAAATAATCAACCAAGCACCTCATTTTGGGGATATCTACGAAGAGTTTTTTCAGATGATGCCCCCGCGCAG 5280
P O A P R S R A 0 F A P P P E E D S S S E E E 0 E E G P S Q A P L D E E D Q L H  136
CCACAAGCACCAAGGTCTCGCGCTGATTTTGCTCCTCCCCCCGAGGAGGACTCATCCAGCGAGGAAGAAGACGAGGAAGGTCCCTCACAAGCTCCGTTGGATGAGGAGGACCAGCTCATG 5400
Y A O Q Y S V G N S S D D N E E D Y L O P E V E Y P T S A E S G E Y H N S G H F  176
TATGCTGACCAATACTCAGTAGGTAACTCTAGTGATGATAACGAAGAAGACTACCTACAGCCAGAAGTTGAATATCCAACTTCCGCAGAATCTGGCGAATATCATAACAGTGGGATGTTT 5520
A E E E P E S E S E S D M E N Y E T Y E E N D T E V I S D D S H R L T R T U L O  216
GCAGAAGAGGAGCCGGAAAGCGAGTCTGAGTCAGACATGGAAAACTACGAAACGTACGAGGAAAATGATACGGAAGTCATATCAGATGATAGCCATAGACTTACTCGTACGTGGTTGGAT 5640
R S I R L H O D A L A O S S E I S K A I T .  K S T R R L Y D S Q F T P G G R G Y K  256 
AGGTCTATACGCTTAATGGACGACGCACTTGCACAGTCTTCTGAAATTTCTAAGGCTATCACTAAATCTACGCGCAGGTTATACGATAGCCAGTTTACTCCAGGGGGTCGAGGCTACAAA 5760
Q T E T P S Q R L V H L S R A G M Y D S D E I V H T G D Y M E V D D D P N S A Y  296
CAAACGGAAACCCCCTCCCAGCGTTTGGTTCATCTATCACGCGCTGGTATGTACGATTCTGACGAAATCGTTATGACAGGGGATTACATGGAGGTTGACGACGACCCAAACAGCGCTTAC 5880
O S W V R A I H H P V A M N P S W E E T I S N H T N T S F S A D I D Y D I D E L  336
CAGTCATGGGTGCGCGCTATTCACCACCCGGTTGCCATGAACCCATCATGGGAGGAAACAATTTCCAATCACACCAATACATCGTTTTCTGCCGACATAGACTATGATATAGACGAGCTA 6000
I E H N L A R T P P V F E G L L D S A D F F Y R I P M L Y T Y A T I T Q D E A Y  376
ATCGAAATGAACTTGGCGCGAACACCCCCAGTGTTTGAGGGATTGCTAGACAGCGCAGACTTTTTTTACAGACTACCCATGCTCTATACATATGCTACTATCACTCAAGACGAGGCCTAC 6120
E E R Q A W S N T Q A L H G H E Q S S W P A L V S D Y S K G G M Y V S P T Q E P  416
GAAGAGCGGCAGGCATGGTCTAATACACAGGCGCTGCATGGACACGAACAAAGTTCTTGGCCAGCGCTTGTGAGTGATTACTCTAAGGGGGGGATGTACGTGTCCCCTACTCAGGAACCC 6240
R G I W R R A I K Q A H A L Q L K L C V L G L T E F V T K R E L T Q H H S A V T  456 
CGCGGGATATGGCGACGCGCGCTAAAACAAGCAATGGCTCTTCAGCTAAAGCTATGTGTGCTTGGTTTAACAGAATTTGTAACTAAGCGTGAGCTCACACAACACCATTCAGCTGTAACT 6360
F L V D S L L R T A K N C Y L A S R L L V F A W E R R R E T G V R R P A E P L I  496 
TTTTTGGTCGACTCGCTCCTTAGAACAGCAAAAAATTGTTACTTGGCCAGCCGACTTTTAGTATTTGCCTGGGAAAGACGCAGGGAAACTGGTGTACGACGCCCAGCAGAGCCCCTCATA 6480 
Sail
A L S G V T L L Q P L P P E V S E L L E Q R T F D I G L R T P Q S G V F R A F F  536 
GCACTCTCCGGGGTTACGCTTCTCCAGCCGCTTCCCCCAGAAGTCTCAGAATTACTTGAGCAGCGTACATTTGATATAGGGTTGCGCACCCCCCAAAGTGGAGTGTTTAGAGCGTTCTTC 6600
G P U V Y W A E L R R A L R D P A A I M C R Y V G F H L Q T S E I Y L L A R A H  576 
GGACCGCTTGTGTATTGGGCAGAACTACGCAGAGCCTTGCGAGACCCAGCTGCCATAAACTGTCGCTATGTTGGATTTCATCTCCAAACATCAGAAATTTATTTATTGGCACGCGCCCAC 6720
S A S P G Y T K E E L V A M E A T L T L G T L M L E V A L Q W I H V A S A O L L  616 
TCTGCCAGCCCGGGCTACACCAAAGAAGAACTGGTTGCAATGGAGGCAACGCTCACACTTGGGACCCTCATGTTAGAGGTAGCGCTACAGTGGATACACGTGGCCAGTGCACAGTTACTT 6840
S E N D A L K A F R R V S A S I P H A L A P L G S I R L H D A E F E V L S N P D  656 
AGCGAAAACGATGCACTGAAAGCTTTTAGGCGTGTGAGTGCGTCTATTCCCCACGCCCTGGCGCCACTTGGTAGCATACGCCTACACGACGCAGAGTTTGAAGTGCTAAGCAACCCAGAT 6960
V M V A R D E T A L S Q A L F L G Y F S V R T A L T A C M R D Y A N  E V D G G S  696
GTGATGGTGGCACGTGATGAAACCGCCCTGAGCCAGGCGTTGTTTCTTGGATATTTTTCTGTTAGGACCGCACTAACTGCGTGCATGCGTGACTATGCTAATGAGGTGGATGGGGGATCT 7080
K E T V T G L F L G V G L I I Q R L A G H M N F L L N C M A G A A L Y G G S K I  736
AAAGAGACCGTTACTGGTTTGTTTTTGGGCGTGGGGCTAATTATTCAGCGCCTCGCTGGCCATATGAACTTTTTACTAAACTGTATGGCCGGCGCGGCACTTTATGGCGGTAGCAAAATC 7200
A I H S L T L P R Y S L L A D  V H A P M L O Q Q S L V D  F W R A R D D M L E E L  776
GCCATACACTCATTAACTCTGCCCAGATACAGCCTATTGGCGGATGTTATGGCCCCTATGCTTCAGCAGCAGTCTTTGGTCGACTTTTGGCGCGCCAGAGACGACATGTTGGAGGAACTA 7320
Sail
E I T P R P G P P T O G K R V V L E M P L P S O O L P A M T P S G O V N M G A G  816
GAAATAACACCACGCCCTGGACCCCCAACGCAAGGCAAGCGCGTGGTGCTGGAGATGCCTTTGCCCTCGGACGATCTTCCAGCTATGACTCCCAGTGGCCAAGTAAACAATGGCGCCGGT 7440
L G R M V D H A K H L O H Y R E T  I I G O D A S S S V G K R G L H K S G V G V R  856
TTGGGGCGCATGGTGGACATGGCCAAACACTTACAGCACTATAGAGAAACAATTATCGGAGACGATGCCTCTTCCTCTGTAGGTAAACGTGGCTTAATGAAATCTGGTGTGGGCGTACGC 7560
H A L E A E K V I  R Y S P K S T -  872
CATGCGCTGGAGGCGGAGAAAGTAATAAGATACTCACCCAAAAGCACTTAATGCTGTTTACGTCCCCGGTATGCTCTCACATTCCGCAAGCACTTTCATGAAACCTCTTCTACTTACCTA 7680
(ORF 87) H E A S G S A S U A R V S K N L  I E R R A V  22
GCACCCAACTTGTTTGTACGTCTTCGTAACAATCTATACATTAACTGAATACAATGGAAGCTAGTGGGTCTGCCTCATGGGCCCGCGTTTCCAAAAACCTAATCGAGCGCCGTGCAGTCA 7800
K G C L L P T P S O V M O A A V M A L K D E R  45
AAGGGTGCCTCTTGCCGACCCCAAGCGATGTTATGGACGCTGCTGTTATGGCCTTAAAAGACGAACGA 7868
T A B L E  6.1
Summary of EHV-4 Sequence Data
ORF ORF ORF 
start, end
ATG
context
sequence
TATA
sequence
Position 
of TATA 
sequence
Length
(amino
acids)
Molecular
mass
(kDa)
B1 592 (l)a AACATGG 7 7 (197)a -
B2 591 1323 GCCATGT TATAACA 473 244 26.2
B3 2394 1416 AAAATGG 7 7 326 35.2
B4 2860 3730 GTGATGT TATAAAA 2712 290 31.5
B5 3845 (4620)b ACCATGG 7 7 (211)b -
B6 4993 7609 AGCATGG TATAAAA 4882 872 97.4
B7 7734 (7868)a ACAATGG 7 7 (45) a -
a Incomplete ORF.
Incomplete ORF, probable termination site identified. 
? No obvious TATA sequence 5' to initiation codon.
Table 6.1 Summary of EHV-4 sequence data. ORFs, putative TATA 
sequences, and lengths and molecular masses of the predicted 
gene products are shown.
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T A B L E  6.2
Homolocrv Between the Gene Products 
of EHV-4. HSV-1 and VZV
Gene Product EHV-4/HSV-1 EHV-4/VZV HSV-1/VZV
B2/UL51/Gene 7 38 45 36
B3/UL5 0 /Gene 8 31 29 26
B4/UL4 9/Gene 9 29 28 26
B5/UL4 8/Gene 10 38 34* 28
B6/UL47/Gene 11 17 27 18
* Denotes value derived from alignment of the first 211 amino 
acids of the EHV-4 protein.
Table 6.2 Percentage homologies for pairwise comparisons of the 
gene products of the alphaherpesviruses EHV-4, HSV-1 and VZV.
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F I G U R E  6.6
Alignment of the Predicted Partial Amino Acid Sequences of EHV-4
B1 and B7 With the Analogous Gene Products of HSV-1 and VZV
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(b) EHV-4 B7 HSV-1 UL46 
VZV Gene 12
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Figure 6.6 Direct alignments of the predicted partial amino 
acid sequences of the gene products of EHV-4 B1 and B7 with the 
analogous gene products of HSV-1 and VZV. (a) Alignment of EHV-4 
B1 with the corresponding region of the gene products of HSV-1 
UL52 and VZV gene 6. (b) Alignment of EHV-4 B7 with the 
corresponding region of the gene products of HSV-1 UL46 and VZV 
gene 12. Identical residues are boxed and dashes denote spaces 
introduced to maximise alignment of the sequences.
F I G U R E  6.7
Alignment of the Predicted Amino Acid Sequence of EHV-4
B2 With the Analogous Gene Products of HSV-1 and VZV
EHV-4 B2 
HSV-1 UL51 
VZV Gene 7
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40
119 
117
120
159 
157
160
199
194
198
237 
232
238
[m] - 0
m ] a (TJ a |k  r li s I~d
s |h h | e QTJ s [k r l aH H
Q| T L| r h
D |V J J  S ff Q| - {sj
e Iv I T  l a p - a
< s|Tl a pf q| L t u  E
V H S IP Ll L S
A R N G D A L
I K P |P Ll I E
(TERM)
P C V L G 0 
T T P A I K
(TERM)
K S H V (TERM)
Figure 6.7 Direct alignment of the predicted amino acid 
sequence of the gene product of EHV-4 B2 with the analogous 
gene products of HSV-1 UL51 and VZV gene 7. Identical residues 
are boxed and dashes denote spaces introduced to maximise 
alignment of the sequences.
Figure 6.8 Dot matrix similarity analysis of the EHV-4 B2 
amino acid sequence against those of the gene products of 
HSV-1 UL51 and VZV gene 7. Analysis was carried out using 
COMPARE and DOTPLOT from the University of Wisconsin 
Genetics Computer Group programmes (Devereux et al.. 1984). 
In each plot, the horizontal axis is the EHV-4 B2 amino 
acid sequence. Vertical axes represent the amino acid 
sequences of the gene products of HSV-1 UL51 (a) and VZV 
gene 7 (b). Points are plotted when at least 15 amino acids 
in a moving window of 30 are identical. Large regions of 
similarity are indicated by uninterrupted diagonal lines 
from lower left to upper right.
F I G U R E  6,8
Dot Matrix Similarity Analysis of the EHV-4 B2
Amino Acid Sequence Against Those of the Gene 
Products of HSV-1 UL51 and VZV Gene 7
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F I G U R E  6.9
Hydropathic Analysis of the Gene Products 
of EHV-4 B2, HSV-1 UL51 and VZV Gene 7
(c) VZV gene 7
0 5 0  1 0 0  1 5 0  2 0 0  2 5 0
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Figure 6.9 Hydropathic plots of the gene products of EHV-4 B2 
(a), HSV-1 UL51 (b) and VZV gene 7 (c) as determined by the 
method of Kyte and Doolittle (1982). Points above the horizontal 
line represent regions of above average hydrophilicity.
T A B L E  6,3
Composition of EHV-4 Protein B2
Codon 
(amino acid)
Frequency % of 
total
Codon 
(amino acid)
Frequency % of 
total
ITT (Phe) 1 0.4 TAT (Tyr) 4 1.6
TTC (Phe) 0 0.0 TAC (Tyr) 1 0.4
TTA (Leu) 2 0.8 TAA (End) 0 0.0
TTG (Leu) 6 2.5 TAG (End) 0 0.0
CTT (Leu) 3 1.2 CAT (His) 3 1.2
CTC (Leu) 6 2.5 CAC (His) 4 1.6
CTA (Leu) 5 2.0 CAA (Gin) 1 0.4
CTG (Leu) 6 2.5 CAG (Gin) 5 2.0
ATT (lie) 3 1.2 AAT (Asn) 8 3.3
ATC (lie) 1 0.4 AAC (Asn) 7 2.9
ATA (He) 2 0.8 AAA (Lys) 5 2.0
ATG (Met) 10 4.1 AAG (Lys) 6 2.5
GTT (Val) 9 3.7 GAT (Asp) 6 2.5
GTC (Val) 0 0.0 GAC (Asp) 5 2.0
GTA (Val) 6 2.5 GAA (Glu) 5 2.0
GTG (Val) 8 3.3 GAG (Glu) 7 2.9
TCT (Ser) 2 0.8 TGT (Cys) 3 1.2
TCC (Ser) 9 3.7 TGC (Cys) 2 0.8
TCA (Ser) 3 1.2 TGA (End) 0 0.0
TCG (Ser) 3 1.2 TGG (Trp) 1 0.4
CCT (Pro) 2 0.8 CGT (Arg) 1 0.4
CCC (Pro) 4 1.6 CGC (Arg) 5 2.0
CCA (Pro) 8 3.3 CGA (Arg) 0 0.0
CCG (Pro) 0 0.0 CGG (Arg) 2 0.8
ACT (Thr) 6 2.5 AGT (Ser) 5 2.0
ACC (Thr) 7 2.9 AGC (Ser) 5 2.0
ACA (Thr) 1 0.4 AGA (Arg) 2 0.8
ACG (Thr) 2 0.8 AGG (Arg) 1 0.4
GCT (Ala) 8 3.3 GGT (Gly) 1 0.4
GCC (Ala) 10 4.1 GGC (Gly) 1 0.4
GCA (Ala) 7 2.9 GGA (Gly) 2 0.8
GCG (Ala) 4 1.6 GGG (Gly) 2 0.8
Table 6.3 Codon usage and predicted amino acid composition of 
EHV-4 B2 (244 amino acids).
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F I G U R E  6.10
Alignment of the Predicted Amino Acid Sequence of EHV-4
B3 With the Analogous Gene Products of HSV-1 and VZV
EHV-4 B3 
HSV-1 UL50 
VZV Gene 8
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Figure 6.10 Direct alignment of the predicted amino acid 
sequence of the gene product of EHV-4 B3 with the analogous 
gene products of HSV-1 UL50 and VZV gene 8. Identical residues 
are boxed and dashes denote spaces introduced to maximise 
alignment of the sequences.
Figure 6.11 Dot matrix similarity analysis of the EHV-4 B3 
amino acid sequence against those of the gene products of 
HSV-1 UL50 and VZV gene 8. Analysis was carried out using 
COMPARE and DOTPLOT from the University of Wisconsin 
Genetics Computer Group programmes (Devereux et al., 1984). 
In each plot, the horizontal axis is the EHV-4 B3 amino 
acid sequence. Vertical axes represent the amino acid 
sequences of the gene products of HSV-1 UL50 (a) and VZV 
gene 8 (b) . Points are plotted when at least 15 amino acids 
in a moving window of 30 are identical. Large regions of 
similarity are indicated by uninterrupted diagonal lines 
from lower left to upper right.
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Hydropathic Analysis of the Gene Products 
of EHV-4 B3. HSV-1 UL50 and VZV Gene 8
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Figure 6.12 Hydropathic plots of the gene products of EHV-4 B3 
(a), HSV-1 UL50 (b) and VZV gene 8 (c) as determined by the 
method of Kyte and Doolittle (1982). Points above the horizontal 
line represent regions of above average hydrophilicity. In each 
plot, the shaded box indicates a region of very hydrophilic 
amino acids which is highly conserved between the proteins (see 
text for details).
T A B L E  6.4
Composition of EHV-4 Protein B3
Codon 
(amino acid)
Frequency % Of 
total
Codon 
(amino acid)
Frequency % of 
total
TTT (Phe) 15 4.6 TAT (Tyr) 8 2.5
TTC (Phe) 0 0.0 TAC (Tyr) 6 1.8
TTA (Leu) 4 1.2 TAA (End) 0 0.0
TTG (Leu) 4 1.2 TAG (End) 0 0.0
CTT (Leu) 3 0.9 CAT (His) 2 0.6
CTC (Leu) 5 1.5 CAC (His) 2 0.6
CTA (Leu) 5 1.5 CAA (Gin) 3 0.9
CTG (Leu) 3 0.9 CAG (Gin) 2 0.6
ATT (He) 5 1.5 AAT (Asn) 9 2.8
ATC (He) 7 2.1 AAC (Asn) 16 4.9
ATA (lie) 8 2.5 AAA (Lys) 4 1.2
ATG (Met) 3 0.9 AAG (Lys) 3 0.9
GTT (Val) 7 2.1 GAT (Asp) 5 1.5
GTC (Val) 3 0.9 GAC (Asp) 8 2.5
GTA (Val) 10 3.1 GAA (Glu) 10 3.1
GTG (Val) 12 3.7 GAG (Glu) 6 1.8
TCT (Ser) 4 1.2 TGT (Cys) 4 1.2
TCC (Ser) 2 0.6 TGC (Cys) 2 0.6
TCA (Ser) 2 0.6 TGA (End) 0 0.0
TCG (Ser) 4 1.2 TGG (Trp) 3 0.9
CCT (Pro) 3 0.9 CGT (Arg) 2 0.6
CCC (Pro) 7 2.1 CGC (Arg) 4 1.2
CCA (Pro) 6 1.8 CGA (Arg) 2 0.6
CCG (Pro) 3 0.9 CGG (Arg) 2 0.6
ACT (Thr) 8 2.5 AGT (Ser) 6 1.8
ACC (Thr) 8 2.5 AGC (Ser) 7 2.1
ACA (Thr) 4 1.2 AGA (Arg) 3 0.9
ACG (Thr) 6 1.8 AGG (Arg) 2 0.6
GCT (Ala) 5 1.5 GGT (Gly) 6 1.8
GCC (Ala) 10 3.1 GGC (Gly) 3 0.9
GCA (Ala) 5 1.5 GGA (Gly) 12 3.7
GCG (Ala) 6 1.8 GGG (Gly) 7 2.1
Table 6.4 Codon usage and predicted amino acid composition of 
EHV-4 B3 (326 amino acids) .
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Alignment of the Predicted Amino Acid Sequence of EHV-4
B4 With the Analogous Gene Products of HSV-1 and VZV
EHV-4 B4 
HSV-1 UL49 
VZV Gene 9
El: : i|3: :E|: :GU
1h J a s s o g d Ir ] l c r -
1 N S V Y - - - IL g I K M [7] C M
P P 0 
£  P Dl 0
- - - R R G A L Q 
D D S ll Gl - Y |T] -
G K D |D I | L A E f71 L L
E 171 E Id L Yl Y r r j r  s s
s jjrJ s g q I y| r It a T r r
C E K T N
G M A S P
S V V V G
F T 
D S
0 H (71 - - N [pj L |yJ G G S S 
K M T -  - T 0 0
Q IE H| I Y E T C P H 3  - - fo] E [fJ Y [&] A c [?] y S
s |e (d d e h p e v p  - - R T R R P V S G A V
R V IHI Q P N D S S 0 S  E [o] D [?3 E [H3 1 D ( I ] -  -
Gl G 
GJ P 
VTVl A A F
k l s t s h g r Q s p t k
P A R A P P P P A G S G G
r e a r l r h e Q v e d a
216
229
209
r] Fjn
E D L | M E ll I 
I D Rill Ia“eL
K A 0 A
G I T T 
T G m  V
1 R ~ T I  I V C E G 
i r F I T v  C E G 
I R ll It V m  E G
S Kj I LI E M 
K IN L L ol R 
i In L r T l Q  A
A N
A N
A N
- - A T M  [ 0  R S P [dI -G A
e l v n p d v v q IdJ v d  
........... [e] a d l g e g
254
269
244
. 288 
279
VI A P J I G
t (aJ t Ir g
S K R G
- - - Y D IR
R S A A S R
- - - H N R
R P R U  A S RI R R
R P R |~A P A [Rj S A
T G D | L | Q G G M G BI K C K fp] - [p| M " '|P| P A D D F F R IpJ V E (TERM) Y A Q V R K P K 0
O S R (TERM)T Q T T G R  I T N R S R A R S A S R T D T R K  (TERM)
Figure 6.13 Direct alignment of the predicted amino acid 
sequence of the gene product of EHV-4 B4 with the analogous 
gene products of HSV-1 UL49 and VZV gene 9. Identical residues 
are boxed and dashes denote spaces introduced •to maximise 
alignment of the sequences.
Figure 6.14 Dot matrix similarity analysis of the EHV-4 B4 
amino acid sequence against those of the gene products of 
HSV-1 UL49 and VZV gene 9. Analysis was carried out using 
COMPARE and DOTPLOT from the University of Wisconsin 
Genetics Computer Group programmes (Devereux et al.. 1984). 
In each plot, the horizontal axis is the EHV-4 B4 amino 
acid sequence. Vertical axes represent the amino acid 
sequences of the gene products of HSV-1 UL49 (a) and VZV 
gene 9 (b). Points are plotted when at least 15 amino acids 
in a moving window of 30 are identical. Large regions of 
similarity are indicated by uninterrupted diagonal lines 
from lower left to upper right.
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Hydropathic Analysis of the Gene Products 
of EHV-4 B4. HSV-1 UL49 and VZV Gene 9
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Figure 6.15 Hydropathic plots of the gene products of EHV-4 B4 
(a), HSV-1 UL49 (b) and VZV gene 9 (c) as determined by the 
method of Kyte and Doolittle (1982). Points above the horizontal 
line represent regions of above average hydrophilicity.
T A B L E  6,5
Composition of EHV-4 Protein B4
Codon 
(amino acid)
Frequency % of 
total
Codon 
(amino acid)
Frequency % of 
total
TTT (Phe) 7 2.4 TAT (Tyr) 3 1.0
TTC (Phe) 3 1.0 TAC (Tyr) 5 1.7
TTA (Leu) 3 1.0 TAA (End) 0 0.0
TTG (Leu) 6 2.1 TAG (End) 0 0.0
CTT (Leu) 2 0.7 CAT (His) 3 1.0
CTC (Leu) 4 1.4 CAC (His) 4 1.4
CTA (Leu) 4 1.4 CAA (Gin) 4 1.4
CTG (Leu) 1 0.3 CAG (Gin) 2 0.7
ATT (lie) 3 1.0 AAT (Asn) 0 0.0
ATC (lie) 1 0.3 AAC (Asn) 8 2.8
ATA (He) 5 1.7 AAA (Lys) 15 5.2
ATG (Met) 6 2.1 AAG (Lys) 5 1.7
GTT (Val) 3 1.0 GAT (Asp) 8 2.8
GTC (Val) 1 0.3 GAC (Asp) 10 3.4
GTA (Val) 6 2.1 GAA (Glu) 6 2.1
GTG (Val) 4 1.4 GAG (Glu) 5 1.7
TCT (Ser) 5 1.7 TGT (Cys) 6 2.1
TCC (Ser) 4 1.4 TGC (Cys) 3 1.0
TCA (Ser) 2 0.7 TGA (End) 0 0.0
TCG (Ser) 2 0.7 TGG (Trp) 2 0.7
CCT (Pro) 3 1.0 CGT (Arg) 5 1.7
CCC (Pro) 6 2.1 CGC (Arg) 4 1.4
CCA (Pro) 14 4.8 CGA (Arg) 2 0.7
CCG (Pro) 2 0.7 CGG (Arg) 1 0.3
ACT (Thr) 4 1.4 AGT (Ser) 2 0.7
ACC (Thr) 5 1.7 AGC (Ser) 7 2.4
ACA (Thr) 7 2.4 AGA (Arg) 2 0.7
ACG (Thr) 10 3.4 AGG (Arg) 4 1.4
GCT (Ala) 6 2.1 GGT (Gly) 7 2.4
GCC (Ala) 7 2.4 GGC (Gly) 2 0.7
GCA (Ala) 16 5.5 GGA (Gly) 3 1.0
GCG (Ala) 8 2.8 GGG (Gly) 2 0.7
Table 6.5 Codon usage and predicted amino acid composition of 
EHV-4 B4 (290 amino acids).
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Figure 6.16 Direct alignment of the predicted amino acid 
sequence of the partial gene product of EHV-4 B5 with the 
analogous gene products of HSV-1 UL48 and VZV gene 10. The 
available 211 amino acids of the EHV-4 gene product, and the 
entire HSV-1 and VZV gene product sequences, are shown. 
Identical residues are boxed and dashes denote spaces introduced 
to maximise alignment of the sequences.
Figure 6.17 Dot matrix similarity analysis of the EHV-4 B5 
partial amino acid sequence against those of the 
corresponding region of the gene products of HSV-1 UL48 and 
VZV gene 10. Analysis was carried out using COMPARE and 
D0TPL0T from the University of Wisconsin Genetics Computer 
Group programmes (Devereux et al.. 1984). In each plot, the 
horizontal axis is the EHV-4 B5 partial amino acid 
sequence. Vertical axes represent the amino acid sequences 
of the corresponding region of the gene products of HSV-1 
UL48 (a) and VZV gene 10 (b). Points are plotted when at 
least 15 amino acids in a moving window of 30 are 
identical. Large regions of similarity are indicated by 
uninterrupted diagonal lines from lower left to upper 
right.
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Hydropathic Analysis of the Partial Gene Product
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Figure 6.18 Hydropathic plots of the partial gene product of 
EHV-4 B5 (a) and the corresponding region of the gene products 
of HSV-1 UL48 (b) and VZV gene 10 (c) as determined by the 
method of Kyte and Doolittle (1982). Points above the horizontal 
line represent regions of above average hydrophilicity. In each 
plot, the shaded box indicates a region of very hydrophilic 
amino acids which is highly conserved between the proteins (see 
text for details).
T A B L E  6.6
Partial Composition of EHV-4 Protein B5
Codon 
(amino acid)
Frequency % of 
total
Codon 
(amino acid)
Frequency % of 
total
TTT (Phe) 5 2.4 TAT (Tyr) 5 2.4
TTC (Phe) 2 0.9 TAC (Tyr) 8 3.8
TTA (Leu) 4 1.9 TAA (End) 0 0.0
TTG (Leu) 3 1.4 TAG (End) 0 0.0
CTT (Leu) 2 0.9 CAT (His) 2 0.9
CTC (Leu) 1 0.5 CAC (His) 2 0.9
CTA (Leu) 6 2.8 CAA (Gin) 3 1.4
CTG (Leu) 8 3.8 CAG (Gin) 3 1.4
ATT (lie) 2 0.9 AAT (Asn) 0 0.0
ATC (lie) 1 0.5 AAC (Asn) 5 2.4
ATA (He) 5 2.4 AAA (Lys) 2 0.9
ATG (Met) 7 3.3 AAG (Lys) 3 1.4
GTT (Val) 3 1.4 GAT (Asp) 6 2.8
GTC (Val) 0 0.0 GAC (Asp) 6 2.8
GTA (Val) 7 3.3 GAA (Glu) 7 3.3
GTG (Val) 2 0.9 GAG (Glu) 13 6.2
TCT (Ser) 2 0.9 TGT (Cys) 3 1.4
TCC (Ser) 2 0.9 TGC (Cys) 0 0.0
TCA (Ser) 2 0.9 TGA (End) 0 0.0
TCG (Ser) 4 1.9 TGG (Trp) 1 0.5
CCT (Pro) 0 0.0 CGT (Arg) 1 0.5
CCC (Pro) 6 2.8 CGC (Arg) 4 1.9
CCA (Pro) 5 2.4 CGA (Arg) 1 0.5
CCG (Pro) 2 0.9 CGG (Arg) 3 1.4
ACT (Thr) 1 0.5 AGT (Ser) 1 0.5
ACC (Thr) 6 2.8 AGC (Ser) 7 3.3
ACA (Thr) 1 0.5 AGA (Arg) 1 0.5
ACG (Thr) 0 0.0 AGG (Arg) 0 0.0
GCT (Ala) 6 2.8 GGT (Gly) 2 0.9
GCC (Ala) 7 3.3 GGC (Gly) 5 2.4
GCA (Ala) 6 2.8 GGA (Gly) 4 1.9
GCG (Ala) 4 1.9 GGG (Gly) 1 0.5
Table 6.6 Partial codon usage and predicted amino acid
composition of EHV-4 B5 (amino-terminal 211 amino acids) .
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B6 With the Analogous Gene Products of HSV-1 and VZV
EHV-4 B6 
HSV-1 UL47 
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Figure 6.19 Direct alignment of the predicted amino acid 
sequence of the gene product of EHV-4 B6 with the analogous 
gene products of HSV-1 UL47 and VZV gene 11. Identical residues 
are boxed and dashes denote spaces introduced to maximise 
alignment of the sequences.
Figure 6.20 Dot matrix similarity analysis of the EHV-4 B6 
amino acid sequence against those of the gene products of 
HSV-1 UL47 and VZV gene 11. Analysis was carried out using 
COMPARE and D0TPL0T from the University of Wisconsin 
Genetics Computer Group programmes (Devereux et al.. 1984). 
In each plot, the horizontal axis is the EHV-4 B6 amino 
acid sequence. Vertical axes represent the amino acid 
sequences of the gene products of HSV-1 UL47 (a) and VZV 
gene 11 (b). Points are plotted when at least 15 amino
acids in a moving window of 30 are identical. Large regions 
of similarity are indicated by uninterrupted diagonal lines 
from lower left to upper right.
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Dot Matrix Similarity Analysis of the EHV-4 B6
Amino Acid Sequence Against Those of the Gene
Products of HSV-1 UL47 and VZV Gene 11
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Hydropathic Analysis of the Gene Products 
of EHV-4 B6. HSV-1 UL47 and VZV Gene 11
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Figure 6.21 Hydropathic plots of the gene products of EHV-4 B6 
(a), HSV-1 UL47 (b) and VZV gene 11 (c) as determined by the 
method of Kyte and Doolittle (1982). Points above the horizontal 
line represent regions of above average hydrophilicity.
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Composition of EHV-4 Protein B6
Codon 
(amino acid)
Frequency % Of
total
Codon 
(amino acid)
Frequency % Of 
total
ITT (Phe) 23 2.6 TAT (Tyr) 15 1.7
TTC (Phe) 2 0.2 TAC (Tyr) 18 2.1
TTA (Leu) 12 1.4 TAA (End) 0 0.0
TTG (Leu) 19 2.2 TAG (End) 0 0.0
CTT (Leu) 20 2.3 CAT (His) 10 1.1
CTC (Leu) 11 1.3 CAC (His) 14 1.6
CTA (Leu) 18 2.1 CAA (Gin) 17 1.9
CTG (Leu) 8 0.9 CAG (Gin) 22 2.5
ATT (lie) 8 0.9 AAT (Asn) 11 1.3
ATC (lie) 6 0.7 AAC (Asn) 13 1.5
ATA (lie) 15 1.7 AAA (Lys) 13 1.5
ATG (Met) 27 3.1 AAG (Lys) 5 0.6
GTT (Val) 13 1.5 GAT (Asp) 25 2.9
GTC (Val) 4 0.5 GAC (Asp) 29 3.3
GTA (Val) 10 1.1 GAA (Glu) 40 4.6
GTG (Val) 18 2.1 GAG (Glu) 30 3.4
TCT (Ser) 25 2.9 TGT (Cys) 4 0.5
TCC (Ser) 8 0.9 TGC (Cys) 1 0.1
TCA (Ser) 18 2.1 TGA (End) 0 0.0
TCG (Ser) 3 0.3 TGG (Trp) 11 1.3
CCT (Pro) 7 0.8 CGT (Arg) 8 0.9
CCC (Pro) 18 2.1 CGC (Arg) 25 2.9
CCA (Pro) 20 2.3 CGA (Arg) 7 0.8
CCG (Pro) 6 0.7 CGG (Arg) 1 0.1
ACT (Thr) 16 1.8 AGT (Ser) 10 1.1
ACC (Thr) 9 1.0 AGC (Ser) 18 2.1
ACA (Thr) 17 1.9 AGA (Arg) 16 1.8
ACG (Thr) 10 1.1 AGG (Arg) 7 0.8
GCT (Ala) 17 1.9 GGT (Gly) 13 1.5
GCC (Ala) 22 2.5 GGC (Gly) 15 1.7
GCA (Ala) 22 2.5 GGA (Gly) 12 1.4
GCG (Ala) 16 1.8 GGG (Gly) 14 1.6
Table 6.7 Codon usage and predicted amino acid composition of 
EHV-4 B6 (872 amino acids) .
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F I G U R E  6.22
Characterisation of the EHV-1 DNA 
Sequence Encoding a gplQ Epitope
( ^ )  A s t i  1/E H V -1 in s e r t
Q A P R P R A D F A P P S G E E S S  18
GAATTCCAAGCACCCAGACCTCGCGCGGACTTTGCACCGCCCTCCGGCGAGGAATCATCT 60
EcoRI
S E E E E E E G P A Q A P L D E E D Q L  38
AGCGAGGAAGAGGAGGAAGAGGGTCCCGCCCAAGCTCCGCTGGACGAGGAAGACCAGCTA 120
M Y A D Q Y S V G D S S D E N D E E E D  58
AT GT AT GCT GACCAGT ACTCTGT AGGGGACT CTAGT GACGAAAACGACGAGGAAGAAGAC 180
P R L G S D Y P T  S A E S  71
CCCCGTCTAGGATCTGACTATCCCACGTCCGCCGAATCCAGAATTC 226
EcoRI
( t > )  EHV-4 B6
EHV-1 in s e r t
98 Q A P R S R A D F A P P P E E D S S S E
I I I I I I I I  I I I I I I  I I
1 Q A P R P R A D F A P P S G E E S S S E
118 E E D E E G P S Q A P L D E E D Q L M Y
II I I I I I I I I I I I I I I I I
21 E E E E E G P A Q A P L D E E D Q L M Y
138 A D Q Y S V G N S S D D N E E D Y L Q P
I I I I I I I III I I
41 A D Q Y S V G D S S D E N D E E E D P R
158 E V E - Y P T S A E S
I I I I I I I
61 L G S D Y P T S A E S
Figure 6.22 Sequence of the DNA insert in a recombinant A gtll 
bacteriophage known to encode an epitope of the EHV-1 
glycoprotein gplO. (a) DNA sequence of the 226bp DNA insert and 
predicted amino acid sequence of the partial gene product it 
encodes. (b) Alignment of the amino acid sequence of the EHV-1 
partial gene product in (a) with the corresponding region of the 
EHV-4 B6 gene product. The upper sequence is that of the EHV-4 
partial gene product, and the lower sequence that of the EHV-1 
partial gene product. Identical residues are indicated with a 
vertical bar, and dashes denote spaces introduced to maximise 
alignment of the two sequences. Residue 1 of the EHV-1 sequence 
aligns with residue 98 of the EHV-4 sequence.
F I G U R E  6.23
DNA Sequence of EHV-4 BamHI-0 and the 
Adjoining Left-Hand End of BamHI-M
(S.) EHV-4 major DNA binding protein (partial)
I L F Y L E R C D A G T F G G R N E T D A L R Y L A N T L E S E V P C G L C T  
GGATCCTATTTTACCTCGAAAGATGTGACGCTGGAACATTTGGGGGTCGCAACGAGACAGATGCACTGCGTTACTTGGCAAACACGCTAGAGTCTGAGGTACCATGTGGGTTGTGTACCC 120 
BamHI-0
P A T R P A C A H T T L H R L R Q R L P R F G T P V R A P I G I F G T M N S T Y  
CAGCTACGCGGCCGGCATGCGCTCATACCACGCTCCATCGTCTCCGGCAGCGTCTGCCACGCTTTGGAACGCCAGTTCGTGCTCCAATAGGAATATTTGGCACAATGAACAGCACGTATA 240
S O C O V L G N Y A S Y G A L I C R P N D N E A P K S I M Q O T Y R A T H E R L V  
GCGACTGTGATGTACTGGGTAACTATGCTTCCTACGGGGCGCTAAAGCGACCCAATGACAACGAAGCCCCCAAAAGCATCATGCAGGATACGTATCGTGCTACTATGGAGCGACTGGTAA 360
N D L E Q A K L I D K E A L A H A G T C S A S T G V V K D Q A S F I N L L S T I  
ATGACCTGGAACAGGCTAAGCTTATTGACAAGGAAGCGCTGGCTCATGCCGGCACCTGCTCGGCCTCCACAGGCGTAGTAAAGGACCAGGCCAGCTTTATAAATCTTTTGTCTACAATCA 480
K D I T E G A A E Q F H R T L V E V R D F K I R E G L A D A N H T M S I S L D P  
AAGACATAACTGAGGGGGCAGCAGAGCAGTTTATGCGCACTTTGGTTGAGGTTCGCGATTTTAAAATCCGCGAAGGCCTGGCAGATGCAAACCATACCATGTCAATTTCCCTGGATCCAT 600
8amHI-M
Y S S S F C P V T S F L S R R T I F A V L Q D L V L S Q C H C L F Y G Q S V E G  
ATTCCAGCAGTTTTTGTCCAGTTACATCATTTCTCTCGCGCCGCACCATTTTTGCTGTTTTGCAGGACCTAGTATTGAGCCAGTGTCACTGTCTTTTCTACGGTCAGTCGGTGGAGGGGC 720
R N F R N Q F Q P V I R R R F L D M L N G G F I T A K T V T
gcaactttcgcaaccagtttcagccagttttaagacgtagatttttagatatgctcaacgggggctttAtcactgctaaaaccgtaaca 809
(b) EHV-4 major DNA binding protein (partial) HSV-1 UL29 
VZV Gene 29
1
465
464
41
505
503
81
545
543
120
584
583
159
623
619
199
660
659
L F Y L E R C
L F Y L E R C
L F Y L E R C
T {7] G |G R I
V I V G R | 
A Q Q  T |G |G
T R PJIA C a |
t r nf |_A C [F
T R Pi v | C a |
Hi R L R Q| R
^ 1 R I R ol R
a l||r y1 l[~a1 N 0 1  
IV F |R Y V Aj D S N  
a l I T ] Y v [ t G (7]  F
f g) t P V [r1 a I P I
F (a_ s [a] a r I g T l  I
F Gj Q [AJ T [rJ O |P I
D C D V L 
D C D V L 
D C D f Pl L
G N 
G N 
G N
Tl s [y] g 
A 1 A 
_AJ P □
n Id l 
A _eQ  L
i |d l
A 1 0
L Q 
E R [I]
3 0 |A l k r p|
F S [a L K R Ia
3  l i t y  R K [Pj
D  1 El  K E [71 L A H [71 - [71 T
Y V Id Q - a V P T IA | h |g | R
F  L [oj r g [aJ p c s s e[gJ l
m  I T |e1 G a A IE Q fJ M R Til V E V R o| F K ij
Id r | - | e I v - - Ie q [ T m r J n l v e g R'[n*|f k [T
a ] r | i [eJ o t t T l o f1|h [k v |i v e t |r ol TJ jcJT]
Gl I I F G T M N
G V F G T H N
G V F G T M N
T G 0 V  k [d] 9  A
I T N R E A L H
m i  v m  h p i □ d Q
N H
N [F] N - IE
D G S - E
g [d] q t Ie
M Si I Si L d | 
H S L T L D
H I"*! L T p lDj
P
P Y 
P
Y sj s s |T"
(A* C G T
Y Sj G A |f
C P| V 0  S |F L
C P L L Q T] L
C P| I [3 N If L
q p l I v Il s q c h
Q D L A L S Q C H
O D L A L S Q C H
G Q S V E
G Q S V E
g o m  V E
239
700
699
G R N F
G R N F
G R N F
R N 
R N 
R N
F Q 
F Q 
F O
P V L R R
P V L R R
P V L R R
r fJ l Id m | l ) n gI g f iJ tJ a k t | v [t]
R M  D » F n E  G F |l fs A K t | L T
R f] V D m  F N G| G F Tl|S I T R S I [tJ
Figure 6.23 DNA sequence of EHV-4 BamHI-Q and the left-hand end 
of BamHI-M which contains a partial ORF encoding the major DNA 
binding protein, (a) DNA sequence of EHV-4 BamHI-Q and the left- 
hand end of BamHI-M and predicted amino acid sequence of the 
partial gene product it encodes, (b) Alignment of the partial 
amino acid sequence of the EHV-4 major DNA binding protein in 
(a) with the corresponding region of the major DNA binding 
proteins of, HSV-1 (encoded by UL29) and VZV (encoded by gene 
29). Identical residues are boxed and dashes denote spaces 
introduced to maximise alignment of the sequences. Residue 1 of 
the EHV-4 sequence aligns with residues 465 and 464 of the HSV-1 
and VZV sequences, respectively.
D I S C U S S I O N
Determination of the DNA sequence of the EHV-4 genome 
between 0.067 and 0.122 m.u. has revealed a gene arrangement in 
this region identical to that in the HSV-1 (IL) and VZV genomes. 
The proteins specified by the EHV-4 genes demonstrated weak to 
moderate homologies with the analogous gene products of HSV-1 
and VZV (Table 6.2). The analysis of these predicted EHV-4 gene 
products and comparison with analogous proteins of HSV-1 and VZV 
sheds new light on the extent of their divergence of structure 
and permits the prediction of a likely function for some of 
these proteins on the basis of our knowledge of the molecular 
genetics of HSV-1.
The protein encoded by EHV-4 ORF B2 is the best conserved 
species of those analysed in this section and shows a 
significantly higher homology to the gene product of VZV gene 7 
(45%) than to that of HSV-1 UL51 (38%) . An important conserved 
function is predicted for the amino-terminal region of the 
molecules whereas the highly divergent carboxyl-terminal region 
may have a less conserved role in protein function. Davison and 
Taylor (1987) have proposed that an analogous protein may be 
specified by EBV BSRF1 on the basis of possessing a hydropathic 
profile similar to that of the gene product of VZV gene 7,
although the proteins share little detectable amino acid 
homology. This indicates that these proteins may have an
important conserved, albeit an as yet unknown, function in EHV- 
4, HSV-1, VZV and EBV.
The protein specified by EHV-4 ORF B3 shows more limited
homology (about 30%) to the dUTPase of HSV-1 and VZV. The even
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distribution of homology across the molecules makes it difficult 
to identify specific regions which may be essential for protein 
function, although the carboxyl-terminal half of the proteins 
shows the greatest identity. A dUTPase is also thought to be 
specified by EBV BLLF2 on the basis of predicted amino acid 
sequence homology (Davison and Taylor, 1987). The conservation 
of this protein in both alpha- and gammaherpesviruses reflects 
the essential role it plays in cell metabolism.
The gene product of EHV-4 ORF B4 shows about 30% homology 
to the gene products of HSV-1 UL49 and VZV gene 9 and only 11% 
of residues are shared by all three proteins. However, a 
relatively well conserved region in the carboxyl-terminal half 
of these proteins corresponding to residues 165 to 243 of the 
EHV-4 protein may have an important role in protein function.
Although only the first 211 amino acids of the EHV-4 B5 
protein were available for analysis, alignment of these residues 
with the amino acid sequences of the analogous proteins of HSV-1 
and VZV identified two well conserved peptides in the EHV-4 
protein, ELRAREE and KWNEDMFS, which may be important for 
protein function. The protein specified by HSV-1 UL48, the 0<- 
TIF, is a particularly well studied virion component which 
activates, in trans, the expression of IE genes. Three 
temporal classes of genes have been distinguished for HSV-1: IE
(©<) , early (3) and late ( ) (Honess and Roizman, 1974, 1975).
Their expression is coordinately regulated and sequentially 
ordered in a cascade fashion. HSV-1 specifies five IE genes, 
referred to as IE1/IE110/ICP0 (two copies) , IE2/IE63/ICP27,
IE3/IE175/ICP4 (two copies), IE4/IE68/ICP22 and IE5/IE12/ICP47 
(Watson et al. . 1979; Murchie and McGeoch, 1982? Everett, 1984,
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1986; McGeoch et al. . 1985, 1986a; Sacks et al.. 1985; Perry et 
al., 1986; Perry and McGeoch, 1988), which are the first genes 
to be expressed after infection and in the absence of de novo 
protein synthesis and whose expression is normally repressed at 
the onset of early transcription (Honess and Roizman, 1974, 
1975; Preston, 1979; Dixon and Schaffer, 1980). One IE protein, 
IE175, has long been recognised as being required for continuous 
expression of early and late genes (Knipe et al., 1978; Preston, 
1979; Dixon and Schaffer, 1980; Watson and Clements, 1980), 
although other IE proteins are also known to be involved in 
regulating transcription of later classes of genes (Everett, 
1984, 1986; O'Hare and Hayward, 1985; Quinlan and Knipe, 1985;
Sacks et al.. 1985; Sears et al.. 1985). Transcription from all 
IE genes was shown to be stimulated by a virion structural 
component (Post et al.. 1981; Mackem and Roizman, 1982;
Cordingley et_al., 1983; Preston et al.. 1984). Analysis of the 
5' regulatory regions of the HSV-1 IE genes identified a cis- 
acting element essential for this stimulatory response, 
TAATGARATTC, which was present in one or more copies upstream of 
all HSV-1 IE genes (Mackem and Roizman, 1982; Murchie and 
McGeoch, 1982; Whitton et al.. 1983; Whitton and Clements, 
1984), and it was concluded that activation of IE gene 
expression occurs by direct or indirect interaction of the 
virion structural component with this sequence. Campbell et al. 
(1984) were the first workers to identify the gene specifying 
the stimulatory virion component, a virion tegument structural 
protein that is the c*-TIF. Recent studies have shown that cK- 
TIF actually interacts with several other cellular factors to 
form a complex which then binds to TAATGARATTC (Kristie et al..
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1989) .
The VZV genome contains three IE genes, namely gene 4, gene 
63/70 and gene 62/71, which are analogous to HSV-1 IE63, IE68 
and IE175, respectively (Davison and Scott, 1986a). Since the 
VZV IE genes do not possess an upstream TAATGARATTC sequence, it 
seems possible that the putative VZV 0<-TIF may either recognise 
a different upstream element or even lack the ability to 
stimulate the transcription of IE genes. EHV-1 has been 
demonstrated to encode four IE proteins generated from a single 
IE transcript present in two copies in IRg/TRg (Caughman et al.. 
1985; Gray et al.. 1987a) . The EHV-1 IE gene has been sequenced 
and its product shown to be homologous to the HSV-1 IE175 and 
VZV gene 62/71 gene products, and it has been reported that the 
EHV-1 IE gene contains a potential TAATGARATTC element upstream 
of its promoter (Grundy et al.. 1989). On the basis of this, it 
seems likely that transcription from the EHV-1 IE gene may 
follow a mechanism similar to that identified for HSV-1 IE 
genes. An interesting point is that, in contrast to findings for 
EHV-1, a homologue of the HSV-1 IE68 gene has been identified in 
the EHV-4 genome (Cullinane et al., 1988) . This suggests that 
EHV-4 may have a different number of IE genes than does EHV-1, 
since the EHV-4 genome is also known to specify a gene analogous 
to HSV-1 IE175 (Cullinane et al. , 1988). Alternatively, the EHV- 
4 gene analogous to HSV-1 IE68 may be regulated as an early 
gene. Detailed characterisation of the EHV-1 and EHV-4 genomes 
will provide an answer to this. The gene product of EBV BMLF1 is 
homologous to the gene products of HSV-1 IE63 and VZV gene 4 and 
represents the only conserved IE protein specified by EBV (Baer 
et al.. 1984; Davison and Taylor, 1987; McGeoch et al., 1988a).
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The gene product of EHV-4 ORF B6 shows limited conservation 
of amino acid sequence with the analogous HSV-1 UL47 and VZV 
gene 11 gene products. Of particular note is the very 
hydrophilic nature of the amino-terminal 200 amino acids of 
these proteins, which may play an important role in protein 
function. The HSV-1 UL47 and UL46 gene products have been 
demonstrated to decrease and increase the CX -TIF-dependent 
activation of IE genes, respectively (McKnight et al., 1987).
McKnight et al. (1987) proposed a number of possible functions 
for the HSV-1 UL47 and UL46 gene products. Their suggestions 
included that these proteins may form a complex with the o<-TIF 
and determine its functions, that they alter the physiological 
state of the cell such that it is not specific for ©<-TIF or, 
alternatively, that they are transcriptional factors in their 
own right. Further studies will be necessary to determine the 
precise function of these proteins in EHV-4, HSV-1 and VZV.
The gene product of EHV-4 ORF B6 is a particularly 
interesting species. The data presented in this chapter 
demonstrated that EHV-4 ORF B6 maps to a region of the genome 
known to contain the gene for glycoprotein gplO (Allen and 
Yeargan, 1987). Glycoprotein gplO of EHV-1 and EHV-4 has been 
regarded as a major glycoprotein on the basis of incorporation 
of [3H]-glucosamine (Allen and Bryans, 1986; Allen and Yeargan,
1987) and additionally for EHV-1 by in vitro labelling with UDP- 
[14C]-galactose and [3H]-borohydride (Turtinen and Allen, 1982). 
It was therefore assumed that gplO would possess features 
typical of herpesvirus envelope glycoproteins, namely a 
hydrophobic signal sequence at the amino terminus and a 
hydrophobic transmembrane domain towards the carboxyl terminus.
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Since the gene product of EHV-4 ORF B6 possesses none of these 
features, it seems likely that gplO may reside in the virion 
tegument as does the analogous protein specified by HSV-1 UL47. 
Further studies have demonstrated that, in accordance with the 
amino acid homology observed between EHV-4 B6 (gplO) and the 
gene product of HSV-1 UL47 in this chapter, these species are 
antigenically cross-reactive (Whittaker et al.. submitted). 
Polyclonal antisera raised against VP13/14, the gene product of 
HSV-1 UL47, was shown to be cross-reactive with gplO of both 
EHV-1 (120kDa) and EHV-4 (123kDa) . By a combination of immune 
precipitation and Western blotting it was confirmed that this 
polyclonal antisera and a monoclonal antibody specific for EHV-1 
gplO (13A9) both reacted with the same protein in EHV-1-infected 
cells. Since EHV-4 gplO has no signal sequence for membrane 
insertion, it may be glycosylated by the addition of O-glycosyl- 
linked N-acetylglucosamine within the cytoplasm of the cell. The 
molecular mass of 123kDa for mature gplO in the EHV-4 virion, 
compared with the predicted molecular mass of about 97kDa for 
the gene product of EHV-4 ORF B6, suggests that carbohydrate 
residues on gplO represent 26kDa. Further characterisation of 
gplO of EHV-1 and EHV-4 should prove particularly interesting 
and help elucidate the precise functions of this novel, 
glycosylated tegument protein.
The DNA sequence of EHV-4 BamHI-Q and the left-hand 
terminus of the adjoining BamHI-M identified part of the gene 
specifying the major DNA binding protein. Homology has been 
demonstrated between the major DNA binding proteins of HSV-1 and 
VZV and the gene product of EBV BALF2 (Quinn and McGeoch, 1985; 
Davison and Taylor, 1987; McGeoch et al.. 1988a). The highly
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conserved nature of the major DNA binding protein of the 
alphaherpesviruses and the observation that an analogous protein 
is also specified by the distantly related EBV is consistent 
with an essential, conserved role for this protein in viral DNA 
replication (Conley et al.. 1981? Weller et al.. 1983?
Challberg, 1986). In contrast to the generally low levels of 
homology displayed by the EHV-4 genes mapping in the region 
0.067 to 0.122 m.u. to their HSV-1 and VZV counterparts, the 
EHV-4 major DNA binding protein gene is contained within a 
cluster of genes specifying proteins that are highly conserved 
between HSV-1 and VZV, and which have detectable homologues in 
the EBV genome. These genes are those encoding glycoprotein gB, 
ICP18.5, major DNA binding protein and DNA polymerase. Although 
sequencing of the EHV-4 genome was not sufficiently extended in 
this region to detect the DNA polymerase gene, it is certain 
that this gene will map to the left of the major DNA binding 
protein gene, within BamHI-J, on the basis of colinearity with 
the HSV-1 and VZV genomes. This gene cluster is located near the 
centre of UL in the alphaherpesvirus genomes but occurs close to 
the right terminus of the EBV genome (Quinn and McGeoch, 1985). 
Furthermore, the EBV DNA polymerase gene is relocated relative 
to the gB and ICP18.5 genes. Conservation of this gene cluster 
has also been reported for the gammaherpesvirus HVS, and the 
order of individual genes within this cluster is identical to 
that seen in EBV although the gene cluster is located near the 
left terminus of the HVS genome and the genes are transcribed in 
the opposite orientation to that found in the EBV genome 
(Albrecht and Fleckenstein, 1990) .
By virtue of transfection studies and characterisation of
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mutants defective in DNA replication, the major DNA binding 
protein and DNA polymerase have been shown to be two of seven 
HSV-1 gene products required for origin-dependent DNA 
replication (Chartrand et al.. 1979; Conley et al.. 1981; Weller 
et al.. 1983? Gibbs et al.. 1985? Challberg, 1986? McGeoch et 
al., 1988b? Wu et al.. 1988). This region of the HSV-1 genome 
(0.38 to 0.43 m.u.) is particularly important in DNA replication 
since it also contains an origin of replication (oriL) between 
the major DNA binding protein and DNA polymerase genes (Gray and 
Kaemer, 1984; Quinn and McGeoch, 1985? Weller et al.. 1985).
The VZV and EBV genomes do not contain an origin of replication 
in this region (Baer et al., 1984; Davison and Scott, 1986a) and 
it would be of interest to determine whether the EHV-4 and EHV-1 
genomes also lack such an element in this region. An additional 
origin of replication (oris) is found in two copies in the short 
repeat sequences of the genomes of HSV-1 (Stow, 1982, 1985? Stow 
and McMonagle, 1983) , VZV (Stow and Davison, 1986) and EHV-1 
(Baumann et al.. 1989). Although no oriL has been detected in 
the VZV genome, such an element appears to localise just 
downstream of the glycoprotein gH gene in the genomes of EHV-1 
and EHV-4 (M. Whalley, personal communication; Nicolson et al.. 
1990a) . The highly conserved nature of the major DNA binding 
protein across the herpesviruses as predicted from DNA sequence 
data is consistent with early studies which reported extensive 
antigenic cross-reactivity between the major DNA binding
proteins of HSV-1, HSV-2, EHV-2, PRV and EHV-1 (Yeo et al.,
1981), and which demonstrated that these cross-reacting proteins 
of all five viruses were very similar in structure by virtue of 
tryptic peptide analysis (Littler et al., 1981). More recently,
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immunofluorescence and Western blot analysis of EBV-transformed 
cell lines has demonstrated the antigenic relatedness between 
the major DNA binding proteins of HSV and EBV (Littler et al..
1988).
All the EHV-4 genes identified in this chapter mapped to 
genomic locations col inear with the analogous genes in the HSV-1 
(IL) and VZV genomes. However, much work remains to be done in 
the characterisation of other EHV-4 genes and the determination 
of the functions of their gene products.
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CHAPTER 7
General Discussion
The involvement of EHV-1 and EHV-4 in abortigenic, 
respiratory and neurological diseases is particularly worrying 
for the horse breeding industry worldwide due to the great 
economic losses associated with outbreaks of disease. Immunity 
to infection, whether by natural infection or vaccination, is 
weak and short lived and horses become reinfected at intervals 
of 3 to 6 months throughout their lifetime (Bryans, 1969). A 
deeper understanding of the horses immune response to viral 
infection is of paramount importance if the virus-induced 
diseases are to be effectively controlled. One means of 
achieving this is by characterisation of the viral envelope 
glycoproteins, the major immunogens of herpesviruses known to 
induce both humoral and cell-mediated immune responses. Most of 
the new generation of herpesvirus vaccines currently being 
developed are based upon the ability of the envelope 
glycoproteins to stimulate a wide range of host immune 
responses.
A major part of the studies presented in this thesis were
concerned with the identification and DNA sequence determination
«»'
of the EHV-4 gene encoding the major glycoprotein gB and 
subsequent evaluation of the immunogenicity of the gene product. 
Analysis of the predicted amino acid sequence of the EHV-4 gB 
protein and comparison with those available for the gB 
homologues of other herpesviruses demonstrated that the proteins 
possess highly conserved primary and predicted secondary 
structures which suggests important, conserved functions for 
these proteins in each virus. HSV-1 gB is known to play an 
essential role in virus entry and cell fusion (Little et al., 
1981; DeLuca et al.. 1982) . However, the precise roles of EHV-4
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gB in viral infection remain to be determined by further 
experimental studies.
Studies presented on the immunogenicity of EHV-4 gB 
indicated that this glycoprotein may play only a minor role in 
eliciting the production of virus neutralising antibodies and is 
probably more important in stimulating other immune mechanisms. 
This was inferred from the observation that neither EHV-4 gB 
fusion proteins or peptides derived from the EHV-4 gB sequence 
could stimulate the production of virus neutralising antibodies 
in hamsters although they elicited anti-protein and anti-peptide 
antibody responses. The protection from a lethal EHV-1 challenge 
of one hamster immunised with the EHV-4 gB fusion protein 
pUR0.6gB in the absence of virus neutralising antibodies 
indicated that other antibody-mediated immune effector 
mechanisms may have been mediating protection, such as ADCC or 
CDL. Additionally, the ability of EHV-4 gB peptides to induce 
the proliferation of lymphocytes in response to whole virus 
antigen in vitro indicated the presence of an important T cell 
epitope on the EHV-4 gB molecule. Although the studies presented 
in this thesis are only the first of a wide range of 
experimental approaches which will be necessary to fully 
elucidate the precise role of EHV-4 gB in the immune response to 
viral infection, it can be regarded as a glycoprotein suitable 
for vaccine development.
By analogy with HSV-1, another EHV-1 and EHV-4 glycoprotein 
also suitable for development as a vaccine is gC. EHV-1 gC 
(gpl3) is the most extensively characterised EHV glycoprotein. 
The genes encoding EHV-1 gC (Allen and Coogle, 1988) and EHV-4 
gC (Nicolson and Onions, 1990) have been identified and
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sequenced. Allen et al. (1988) identified at least 16 epitopes 
on EHV-1 gC, of which were 85% were type-specific and 20% 
elicited virus neutralising antibody production. A predicted 
immunodominant site was localised to residues 145 to 150 (Glu- 
Arg-Lys-Lys-Ser-Arg) of EHV-1 gC (Allen and Coogle, 1988). The 
EHV-1 gC and EHV-4 gC molecules show a sequence identity of 79% 
and, given this high degree of conservation of amino acid 
sequences, it is somewhat surprising that the epitopes on the gC 
molecules are predominantly type-specific. Detailed 
characterisation of the epitopes of EHV-1 gC and EHV-4 gC should 
identify the precise antigenic relationship between these 
glycoproteins.
Two separate studies have illustrated the antigenic nature 
and importance of EHV-1 gC in protective immunity. Immunisation 
of guinea pigs with a recombinant vaccinia virus expressing EHV- 
1 gC elicited the production of EHV-1 neutralising antibodies 
and hamsters vaccinated with this recombinant virus were
protected from a lethal EHV-1 challenge (Guo et al.. 1989).
Stokes et al. (1990) demonstrated that hamsters immunised with 
purified EHV-1 gC produced antibodies with virus neutralising
activity and which participated in complement-mediated lysis of 
EHV-l-infected cells, and that these hamsters were also 
protected from a lethal EHV-1 challenge. Peptides from the EHV-4 
gC sequence have been shown to elicit the production of anti­
peptide antibodies upon immunisation of hamsters which in some 
instances reacted with whole virus, but could not protect
hamsters from a lethal EHV-1 challenge (Stokes et al., 1990), a 
situation analogous to that seen when using peptides from the 
EHV-4 gB sequence. However, one EHV-4 gC peptide was predicted
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to contain an important linear B cell epitope on the basis of 
strong reactivity with an EHV-1 gC-specific monoclonal antibody. 
Thus, studies so far carried out on the immunogenicity of EHV-1 
gC clearly indicate that it is a highly antigenic molecule 
that plays a major role in protective immunity and, as such, is 
an ideal candidate for EHV vaccine development. These findings 
are in accordance with the similar role of the gC-like proteins 
of other alphaherpesviruses in both humoral and cell-mediated 
immunity. HSV-1 gC is an important antigen that can elicit the 
production of virus neutralising antibodies (Glorioso et al., 
1984; Roberts et al.. 1985; Weir et al. . 1989), CTL responses 
(Glorioso et al.. 1985; Rosenthal et al.. 1987), and can confer 
protective immunity (Glorioso et al. . 1984; Roberts et al., 
1985; Weir et al. . 1989) in mice. BHV-1 gill has been shown to 
elicit the production of antibodies in cattle with virus 
neutralising activity and which participate in ADCC of BHV-1-
infected cells (Babiuk et al.. 1987; van Drunen Littel-van den 
Hurk et al.. 1989) and to protect cattle from- virus challenge 
(Babiuk et al.. 1987). In mice, BHV-1 gill elicited virus
neutralising antibody production and was recognised by murine
CTLs and antibody in immune-mediated cytotoxicity assays 
(Fitzpatrick et al.. 1988). PRV gill is a major target for virus 
neutralising antibodies (Ben-Porat et al.. 1986a) and for murine 
and swine CTLs (Zuckermann et al., 1990) , and monoclonal
antibodies to PRV gill can protect mice and swine against PRV 
challenge (Marchioli et al.. 1988).
Although the development of individual antigenic 
glycoproteins as subunit vaccines by their expression as fusion
products in E.coli is a well documented approach, the method
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does have several drawbacks. In particular, the expressed 
protein product is not glycosylated by E.coli and does not 
retain its native conformation and biological activity and any 
immunity afforded is generally short lived. Chapter 5 of this 
thesis dealt with the expression of segments of the EHV-4 gB 
gene in E.coli as fusion products with (3 -galactosidase and 
glutathione-S-transf erase. An obvious problem with (S - 
galactosidase fusion proteins is that, due to the large size of 
the (3 -galactosidase moiety (116kDa), a major portion of any 
immune response may be directed against this region unless the 
expressed exogenous product is particularly antigenic. This 
potential problem can be partly overcome by expression as fusion 
products with the relatively small glutathione-S-transf erase 
(26kDa). Furthermore, this expression system allows cleavage of 
the carrier protein from the protein of interest and rapid 
purification of protein products by immunoaffinity 
chromatography. In general, subunit vaccines developed by 
expression of glycoproteins in E.coli may be regarded as 
suitable for the initial characterisation of potentially 
immunogenic glycoproteins for incorporation into genetically 
attenuated virus vaccine strains but not as final vaccine 
products.
Expression of foreign antigens in systems derived from the 
insect baculovirus Autoorapha califomica nuclear polyhedrosis 
vims is a more favoured approach for the development of 
glycoproteins as subunit vaccines (reviewed in Luckow and 
Summers, 1988). In this system, the foreign gene to be expressed 
is linked to the strong viral polyhedrin gene promoter by 
homologous recombination in insect cells. Foreign antigens
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produced by this system are expressed to particularly high 
levels, although insect cells do not always authentically 
glycosylate and process the expressed protein. Many eukaryotic 
genes have been successfully expressed in this way (Prehaud et 
al.. 1989; Koener and Leong, 1990; Tratner et al.. 1990). In
particular, HCMV gB has been successfully expressed in insect 
cells using a recombinant baculovirus (Wells et al.. 1990). The 
mature protein was processed by proteolytic cleavage in insect 
cells, although this step was less efficient than in mammalian 
cells. More importantly, authentic processing and glycosylation 
of HCMV gB did not appear to be required for immunogenicity 
since immunisation of mice with the recombinant virus stimulated 
the production of virus neutralising antibodies to a level 
comparable with that previously reported following immunisation 
of mice with a vaccinia virus expressing HCMV gB (Britt et al.,
1988).
Vaccinia virus and human adenoviruses have been used as 
biological delivery systems for the presentation of foreign 
antigens and in studying the nature of the immune responses 
elicited by these antigens. The use of vaccinia virus as a 
vector is by far the most widely exploited approach (Mackett et 
al. . 1982; Mackett and Smith, 1986; Moss and Flexner, 1987).
Vaccinia virus is the prototypic orthopoxvirus with a large 
genome of about 187kb, possessing great capacity for foreign DNA 
without destruction of infectivity and a wide host range. The 
insertion of foreign genes into the vaccinia virus genome is 
achieved using a two-step strategy. Firstly, a plasmid insertion 
vector is constructed which contains the foreign gene linked to 
a vaccinia virus promoter flanked by vaccinia virus DNA taken
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from a non-essential region of the genome. The next step 
involves insertion of the chimeric gene into the vaccinia virus 
genome by transfection of the recombinant plasmid into cells 
infected with wild-type vaccinia virus. Homologous recombination 
in cells between the vaccinia virus DNA sequences flanking the 
chimeric gene and the vaccinia virus genome results in the 
generation of a recombinant virus containing the foreign gene. 
Recombinant genomes are replicated and packaged into infectious 
vaccinia virus. The site in the vaccinia virus genome at which 
the foreign gene is inserted is determined by the vaccinia virus 
DNA flanking the chimeric gene. Although any site non-essential 
for virus growth can be used for insertion of foreign genes, the 
TK gene is most often used since insertional inactivation of the 
TK gene greatly decreases the virulence of vaccinia virus and, 
as such, produces a safer, attenuated virus for vaccination 
purposes (Buller et al.. 1985). Furthermore, TK-negative
recombinant viruses can be readily selected by their resistance 
to 5-bromodeoxyuridine (BUdR) by plaquing on a TK-negative cell 
line in the presence of BUdR. Vaccinia virus recombinants 
expressing HSV-1 glycoproteins have been demonstrated to invoke 
humoral, cell-mediated and protective immune responses. A 
recombinant vaccinia virus expressing HSV-1 gB has been shown to 
induce the production of anti-HSV-1 CTLs (McLaughlin-Taylor et 
al.. 1988), and virus neutralising antibodies and protective
immunity (Cantin et al., 1987), in mice. Immunisation of mice 
with an HSV-1 gC-vaccinia virus recombinant virus elicited the 
production of virus neutralising antibodies and protected mice 
from a lethal HSV-1 challenge (Weir et al., 1989) . Similarly,
vaccinia virus recombinants expressing HSV-1 gD could also
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induce virus neutralising antibody production in mice, 
protect mice from a lethal HSV-1 challenge and prevent the 
establishment of a latent HSV-1 infection (Paoletti et al.. 
1984? Cremer et al.. 1985? Rooney et al.. 1988), and were also 
shown to activate HSV-specific human CTLs (Zarling et al.. 
1986b) and other T cells in mice (Martin et al.. 1987, 1989).
Immunisation of mice with recombinant vaccinia viruses 
expressing the minor HSV-1 glycoproteins gG (Sullivan and Smith,
1987) and gl (Sullivan and Smith, 1988) resulted in the 
production of virus neutralising antibodies. Other herpesvirus 
glycoproteins expressed in vaccinia virus and shown to induce 
virus neutralising antibody production upon immunisation of 
animals include HCMV gB (Cranage et al. . 1986; Britt et al..
1988), BHV-1 gl and gill (van Drunen Littel-van den Hurk et al..
1989) and PRV gp50 (Marchioli et al.. 1987a).
The use of human adenoviruses, particularly type 5 (Ad5),
as model vaccine vector systems is well documented. Regions of 
the virus genome available for insertion of foreign genes by 
homologous recombination are the early regions 1 (El) and 3 
(E3) . Sequences in the E3 region can be deleted without 
affecting the ability of Ad5 to replicate in cells permissive 
for human adenoviruses and up to 4kb of foreign DNA sequences 
can be inserted in the E3 region (Ghosh-Choudhury et al., 1986; 
Haj-Ahmad and Graham, 1986) . Although most of the sequences in 
the El region can be deleted, the resulting mutant viruses can 
only replicate in 293 cells (Graham et al.. 1977). Adenovirus
vectors with deletions in both the El and E3 regions can 
accommodate up to 7.5kb of foreign DNA sequences (Ghosh- 
Choudhury et al.. 1986; Ha j-Ahmad and Graham, 1986). Recombinant
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adenovirus vectors have been successfully used to express a wide 
range of foreign antigens in cell culture (Ballay et al. . 1985;
Haj-Ahmad and Graham, 1986; Davidson and Hassell, 1987; Prevec 
et al.. 1989). In particular, human adenovirus vectors have been 
successfully used to express HSV-1 gB (Johnson et al., 1988b)
and immunisation of mice with this recombinant adenovirus 
stimulated the production of virus neutralising antibodies to 
HSV-1 and HSV-2 and protected animals from lethal HSV-1 and HSV- 
2 challenges (McDermott et al., 1989) . Adenovirus vectors
expressing HSV-1 gB and gC have been used in the study of CTL 
responses specific for HSV in mice (Witmer et al., 1990) . This 
study demonstrated that HSV-specific CTLs could lyse cells 
transfected with the Ad-gB recombinant virus but not with the 
Ad-gC recombinant virus.
Preferred herpesvirus vaccines are those which comprise 
whole virus. Killed virus vaccines prepared from whole virus 
have been used to induce the production of protective antibodies 
against a wide range of virus-induced diseases (Melnick, 1985). 
However, several disadvantages are associated with such 
vaccines. These include the production of only brief immunity 
which must be boosted, the ability of some vaccines to induce 
hypersensitivity to infection by wild-type virus and extreme 
care required in ensuring that all virulent live virus is 
removed from the vaccine preparation. Genetic manipulation 
techniques have made possible the development of safer, live 
attenuated viruses. Using this approach virus mutants with 
deletions in virulence genes and temperature-sensitive mutants 
have been generated to serve as live virus vaccines. In 
particular, the TK gene, which is known to play an important
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role in herpesvirus virulence (Field and Wildy, 1978? Tenser et 
al.. 1981; Ben-Hur et al., 1983) and can enhance herpesvirus
replication in non-dividing cells (Jamieson et al., 1974), has 
been the focus of much attention. Several TK-negative 
attenuated herpesviruses with deletions in the TK gene that 
cannot revert to virulence have been successfully used in the 
control of herpesvirus-induced diseases. TK-negative PRV mutants 
have been shown to be immunogenic, avirulent and capable of 
protecting swine from a virulent PRV infection (Kit et al., 
1985a,b? McGregor et al.. 1985? Marchioli et al.. 1987b). In a 
similar vein, a TK-negative BHV-1 mutant virus was also shown to 
be highly attenuated for calves and capable of protecting 
animals from challenge with virulent BHV-1 (Kit and Qavi, 1983? 
Kit et al.. 1985c). Pregnant cows vaccinated with this mutant 
virus were also protected from BHV-1 challenge (Kit et al.. 
1986). A PRV virus vaccine with deletions in the TK, gl and gill 
genes has also been constructed (Kit et al., 1987) . The
generation of TK-negative EHV-1 and EHV-4 viruses for use as 
vaccines in the horse could readily be accomplished since the TK 
genes of these viruses have been mapped and sequenced (Robertson 
and Whalley, 1988; Nicolson et al. . 1990b). An EHV-1 TK-negative 
mutant has been prepared by passaging of the Vero-adapted TK- 
positive EHV-1 (RQ) strain in media containing the nucleoside 
analogues BUdR and 1-B-D arabinofuranosylthymine, and its safety 
and efficacy as a vaccine in young horses evaluated (Comick et 
al.. 1990). The vaccine was safe when administered either
intramuscularly or intravenously, with no EHV-1 being shed 
intranasally during the 12 days following its administration, 
and was shown to be antigenic since serum neutralising antibody
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levels in vaccinated animals increased significantly following 
intranasal challenge with virulent EHV-1. However, the vaccine 
could not prevent clinical signs of respiratory disease 
following intranasal challenge with virulent EHV-1. It was 
suggested that the inability of the vaccine to protect against 
respiratory disease may have been due to the requirement for 
more than a single inoculation to stimulate adequate immunity, 
possible over-attenuation of the vaccine virus prior to deletion 
of the TK gene or simply a result of the EHV-1 challenge dose 
used in the experiments being greater than that of a natural 
infection.
The avirulent PRV vaccine strains NIA-4, Norden and Bartha 
contain deletions in the Us region which contribute to their 
reduced virulence (Lomniczi et_al., 1984a,b? Bems et al., 
1985). These strains do not contain the gene coding for the PRV 
glycoprotein gl which is analogous to HSV-1 gE (Mettenleiter et 
al., 1985a,b? Ben-Porat et al.. 1986b). Additional studies
demonstrated that the Bartha strain also contains a deletion in 
the gene for glycoprotein gp63 (Petrovskis et al., 1986b), the 
analogue of HSV-1 gl. Quint et al. (1987) constructed PRV 
mutants with deletions in Us which, when inoculated into pigs, 
protected vaccinated animals from challenge with virulent wild- 
type PRV. Thus, the Us region of the PRV genome encodes two 
glycoproteins, gl and gp63, which contribute to virulence and 
are not essential for viral growth. It would not be prudent to 
assume that the analogous glycoproteins of HSV-1 (gE and gl) and 
other alphaherpesviruses will also contribute to virus virulence 
and can also be deleted to produce avirulent vaccine strains. 
This approach for the development of attenuated EHV-1 and EHV-4
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vaccine strains awaits the determination of the DNA sequence of 
the Us region of their genomes. The generation of mutant viruses 
with further deletions in other virulence genes from other 
regions of the genome, including the TK gene, as well as 
deletions in sequences involved in cell transformation, should 
prove to be particularly safe and effective vaccines.
Both EHV-1 and EHV-4 have the upper respiratory tract as 
the site of entry and primary site of virus replication. Live 
intranasal vaccines are an attractive proposition if stable non- 
revertant temperature-sensitive mutants could be produced. This 
could be achieved by in vitro mutagenesis of cloned restriction 
endonuclease fragments from selected regions of the EHV-1 and 
EHV-4 genomes with nitrous acid. Transfection of these fragments 
into cells together with parental virus would generate 
recombinant viruses containing the engineered mutations. The 
screening of progeny virions for temperature-sensitivity and 
stability on passage and confirmation of the lesions by marker 
rescue studies, restriction mapping and DNA sequence analysis 
would identify suitable mutants for testing as vaccine viruses. 
Using this method, multiple lesions can be induced which 
eliminate spontaneous reversion to virulence. Herpesvirus 
temperature-sensitive mutants have proved to be safe and 
effective vaccines against disease caused by BHV-1 and FHV-1.
To effectively protect against both EHV-1- and EHV-4- 
induced diseases, a bivalent vaccine containing immunogenic 
components from both virus types is desirable. This would be 
achieved by development of EHV-1 and EHV-4 as virus vectors. 
Genes coding for the immunogenic glycoproteins, for example gB 
and gC, of one virus could be inserted into the TK gene of the
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other virus. The resulting TK-negative recombinant viruses 
generated by homologous recombination would then be selected by 
their resistance to BUdR as previously described. Coexpression 
of gB and gC is particularly desirable since it has been shown 
that the expression of both EHV-1 gB and gC in vaccinia virus 
greatly enhances the protective efficacy in the hamster 
challenge model over that obtained with the singular expression 
of either gB or gC (Guo et al.. 1990). Deletions of a
combination of other non-essential genes contributing to 
virulence could also be incorporated into such vaccine viruses 
to create even higher levels of safety and efficiency.
An immune stimulating complex (ISCOM) vaccine prepared from 
the abortigenic EHV-1 strain V592, and which contains all the 
major viral glycoproteins, has been shown to fully protect 
hamsters from a lethal EHV-1 challenge (Cook et al., 1990).
Studies with this vaccine are now underway to determine whether 
it can protect horses from challenge with virulent EHV-1.
Although studies on antiviral immunity to herpesvirus 
infection have concentrated on the surface glycoproteins as the 
principal immunogens against which antiviral responses are 
directed, it is now apparent that non-glycoprotein and non- 
structural antigens may also act as targets for such responses. 
For example, the IE gene products of human and murine 
cytomegaloviruses and HSV-1 have been shown to act as major, 
even dominant, targets for antiviral CTLs (Reddehase et al.. 
1984; Reddehase and Koszinowski, 1984; Koszinowski et al.. 1987; 
Martin et al.. 1988). The CTL response to herpesvirus infection 
would therefore appear to be a multi-faceted entity. The manner 
in which these IE proteins, normally confined to the nucleus,
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can appear at the cell surface to act as targets for CTLs 
remains to be determined. In a similar vein, it was shown in 
Chapter 6 of this thesis that a major, antigenic glycoprotein of 
EHV-1 and EHV-4, gplO, resides not in the virus envelope as 
previously thought but probably in the virus tegument.
An alternative approach to a vaccination programme for the 
control of herpesvirus-induced diseases is the development of 
antiviral compounds which block specific virus-coded functions 
and consequently interfere with the production of infectious 
virus. One particular compound which has undergone much 
investigation is the nucleoside analogue acyclovir (ACV? 9-[2- 
hydroxyethoxymethyl] guanine). The triphosphate derivative of ACV 
acts as a competitive inhibitor with dGTP for the HSV-1 DNA 
polymerase, interfering with viral DNA synthesis and the 
production of infectious virus (Elion et al., 1977). Although
ACV demonstrates activity against some human herpesviruses 
(Schaeffer et al.. 1978; Collins and Bauer, 1979; Bridgen et 
al., 1981) it is not effective against HCMV (Plotkin et al.. 
1982; Wade et al.. 1982). The HSV-1 ribonucleotide reductase, 
which is essential for virus pathogenicity in mice (Cameron et 
al., 1988), has been targeted as another viral component against 
which antivirals may be effective. The synthetic nonapeptide 
YAGAWNDL, which represents the carboxyl-terminal nine amino 
acids of the small subunit of HSV-1 ribonucleotide reductase, 
has been shown to specifically inhibit the HSV-1 enzyme (Cohen 
et al.. 1986; Dutia et al.. 1986) by causing dissociation of the 
two subunits of the enzyme (McClements et al., 1988) . Since
serological studies indicated that the carboxyl-terminal region 
of the small subunit of ribonucleotide reductase was highly
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conserved with that of other herpesviruses, it was speculated 
that this nonapeptide may also inhibit other herpesvirus 
ribonucleotide reductase enzymes (Dutia et al.. 1986). This was 
borne out by the observations that the activities of the 
ribonucleotide reductase of PRV (Cohen et al.. 1987) and EHV-1 
(Telford et al., 1990) were also blocked by this nonapeptide. An 
antiviral drug based on this nonapeptide may be of value in 
treating EHV-1 and EHV-4 infections in the horse. Treatment of 
EHV-1-infected mice with the antiviral agent (S)-9-(3-hydroxy-2- 
phosphonylmethoxypropyl)adenine (HPMPA) resulted in the 
successful clearance of viraemia and reversed the progression of 
clinical signs, thereby demonstrating the potential for this 
compound in effective chemotherapy of EHV-1 (Field and Awan,
1990). HPMPA probably acts by directly inhibiting the viral DNA 
polymerase (Votruba et al.. 1987). The development of antiviral 
drugs against other targets which contribute to virus 
pathogenicity is an exciting prospect for the future.
The data presented in Chapter 6 comprise the largest piece 
of DNA sequence so far reported for the EHV-4 genome and 
represents an early step in the characterisation of the genetic 
content of this virus. Knowledge of the DNA sequence of
herpesvirus genomes will yield important information with 
respect to the genetic and antigenic relatedness of these
viruses and provide an insight into the manner in which they
have undergone evolutionary divergence at the genetic level.
Comparison of the EHV-4 gene products analysed with the 
analogous gene products of HSV-1 and VZV suggests that EHV-4 may 
be more closely related to VZV than HSV-1, although this can 
only be confirmed by comparison of the complete DNA sequence of
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the EHV-4 genome when this becomes available with those of the 
HSV-1 and VZV genomes. Comparison of the proteins and antigens 
of HSV-1, HSV-2, BMV, PRV and EHV-1 by SDS-PAGE of purified 
virus, and by virus neutralisation and agar gel immunodiffusion 
tests, has demonstrated that PRV and EHV-1 are more closely 
related to each other at the antigenic level than to BMV, HSV-1 
or HSV-2 (Killington et al., 1977). Such findings made at the 
antigenic level can now be confirmed at the DNA level as the DNA 
sequences of these herpesvirus genomes come to light. The 
complete DNA sequence of the genomes of the alphaherpesviruses 
HSV-1 (McGeoch et__al., 1985, 1986a, 1988a; Perry and McGeoch,
1988) and VZV (Davison and Scott, 1986a), the gammaherpesvirus 
EBV (Baer et al.. 1984) and the betaherpesvirus HCMV (Chee et 
al.. 1990) are currently available. Comparison of the genes
specified by the genomes of HSV-1 and VZV revealed that the two 
viruses possess a near identical gene arrangement in UL; the 
only differences are that VZV gene 13, which encodes a 
thymidylate synthetase, is replaced by a gene of unknown 
function (UL45) in HSV-1, whilst the genomic position occupied
by VZV genes 1 and 2 at the start of UL is occupied by the 
unrelated gene UL56 in HSV-1. Interestingly, the EHV-4 genome 
contains a gene in a position col inear with HSV-1 UL45 and VZV
gene 13 whose predicted product is unrelated to the gene
products of both HSV-1 UL45 and VZV gene 13 (Nicolson and
Onions, 1990). The S segment of the HSV-1 and VZV genomes has 
undergone extensive divergence. HSV-1 contains 13 genes in this 
region, VZV only 7. Each VZV gene has a homologue in HSV-1 and 
the remaining 6 extra HSV-1 genes with no VZV homologues 
include those for glycoproteins gD and gG and the IE protein
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IE12. The layout of conserved genes in the S segment is 
different but the S segments are clearly related and a mechanism 
has been proposed for their descent from the S segment of an 
ancestral herpesvirus genome by expansion and contraction of the 
inverted repeats (Davison and McGeoch, 1986). Comparison of the 
DNA sequence of the VZV genome with that of the distantly 
related EBV identified 29 VZV genes with detectable counterparts 
in EBV, all of which are contained within the UL region of their 
genomes and located in a generally colinear fashion in three 
major regions, although these regions are arranged differently 
in the two genomes (Davison and Taylor, 1987) . Conserved genes 
include those for the two subunits of ribonucleotide reductase, 
DNA polymerase, major capsid protein, exonuclease, dUTPase, 
major DNA binding protein, TK and glycoproteins gB and gH. The 
use of immunological probes in immunofluorescence and Western 
blot analyses of EBV-transformed cells identified EBV-coded 
proteins antigenically related to the HSV alkaline 
deoxyribonuclease, glycoprotein gB, TK, major DNA binding 
protein and infected cell-specific protein 34/35 (Littler et 
al., 1988).
DNA sequence analysis has also been employed in the 
determination of gene arrangement in other herpesviruses. For 
example, the A+T-rich J 2"herpesvirus HVS genome has been shown 
to share a generally colinear arrangement with the G+C-rich $i” 
herpesvirus EBV genome, encoding closely related proteins, and 
this gene arrangement is in turn different from that of the 
alphaherpesviruses HSV-1 and VZV (Gompels et al., 1988) . DNA
sequence analysis has also led to the reclassification of some 
herpesviruses originally classified on the basis of biological
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properties. MDV and HVT, originally classified as 
gammaherpesviruses due to their tropism for lymphocytes, are now 
regarded as alphaherpesviruses (Buckmaster et al.. 1988; Ross et 
al., 1989) . Large scale DNA sequencing has established that HHV- 
6, originally classified as a gammaherpesvirus, more closely 
resembles HCMV than EBV, HSV or VZV at the genetic level and is 
now regarded as a betaherpesvirus (Efstathiou et al.. 1988;
Lawrence et al., 1990; Littler et al.. 1990).
Determination of the complete DNA sequence of the genomes 
of EHV-1 and EHV-4 would be expected to reveal a similar gene 
complement and organisation to that observed for HSV-1 and VZV, 
at least within UL. However, the S segment will prove to be the 
most interesting region. This has been shown to be the most 
divergent region of the alphaherpesvirus genomes and it seems 
highly likely that differences in genetic layout may account for 
the differing pathogenicity and disease-forming potential of 
each herpesvirus. In particular, differences in the S segments 
of the EHV-1 and EHV-4 genomes may contribute to the differing 
disease spectra of these two viruses.
All of the 12 ORFs in the S component of the HSV-1 genome, 
with the exception of US6 (gD), have been deleted and shown to 
be dispensable for virus growth in cell culture (Post and 
Roizman, 1981; Longnecker and Roizman, 1986, 1987; Longnecker et 
al., 1987). These non-essential genes include those encoding the 
glycoproteins gG (US4), gl (US7) and gE (US8), and a protein 
kinase (US3). This pronounced clustering of genes not essential 
for viral growth is in contrast with the small number and wide 
scattering of such genes in the L component of the HSV-1 genome, 
which include those for gC and TK. One hypothesis proposed to
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explain this clustering of dispensable genes is that these genes 
have evolved in the S component to allow HSV to survive in the 
ecological niche of its human host rather than to replicate or 
package its genome, and that they have evolved from DNA 
sequences acquired by a progenitor virus (Roizman, 1979) . Genes 
non-essential for viral growth which are known to map in the S 
component of the PRV genome include those for the glycoproteins 
gl, gp63 and gX. It therefore seems highly probable that many 
genes non-essential for viral growth will also cluster in the S 
component of other herpesvirus genomes. Identification of such 
genes in the genomes of EHV-1 and EHV-4 will aid vaccine 
development. Genes non-essential for viral growth have generally 
been identified by site-specific deletion or insertional 
mutagenesis techniques. A rapid mutagenesis procedure for 
exploring herpesvirus genomes and identifying such genes is that 
of Tn5 mutagenesis (Weber et al.. 1987).
The detection of EHV-1 and EHV-4 DNA in clinical specimens 
from natural infections has frequently been accomplished by the 
use of cloned viral DNA fragments as hybridisation probes. 
Morris and Field (1988) directly analysed infected tissue from 
aborted foetuses using dot blot and Southern blot hybridisation 
techniques and successfully confirmed the presence of EHV-1 DNA 
sequences in these specimens. Moreover, using this approach it 
was possible to distinguish between EHV-1 and EHV-4, to detect 
intratypic strain variation and to reveal information on the 
conformational state of the viral genome. However, the Southern 
blot method is relatively labour intensive, although the dot 
blot method was reported to have potential as a rapid diagnostic 
procedure. The problem of non-specific hybridisation is always
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possible, leading to false positive results. The extremely 
sensitive, highly specific and rapid technique of polymerase 
chain reaction (Saiki et al.. 1988) is now finding wide
application as a powerful tool for the diagnosis of latent and 
non-latent EHV in equine tissues. Using this technique, single- 
copy genomic sequences can be amplified by a factor of more than 
107 with very high specificity, with DNA segments up to 2000bp 
in length being readily amplified. Due to the extremely high 
sensitivity of the technique, an exceptionally high standard of 
laboratory practice is essential to prevent amplification of 
contaminating material.
The rapidly growing discipline of molecular biology has now 
revolutionised scientists approach to the study of herpesviruses 
and attempts to control the diseases they cause. The continued 
application of this technology in this field promises to develop 
suitable vaccines and antiviral compounds which will severely 
curtail the incidence of herpesvirus-induced diseases and allow 
for improved treatment of infected individuals. The work 
presented in this thesis represents an initial step in the 
attempt to determine the genetic structure of EHV-4 and in the 
development of potentially effective recombinant vaccines 
against both EHV-1 and EHV-4.
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